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ABSTRACT 
Whey proteins are a by-product of cheese manufacture that have been shown to 
suppress high fat diet (HFD)-induced weight gain and adiposity independently of 
changes to energy intake. This project tested the hypothesis that whey protein 
isolate (WPI) directly impacts on adiposity by influencing tissue lipid metabolism.  
The hypothesis was tested using C57BL/6J mice fed WPI enriched high fat (HFD) 
or low-fat diets (LFD) and by assessing the functionality of the lysophosphatidic 
acid receptor 5, as a potential candidate mediating direct protein effects on 
adipose tissue. 
WPI suppressed HFD-induced body fat at 8 weeks of dietary challenge and 
augmented lean mass. At a cellular level, WPI reduced HFD-associated 
hypothalamic leptin receptor, insulin receptor (IR), and carnitine 
palmitoyltransferase 1b (CPT1b) mRNA expression, and prevented HFD-associated 
reductions in adipose tissue expressions of IR and glucose transporter 4 (GLUT4). 
These changes occurred in a background of elevated plasma triacylglycerol (TAG), 
suggesting a reduced TAG storage in the tissues with WPI intake. While most of 
these effects were largely absent when the study was extended to 21 weeks, 
notably WPI specifically increased lean mass and caused a trend towards a 
decrease in fat mass. Analysis of faecal microbial populations revealed specific 
effects of WPI, namely increased proportions of Lactobacillus and decreased 
Clostridium. Increasing the (whey) protein to carbohydrate ratio within the HFD 
enhanced WPI specific effects on adiposity, and lean mass, similar to that observed 
in the short-term study and caused a shift in the composition of gut microbiota 
away from the HFD group.  
xxii 
 
  
Using mice fed a LFD enriched with WPI (LFD-WPI), the effect of the dietary 
protein on insulin and lipid-associated gene expression in the adipose tissue was 
further evaluated. The 7 weeks of LFD-WPI intake decreased insulin and lipid-
related gene expression in the adipose tissue. In contrast, 15 weeks of LFD-WPI did 
not affect insulin-related gene expression but augmented lipid metabolism related 
gene expression. In both studies, WPI intake also reduced intestinal weight and 
length, suggesting a potential functional relationship between WPI, gastro-
intestinal morphology and insulin and lipid metabolism related signalling in the 
adipose.  
To obtain evidence of a direct route of action for WPI on adipose tissue, the 
functionality of LPA5 in these cells were assessed. The gene expression of the 
receptor was increased in the adipose tissue by HFD feeding and ob gene mutation, 
as well as by the differentiation in 3T3-L1 cells. Over-expression of the receptor in 
3T3-L1 pre-adipocytes provided a growth advantage to the cells and suppressed 
their cellular differentiation. These data suggest an important role for LPA5 in pre-
adipocyte growth and differentiation. 
In conclusion, the data presented here provides support to the hypothesis 
that WPI can impact on adiposity by influencing lipid metabolism, by affecting lean 
mass, hypothalamic gene expression, changes to gut microbiota and alterations to 
gastrointestinal morphology. These effects were dependent on the macronutrient 
composition in the WPI enriched diet and its duration of feeding. Our data also 
showed the LPA5 is a novel candidate in the regulation of pre-adipocyte growth 
and differentiation, and thus could potentially mediate direct effects of WPI on 
adipose cellular activity. 
 
    
 
 
 
 
Chapter 1  
The current understanding of how whey 
proteins influence the regulation of energy 
balance 
 
 
 
 
 
 
Published works associated with this chapter are: 
McAllan L, Cotter PD, Roche HM, Korpela R, Nilaweera KN (2012) Bioactivity in 
whey proteins influencing energy balance. Journal of Metabolic Syndrome 1: 107. 
 
McAllan L, Cotter PD, Roche HM, Korpela R, Nilaweera KN (2013) Impact of leucine 
on energy balance. Journal of Physiology and Biochemistry 69: 155-163 
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1.1 ABSRACT 
Body weight is determined by the balance between energy intake and energy 
expenditure. When energy intake exceeds energy expenditure, the surplus energy 
is stored as fat in the adipose tissue, which causes its expansion and eventually 
leads to the development of obesity. Regulation of energy balance is a complex 
physiological process that requires the interaction between multiple tissues, 
including the gastrointestinal tract, liver, pancreas, adipose tissue and the brain, 
and includes the regulation of lipid metabolism and glucose homeostasis. Nutrients 
that reduce the positive energy balance and thereby fat accumulation are thus 
being considered as therapies to combat obesity. In this regard, much interest has 
been focussed on the ability of whey proteins to suppress obesity development. 
Here, we review the literature related to the physiological, cellular and endocrine 
effects of intake of whole whey protein isolate/concentrate and individual whey 
proteins (α-lactalbumin, β-lactoglobulin, glycomacropeptide and lactoferrin). 
Moreover, we discuss how dietary composition and obesity may influence whey 
protein effects on the above parameters. Evidence suggests that intake of whey 
proteins causes a decrease in energy intake, increase in energy expenditure, 
influences insulin sensitivity and glucose homeostasis and alters lipid metabolism 
in the adipose, liver and muscle. These physiological changes are accompanied by 
alterations in the plasma levels of energy balance related hormones 
(cholecystokinin, ghrelin, insulin and glucagon-like peptide-1) and the expression 
of catabolic and anabolic genes in the above tissues in the direction of a negative 
energy balance. Evidence is also presented that whey proteins could reduce fat 
mass accumulation without substantial changes in energy intake or energy 
expenditure. 
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1.2 INTRODUCTION 
Obesity has reached epidemic proportions globally (Caterson et al, 2004). The 
World Health Organisation is projecting 1.5 billion adults will be overweight and 
over 700 million will be obese by 2015. Due to its propensity to increase the risk of 
developing several clinical conditions including cardiovascular disease, stroke, 
hypertension, and type 2 diabetes, it is one of the major health problems 
associated with the world today (Schelbert, 2009). With the increased prevalence 
of obesity, economic costs are also projected to increase, with costs for a country 
such as the UK being predicted to increase by 1.9-2.0 billion £/year by 2030 in 
order to cope with a projected 11 million increase in obese individuals (Wang et al, 
2011). Similarly, in Ireland, according to the National Task Force, obesity-related 
costs were up to €4 billion/year in 2005. This is expected to rise in the future, 
primarily because of the increasing prevalence of childhood obesity in Ireland, 
which at the time of this report was estimated at over 300,000 overweight and 
obese children, with this number projected to rise by 10,000 per annum. 
Importantly, the reversal of obesity is difficult to achieve as body fat is defended 
against acute perturbations, and the set point at which body fat is defended 
increases during obesity development (Ryan et al, 2012). Therefore, the growing 
opinion is that prevention of obesity from early on in life is the best solution to the 
future obesity epidemic. Thus, the discovery of nutritional factors which can 
reduce body weight is of critical importance in the prevention and/or reduction of 
obesity.  
Epidemiological studies show that there is an inverse relationship between 
the consumption of diets high in dairy products and body mass index, as well as a 
decrease in the risk of developing type-2 diabetes and metabolic syndrome (Baxter 
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et al, 2006; Gao et al, 2013). Dairy proteins, particularly whey proteins, which are a 
by-product of cheese manufacture, have been linked to the weight regulating 
effects of dairy intake (Bendtsen et al, 2013). In this regard, whey protein isolate 
(WPI), which is the enriched protein form of whey, has received increasing 
research interest in relation to its impact on energy balance (Jakubowicz & Froy, 
2013; Luhovyy et al, 2007). In fact, evidence suggests that whey proteins can 
impact on food intake (Luhovyy et al, 2007) and energy expenditure (Acheson et 
al, 2011; Hursel et al, 2010), and even on bodyweight in the absence of these latter 
changes (Pilvi et al, 2009; Royle et al, 2008). However, it is still not entirely 
understood how whey proteins mediate their action, although emerging evidence 
suggests that whey proteins may directly impact on the peripheral and central 
mechanisms regulating lipid metabolism. 
Functional Foods are those that deliver health benefits beyond basic 
nutrition (Hasler, 2002). In this regard, WPI appears to be an attractive option for 
this use because of the energy balance-related effects described above and because 
this milk protein fraction is readily available and relatively inexpensive to isolate. 
Therefore, this offers the opportunity to assign considerable added value to WPI 
and to market it as a health promoting ingredient. In terms of the Irish Functional 
Food industry, such product development will allow job creation and expansion of 
the strong internationally recognised dairy industry in Ireland, and also contribute 
to the recovery of the Irish economy.   
The main purpose of this thesis was to further investigate the potential of 
WPI to prevent the development of obesity, focusing on the impact of WPI on lipid 
metabolism and the mechanisms involved. The output of this research may help in 
the identification of bioactive components within whey proteins that could 
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specifically affect lipid metabolism. This introductory chapter will first briefly 
describe some of the key components and pathways involved in the regulation of 
energy balance and body weight, and then will provide an overview of the current 
understanding of how these systems are impacted upon by whey proteins.  
 
1.3 REGULATION OF ENERGY BALANCE 
Body weight is determined by a number of different components that fall under 
the three main categories of energy intake, energy expenditure and lipid 
metabolism (i.e. energy storage)(Hill et al, 2012). Mammals, including humans, 
obtain energy from food consumed daily, with this intake showing a rhythmic 
pattern, where food is ingested until fullness is achieved (satiation) and it will not 
resume for a period of time (satiety) to allow for the meal to be digested and its 
energy extracted. The energy consumed will replenish that spent on metabolic 
activity related to basal metabolic rate (BMR), physical activity and adaptive 
thermogenesis (Clarke & Henry, 2010). BMR is the amount of energy expended 
while at rest in the post-absorptive state to maintain the functions of vital organs, 
while adaptive thermogenesis is the regulated production of heat in response to 
environmental or dietary factors (Clarke & Henry, 2010; Lowell & Bachman, 2003). 
Positive energy balance occurs where energy consumed in excess of physical and 
metabolic requirements gets stored as triacylglycerol (TAG) in the adipose tissue. 
If the positive energy balance is sustained beyond the capacity of the adipose 
tissue to store it, then the progression of obesity development will occur, leading 
to the ectopic deposition of fat in other tissues (Fair & Montgomery, 2009).  
Regulation of energy balance is a complex physiological process that 
requires the interaction between multiple tissues, including the gastrointestinal 
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tract (GIT), liver, pancreas, adipose tissue, skeletal muscle and the brain (Lenard & 
Berthoud, 2008). When there is a positive or negative energy balance, which is 
reflected by nutrient abundance or deficit respectively, the tissues are able to 
communicate this information, via the production of hormones (peripheral 
tissues) or neuropeptides (brain), to achieve energy homeostasis (Lenard & 
Berthoud, 2008). Thus, tissues not only metabolise nutrients, but also act as 
sensors of their abundance.  
Lipid metabolism begins with the GI digestion of dietary proteins, fats and 
carbohydrates generating peptides, amino acids, fatty acids and glucose, which can 
then be absorbed through the intestine either passively or via active transport. 
Fatty acids that enter intestinal enterocytes are reconstituted as TAG and exported 
into the circulation within lipoproteins called chylomicrons (Mu & Hoy, 2004). The 
hydrolysis of circulating lipoprotein bound TAG, by lipoprotein lipase (LPL) at the 
outer cell surface, allows the uptake of fatty acids into tissues such as the skeletal 
muscle and adipose tissue, for the production of energy and/or storage as TAG, 
respectively (Voshol et al, 2009). Hydrolysis of adipose TAG stores generates free 
fatty acids (Robidoux et al, 2004), that when released into the circulation can be 
used as an energy source for other tissues (e.g. liver and muscle) (Frayn et al, 
2006). Glucose is primarily utilised for the production of energy in the skeletal 
muscle, while in the liver and adipose tissue it is metabolised via the glycolytic and 
lipogenic pathways to generate fatty acids (Kersten, 2001), which can then be 
either stored as TAG (mainly by adipose), exported back into the circulatory 
system in lipoproteins (mainly by liver), or oxidised in the mitochondria to 
generate ATP (mainly by liver & skeletal muscle)(Frayn et al, 2006; Redinger, 
2009).  
6 
 
  
The energy status in peripheral tissues is conveyed to the regions of the 
central nervous system (CNS) involved in the regulation of food intake and energy 
expenditure by hormones produced by the GIT, adipose tissue and pancreas. The 
main short-term satiety/satiation hormones are cholecystokinin (CCK), glucagon 
like protein 1 (GLP-1), peptide tyrosine-tyrosine (PYY) and ghrelin, and the long-
term energy status-related signals are insulin and leptin (Woods & D'Alessio, 
2008) (Table 1.1). The hindbrain and the hypothalamic nuclei, primarily the 
arcuate nucleus (ARC), are the principal brain sites for receiving and processing 
these peripheral signals (Berthoud et al, 2006; Lenard & Berthoud, 2008) (Figure 
1.1). These hormonal signals are transmitted via vagal afferent neuronal fibres 
projecting into the nucleus of solitary tract (NTS) in the hindbrain, or via crossing 
the blood brain barrier (BBB) and acting directly on their target sites located in the 
CNS (Figure 1.1 & 1.2)(Berthoud et al, 2006; Sam et al, 2012). Neural projections 
between the hindbrain and hypothalamus transmit and allow integration of the 
hormonal signals via changes in neuronal activity and expression of several 
important neuropeptides, including pro-opiomelanocortin (POMC), Neuropeptide 
Y (NPY) and Agouti-related protein (AgRP) (Woods & D'Alessio, 2008) (Figure 1.2). 
The resulting behavioural, autonomic and endocrine responses are mediated 
through catabolic and anabolic output pathways originating from the activation of 
second order neurons. Indeed, the sympathetic nervous system (SNS) regulates 
peripheral lipid metabolism through its direct innervation of peripheral tissues, 
resulting from the balance between catabolic and anabolic CNS outputs (Figure 
1.3) (Geerling et al, 2014). Thus, signals generated from multiples inputs are 
integrated centrally with the net result being changes to food intake, energy 
expenditure and/or lipid metabolism. 
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1.3.1 Short-term energy status-relaying signals 
The underlying molecular mechanisms by which satiation and satiety arise, 
involves an interaction between the GIT and the CNS mediated through GI-
produced hormones, namely ghrelin, CCK, GLP-1 and PYY. The hormone ghrelin, 
produced in the stomach, acts to initiate food intake (orexigenic effect) (Tschop et 
al, 2000; Wren et al, 2001a), and thus, its production increases prior to food 
ingestion. Once the food intake begins, ghrelin production decreases (Cummings et 
al, 2002). In contrast, CCK, GLP-1 and PYY are produced by the enteroendocrine 
cells in the intestinal epithelium in response to the availability of nutrients in the 
lumen (Nilaweera et al, 2010; Suominen et al, 1998) and inhibit food intake 
(anorexigenic) by inducing satiation and/or satiety (Neary & Batterham, 2009).  
 
1.3.1.1 Cholecystokinin (CCK) 
CCK is a peptide produced by mucosal enteroendocrine I cells in the proximal 
small intestine and is secreted in response to food ingestion (Figure 1.1). The 
principal stimulators of its release are dietary fats (fatty acids) and proteins 
(amino acids and peptides)(Woods & D'Alessio, 2008) (Table 1.1). Recent in vitro 
work using the enteroendocrine cell line STC-1 has demonstrated that protein 
hydrolysate stimulation of CCK gene expression and release is mediated through 
the activation of the G-protein coupled receptor, lysophosphatidic acid receptor 5 
(LPA5) (GPR92/93; see below) (Choi et al, 2007a; Choi et al, 2007b).  
 The ability of CCK to reduce food intake was first shown by Gibbs et al., 
(1973), where a significant reduction in subsequent meal size was found in rats 
following the peripheral administration of CCK prior to food consumption. Since 
then, the ability of CCK to suppress short-term energy intake in both lean and 
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Figure 1.1. Overview of peripheral signals that influence energy balance regulation. During 
food ingestion short-term satiety/satiation signals, namely cholecystokinin (CCK), Glucagon-like 
peptide 1 (GLP-1) and Peptide YY (PYY) are released from small intestine. These anorexigenic 
signals are transmitted from gastrointestinal tract (GIT) to the hindbrain via vagal afferent 
neuronal fibres, or they can cross the blood brain barrier (BBB) and act directly upon their target 
sites located in the hindbrain and the hypothalamus. In contrast, the levels of ghrelin produced in 
the stomach rise in anticipation of food intake, and it induces its orexigenic effects via both vagal 
nerve activity and by direct action in the hypothalamus. Signals related to the body’s long-term 
energy status, represented by the hormones leptin and insulin, are transported via the circulation 
to the brain, where they can cross the BBB and act upon hypothalamic (both) and hindbrain 
(leptin) areas involved in energy balance regulation. (Adapted from  Duca & Covasa (2012)). 
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obese humans has been documented (Kissileff et al, 1981; Lieverse et al, 1995; 
Lieverse et al, 1994). Moreover, CCK has also been shown to suppress gastric 
emptying and transit, which would contribute to its satiating effect (Grider, 1994). 
 CCK mediates its anorexic effects by activation of its CCK-1 receptors, which 
are abundantly expressed on peripheral vagal afferents fibres, and in the hindbrain 
and the hypothalamus (Neary & Batterham, 2009) (Figure 1.1). Genetic deletion or 
pharmacological antagonism of these CCK-1 receptors abolishes the anorexic effect 
of CCK (Kopin et al, 1999; Moran et al, 1998). Also, given that complete ablation of 
the NTS (Edwards et al, 1986) or vagotomy (Smith et al, 1981) abolishes the 
anorexic effects of CCK, the primary route by which these effects are mediated 
appears to be through vagal afferents nerve fibres projecting to the hindbrain 
(Ritter et al, 1999). Indeed, only peripheral, and not central, CCK-1 receptor 
antagonism impairs the ability of peripheral CCK to suppress food intake (Brenner 
& Ritter, 1998; Reidelberger et al, 2003).  
In summary, CCK influences food intake by reducing meal size (satiation) 
via signalling along the vagal afferent fibres from the GIT to the NTS in the 
hindbrain. 
 
1.3.1.2 Glucagon-like peptide 1 (GLP-1) 
GLP-1 is a peptide produced in L cells of the ileum and colon following enzymatic 
cleavage of proglucagon. It is secreted in response to nutrient ingestion and is 
rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPPIV) (Orskov et al, 
1993) (Figure 1.1). Administration of GLP-1, either centrally or peripherally, 
reduces food intake in several species (Donahey et al, 1998; Tang-Christensen et 
al, 1996; Turton et al, 1996), including humans (Verdich et al, 2001). In addition, 
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GLP-1 has a variety of other functions, including reducing gut motility and 
glucagon synthesis, as well as enhancing insulin release and pancreatic β-cell 
growth (Donnelly, 2012). 
GLP-1 receptors (GLP-1R) specifically mediate the anorexic effects of GLP-1, 
and are found in the hindbrain, hypothalamus, and on vagal afferents fibres 
projecting from the GIT to the NTS (Bullock et al, 1996) (Figure 1.1). Indeed, GLP-
1’s ability to suppress food intake is absent in rodents lacking GLP-1R (glp1r-/-) 
and in those peripherally treated with the GLP-1R antagonist, exendin 9-39 
(Baggio et al, 2004; Williams et al, 2009a). Furthermore, peripheral GLP-1R 
agonist, exendin-4, administration, both reduces the subsequent meal size 
(satiation) and increases the inter-meal interval (satiety) (Williams et al, 2009a). 
Evidence has shown that the anorexic response to gut-derived GLP-1 is abolished 
following either vagotomy or disruption of the hindbrain-hypothalamus neural 
projections (Abbott et al, 2005).  
In terms of energy expenditure, there are conflicting results for GLP-1. 
Firstly, infusion of GLP-1 in humans has both been reported to increase resting 
energy expenditure (Shalev et al, 1997) and contrastingly decrease diet-induced 
thermogenesis (Flint et al, 2000). Meanwhile, in rodents, central or peripheral 
GLP-1 injection dose-dependently increased oxygen consumption, heart rate and 
core body temperature (Osaka et al, 2005). In contrast, another study 
demonstrated a reduction in oxygen consumption (VO2) and fat oxidation in mice 
receiving peripheral or central administration of exendin-4 (Baggio et al., 2004). 
Thus, further studies are needed to determine the true nature of GLP-1’s impact on 
energy expenditure.  
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In summary, GLP-1 can reduce food intake (satiety and/or satiation), via 
signalling along the vagus nerve to the hindbrain and/or by crossing the BBB and 
directly acting on GLP-1R’s in the CNS. 
 
1.3.1.3 Peptide tyrosine-tyrosine (PYY) 
PYY is a peptide of the pancreatic polypeptide family which, like GLP-1, is 
synthesised and secreted from L-cells in the ileum and colon (Table 1.1). PYY is 
produced in proportion to the caloric intake, and is initially secreted as PYY1-36, 
before being readily cleaved into its main active form PYY3-36 by the enzyme DPPIV 
(Batterham et al, 2006). Peripheral PYY3-36 administration decreases food intake in 
several species (Adams et al, 2004; Moran et al, 2005; Scott et al, 2005) including 
humans (Batterham et al, 2003; Degen et al, 2005), and daily injections are 
accompanied by decreases in adiposity (Chelikani et al, 2006).  
PYY3-36 is a selective agonist for the NPY2-R receptor of the NPY-receptor 
family (NPY1-R – NPY5-R), and these NPY2-R are expressed on vagal afferent 
nerves and central locations, including the hypothalamus and hindbrain (Karra & 
Batterham, 2010)(Figure 1.1). The evidence that the NPY2-R, which is an auto-
inhibitory pre-synaptic receptor commonly found on NPY neurons, specifically 
mediates the anorexic effects of PYY has been shown by both antagonism and gene 
knockout of this receptor abolishing the anorexic effects of PYY (Batterham & 
Bloom, 2003; Scott et al, 2005). Moreover, direct ARC administration of PYY dose-
dependently suppresses energy intake, indicating PYY has the ability to directly 
influence central energy balance regulation (Batterham et al, 2002). Furthermore, 
peripheral injection of PYY decreases hypothalamic NPY expression and release, 
while increasing the expression of POMC (Batterham et al, 2002; Challis et al, 
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2003). Yet, despite evidence of direct central action, both vagotomy and disruption 
of the hindbrain-hypothalamus neural pathway have demonstrated the 
importance of the hindbrain to PYY’s anorexic effects (Abbott et al, 2005; Koda et 
al, 2005).  
In recent years, it has emerged that PYY also influences energy expenditure, 
with elevated circulating PYY levels being associated with increased post-prandial 
energy expenditure (Doucet et al, 2008). Contrastingly, another study found 
fasting PYY levels to be negatively correlated with resting metabolic rate (Guo et al, 
2006). However, transgenic mice over-expressing PYY have increased basal body 
temperatures, indicative of increased adaptive thermogenesis (Boey et al, 2008). 
Similarly, in humans peripheral injections of PYY stimulates lipolysis, enhancing 
thermogenesis and fat oxidation (Sloth et al, 2007). Furthermore, chronic PYY 
administration leads to a preference for fat as an energy substrate (Adams et al, 
2006; van den Hoek et al, 2007). Overall, the evidence suggests PYY can increase 
energy expenditure, but the mechanism involved remains to be elucidated. 
In summary, PYY reduces food intake (satiety and/or satiation), and 
potentially increases energy expenditure and fat oxidation, via signalling along the 
vagus nerve to the hindbrain and/or by directly acting on NPY2-R in the 
hypothalamus to inhibit NPY/AgRP neuronal activity. 
 
1.3.1.4 Ghrelin 
Ghrelin is a peptide formed from the cleavage of pre-proghrelin, and is released 
principally from gastric X/A-like cells in the stomach (Kojima et al, 1999) (Figure 
1.1). In rodents, peripheral injections of ghrelin cause a dose-dependent rise in 
food intake (Bagnasco et al, 2003; Chen et al, 2004; Toshinai et al, 2003; Wren et al, 
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2000), with chronic administration increasing weight gain and adiposity (Tschop 
et al, 2000; Wren et al, 2001b). This effect has been similarly demonstrated in both 
lean and obese humans (Druce et al, 2005; Wren et al, 2001a). Central ghrelin 
action resulting from intracerebroventricular (ICV) administration also increases 
food intake and suppresses energy expenditure, leading to an increase in adiposity 
when chronically administered (Kamegai et al, 2001; Tschop et al, 2000). 
Ghrelin acts via the growth hormone secretagogue receptor (GHS-R), which 
is expressed in the hypothalamus, hindbrain, and vagus afferent neurons 
(Faulconbridge et al, 2008; Shuto et al, 2001; Wren et al, 2001b) (Figure 1.1). In 
fact, the ability of ghrelin to induce food intake is absent in rodents lacking GHS-R 
(ghsr-/-) and in those treated with GHS-R antagonists (Asakawa et al, 2003; 
Zigman et al, 2005). Ghrelin signalling via the vagus nerve to the NTS seems to be 
important for ghrelin action (Date et al, 2002; Date et al, 2005), with both vagus 
nerve blockade or vagatomy abolishing ghrelin-induced feeding and NPY activity 
(Asakawa et al, 2001; Date et al, 2002; Faulconbridge et al, 2008). The central 
activation of GHS-R in the ARC stimulates the activity of NPY/AgRP neurons, 
promoting the release of orexigenic neuropeptides NPY and AgRP (Kamegai et al, 
2001; Wang et al, 2002). The importance of this interaction to ghrelin’s orexigenic 
ability can be seen following the treatment with NPY receptors antagonists 
(Shintani et al, 2001).  
Increasing evidence suggests ghrelin also impacts on energy expenditure. 
Firstly, transgenic down-regulation of GHS-R in the ARC increases energy 
expenditure related parameters in mice, including VO2, locomotor activity and BAT 
uncoupling protein 1 (UCP-1) expression (Mano-Otagiri et al, 2010). In fact, central 
ghrelin administration inhibits SNS activity in BAT, thereby suppressing 
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noradrenalin release and BAT thermogenesis (Mano-Otagiri et al, 2009; Yasuda et 
al, 2003). These finding support an inhibitory role for ghrelin in energy 
expenditure, and in particular adaptive thermogenesis.   
In summary, ghrelin stimulates food intake and weight/fat mass gains and 
suppresses thermogenesis via its signalling along the vagus nerve to the hindbrain 
and by directly acting on its receptors in the hypothalamus, leading to a 
stimulation of NPY/AgRP neuronal activity and neuropeptide release. 
 
1.3.2 Long-term energy status relaying signals 
These signals include hormones that are found in circulation in proportion to body 
fat content, and as such, provide a signal of the body’s energy stores to the CNS 
(Woods et al, 2004). These long-term acting signals regulate body weight by 
providing a negative feedback signal in response to changes in body fat mass, in 
order to facilitate appropriate changes in energy intake and energy expenditure 
(Morton et al, 2006). The two hormones that meet these criteria are leptin and 
insulin. Leptin is produced mainly by adipocytes and secreted into circulation in 
direct proportion to the levels of body fat, while insulin, which is secreted from 
pancreatic β-cells in response to elevated blood glucose levels, has fasting levels 
that are proportional to that of body fat (Woods & D'Alessio, 2008). 
 
1.3.2.1 Leptin 
Leptin is the product of the ob gene and is secreted from adipose tissue in 
proportion to the levels of body fat, with plasma levels rising and falling with 
weight gain and weight loss, respectively (Maffei et al, 1995) (Table 1.1). The 
administration of leptin, either centrally or peripherally, suppresses energy intake 
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and increases energy expenditure, and chronic administration leads to a reduction 
in body weight and to improvements in glucose tolerance (Halaas et al, 1997; 
Keung et al, 2011; Sivitz et al, 1997; Tang-Christensen et al, 1999). Genetic 
deficiency of the leptin gene (ob/ob) or its receptor (db/db) causes hyperphagia 
and decreases energy expenditure, resulting in severe obesity (Friedman & Halaas, 
1998). Exogenous administration of leptin reverses this phenotype in ob/ob mice 
(Mercer et al, 1997). In contrast, HFD-induced obesity leads to increased 
resistance to leptin action both centrally and peripherally (Lin et al, 2000).  
The leptin receptor has at least six isoforms, yet the expression of the long 
form Ob-Rb has been shown to be necessary and sufficient to mediate the actions of 
leptin on energy balance (Dam & Jockers, 2013). These receptors are highly 
expressed in the hypothalamus, including the ARC (Elmquist et al, 1998; Leshan et 
al, 2006), the hindbrain (Leshan et al, 2006; Williams et al, 2009b) and on vagal 
afferent fibres (Dockray, 2013). Leptin mediates its effects on energy balance by 
direct action on these receptors within the hypothalamus (Faouzi et al, 2007) and 
the hindbrain (Kanoski et al, 2012; Scott et al, 2011) (Figure 1.1). 
 Leptin action also impacts on short-term meal-related energy intake 
through interactions with satiety/satiation signals (Morton et al, 2005; Williams et 
al, 2006; Williams et al, 2009b; Williams et al, 2008). Leptin administration to the 
hindbrain at either the 4th ventricle or directly into the dorsal vagal complex, at 
doses which do not themselves influence food intake, significantly augments the 
anorexic response to IP injection of CCK (Williams et al, 2009b). Notably, the 
absence of functional leptin receptors in either the hypothalamus (Morton et al, 
2005) or hindbrain (Hayes et al, 2010) blunts the response to CCK, while 
peripheral CCK-1 receptor antagonism abolishes the anorexic response to 
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hindbrain delivery of leptin (Williams et al, 2009b). Leptin similarly influences the 
anorexic response to GLP-1, with leptin pre-treatment significantly enhancing the 
anorexic effect of both GLP-1 and exendin-4, while leptin receptor deficiency in the 
NTS strongly attenuated this response (Williams et al, 2006).  
In summary, leptin suppresses food intake and increases energy 
expenditure by directly acting upon its receptors within the ARC of the 
hypothalamus. Leptin action in the hindbrain also impacts on short-term energy 
intake by influencing the actions of satiety/satiation signals, CCK and GLP-1. 
 
1.3.2.2 Insulin 
Insulin is synthesised in β-cells of the pancreas in response to increases in blood 
glucose, although, as indicated above, fasting plasma levels are directly 
proportional to the adipose tissue mass (Bagdade et al, 1967) (Table 1.1). In 
addition, the incretin hormones GLP-1 and glucose-dependent insulinotropic 
peptide (GIP) both enhance glucose-dependent insulin release, as well pancreatic 
β-cell function (Garber, 2011). The central effects of insulin are also anorexigenic 
like leptin, with dose-dependent decreases in food intake and body weight 
following ICV administration of insulin (Chavez et al, 1995; McGowan et al, 1990; 
Sipols et al, 1995; Woods et al, 1979). Furthermore, the antagonism of insulin 
signalling via central administration of antibodies towards insulin, has been found 
to increase food intake and body weight (McGowan et al, 1992).  
The central effects of insulin are mediated via direct activation of the insulin 
receptor (IR) and these are found to be extensively expressed in the CNS and 
particularly co-localised with POMC neurons within the ARC (Benoit et al, 2002; 
Havrankova et al, 1978) (Figure 1.1). Notably, like leptin, DIO induces resistance to 
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insulin action, thereby blunting the anorexic response to central insulin infusion 
(Clegg et al, 2005; Posey et al, 2009). In summary, insulin suppresses food intake 
by directly acting on its receptors within the hypothalamus. 
 
1.3.3 Central regulation of energy balance 
The ARC located in the mediobasal hypothalamus serves as the primary site for 
processing energy balance-related signals (Berthoud et al, 2006; Lenard & 
Berthoud, 2008). As discussed above, hormonal signals can either cross the 
relatively leaky BBB at the ARC (hypothalamus) or area postrema (hindbrain), and 
act directly upon their target sites, or they can relay their signal to the ARC via the 
hindbrain, following transduction along the vagal nerve from the GIT to the NTS 
(Berthoud et al, 2006; Cummings & Overduin, 2007). These signals are then 
integrated in the ARC and other hypothalamic nuclei to influence neuronal activity 
of two main neuronal populations, POMC and NPY/AgRP, that have opposing 
effects on energy balance regulation; POMC neurons propagate the catabolic 
response from peripheral signal inputs, while NPY/AgRP neurons facilitate the 
anabolic response (Woods & D'Alessio, 2008). 
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Table 1.1 Overview of peripheral hormones known to influence energy balance (adapted from Neary & Batterham (2009)).    
Hormone Site of production 
Factors influencing 
hormone release 
 
(arrows denote effect 
on hormone release) 
Hormone receptor 
Location of 
action 
Effects on energy balance 
Cholecystokinin 
(CCK) 
I cells  
(proximal intestine) 
↑ Fat & protein intake 
↑ Bariatric surgery 
Cholecystokinin 1 
receptor  
(CCK-1R) 
Vagus nerve 
Hindbrain 
↑ Satiation 
Glucagon-like 
peptide 1 (GLP-1) 
L cells 
(ileum/colon) 
↑ Food intake 
↑ Bariatric surgery 
↓ Calorie restriction 
Glucagon-like peptide 
1 receptor 
(GLP-1R) 
Vagus nerve 
Hindbrain 
Hypothalamus 
↑ Satiety and/or satiation 
↑ Insulin release 
↓ Tissue lipid storage 
Peptide YY (PYY) L cells 
(ileum/colon) 
↑ Food intake 
↑ Bariatric surgery 
↑ Exercise 
Neuropeptide Y2 
receptor  
(NPY2-R) 
Vagus nerve 
Hindbrain 
Hypothalamus 
↑ Satiety and/or Satiation 
↑ Energy expenditure 
   Alters fuel partitioning 
Ghrelin 
X/A- like cells 
(stomach) 
↓ Food intake 
↓ Bariatric surgery 
↑ Calorie restriction 
Growth hormone 
secretagogue receptor  
(GHS-R) 
Vagus nerve 
Hindbrain 
Hypothalamus 
↑ Food intake 
↓ Energy expenditure 
↑ Tissue lipid storage  
   Alters fuel partitioning 
Leptin 
Adipocytes 
(adipose tissue) 
Levels of body fat 
↑ Body fat gain 
↓ Body fat loss 
Leptin 
Receptor 
(ObR) 
Hindbrain 
Hypothalamus 
↓ Food intake 
↑ Energy expenditure 
↓ Tissue lipid storage 
Insulin 
β-cells 
(pancreas) 
 
Levels of blood glucose 
↑ Glucose increase 
↓ Glucose decrease 
Insulin receptor 
(IR) 
Hypothalamus 
↓ Food intake 
↑ Energy expenditure 
↑ Tissue lipid storage 
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1.3.3.1 Melanocortin pathway 
The POMC protein serves as the precursor to all melanocortin peptides, including 
the main mediator of the catabolic response, α-melanocortin stimulating hormone 
(α-MSH) (Pritchard et al, 2002). A deficiency in POMC gene expression induces 
hyperphagia and suppresses energy expenditure, resulting in severe obesity 
(Yaswen et al, 1999). In contrast, ICV administration of α-MSH to rodents 
suppresses food intake (McMinn et al, 2000; Petervari et al, 2009; Vergoni et al, 
1998), and increases physical activity, oxygen consumption and BAT 
thermogenesis (Semjonous et al, 2009; Yasuda et al, 2004).  
α-MSH acts via G-protein coupled melanocortin receptors 3 and 4 
(MC3/4R), which are highly expressed within the hypothalamus (Shimizu et al, 
2007), as well as being expressed within the NTS of the hindbrain (Li et al, 2007; 
Mountjoy et al, 1994; Voss-Andreae et al, 2007). Central administration of the non-
selective melanocortin receptor agonist, melanotan II (MTII), suppresses food 
intake and increases oxygen consumption in rats (Skibicka & Grill, 2008; Skibicka 
& Grill, 2009), while central treatment with non-selective antagonists to 
melanocortin receptors, such as AgRP or SHU-9119, has the opposite effect (Fan et 
al, 1997). Notably, the effect of MTII is abolished in MC4R (mc4r-/-), but not MC3R 
(mc3r-/-), deficient mice (Chen et al, 2000a; Chen et al, 2000b; Marsh et al, 1999), 
thus suggesting MC4R is the primary regulator of the effects of α-MSH on food 
intake and energy expenditure.  
 
1.3.3.2 Neuropeptide Y/ Agouti-related protein pathway 
In the ARC, two orexigenic neuropeptides NPY and AgRP are expressed and 
released from a population of neurons distinct from those expressing POMC (Elias 
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et al, 1999). Central infusion of NPY increases food intake and reduces energy 
expenditure, with chronic administration leading to the development of obesity via 
sustained hyperphagia (Clark et al, 1984; Hwa et al, 1999; Stanley et al, 1986; 
Stanley & Leibowitz, 1985; Zarjevski et al, 1993). Notably, the release of the γ-
aminobutyric acid (GABA) from NPY/AgRP neurons following their activation also 
inhibits POMC neuronal activity (Cowley et al, 2001).  
Six NPY receptors (NPY1-6-R) have been identified, of which NPY1-R and 
NPY5-R principally mediate its influence on energy balance. Administering rats 
with selective agonists for NPY1-R or NPY5-R receptors has been shown to induce 
hyperphagia (Della-Zuana et al, 2004; Fekete et al, 2002; Jewett et al, 1993; Kalra 
et al, 1991; Mullins et al, 2001), with chronic administration in mice significantly 
increasing bodyweight and adiposity (MacNeil, 2007; Mashiko et al, 2003). 
However, in rodent models with either NPY1-R or NPY5-R receptor gene knockout, 
there is no significant reduction in food intake (Lin et al, 2004), suggesting a level 
of redundancy in the system of energy balance regulation. 
Similar orexigenic effects as that described for NPY are also seen with acute 
and chronic central administration of AgRP (Hagan et al, 2000; Small et al, 2001; 
Small et al, 2003). However, the orexigenic effects of AgRP are mediated by 
inhibition of melanocortin signalling via an antagonism of MC3/4R (Ollmann et al, 
1997). Indeed, co-administration of AgRP with MTII completely abolished the 
anorexic effects of this non-selective MC3/4R agonist (Hagan et al, 2000). 
Interestingly, a recent study showed by triple knockout of genes for NPY, AgRP and 
the associated neurotransmitter GABA, which is released by NPY/AgRP neurons 
and induces a potent orexigenic response, that the orexigenic effect of NPY/AgRP 
neuronal activation was completely abolished, while this response was unaffected 
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by any single gene knockout (Krashes et al, 2013). This suggests these three 
components are responsible for the orexigenic effects of NPY/AgRP neuronal 
activation. 
 
1.3.3.3 Central integration of peripheral signals 
In the ARC, leptin and insulin receptors are expressed within NPY/AgRP and POMC 
neurons (Benoit et al, 2002; Cheung et al, 1997; Mercer et al, 1996; Morton et al, 
2006; Wilson et al, 1999). Notably evidence does suggest a degree of segregation of 
these two receptors, and thus their actions, into distinct POMC subpopulations 
(Williams et al, 2010). Activation of hypothalamic ARC leptin receptors inhibits 
NPY/AgRP neuronal activity, significantly decreasing the mRNA expression and 
release of orexigenic neuropeptides NPY and AgRP (Broberger et al, 1998; Elias et 
al, 1999; Morrison et al, 2005). Conversely, leptin activates POMC neurons, 
increasing the expression of POMC, and thereby the production of ɑ-MSH (Elias et 
al, 1999; Elias et al, 1998; Vrang et al, 2002).  
In a similar way to leptin, insulin administration into the 3rd ventricle has 
been shown to significantly increase ARC expression of POMC (Benoit et al, 2002; 
Fekete et al, 2006), while decreasing NPY expression (Fekete et al, 2006; Sato et al, 
2005; Schwartz et al, 1991), thereby causing the associated reduction in energy 
intake. Evidence demonstrates that suppressing melanocortin signalling via 
MC3/4R antagonism, blocks the catabolic actions of both insulin and leptin (Benoit 
et al, 2002; Choi et al, 2003). As with central leptin receptor deficiency (i.e. db/db 
mice), complete insulin receptor deficiency in the CNS leads to hyperphagia and 
the development of obesity (Bruning et al, 2000). Interestingly however, specific 
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insulin receptor ablation in both POMC and AgRP neurons does not result in 
pronounced hyperphagia or obesity (Konner et al, 2007).  
In addition to long-term energy status-relaying signals, short-term 
satiety/satiation signals can also act on hypothalamic neuronal populations 
important in energy balance regulation. Indeed, direct activation of central GLP-1R 
in fasting mice was shown to increase hypothalamic POMC expression, while 
suppressing fasting induced-increases in AgRP and NPY expression (Seo et al, 
2008). In contrast to GLP-1, peripheral PYY administration has been shown to act 
centrally to suppress food intake by binding to NPY2-R’s and suppressing 
hypothalamic NPY/AgRP neural activity and neuropeptide expression(Batterham 
et al, 2002). In fact, the anorexic effect of PYY does not appear to involve the 
melanocortin signalling pathway as it is still evident in both POMC and MC3/4R 
knock-out mice. In contrast, ghrelin activation of central GHS-R has been shown to 
stimulate NPY/AgRP neural activity and NPY and AgRP neuropeptide expression 
(Kamegai et al, 2001). This is associated with a simultaneous inhibition of POMC 
neuronal activity, which is a product of the latter effect on NPY/AgRP neural 
activity rather than a direct inhibitory effect (Cowley et al, 2003). Finally, the food 
intake suppressive effects of CCK have been shown to be influenced by 
melanocortin signalling in the NTS, with 4th, but not 3rd ventricle SHU-9119 
treatment preventing the effects of CCK action (Blevins et al, 2009).  
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Figure 1.2. Central effects of peripheral hormones on neuronal activity in the arcuate 
nucleus (ARC) of the hypothalamus. Leptin, insulin and GLP-1 stimulate POMC neuronal 
activity, while leptin, insulin and PYY inhibit NPY/AgRP neuronal action, which promotes the 
activation of melanocortin signalling via MC3/4R. This initiates a catabolic response, which leads 
to a reduction in food intake and an increase in energy expenditure. In contrast, stimulation of 
NPY/AgRP neurons by ghrelin promotes an anabolic response via direct NPY effects, as well as 
indirect effects via AgRP inhibition of MC3/4R signalling, resulting in an increase in food intake 
and a reduction in energy expenditure.  
 
AgRP, agouti-related protein; GHS-R, growth hormone secretagogue receptor; GLP-1, glucagon-
like peptide 1; GLP-1R, GLP-1 receptor; IR, insulin receptor; MC3/4R,  melanocortin 3/4 
receptors; ObR, leptin receptor; NPY, neuropeptide Y; NPY2-R, NPY 2 receptor; POMC, pro-
opiomelanocortin; PYY, Peptide YY; BBB, Blood brain barrier. 
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1.4 REGULATION OF LIPID AND GLUCOSE METABOLISM 
1.4.1 Introduction 
This section provides background information on lipid metabolism in the intestine, 
liver and adipose tissue, with the view of providing an overview of the regulators 
of this physiological process. Firstly, due to the intimate involvement of insulin 
signalling in glucose homeostasis, a brief overview of this interaction and its 
influence on tissue lipid metabolism is provided, before providing a more detailed 
background in subsequent sections.   
 
1.4.2 Insulin signalling and glucose metabolism 
The classically defined function of insulin is to regulate glucose homeostasis by 
acting on key energy balance-related tissues, such as the skeletal muscle, liver, and 
adipose tissue. This is achieved by both direct action on these tissues and indirect 
action via the CNS (Marino et al, 2011; Saltiel & Kahn, 2001). In the former case, 
insulin binds to its receptor (IR), located at the cell membrane, phosphorylating 
nearby insulin receptor substrate (IRS) proteins, which in turn recruit and activate 
the phosphatidylinositol 3-Kinase (PI3K) pathway, ultimately resulting in a 
stimulation of its downstream targets, including protein kinase B (PKB/Akt) and 
protein kinase C (PKC) (Watson et al, 2004). The activation of the PI3K pathway 
facilitates the uptake of glucose into adipose and skeletal muscle cells by 
increasing the translocation of the glucose transporter 4 (GLUT4) to the cell 
membrane (Clarke et al, 1994). Upon entry into adipocytes, glucose can be 
converted by glycolysis to a substrate for insulin-induced de novo lipogenesis 
(Large et al, 2004). In the skeletal muscle, insulin promotes the disposal of excess 
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glucose by promoting its conversion into glycogen, which can then be utilized in 
times of energy deficit (Jensen & Lai, 2009). In contrast, in the liver, insulin does 
not facilitate glucose uptake, but instead regulates production and release of 
glucose by the inhibition of hepatic gluconeogenesis (Michael et al, 2000). Central 
insulin signaling, acting through the SNS, also suppresses hepatic glucose 
production (Obici et al, 2002), as well as stimulating muscle glycogen synthesis 
(Perrin et al, 2004). Lastly, as in adipose tissue, insulin also stimulates the 
conversion of glucose to TAG in the liver by prompting glycolysis and lipogenesis 
(Saltiel & Kahn, 2001).  
 
1.4.3 Intestinal lipid metabolism 
Dietary lipids in the intestinal lumen are digested by pancreatic lipases in order to 
release free fatty acids for subsequent uptake (Mu & Hoy, 2004). The uptake of 
these fatty acids into enterocytes occurs via both passive diffusion and transport 
protein mediated mechanisms (Mansbach & Gorelick, 2007). The main transport 
proteins involved are cluster of differentiation 36 (CD36) and fatty acid transport 
protein 4 (FATP4) (Drover et al, 2005; Nassir et al, 2007; Stahl et al, 1999). Once 
inside the enterocytes, the fatty acids are used to re-synthesis TAG for inclusion 
into lipoproteins called chylomicrons. This process begins in the endoplasmic 
reticulum (ER), where fatty acids are used by monoacylglycerol acyltranferase 
(MGAT) and diacylglycerol acyltransferase (DGAT) sequentially to re-synthesise 
TAG for inclusion into pre-chylomicron particles (Mansbach & Gorelick, 2007). 
These particles are further modified in the Golgi apparatus before being released 
into the lymph and eventually finding their way into the circulation via the thoracic 
duct (Black, 2007; Pan & Hussain, 2012). The chylomicrons are then transported 
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via the circulatory system and hydrolysed by tissue specific lipoprotein lipase 
(LPL) at the cell surface to release free fatty acids, which can then be utilised by 
tissues such as the skeletal muscle and adipose tissue, for energy production and 
storage, respectively (Voshol et al, 2009).  
 
1.4.4 Hepatic lipid metabolism  
The liver is involved in lipid production (lipogenesis & TAG synthesis), lipid export 
(lipoprotein production), and lipid-derived energy production (β-oxidation) 
(Nguyen et al, 2008). Fatty acids taken up into the liver from the circulation are 
derived from chylomicron remnants and the non-esterified fatty acid (NEFA) pool. 
The latter is the primary source of fatty acids for the liver and it is predominately 
made up of fatty acids released from the adipose tissue following TAG storage 
hydrolysis (Tamura & Shimomura, 2005). Like in the intestine, the process of fatty 
acid uptake occurs in the liver by both membrane protein mediated transport 
(FATP’s and CD36) and by passive mechanisms (Glatz et al, 2010). In addition to 
external sources, hepatic fatty acids can also be derived via endogenous 
production which is termed de novo lipogenesis. This process involves the 
synthesis of fatty acids from precursor substrates by the sequential conversion of 
acetyl-CoA to malonyl-CoA and then fatty acids via lipogenic enzymes acetyl CoA 
carboxylase (ACC) and fatty acid synthase (FASN), respectively (Large et al, 2004; 
Nguyen et al, 2008).  
Insulin and glucose are key regulators of hepatic lipogenesis by activation of 
sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate 
responsive element-binding protein (ChREBP) transcription factors, respectively 
(Xu et al, 2013b). These, along with the liver X receptor (LXR), induce the 
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expression of genes involved in glucose uptake, glycolysis and lipogenesis within 
the liver, including glucose transporter 2 (GLUT2), pyruvate kinase, ACC, FASN, 
stearoyl-CoA desaturase (SCD-1) and glycerol phosphate acyltransferase (GPAT) 
(Iizuka & Horikawa, 2008; Jump, 2011). Fatty acids derived from direct plasma 
uptake and/or endogenous production can then be utilised either to synthesise 
TAG for storage or for export within very low density lipoprotein (VLDL), or to 
produce energy via β-oxidation (Nguyen et al, 2008). β-oxidation of fatty acids 
generates energy in the form of ATP for crucial cellular processes, and this process 
is under the influence of the transcription factor peroxisome proliferator-activated 
receptor (PPAR)-α, given its ability to regulate the expression of key β-oxidation 
associated enzymes (Reddy et al, 1986; Reddy & Hashimoto, 2001), namely 
carnitine palmitoyltransferase 1a (CPT1a), which is the rate limiting enzyme in the 
process and regulates long-chain fatty acid entry into mitochondria (Kerner & 
Hoppel, 2000; Reddy & Hashimoto, 2001). Notably, CPT1 activity is inhibited by 
the product of ACC enzyme activity, malonyl-CoA, thus highlighting the reciprocal 
regulation of lipogenesis and β-oxidation (Kerner & Hoppel, 2000).  
 
1.4.5 Adipocyte lipid metabolism 
The adipose tissue sources fatty acids primarily from TAG-rich lipoproteins (i.e. 
VLDL and chylomicrons), and albumin-bound fatty acids in the plasma (Voshol et 
al, 2009). The actions of cell surface LPL on circulating lipoproteins liberates TAG 
and further hydrolyses it to release fatty acids, which are then available for 
subsequent uptake into the cell (Weinstock et al, 1997). Insulin is a primary 
regulator of LPL function, up-regulating both its expression and activity (Goldberg 
et al, 2009; Semenkovich et al, 1989). The uptake of fatty acids into adipocytes is 
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primarily mediated by specific membrane transporters, namely FATP1, FATP4 and 
CD36 (Goldberg et al, 2009; Lobo et al, 2007). In addition to facilitating fatty acid 
uptake, insulin also regulates the uptake of glucose into adipocytes by increasing 
the expression and translocation of GLUT4 to the cell surface (Saltiel & Kahn, 
2001). Upon transport into the cell, glucose can be converted by glycolysis to 
acetyl-CoA and then serve as a substrate for de novo lipogenesis (Large et al, 2004). 
Moreover, as in the liver, insulin-induced SREBP-1c actively regulates lipogenesis 
in adipocytes by promoting lipogenic enzymes, such as ACC and FASN  (Carobbio et 
al, 2013). Fatty acids, both from extracellular sources and de novo lipogenesis, are 
either utilised for the production and storage of TAG via successive esterification 
steps (Large et al, 2004) or are oxidised via β–oxidation to generate energy.  
In times of energy shortage, such as during periods of sustained physical 
activity, hydrolysis of adipose TAG stores, termed lipolysis, releases fatty acids into 
circulation for utilisation as an energy substrate in other tissues (Horowitz & Klein, 
2000). This is initiated by the activation of the SNS innervating the adipose tissue 
(Thompson et al, 2010). In this instance the release of catecholamine’s at the nerve 
axon terminals activates β-adrenergic receptors located at the cell surface (Frayn 
et al, 2003; Lafontan & Berlan, 1993). Three subtypes of β-adrenergic receptor (β1-
AR, β2-AR and β3-AR) are found in white adipose tissue (WAT); β3AR is the major 
lipolysis mediator in rodents, while in humans its β1-AR and β2-AR (Lafontan & 
Berlan, 1993). Specifically, binding of catecholamine’s to β-AR receptors in 
adipocytes leads to the phosphorylation of both perilipin and hormone sensitive 
lipase (HSL)(Belfrage et al, 1980; Clifford et al, 2000). Upon phosphorylation, 
perilipin dissociates from the surface of TAG-rich lipid droplets (Clifford et al, 
2000), allowing HSL and adipose triglyceride lipase (ATGL) access, in order to 
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facilitate their hydrolysis (Lass et al, 2006; Miyoshi et al, 2007; Miyoshi et al, 
2006). The main physiological inhibitor of adipose tissue lipolysis is insulin and it 
inhibits lipolysis by both reducing cAMP levels and dephosphorylating HSL 
(Carmen & Victor, 2006; Langin, 2006; Nilsson et al, 1980).  
In addition to the effects noted above, insulin is also  a potent stimulator of 
adipogenesis (Fajas et al, 1999), the process by which pre-adipocytes are 
differentiated into their mature fat cells. The key transcription factors controlling 
differentiation and maturation of adipocytes include PPAR-γ, CCAAT/enhancer-
binding proteins (C/EBPs α, β & δ) and SREBP-1c (White & Stephens, 2010). 
PPARγ is considered the master regulator of adipogenesis, as its expression is not 
only sufficient but necessary to induce adipocyte differentiation (Rosen & 
MacDougald, 2006). Indeed, insulin’s ability to promote adipocyte differentiation 
occurs by up-regulation of PPARγ and SREBP-1 activity, with the latter further 
augmenting PPARγ expression (Fajas et al, 1999).  
 
1.4.6 Lysophosphatidic acid 
LPA is small bioactive glycerophospholipid that functions as an extracellular 
signalling molecule (Choi et al, 2010). Through binding to G-protein coupled 
receptors (GPCRs), it regulates a wide range of biological responses including 
mitogenesis (Fang et al, 2002), cell survival (Weiner & Chun, 1999), cell migration 
(Panetti et al, 2001), platelet aggregation (Rother et al, 2003) and hormone 
secretion (Choi et al, 2007b). There are currently six LPA receptors (LPA1-6), with 
more awaiting validation (Choi et al, 2010).  
LPA is produced by the hydrolysis of phospholipids by the enzyme 
autotaxin (ATX) (Ferry et al, 2003) and is found in serum and in other biological 
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fluids, including that associated with the adipose tissue (Valet et al, 1998). Indeed, 
LPA is endogenously produced in the extracellular fluid of adipose tissue (Ferry et 
al, 2003; Valet et al, 1998) and has been shown to increase the proliferation of pre-
adipocytes (Pages et al, 2001; Valet et al, 1998). Furthermore, a study by Simon et 
al, (2005) evaluated the effects of LPA treatment on differentiating 3T3F442A 
adipocytes and found that it significantly down-regulates the expression of PPARγ. 
The authors suggested the involvement of LPA1,  with knockout mice for LPA1 being 
found to have 24% increased lipid content in their adipocytes, while pre-
adipocytes isolated from these transgenic mice did not show an anti-adipogenic 
response to LPA stimulation (Simon et al, 2005). Thus, the data demonstrates that 
LPA action, possibly though LPA1, can both induce pre-adipocyte proliferation 
while suppressing their differentiation into mature lipid laden adipocytes. 
 Another LPA receptor, LPA5 (GPR93 or 92) is widely expressed in murine 
tissues (Choi et al, 2010), and as mentioned previously, its activation by protein 
hydrolysate has been shown to stimulate CCK gene expression and peptide release 
in the STC-1 enteroendocrine cell line (Choi et al, 2007b). This raises the 
possibility that this receptor may mediate dietary proteins effects on other tissues, 
including adipose tissue. Interestingly, the whey associated protein, bovine serum 
albumin (BSA) has been shown to activate LPA5 in enterocytes (Choi et al, 2007a) 
and suppress adipogenesis in 3T3-L1 adipocytes (Schlesinger et al, 2006). It 
remains to be determined whether whey proteins could directly activate LPA5 in 
the adipose tissue and thereby affect lipid metabolism in the cell. 
 
1.4.7 Central control of peripheral lipid metabolism 
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The SNS outflow from the CNS has been shown to play an important role in the 
regulation of peripheral lipid metabolism, as evidenced by direct SNS innervation 
of both the liver and WAT causing a change to their lipid metabolism (Geerling et 
al, 2014). This SNS control of lipid metabolism appears to be regulated by the 
balance between catabolic and anabolic outputs from hypothalamic POMC and NPY 
neuronal signalling; therefore, central effects of ghrelin, leptin, insulin and GLP-1 
on peripheral lipid metabolism are thought to be mediated through their actions 
on these two neuronal populations (Geerling et al, 2014; Nogueiras et al, 2010). 
 The melanocortin system in the hypothalamus is a key component of CNS 
regulation of peripheral lipid metabolism and nutrient partitioning (Nogueiras et 
al, 2009; Nogueiras et al, 2007; Shrestha et al, 2010) (Figure 1.3). Indeed, 
melanocortin-mediated SNS outflow to WAT directly influences adipocyte 
metabolism independently of energy intake, with central administration of 
melanocortin receptor agonist, MTII, reducing body fat levels and increasing 
adipose tissue lipolytic gene expression, while blockade of this signalling pathway, 
using SHU9119, increases fat accumulation in association with augmented 
expression of lipogenic enzymes (Nogueiras et al, 2007; Raposinho et al, 2003; 
Shrestha et al, 2010). Furthermore, these effects on adipocyte metabolism have 
been shown to be absent in mice lacking all three forms of β-adrenergic receptors 
in the adipose tissue (Nogueiras et al, 2007). In addition, data also suggests 
melanocortin signalling regulates hepatic lipid metabolism, with central MTII 
administration reducing both liver TAG and hepatic lipogenic gene expression in 
both rats and diabetic mice (Leckstrom et al, 2011; Wiedmer et al, 2012).   
 Central infusions of NPY into rats pair fed to saline treated controls, results 
in significant increases in adiposity, that are thus independent of its effect on food 
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intake (Zarjevski et al, 1993; Zarjevski et al, 1994) (Figure 1.3). Accompanying 
these effects, the gene expressions of ACC, LPL and GLUT4 were up-regulated in 
the adipose tissue, while ACC expression was also increased in the liver. Moreover, 
the administration of NPY has also been shown to inhibit melanocortin induced 
lipolysis (Bradley et al, 2005; Martinez et al, 2000). Correspondingly, antagonism 
of the NPY signalling or knockdown of its expression in the dorsomedial nucleus, 
increases lipolysis and lipolytic gene expression, as well reduces body fat (Chao et 
al, 2011; Margareto et al, 2000). ICV administration of NPY has also been shown to 
enhance TAG synthesis in the liver, augmenting VLDL production and release even 
under hyperinsulinemic conditions (Stafford et al, 2008; van den Hoek et al, 2004). 
Denervation of the sympathetic nerve to the liver has been shown to block most of 
the effects of NPY, supporting SNS involvement in NPY action on hepatic lipid 
metabolism (Bruinstroop et al, 2012).  
Central leptin and insulin show contrasting effects on peripheral lipid 
metabolism. Central leptin action suppresses lipogenesis-related gene expression 
and TAG content in both the adipose and liver, whilst also increasing lipolytic gene 
expression in the adipose (Buettner et al, 2008; Gallardo et al, 2007; Shen et al, 
2007; Tajima et al, 2005) (Figure 1.3). In contrast, insulin causes an anabolic effect 
on peripheral lipid metabolism by specifically suppressing SNS outflow to the 
adipose tissue, suppressing lipolysis and increasing lipogenesis (Koch et al, 2008; 
Scherer & Buettner, 2011; Scherer et al, 2011). The involvement of the 
melanocortin signalling in leptin action is supported by evidence that pre-
treatment with the melanocortin receptor antagonist SHU119 completely 
abolishes leptin induced suppression of adipose tissue lipogenesis (Choi et al, 
2003; Lin et al, 2003) (Figure 1.3). In addition to its effect on adipose tissue 
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metabolism, hypothalamic leptin action has also been shown to suppress hepatic 
lipogenesis and TAG accumulation via a SNS route (Warne et al, 2011).  
 Given the ability of ghrelin to stimulate NPY/AgRP neuronal activity it is no 
surprise that central ghrelin administration promotes the storage of lipid in the 
adipose tissue independently of its effects on food intake, by up-regulating the 
expression of lipogenic genes (Andrews et al, 2010; Sangiao-Alvarellos et al, 2009; 
Theander-Carrillo et al, 2006) (Figure 1.3). These studies also showed a 
corresponding suppression of adipose tissue β-oxidation via a down-regulation of 
CPT1b expression. The ability of ghrelin to induce body weight gain and alter lipid 
metabolism-related gene expression is lost in mice lacking β-adrenergic receptors 
in the adipose tissue, thus supporting an SNS pathway involvement (Theander-
Carrillo et al, 2006). Similarly, this study also showed that ghrelin gene knockout 
(Ghrl-/-) in mice results in an opposite effect on lipogenic gene expression to that 
induced by central ghrelin treatment.   
Centrally administrated GLP-1 significantly decreases adipocyte lipogenesis 
and lipid storage independently of its effect on food intake (Nogueiras et al, 2009) 
(Figure 1.3). This corresponded to the down-regulation of key lipogenic enzymes, 
FASN, ACC and SCD-1 in association with increased SNS activity at the adipose 
tissue. Furthermore, mice lacking β-adrenergic receptors did not display these 
responses to centrally administered GLP-1. In addition, central GLP-1 action has 
also been shown to influence hepatic lipid metabolism, resulting in a reduction in 
liver TAG accumulation and a suppression of hepatic lipogenic enzyme expression 
(Nogueiras et al, 2009; Panjwani et al, 2013). 
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Figure 1.3. Model of central nervous system (CNS) effects on peripheral tissue lipid 
metabolism. Leptin and GLP-1 activate POMC neurons, while leptin inhibits NPY/AgRP neuronal 
activity, promoting melanocortin signalling via MC3/4R activation. This initiates a catabolic 
response on peripheral lipid metabolism via the sympathetic nervous system (SNS), which results 
in a reduction in lipid storage. In contrast, stimulation of NPY/AgRP neurons by ghrelin, promotes 
an anabolic response on peripheral lipid metabolism via the direct effects of NPY on SNS outflow, 
as well as the indirect effects of AgRP inhibition of MC3/4R, which result in increased lipid storage. 
Green arrows (  ,  ) denote the effects on tissue lipid metabolism in response to central 
melanocortin signalling via the SNS, whereas red arrows (   ,   ) denote the tissue lipid metabolism 
effects of central NPY/AgRP neuronal activation. (Adapted from (Nogueiras et al, 2010). 
 
AgRP, agouti-related protein; GLP-1, glucagon-like peptide 1;  MC3/4R, melanocortin 3/4 
receptors; NPY, neuropeptide Y; POMC, pro-opiomelanocortin; VLDL, very low density lipoprotein; 
TAG, triacylglycerol. 
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1.5 HIGH FAT DIET DYSREGUALTION OF ENERGY BALANCE  
1.5.1 Lipotoxicity 
Under normal physiological conditions the adipose tissue is able to store excess 
energy as TAG, while high fat consumption increases the amount of energy that 
needs to be stored in this tissue (Slawik & Vidal-Puig, 2007). To accompany this 
increased availability of TAG, adipocytes first undergo hypertrophy (enlargement) 
to store the excess lipid, followed by hyperplasia (increase in cell number) (Cusi, 
2012). If the latter changes are not able to reduce plasma TAG levels, there is then 
an ectopic deposition of the excess energy as fat in other tissues such as the 
skeletal muscle and liver (Despres et al, 2008). In fact, HFD-induced increases in 
plasma NEFA results in increased liver and skeletal muscle lipid accumulation, and 
this has been linked to a dramatic reduction in the sensitivity to insulin action in 
both tissues (Bachmann et al, 2001; Longato et al, 2012). Storage of excess lipid 
increases both cellular stress and the accompanying inflammatory response, 
further exacerbating the dysregulation of cellular signalling pathways including 
that of leptin and insulin, thereby increasing the risk of developing associated co-
morbidities such as type 2 diabetes (Donath et al, 2013). Notably, the gut 
microbiota has also been implicated in the development of lipotoxicity and the 
inflammatory response associated with HFD-induced dysregulation of energy 
balance (Cani et al, 2007; Cani et al, 2008). 
 
1.5.2 Insulin resistance 
The metabolic stress resulting from the continued expansion of the adipose tissue 
during obesity development eventually leads to an increased inflammatory 
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response in these cells, which is characterised by increased endogenous 
inflammatory cytokine release from adipocytes and the infiltration of macrophages 
(Maury & Brichard, 2010). Accompanying the inflammation is a reduction in the 
sensitivity to insulin action in the adipose tissue (Gustafson et al, 2009; Ruan & 
Lodish, 2003). This leads to adipose TAG breakdown and release as NEFA into the 
circulation (hyperlipidemia), along with increasing plasma glucose levels 
(hyperglycemia)(Groop et al, 1989; Karpe et al, 2011). Notably, circulating levels of 
NEFA are a major contributor to ectopic fat accumulation and associated tissue 
lipotoxicity in tissues such as the skeletal muscle and liver (Karpe et al, 2011; 
McQuaid et al, 2011). 
 Given the major contribution of the skeletal muscle to whole body glucose 
clearance, increased IMCL accumulation is of great consequence to whole body 
glucose homeostasis (DeFronzo & Tripathy, 2009). Notably, it is not necessarily 
total lipid content per se that is detrimental to insulin signalling and glucose 
transport, but rather the increased storage of the lipid derived toxic metabolites 
such as ceramides, diacylglycerols (DAG) and acyl-CoA’s (Bosma et al, 2012; 
Corcoran et al, 2007). Increased synthesis and accumulation of these toxic lipid-
intermediates, particularly DAG and ceramide, leads to activation of inflammatory 
pathways which then phosphorylate IRS-1, thereby reducing GLUT4 translocation 
to the plasma membrane (Bosma et al, 2012; Eckardt et al, 2011; Itani et al, 2002). 
Hepatic lipid accumulation results in the reduced ability of insulin to 
stimulate glycogen synthesis and suppress hepatic glucose production in the liver 
(Samuel et al, 2004). Moreover, the hyperinsulinemia present in obesity not only 
increases fatty acid uptake into the liver, but also increases hepatic de novo 
lipogenesis and TAG production (Diraison et al, 2003; Schwarz et al, 2003; 
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Shimomura et al, 1999), thus increasing both lipid storage and export in VLDL 
(Adiels et al, 2008; Donnelly et al, 2005). The progression of NAFLD to 
steatohepatitis (NASH) occurs by the promotion of a chronic inflammatory 
response in the liver via increased storage of toxic lipid derivatives (Reddy & Rao, 
2006).  
In addition to the development of peripheral tissue insulin resistance, HFD-
induced obesity also induces central (hypothalamic) insulin resistance, and this 
leads to an attenuation of insulin’s ability to suppress food intake (Yue & Lam, 
2012). This diminished central response occurs via both reduced transport of 
insulin across the BBB (Kaiyala et al, 2000), as well as impaired insulin signalling 
in target neurons in the hypothalamus (Belgardt & Bruning, 2010). This 
impairment of insulin action involves an increase in hypothalamic pro-
inflammatory lipid accumulation (Posey et al, 2009). Indeed, the induction of a 
hypothalamic inflammatory response attenuates the anorexic effects of central 
insulin action (Kleinridders et al, 2009; Milanski et al, 2009; Zhang et al, 2008). In 
addition, high fat feeding also impairs the ability of central insulin action to 
suppress hepatic glucose production (Ono et al, 2008), which further contributes 
to the development of peripheral tissue insulin resistance and  will eventually lead 
to type-2 diabetes.  
 
1.5.3 Leptin resistance  
HFD-induced obesity is associated with the progressive reduction in peripheral 
and central sensitivity to leptin action despite the fact that leptin levels continue to 
be released into circulation in proportion to body fat levels, and as such are 
elevated in obese individuals/animals (Kolaczynski et al, 1996; Lin et al, 2000). 
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This resistance to leptin action leads to further hyperphagia and obesity, which in 
turn further exacerbates leptin resistance (Enriori et al, 2007). Leptin resistance, 
like insulin resistance, has been proposed to result from both reduced transport of 
leptin into the brain and impaired leptin signalling in hypothalamic target neurons 
(Morris & Rui, 2009). Evidence suggests the latter to be more important, given that 
even the response to direct central leptin administration is attenuated in obesity; 
this outcome manifests itself as dramatic reductions in the sensitivity of both 
POMC and NPY/AgRP neurons to leptin action (Enriori et al, 2007). 
 
1.5.4 Gut microbiota 
There is a growing body of evidence suggesting that the gut microbiota plays a 
crucial role in host energy metabolism (Tremaroli & Backhed, 2012). Their 
importance in energy balance regulation has been demonstrated by germ free (GF) 
mice (an absence of gut microbiota) being both protected against HFD-induced 
obesity (Backhed et al, 2007) and considerably leaner than conventionally raised 
(CON-R) mice, despite consuming more energy (Backhed et al, 2004). Moreover, 
colonisation of GF mice with cecum microbiota from CON-R mice, leads to a 
dramatic increase in adiposity. Interestingly, this suggests that gut microbiota 
composition is an important determinant of adiposity via food intake independent 
mechanism(s). Moreover, by analysis of the gut microbial composition, clear links 
between the gut microbiota profile and the obese state have been found (Ley et al, 
2005; Murphy et al, 2010; Turnbaugh et al, 2008), whereby certain microbes 
display a greater capacity to promote energy harvest (Turnbaugh et al, 2006). 
The underlying mechanisms of microbiota induced adiposity appear to 
involve changes in the activity and morphology of cells associated with the 
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intestine, liver and adipose tissue (Backhed et al, 2004; Cani et al, 2008; Cani et al, 
2009). Indeed, evidence has demonstrated gut microbiota can contribute to the 
pathophysiology of HFD-induced obesity by causing metabolic endotoxemia as a 
result of increased gut permeability and associated absorption of bacterially-
derived lipopolysaccharide (LPS) (Cani et al, 2007; Cani et al, 2008). This involves 
an impairment of intestinal tight-junction protein expression, namely zona 
occludens 1 (ZO-1) and occludin, and an increased incidence of LPS producing 
microbiota; thereby allowing increased LPS translocation across the gut wall into 
the circulation (Cani et al, 2008). The observed endotoxemia is thought to be 
responsible for the progression of inflammation and associated metabolic 
disorders, such as insulin resistance. Correspondingly, it has been shown that 
subcutaneous infusion of LPS induces obesity and associated metabolic disorders, 
to the same extent as that caused by a HFD feeding (Cani et al, 2007). In contrast, 
antibiotic treatment recovers intestinal integrity, significantly decreasing the 
incidence of metabolic endotoxemia and as such the development of HFD-induced 
obesity and inflammation (Cani et al, 2008).  
Thus, the data suggests that HFD-induced changes in gut microbiota not 
only influence the production of LPS but also facilitate its passage through the gut 
wall by affecting gut wall integrity, thereby increasing the effect of metabolic 
endotoxemia on tissues such as the liver and the adipose tissue. In addition, in the 
adipose tissue LPS also inhibits adipocyte differentiation (Muccioli et al, 2010), 
which would no doubt cause hypertrophy by increased storage of TAG in the 
existing mature adipocytes, and thereby exacerbating the inflammatory response 
by augmenting cytokine release, macrophage infiltration and  cell apoptosis. 
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1.6 WHEY PROTEINS INFLUENCE ON THE REGULATION OF 
ENERGY BALANCE  
1.6.1 Introduction 
Whey is the milk serum that remains after precipitation of casein during cheese 
production, and it contains proteins, vitamins, minerals and trace amounts of fat. 
In this regard, its potential as a nutritional and health promoting product is of 
great research interest and economic value to the dairy industry, especially to 
those involved in cheese manufacture. Whey associated proteins include α-
lactalbumin, β-lactoglobulin, glycomacropeptide (GMP), BSA and lactoferrin 
(Krissansen, 2007). There is accumulating evidence suggesting that whey protein 
intake influences the balance between energy (food) intake and energy 
expenditure, insulin sensitivity and glucose homeostasis, as well as tissue lipid 
metabolism (Jakubowicz & Froy, 2013). Data from recent studies also suggests the 
potential for whey proteins to influence the gut microbiota composition, which 
may likewise impact on energy balance regulation. Here, data are reviewed from in 
vivo (human and rodent) and in vitro studies related to the above effects of whole 
WPI/whey protein concentrate (WPC) and individual whey proteins. Furthermore, 
how dietary composition and obesity could influence the actions of these dietary 
proteins is discussed, exposing several unanswered questions which we aim to 
further investigate in this study.  
 
1.6.2 Energy intake 
Studies conducted in humans have shown that 20 to 50g of whey protein intake 
reduces short-term ad libitum food intake. Akhavan et al, showed that WPC (20-
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40g) dose-dependently reduced subsequent (30 min) ad libitum pizza meal energy 
intake in lean subjects, with the 40g dose having the greatest impact compared to 
the water control (Akhavan et al, 2010). This effect extends up to 2h in lean 
subjects (Anderson et al, 2004). In comparison to casein, whey protein (48g) 
preloads were found to suppress subsequent ad libitum lunch energy intake and 
reduce the desire to eat for up to 180 mins in lean subjects (Hall et al, 2003), 
suggesting that whey proteins induce satiety in comparison to casein intake. 
Differences in the kinetics of digestion of these two protein sources have been 
proposed as being involved in the differential effects on satiety, with whey being 
described as a “fast” digesting protein and casein a “slow” digesting protein (Boirie, 
2013; Boirie et al, 1997; He & Giuseppin, 2014). Indeed, compared to casein, whey 
proteins rapidly increase post-prandial plasma amino acids levels, which correlate 
with increases in satiety (Hall et al, 2003). The results of rodent studies with 
regard to the effects of whey proteins on food (energy) intake are largely in 
agreement with that observed in humans. Indeed, the suggestion that whey 
proteins induce satiety has been further confirmed in mice by showing that WPI 
providing 30% of total dietary energy increases the intermeal interval (satiety) 
compared to soy protein during a 7 day study period (Yu et al, 2009). Similar 
findings have been reported from a long term study lasting 10 weeks (Zhou et al, 
2011). These data are consistent with the findings from human studies that  whey 
proteins reduce food intake by inducing satiety in the lean state. However, a 
functional relationship between whey proteins and food intake has not been 
consistently reported. For instance, although Hall et al, showed that whey proteins 
reduce food intake compared to casein in humans (Hall et al, 2003), this same 
response was not observed in rats given a WPI diet for 7 weeks in comparison to 
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casein (300g/kg diet), despite the fact that the rats on the WPI diet showed a 
significantly reduced weight gain compared to the those on the casein diet (Royle 
et al, 2008). It is possible that physiological and neuroendocrine differences that 
exist between the species (humans vs. rats) may have given rise to the inconsistent 
effects of whey protein on food intake.  
There is evidence that macronutrient composition in the diet could also 
impact upon the effect of whey proteins on food intake. Veldhorst et al, showed 
that a diet containing proteins, carbohydrates and fat providing 10, 55 and 35% 
energy, respectively, reduces hunger in humans if whey proteins were included in 
comparison to either soy and casein, but when the macronutrient composition was 
altered to 25, 55 and 20 % energy from proteins, carbohydrates and fat, this satiety 
effect was no longer observed (Veldhorst et al, 2009a). Similar results have been 
obtained from a study conducted in rats, which showed that WPC with an energy 
content of 55% reduced cumulative energy intake compared to whole milk protein 
if the former protein was supplied in a diet with 35% and 10% energy from 
carbohydrates and lipids, respectively, or in a diet with 45% energy solely derived 
from lipids (Pichon et al, 2008). No differences in cumulative energy intake were 
observed if the proteins were provided in a diet with 15% and 30% energy from 
carbohydrates and fats, respectively. These data highlights the importance of the 
macronutrient composition in the diet to whey protein effects on food intake. In 
addition to dietary composition, weight gain also seems to influence the effect of 
whey proteins on short-term food intake. This is revealed by the finding that intake 
of WPI (50g) reduced subsequent pizza intake in normal weight but not in obese 
subjects (Bellissimo et al, 2008). Similar findings have been reported by other 
human studies (Bowen et al, 2006a; Bowen et al, 2007; Bowen et al, 2006b) and in 
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HFD-induced obese mice (Pilvi et al, 2007; Shertzer et al, 2011; Shi et al, 2011b). In 
fact, studies have shown that the reductions in weight gain with whey protein 
intake in HFD fed mice can occur independently of an impact on energy intake 
(Pilvi et al, 2007; Shertzer et al, 2011). In the case of Shertzer et al, (2011), HFD-
fed mice that drank water supplemented with WPI at 100g/L for 11 weeks showed 
a similar energy intake to those on the un-supplemented water, despite the former 
showing a significant decrease in body weight. Thus, in addition to protein source, 
quality and time of consumption mentioned by Anderson et al, (2004), both 
macronutrient composition in the diet and state of energy balance (lean vs. obese), 
should be considered as important factors influencing the whey protein effects on 
food intake. 
A number of studies have attempted to identify the individual whey 
proteins that might be causing the reduction in food intake in humans and rodents. 
Because GMP has been shown to stimulate the production of the satiation hormone 
CCK (Pedersen et al, 2000), a role for this whey protein in the regulation of food 
intake has been suggested. The findings of Veldhorst et al, support the latter 
suggestion, as ingestion of a breakfast diet with whey protein providing 10% 
energy reduced lunchtime energy intake in lean subjects more than the intake of a 
whey protein without GMP associated breakfast (Veldhorst et al, 2009c). This 
finding is however not in agreement with data from other studies performed on 
lean subjects with diets containing whey protein without GMP (providing 44% 
energy)(Burton-Freeman, 2008), and whey protein diets with added GMP (21% 
w/w) (Lam et al, 2009).  Taking into account the data from another study involving 
rats, which revealed that GMP does not impact on food intake (Royle et al, 2008), it 
could be argued that this whey protein does not have a significant effect on this 
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physiological process. However, a more recent study has shown that rats fed a 
GMP supplementation with a HFD show an improvement in their plasma and 
tissue lipid profiles in association with significant reductions in their food intake 
compared to HFD fed controls (Xu et al, 2013a). Utilising a similar approach as in 
their previous studies, Veldhorst et al, showed that breakfast diets with α-
lactalbumin providing 10% or 25% energy reduces lunch time energy intake in 
lean subjects compared to a breakfast diet with casein, soy or whey (Veldhorst et 
al, 2009b). This data is in agreement with the results of another study (Hursel et al, 
2010), which together suggest an important role for α-lactalbumin in the 
suppression of food intake in lean humans. In addition to this, Pichon et al, (2008) 
also found β-lactoglobulin consumption in rats to reduce energy intake in 
comparison to whole milk proteins.  
In summary, consumption of whey proteins as an isolate or concentrate 
appears to reduce food (energy) intake in humans and rodents by inducing satiety 
compared to casein, soy or carbohydrates. This effect appears to be influenced by 
the macronutrient composition of the whey protein diet and by the development of 
obesity. Of the whey proteins that have been studied, data suggests an important 
role(s) for α-lactalbumin and β-lactoglobulin in the regulation of food (energy) 
intake, but a regulatory role for GMP in this physiological process is still unclear. 
Moreover, despite progress in the understanding of the effects of whey proteins on 
energy intake, there is still insufficient information on the mechanisms by which 
these proteins influence satiety and alter energy intake, and how variations to 
dietary composition and energy status (lean vs obese) can influence their action. 
Currently, to our knowledge, data is lacking on how WPI changes energy intake 
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during the 24 hr period, or how the intake of whey proteins can influence daily 
meal pattern (i.e. meal size and meal number). 
 
1.6.3 Satiety hormones 
It is well established that the hormones CCK, PYY, ghrelin, insulin, leptin and GLP-1 
play important roles in energy balance by inhibiting (CCK, insulin, leptin and GLP-
1) and stimulating (ghrelin) food (energy) intake and/or by inducing catabolic 
(GLP-1 and leptin) and anabolic (ghrelin and insulin) responses on lipid 
metabolism in tissues (Cummings & Overduin, 2007; Nogueiras et al, 2010). Given 
the effects of whey proteins on food intake and body weight, it is no surprise that 
whey proteins modulate these hormones. A study by Bowen et al, showed that 
whey protein decreases in energy intake in humans are accompanied by increased 
plasma levels of CCK and GLP-1, and reduced levels of ghrelin (Bowen et al, 
2006a). These changes were noted as early as 15 mins and continued up to 180 
mins after the dietary challenge, suggesting potential acute and chronic effects of 
whey proteins on hormonal levels. Hall et al, (2003) also demonstrated that 
increases in satiety with whey protein intake were associated with elevations in 
post-prandial CCK and GLP-1 levels up to 180mins compared to casein. Others 
have confirmed these post-prandial increases in GLP-1, as well as showing 
enhanced plasma PYY levels with whey protein intake (Akhavan et al, 2014; 
Veldhorst et al, 2009a). Furthermore, as the hydrolysis of WPI releases peptides 
that can suppress DPPIV activity (Lacroix & Li-Chan, 2012), whey protein intake 
may improve the maintenance of incretin hormone activity as well as their release. 
Prolonged whey protein intake has also been associated with reduced fasting 
ghrelin hormone levels compared to carbohydrate or soy protein supplementation 
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in humans, although no corresponding effects on energy intake were seen (Baer et 
al, 2011). In the case of insulin, whey proteins appear to acutely increase its 
release (Power et al, 2009), but with prolonged intake there appears to be a 
reduction in fasting insulin levels (Baer et al, 2011). The fact that similar effects on 
hormone levels have been observed in studies conducted using only lean (Hall et 
al, 2003) or only obese subjects (Bowen et al, 2007), suggests that whey proteins 
can modulate hormone levels independent of weight gain and that the changes are 
consistent with an attempt to increase catabolism. 
Comparable data has been obtained from rodent studies. Zhou et al, showed 
that the reduction in food intake in lean rats on a diet supplemented with 24% 
(wt/wt) WPC, is accompanied by an increased GLP-1 level in the plasma (Zhou et 
al, 2011). Rodent studies have also highlighted whey protein effects on long-term 
signals involved in energy balance regulation. Similar to the effects in humans, 
whey proteins acutely promote an insulinotropic response in rodents, while also 
reducing fasting plasma insulin levels in the long-term (Belobrajdic et al, 2004; 
Gaudel et al, 2013). Acute insulin production may be, in part, related to stimulatory 
effect of whey proteins on the release of incretin hormones GLP-1 and GIP 
(Drucker, 2006), given that both these hormones enhance glucose-dependent 
insulin secretion from pancreatic β-cells (Garber, 2011; Hansotia et al, 2007). 
Additionally, a detailed microarray analysis of gene expression in the adipocytes of 
obese mice that had ingested whey proteins revealed an increased expression of 
leptin and several genes involved in the insulin signalling pathway in the whey 
protein group compared to the casein control (Pilvi et al, 2008b). Since the mass of 
the adipose tissue and the gene expression of leptin have previously been shown to 
be closely linked (Galic et al, 2010), the significance of this increased expression of 
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leptin in adipocytes with reduced adipocyte cross sectional area remains to be 
determined. 
As mentioned above, GMP has been demonstrated to enhance plasma CCK 
levels (Pedersen et al, 2000), yet this is not consistently shown (Keogh et al, 2010). 
However, data from Royle et al, (2008) does suggest a role for GMP in mediating 
the reduction in fasting insulin levels observed with prolonged whey protein 
intake; the data show that rats fed a GMP-free WPI diet have elevated fasting 
insulin levels compared to casein and BBQ beef diets, while the same WPI diet with 
added GMP at either 100 or 200 g/kg resulted in fasting insulin levels that were 
significantly lower than all other diets groups. So far, only one study, using healthy 
lean subjects, failed to find the consumption of a α-lactalbumin breakfast meal to 
influence postprandial levels of GLP-1, ghrelin and insulin compared to a 
comparable breakfast meal with gelatin or gelatin plus tryptophan, despite having 
significantly reduced hunger scores (Nieuwenhuizen et al, 2009).  
In summary, whey proteins appear to drive endocrine and cellular changes 
consistent with a catabolic effect in comparison to casein and carbohydrates 
(glucose and fructose). This is achieved by up-regulation of the production of 
catabolic hormones (CCK, GLP-1, PYY, leptin and insulin), and by the reduction in 
the production of the anabolic hormone ghrelin. The decrease in insulin levels 
observed over time with whey protein intake might be a mechanism to reduce the 
anabolic effects of this hormone upon adipocytes (Coomans et al, 2011). Here we 
reviewed how whey proteins impact on peripheral signals in energy balance 
regulation, but to our knowledge no investigations to date have been conducted to 
assess the impact of whey proteins on gene expression in centres of the brain 
important for regulation of energy balance.  
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1.6.4 Energy expenditure and muscle protein synthesis 
Whey protein (18g) intake prior to a bout of heavy resistance training increases 
post-training resting energy expenditure in humans compared to carbohydrate 
intake (Hackney et al, 2010). Others have shown similar augmentations in 
carbohydrate oxidation and lean body mass in response to combined whey protein 
intake and resistance exercise (Betts et al, 2007; Volek et al, 2013), which may be 
related to the observed effect on energy expenditure. Interestingly, the effect on 
energy expenditure diminishes if the whey protein meal is ingested after the 
resistance exercise, even if the protein content in the diet is at 30g (Benton & 
Swan, 2007). The data suggest that the timing of the dietary challenge is crucial for 
detecting whey protein induced changes in resting energy expenditure. Intake of 
whey proteins also appears to increase thermogenesis, possibly because of its 
higher thermic effect compared to soy or casein (Acheson et al, 2011). Data from a 
recent rodent study clearly suggests such an effect, with diet-induced obese mice 
drinking water supplemented with whey proteins (100g/L) increasing their O2 
consumption compared to obese mice drinking un-supplemented water (Shertzer 
et al, 2011).  
These effects on energy expenditure may possibly be due to the whey 
protein induced increased protein metabolism in tissues (Boirie et al, 1997), given 
that the bulk of resting energy expenditure is linked to lean body mass and that 
whey proteins both enhance the development of lean muscle mass and spare its 
loss during energy restriction (Frestedt et al, 2008; Volek et al, 2013).  Indeed, a 
number of other reports have shown that whey intake increases muscle protein 
synthesis in comparison to casein (Pennings et al, 2011; Tang et al, 2009), and 
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evidence suggests that this response may be related to its ability to stimulate 
skeletal muscle mTOR activity (Farnfield et al, 2012; Kakigi et al, 2014). Moreover, 
whey has also been shown to be effective at stimulating muscle protein synthesis 
in elderly humans and animals, thus reducing their susceptibility to age related 
muscle loss (sarcopenia) (Pennings et al, 2011; Rieu et al, 2007; Walrand et al, 
2011). However, findings that whey specifically promotes muscle protein synthesis 
compared to other proteins sources, are not consistently reported (Dideriksen et 
al, 2011; Reitelseder et al, 2011). A recent study comparing post-prandial muscle 
protein synthesis, in response to different dietary proteins (egg, soy, wheat, whey) 
showed that the WPI was the most effective protein source for stimulating protein 
synthesis (Norton et al, 2012). The leucine content was a crucial factor in this 
effect, as supplementing the wheat protein diet with leucine to match the content 
in the whey diet led to similar levels of protein synthesis. This influence of leucine 
is not surprising as in addition to being a key protein synthesis substrate, leucine is 
also a regulator of the signalling pathway involved in protein synthesis via its 
effect on mTOR (Lynch et al, 2003; Lynch et al, 2002.).  
To our knowledge, of the whey proteins associated with regulation of 
energy balance, only α-lactalbumin has been shown to influence energy 
expenditure. The study by Hursel et al, which reported an effect of α-lactalbumin 
(41% energy from the protein) ingestion on lunchtime meal intake in the healthy 
humans, also found that this whey protein significantly increases diet-induced 
thermogenesis compared to intake of a whole milk protein rich diet (Hursel et al, 
2010). Whether α-lactalbumin, or any other individual whey protein, could 
influence energy expenditure in obese humans remains to be determined.  
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In summary, compared to carbohydrates, soy and casein, intake of whey 
proteins appears to increase energy expenditure in lean and obese states by 
influencing thermogenesis and resting energy expenditure. In the latter case, the 
timing of the dietary challenge might be important, in particular when associated 
with exercise, for obtaining an effective change in this parameter linked to energy 
expenditure. Enhanced protein synthesis associated with whey protein intake is no 
doubt a contributing factor in this effect, and most likely influenced by the high 
leucine content in whey proteins. It is also tempting to suggest that the effect of 
whey proteins on energy expenditure might be due to the actions of α-lactalbumin 
present in the WPI or WPC, however, this may be premature given that there are 
no data showing whether other whey proteins could influence energy expenditure 
to the same extent.  Finally, a key unanswered question to date is, do alterations to 
energy expenditure and/or muscle protein synthesis play a role in the reductions 
in HFD-induced adiposity associated with whey protein intake?   
 
1.6.5 Adiposity and Lipid metabolism  
Over the last decade, an increasing number of reports have demonstrated that 
inclusion of WPI in the diet suppresses body weight gain in comparison to other 
dietary proteins, including casein (Pichon et al, 2008; Pilvi et al, 2007; Royle et al, 
2008; Shi et al, 2012a; Shi et al, 2011b; Zhou et al, 2011). The reduction in body 
weight appears to be primarily driven by the pronounced decease in body fat gain 
in these animals (Pilvi et al, 2007; Shertzer et al, 2011; Shi et al, 2011b). This effect 
is particularly visible during energy restriction, where whey protein intake 
enhances fat loss, while preserving lean mass content (Coker et al, 2012; Frestedt 
et al, 2008). As described earlier, whey protein induced reductions in body fat can 
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occur independently of an effect on energy intake (Pilvi et al, 2007; Shertzer et al, 
2011), suggesting the involvement of alternative mechanisms in these outcomes. 
Given the importance of lipid metabolism for the storage and accumulation of fat, 
whey proteins may directly affect mechanisms regulating lipid metabolism in the 
tissues and this may underlie their ability to suppress adiposity. 
 In over-weight and/or obese humans and rodents, whey proteins have 
been shown to improve lipid metabolism, by reducing plasma, adipose and hepatic 
TAG levels. Recently Pal et al, demonstrated that intake of WPI (27g) twice daily 
for 12 weeks causes a reduction in fasting TAG levels in over-weight and obese 
subjects compared to casein intake (Pal et al, 2010). A similar effect has also been 
observed in obese rats with intake of WPC at 32% (wt/wt)  (Belobrajdic et al, 
2004). Additionally, even at a modest level of WPI (24% wt/wt providing 18% 
energy), these dietary proteins can reduce HFD (providing 60% energy)-induced 
weight gain and body fat accumulation in mice compared to those fed a HFD with 
casein (Pilvi et al, 2007). As the reduction in body weight and fat content was not a 
result of differences in energy intake or intestinal fat absorption between the two 
groups, the authors then investigated whether the WPI intake may have affected 
adipocyte lipid metabolism (Pilvi et al, 2008b) and demonstrated a reduction in 
adipocyte cross sectional area in the mice fed the HFD with WPI. This suggests that 
whey proteins influence lipid metabolism in adipocytes much more than casein, 
although the extent of the reduction in adipocyte size may have been influenced by 
the fact the diets had a high calcium content, which in itself is known to influence 
adipocyte lipid metabolism (Zemel, 2004). Furthermore, recent data has shown 
whey proteins to influence lipid metabolism-related gene expression in adipocytes, 
hepatocytes and skeletal muscle cells (Freudenberg et al, 2012; Morifuji et al, 
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2005; Pilvi et al, 2008b; Tauriainen et al, 2011). The study by Pilvi et al, (2008b) 
mentioned above performed a detailed microarray analysis of adipose tissue gene 
expression in the HFD fed mice that had ingested whey proteins. The microarray 
data revealed an increased expression of β3-AR, suggesting a potential functional 
relationship between the reduction in the adipose tissue and increased β3-AR 
expression, given that activation of this receptor is known to increase HSL-
mediated hydrolysis of fat, increase fat oxidation and induce uncoupling protein-
mediated thermogenesis (Holm, 2003; Weyer et al, 1999), all of which are likely to 
reduce the mass of the adipose tissue. 
Given that the liver is also important for regulation of lipid metabolism, 
Pilvi et al, also assessed in a separate study how the same dietary challenge may 
impact upon the lipid metabolism in the liver of HFD-induced obese mice subjected 
to a 7 week calorie restriction (Pilvi et al, 2008a). Indeed, compared to obese mice 
on the calorie restricted casein diet, hepatic TAG levels in obese mice on the calorie 
restricted WPI diet were reduced to a far greater extent. The specificity with which 
WPI reduces hepatic lipid content has been further demonstrated in the absence of 
calorie restriction (Hamad et al, 2011; Shertzer et al, 2011). In the studies 
mentioned above, except for the study by Shertzer et al, (2011), the observed 
effects of whey protein on lipid metabolism were shown relative to casein. 
Interestingly, rats fed a LFD containing soy proteins at 24% (wt/wt) had a body 
weight and an abdominal fat mass that was comparable to rats fed a similar diet 
with WPC (Zhou et al, 2011). This data could be interpreted to suggest that whey 
protein effects on lipid metabolism are detectable only when casein is used as the 
control protein or that the lack of an effect on adiposity in comparison to soy might 
be due to macronutrient composition, in particular the fat content in the diet, with 
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body fat content in HFD fed animals being more likely to be counteracted by whey 
protein effects on lipid metabolism. At the molecular level, whey protein intake in 
rats, in comparison to casein intake, reduces the activity of several lipogenic 
enzymes including FASN in the liver, while contrastingly increasing FASN 
expression and activity in the muscle (Morifuji et al, 2005), possibly to reduce 
hepatic production of lipids and to promote lipid oxidation in the muscle cells to 
generate energy in the form of ATP. 
A number of studies have attempted to determine how individual whey 
proteins affect lipid metabolism. By providing overweight human subjects with 
enteric coated lactoferrin (300mg/d) or placebo tablets for a period of 8 weeks, it 
has been found that lactoferrin reduces body weight, visceral fat mass, as well as 
hip circumference (Ono et al, 2010). In rats ingesting a WPI diet supplemented 
with GMP at 100 and 200g/kg a reduced carcass fat was found compared to rats on 
either a WPI or casein diet (Royle et al, 2008). Because there were no differences 
in food intake between the groups, the data suggests a food intake-independent 
effect of GMP on lipid metabolism (fat content) in these animals. Likewise, in 
another recent rat study, similar reductions in body fat and improved plasma and 
hepatic lipid profiles were seen following daily intragastric GMP supplementation 
to HFD fed obese rats (Xu et al, 2013a). 
With the view to assessing how whey proteins, namely α-lactalbumin, β-
lactoglobulin and lactoferrin influence body weight and body fat content in 
rodents, Pilvi et al, subjected HFD-induced obese mice to a 70% energy restricted 
diet containing WPI, α-lactalbumin, β-lactoglobulin or lactoferrin at 18% of dietary 
energy content for a period of 7 weeks to induce weight loss, and then 
subsequently allowed ad libitum access to these diets for a further 7 weeks to 
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allow weight gain (Pilvi et al, 2009). Results suggest that α-lactalbumin is the most 
beneficial whey protein in terms of causing fat loss when provided as part of an 
energy restricted diet or fed ad libitum, and similar findings to these were 
subsequently demonstrated in Shi et al, (2011a) by this same research group. In 
contrast to Pilvi et al, (2009), who showed that β-lactoglobulin was the least 
effective whey protein for inducing weight loss and for preventing weight gain, 
another study by Pichon et al, (2008) found that β-lactoglobulin (55% energy) 
causes the least weight gain when supplemented in a carbohydrate free diet 
containing 45% energy as fat, in comparison to a diet containing 35% and 10% 
energy from carbohydrates and fat or in a diet with 15% and 30% energy from the 
same macronutrients, respectively. The data again highlights the importance of 
macronutrient composition on whey proteins effects on energy balance. With 
regard to the above mentioned changes in the cellular activity observed in the 
adipose, muscle and liver, it is important to further define how they arise by 
investigating the impact of these whey proteins implicated in lipid metabolism, 
namely α-lactalbumin, β-lactoglobulin, lactoferrin and GMP. 
In summary, WPI appears to reduce body weight and lipid metabolism in 
both obese humans and rodents compared to casein intake, with specific effects 
observed in the adipocytes and in the liver; although these effects appear to be 
influenced by macronutrient composition in the diet. Additionally whey proteins 
alter the expression or activity of lipogenic, lipolytic and fat oxidation related 
genes in the liver, adipose and in the muscle. Available data suggest an important 
role(s) for α-lactalbumin, β-lactoglobulin, lactoferrin and GMP in the regulation of 
lipid metabolism in humans and/or in rodents, but this requires further 
investigation to clarify the roles and to understand the mechanisms involved. It is 
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important to note that the above mentioned changes in adiposity and lipid 
metabolism occurred, for the most part, independently of changes to energy intake 
and/or expenditure, but the underlying mechanisms involved remain to be 
determined.  
 
1.6.6 Insulin sensitivity and glucose homeostasis 
In both humans and rodents, whey protein intake has been shown to cause an 
acute insulinotropic response (Gaudel et al, 2013; Power et al, 2009). This has 
been demonstrated by supplementation of whey proteins into glucose drinks or 
test meals, which augments postprandial insulin release, resulting in an 
enhancement of glucose disposal in both healthy (Acheson et al, 2011; Nilsson et 
al, 2007) and type-2 diabetic subjects (Frid et al, 2005). Similar effects have been 
observed in anesthetised mice, where gastric gavage of whey protein (75mg) and 
glucose (75mg) together augmented the insulin response 3-fold and increased the 
glucose disposal by 31% in comparison to glucose alone (Gunnarsson et al, 2006). 
In vitro work using the pancreatic BRIN-BD11 β-cell line has also demonstrated 
that whey protein hydrolysate can directly stimulate insulin release in a dose 
dependent manner (Gaudel et al, 2013). In addition to these acute responses, 
prolonged whey protein intake also improves insulin sensitivity in the obese state 
of both rodents (Belobrajdic et al, 2004; Huang et al, 2008; Pilvi et al, 2008a; 
Shertzer et al, 2011; Shi et al, 2011b) and humans (Pal et al, 2010). In fact, a recent 
study has demonstrated significant improvements to glycaemic control in obese 
ob/ob mice consuming a whey protein hydrolysate diet (Gaudel et al, 2013). At the 
molecular level, the mRNA expression of GLUT4 was increased by augmenting the 
WPI content in a HFD fed to mice (Freudenberg et al, 2012). Moreover, Morato et 
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al, (2013) examined the acute effects of WPI and its hydrolysate on GLUT4 
translocation to the cell surface in Wistar rats and showed enhanced GLUT4 
translocation to the plasma membrane without any alterations to fasting insulin 
levels in comparison to casein fed animals. The authors proposed that this could 
indicate a whey protein insulin-independent effect on GLUT4. This notion was also 
proposed by Akhavan et al, (2014), as they found comparable post-meal glucose 
levels in young lean males given whey protein and glucose preloads, despite 
reduced levels of post-meal insulin levels in the whey preload group. As discussed 
before, the ability of whey protein to stimulate the release of the incretin 
hormones GIP and GLP-1, and also to increase their activity by the suppression of 
DPPIV, may have also contributed to the insulinotropic effect associated with whey 
protein intake. 
Of the whey proteins that have been tested, both α-lactalbumin and GMP 
have been found to increase the postprandial insulin release (in comparison to 
casein) with GMP having a greater effect (Veldhorst et al, 2009b). Long-term GMP 
intake has also been shown to improve fasting blood insulin levels in both humans 
(Keogh & Clifton, 2008) and rats (Royle et al, 2008). Similarly a high protein diet 
(55% kcal) with β-lactoglobulin as it source of protein was shown to reduce insulin 
resistance and improve fasting blood insulin levels in rats to a greater extent than 
the comparable high WPC diet (Pichon et al, 2008). Lactoferrin circulating levels 
also correlate negatively with hyperglycemia and positively with insulin sensitivity 
(Moreno-Navarrete et al, 2009), and inclusion of lactoferrin (Shi et al, 2012b) or a 
lactoferrin-rich WPI (Shi et al, 2011b) into a HFD, improves glucose tolerance in 
mice in comparison to casein fed controls. 
57 
 
  
In summary, whey protein intake appears to acutely stimulate insulin 
release and improve glucose tolerance and insulin sensitivity in the long-term, 
even when accompanied by high fat feeding. The available data also suggest that 
the improvement of insulin sensitivity may be a common feature of α-lactalbumin, 
β-lactoglobulin, lactoferrin and GMP, with the latter being more potent than α-
lactalbumin. The question of whether whey proteins directly influence insulin 
signalling or mediate their effect indirectly via lipid metabolism and adiposity 
remains to be determined. Similarly it is also unclear as to how these effects 
manifest in individual tissues (e.g. muscle, liver and adipose tissue), and whether 
there are associated changes in inflammatory markers. 
 
1.6.7 Gut microbiota 
Given the increasing evidence of the importance of gut microbiota for energy 
balance regulation (Backhed et al, 2004; Murphy et al, 2010; Turnbaugh et al, 
2006), the impact of whey proteins on gut microbiota composition, and associated 
beneficial effects on weight management, will be an area of great research interest. 
Currently, a number of studies have shown that whey protein hydrolysate, as well 
as specific whey proteins, such as β-lactoglubulin, ɑ-lactalbumin, GMP and 
lactoferrin, to have anti-microbial activity (Freedman et al, 1998; Pihlanto-Leppala 
et al, 1999; Shin et al, 2000; Yamauchi et al, 1993). In addition to the anti-microbial 
effect, whey proteins have also been associated with the promotion of certain 
types of gut bacteria, namely Bifidobacteria (Petschow & Talbott, 1990). Similar 
Bifidobacterium growth promoting capabilities have been ascribed to both GMP 
and lactoferrin (Brody, 2000; Petschow et al, 1999; Rahman et al, 2009).  
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To date, only three studies have assessed the whey proteins effects on gut 
microbiota composition, and none of them have gone into any great detail of the 
specific effects of WPI. Firstly, a study by Sprong et al, (2010) demonstrated in a 
rat model of colitis, that whey protein intake increased the levels of Lactobacilli 
and Bifidobacteria in comparison to casein intake. Similar gut microbiota changes 
were also described in a study that investigated the influence of GMP consumption 
on gut microbiota composition (Chen et al, 2012). However, a more recent study 
using HFD fed mice failed to find any significant difference in gut microbiota 
composition between mice consuming casein or whey (Tranberg et al, 2013), 
albeit here the mice were consuming a HFD, which may have affected the ability of 
whey proteins to influence the gut microbiota. In addition to influencing the gut 
microbiota, whey proteins, namely lactoferrin, have also been linked to improving 
gut wall integrity and to suppressing the detrimental effects of bacterial 
endotoxins, such as LPS (Kruzel et al, 2000; Lee et al, 1998). This suggests that 
whey proteins are possibly able to suppress the development of metabolic 
endotoxemia associated with HFD intake, through changes to the intestinal 
environment. 
In summary, the findings suggest that whey proteins have a pre-biotic effect 
through promoting the growth of beneficial bacteria (Lactobacillus and 
Bifidobacteria), while suppressing pathogenic bacteria such as E. coli and 
Salmonella (Entreobactericaccea), and also may be able to protect gut integrity and 
suppress the impact of bacterial entotoxins (e.g. LPS). However, there is a lack of 
knowledge of how whey proteins effect gut microbial composition and how these 
changes may relate to the physiological outcomes observed with whey protein 
intake? Thus, there needs to be further investigation into these matters. 
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1.7 OVERALL SUMMARY 
Body weight is determined by the balance between energy intake and energy 
expenditure, and obesity develops from the sustained consumption of energy in 
excess of that spent. The regulation of energy balance is a complex physiological 
process that requires the interaction between multiple tissues, including the GIT, 
liver, pancreas, adipose tissue and the brain, with energy status in the peripheral 
tissues being conveyed to the CNS by hormones produced by the GIT, adipose 
tissue and pancreas. Integration of these signals in the CNS controls the expression 
of several neuropeptides important for energy balance regulation, and the 
resulting responses generated from multiples inputs results in changes in food 
intake, energy expenditure and lipid metabolism. 
Overall the current evidence presented here shows whey protein intake is 
associated with a range of positive benefits related to weight management. These 
include an ability to decrease food intake, possibly by altering the plasma levels of 
hormones (CCK, GLP-1, ghrelin and insulin) important for energy balance 
regulation. Notably however, evidence suggests that whey protein induced 
reductions in weight gain and adiposity in HFD fed and obese animals/subjects are 
unrelated to effects on energy intake, and that whey proteins directly influence 
lipid and glucose metabolism in tissues such as the liver and adipose tissue. These 
effects could be correlated to improved insulin sensitivity and glucose tolerance, 
with evidence demonstrating WPI ability to suppress the development of HFD-
induced insulin resistance, to increase energy expenditure and to alter the gut 
microbiota composition, which could also be important in energy balance 
regulation and weight management. Finally, the evidence also shows that both the 
macronutrient composition in the diet and the body energy status of the 
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animals/subjects involved, appear to greatly impact upon the ability of whey 
proteins to influence the balance between energy intake and energy expenditure. 
Thus a better understanding of the specific mechanisms by which whey proteins 
influence body weight and energy balance may help in the formulation of more 
effective dietary interventions that could prevent and/or reduce obesity 
development. 
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1.8 OBJECTIVES OF THE STUDY 
WPI has been increasingly demonstrated to suppress HFD-induced weight gain 
and adiposity independently of significant changes to energy intake. Therefore, 
this project tested the hypothesis that WPI directly impacts on adiposity by 
influencing tissue lipid metabolism. 
 
The specific objectives of the project were: 
Objective 1: To ascertain the contribution of energy intake and energy 
expenditure to WPI effects related to lipid metabolism. 
Objective 2: To study the effects of WPI on lipid metabolism and insulin signalling 
in peripheral tissues (adipose tissue, liver), and to determine the 
underlying mechanisms of their action. 
Objective 3: To utilise the 3T3-L1 pre-adipocyte cell line as a model of fat cells to 
investigate the functionality of lysophosphatidic acid receptor 5 
(LPA5), as a candidate in mediating whey protein effects on adipose 
tissue lipid metabolism. 
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1.9 APPROACH 
HFD-fed C57BL/6J mice were used as a model to better understand how WPI alters 
tissue lipid metabolism without substantially changing energy intake. HFD fed 
mice display temporal changes in their energy intake pattern compared to LFD fed 
mice, with no difference in energy intake observed during weeks 1-4, a significant 
reduction during weeks 5-12, followed by an increase in energy intake which 
exceeds LFD fed mice beyond week 19 (Lin et al, 2000). In contrast, an increase in 
body weight was observed in these HFD fed mice by week 2, and this continued to 
increase even during periods of reduced energy intake. Therefore, this project 
sought to investigate the effect of WPI inclusion into a HFD on lipid metabolism 
and other energy balance parameters during the periods of hypophagia (weeks 5-
12) and hyperphagia (week 19 onwards) in this HFD fed mouse model, by 
conducting trials over an 8 week (short-term) and 21 week (long-term) period. 
In an attempt to further explore whether WPI or its related bioactives could 
directly affect adipose tissue lipid metabolism, we utilised the 3T3-L1 pre-
adipocyte cell line as a model to investigate the functionality of the receptor, LPA5, 
as a candidate for mediating WPI effects on lipid metabolism in these cells.  The 
receptor was selected based on its responsiveness to dietary protein hydrolysate 
(Choi et al, 2007a; Choi et al, 2007b), and the fact that its endogenous ligand, LPA, 
had previously been shown to both stimulate pre-adipocyte proliferation and 
suppress their differentiation into mature lipid laden adipocytes. This initial work 
was intended to characterise the role of LPA5 in 3T3-L1 pre-adipocytes growth and 
differentiation, in order to evaluate its potential to mediate WPI impact on the 
cellular activity of these cells. 
 
63 
 
  
1.10 REFERENCES 
Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, 
Bloom SR (2005) The inhibitory effects of peripheral administration of peptide 
YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of 
the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127-131 
 
Acheson KJ, Blondel-Lubrano A, Oguey-Araymon S, Beaumont M, Emady-Azar S, 
Ammon-Zufferey C, Monnard I, Pinaud S, Nielsen-Moennoz C, Bovetto L (2011) 
Protein choices targeting thermogenesis and metabolism. Am J Clin Nutr 
 
Adams SH, Lei C, Jodka CM, Nikoulina SE, Hoyt JA, Gedulin B, Mack CM, Kendall ES 
(2006) PYY[3-36] administration decreases the respiratory quotient and reduces 
adiposity in diet-induced obese mice. J Nutr 136: 195-201 
 
Adams SH, Won WB, Schonhoff SE, Leiter AB, Paterniti JR, Jr. (2004) Effects of 
peptide YY[3-36] on short-term food intake in mice are not affected by prevailing 
plasma ghrelin levels. Endocrinology 145: 4967-4975 
 
Adiels M, Olofsson SO, Taskinen MR, Boren J (2008) Overproduction of very low-
density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. 
Arterioscler Thromb Vasc Biol 28: 1225-1236 
 
Akhavan T, Luhovyy BL, Brown PH, Cho CE, Anderson GH (2010) Effect of premeal 
consumption of whey protein and its hydrolysate on food intake and postmeal 
glycemia and insulin responses in young adults. Am J Clin Nutr 91: 966-975 
 
Akhavan T, Luhovyy BL, Panahi S, Kubant R, Brown PH, Anderson GH (2014) 
Mechanism of action of pre-meal consumption of whey protein on glycemic control 
in young adults. J Nutr Biochem 25: 36-43 
 
Anderson GH, Tecimer SN, Shah D, Zafar TA (2004) Protein source, quantity, and 
time of consumption determine the effect of proteins on short-term food intake in 
young men. J Nutr 134: 3011-3015 
 
Andrews ZB, Erion DM, Beiler R, Choi CS, Shulman GI, Horvath TL (2010) 
Uncoupling protein-2 decreases the lipogenic actions of ghrelin. Endocrinology 
151: 2078-2086 
 
Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, Kasuga M (2003) 
Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. 
Gut 52: 947-952 
 
Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, 
Niijima A, Fujino MA, Kasuga M (2001) Ghrelin is an appetite-stimulatory signal 
from stomach with structural resemblance to motilin. Gastroenterology 120: 337-
345 
 
64 
 
  
Bachmann OP, Dahl DB, Brechtel K, Machann J, Haap M, Maier T, Loviscach M, 
Stumvoll M, Claussen CD, Schick F, Haring HU, Jacob S (2001) Effects of 
intravenous and dietary lipid challenge on intramyocellular lipid content and the 
relation with insulin sensitivity in humans. Diabetes 50: 2579-2584 
 
Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI 
(2004) The gut microbiota as an environmental factor that regulates fat storage. 
Proc Natl Acad Sci U S A 101: 15718-15723 
 
Backhed F, Manchester JK, Semenkovich CF, Gordon JI (2007) Mechanisms 
underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad 
Sci U S A 104: 979-984 
 
Baer DJ, Stote KS, Paul DR, Harris GK, Rumpler WV, Clevidence BA (2011) Whey 
protein but not soy protein supplementation alters body weight and composition 
in free-living overweight and obese adults. J Nutr 141: 1489-1494 
 
Bagdade JD, Bierman EL, Porte D, Jr. (1967) The significance of basal insulin levels 
in the evaluation of the insulin response to glucose in diabetic and nondiabetic 
subjects. J Clin Invest 46: 1549-1557 
 
Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) Oxyntomodulin and glucagon-
like peptide-1 differentially regulate murine food intake and energy expenditure. 
Gastroenterology 127: 546-558 
 
Bagnasco M, Tulipano G, Melis MR, Argiolas A, Cocchi D, Muller EE (2003) 
Endogenous ghrelin is an orexigenic peptide acting in the arcuate nucleus in 
response to fasting. Regul Pept 111: 161-167 
 
Batterham RL, Bloom SR (2003) The gut hormone peptide YY regulates appetite. 
Ann N Y Acad Sci 994: 162-168 
 
Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, 
Bloom SR (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N 
Engl J Med 349: 941-948 
 
Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, 
Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR (2002) Gut hormone PYY(3-36) 
physiologically inhibits food intake. Nature 418: 650-654 
 
Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H, Le Roux 
CW, Thomas EL, Bell JD, Withers DJ (2006) Critical role for peptide YY in protein-
mediated satiation and body-weight regulation. Cell Metab 4: 223-233 
 
Baxter AJ, Coyne T, McClintock C (2006) Dietary patterns and metabolic syndrome-
-a review of epidemiologic evidence. Asia Pac J Clin Nutr 15: 134-142 
 
65 
 
  
Belfrage P, Fredrikson G, Nilsson NO, Stralfors P (1980) Regulation of adipose 
tissue lipolysis: phosphorylation of hormones sensitive lipase in intact rat 
adipocytes. FEBS Lett 111: 120-124 
 
Belgardt BF, Bruning JC (2010) CNS leptin and insulin action in the control of 
energy homeostasis. Ann N Y Acad Sci 1212: 97-113 
 
Bellissimo N, Desantadina MV, Pencharz PB, Berall GB, Thomas SG, Anderson GH 
(2008) A comparison of short-term appetite and energy intakes in normal weight 
and obese boys following glucose and whey-protein drinks. Int J Obes (Lond) 32: 
362-371 
 
Belobrajdic DP, McIntosh GH, Owens JA (2004) A high-whey-protein diet reduces 
body weight gain and alters insulin sensitivity relative to red meat in wistar rats. J 
Nutr 134: 1454-1458 
 
Bendtsen LQ, Lorenzen JK, Bendsen NT, Rasmussen C, Astrup A (2013) Effect of 
dairy proteins on appetite, energy expenditure, body weight, and composition: a 
review of the evidence from controlled clinical trials. Adv Nutr 4: 418-438 
 
Benoit SC, Air EL, Coolen LM, Strauss R, Jackman A, Clegg DJ, Seeley RJ, Woods SC 
(2002) The catabolic action of insulin in the brain is mediated by melanocortins. J 
Neurosci 22: 9048-9052 
 
Benton MJ, Swan PD (2007) Effect of protein ingestion on energy expenditure and 
substrate utilization after exercise in middle-aged women. Int J Sport Nutr Exerc 
Metab 17: 544-555 
 
Berthoud HR, Sutton GM, Townsend RL, Patterson LM, Zheng H (2006) Brainstem 
mechanisms integrating gut-derived satiety signals and descending forebrain 
information in the control of meal size. Physiol Behav 89: 517-524 
 
Betts J, Williams C, Duffy K, Gunner F (2007) The influence of carbohydrate and 
protein ingestion during recovery from prolonged exercise on subsequent 
endurance performance. J Sports Sci 25: 1449-1460 
 
Black DD (2007) Development and physiological regulation of intestinal lipid 
absorption. I. Development of intestinal lipid absorption: cellular events in 
chylomicron assembly and secretion. Am J Physiol Gastrointest Liver Physiol 293: 
G519-524 
 
Blevins JE, Morton GJ, Williams DL, Caldwell DW, Bastian LS, Wisse BE, Schwartz 
MW, Baskin DG (2009) Forebrain melanocortin signaling enhances the hindbrain 
satiety response to CCK-8. Am J Physiol Regul Integr Comp Physiol 296: R476-484 
 
Boey D, Lin S, Enriquez RF, Lee NJ, Slack K, Couzens M, Baldock PA, Herzog H, 
Sainsbury A (2008) PYY transgenic mice are protected against diet-induced and 
genetic obesity. Neuropeptides 42: 19-30 
 
66 
 
  
Boirie Y (2013) "Slow proteins", "fast proteins": a useful or futile concept? Corresp 
Mhdn 17: 124-+ 
 
Boirie Y, Dangin M, Gachon P, Vasson MP, Maubois JL, Beaufrere B (1997) Slow and 
fast dietary proteins differently modulate postprandial protein accretion. Proc Natl 
Acad Sci U S A 94: 14930-14935 
 
Bosma M, Kersten S, Hesselink MK, Schrauwen P (2012) Re-evaluating lipotoxic 
triggers in skeletal muscle: relating intramyocellular lipid metabolism to insulin 
sensitivity. Prog Lipid Res 51: 36-49 
 
Bowen J, Noakes M, Clifton PM (2006a) Appetite regulatory hormone responses to 
various dietary proteins differ by body mass index status despite similar 
reductions in ad libitum energy intake. J Clin Endocr Metab 91: 2913-2919 
 
Bowen J, Noakes M, Clifton PM (2007) Appetite hormones and energy intake in 
obese men after consumption of fructose, glucose and whey protein beverages. Int 
J Obes (Lond) 31: 1696-1703 
 
Bowen J, Noakes M, Trenerry C, Clifton PM (2006b) Energy intake, ghrelin, and 
cholecystokinin after different carbohydrate and protein preloads in overweight 
men. J Clin Endocr Metab 91: 1477-1483 
 
Bradley RL, Mansfield JP, Maratos-Flier E (2005) Neuropeptides, including 
neuropeptide Y and melanocortins, mediate lipolysis in murine adipocytes. Obes 
Res 13: 653-661 
 
Brenner LA, Ritter RC (1998) Intracerebroventricular cholecystokinin A-receptor 
antagonist does not reduce satiation by endogenous CCK. Physiol Behav 63: 711-
716 
 
Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T (1998) The 
neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, 
anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci U S A 95: 
15043-15048 
 
Brody EP (2000) Biological activities of bovine glycomacropeptide. Br J Nutr 84 
Suppl 1: S39-46 
 
Bruinstroop E, Pei L, Ackermans MT, Foppen E, Borgers AJ, Kwakkel J, Alkemade A, 
Fliers E, Kalsbeek A (2012) Hypothalamic neuropeptide Y (NPY) controls hepatic 
VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes 
61: 1043-1050 
 
Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, 
Muller-Wieland D, Kahn CR (2000) Role of brain insulin receptor in control of body 
weight and reproduction. Science 289: 2122-2125 
 
67 
 
  
Buettner C, Muse ED, Cheng A, Chen L, Scherer T, Pocai A, Su K, Cheng B, Li X, 
Harvey-White J, Schwartz GJ, Kunos G, Rossetti L (2008) Leptin controls adipose 
tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 14: 667-
675 
 
Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger 
ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 
137: 2968-2978 
 
Burton-Freeman BM (2008) Glycomacropeptide (GMP) is not critical to whey-
induced satiety, but may have a unique role in energy intake regulation through 
cholecystokinin (CCK). Physiol Behav 93: 379-387 
 
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, 
Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpice T, Chamontin B, 
Ferrieres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM et al (2007) Metabolic 
endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772 
 
Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R 
(2008) Changes in gut microbiota control metabolic endotoxemia-induced 
inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 
1470-1481 
 
Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, 
Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM (2009) Changes in 
gut microbiota control inflammation in obese mice through a mechanism involving 
GLP-2-driven improvement of gut permeability. Gut 58: 1091-1103 
 
Carmen GY, Victor SM (2006) Signalling mechanisms regulating lipolysis. Cell 
Signal 18: 401-408 
 
Carobbio S, Hagen RM, Lelliott CJ, Slawik M, Medina-Gomez G, Tan CY, Sicard A, 
Atherton HJ, Barbarroja N, Bjursell M, Bohlooly YM, Virtue S, Tuthill A, Lefai E, 
Laville M, Wu T, Considine RV, Vidal H, Langin D, Oresic M et al (2013) Adaptive 
changes of the Insig1/SREBP1/SCD1 set point help adipose tissue to cope with 
increased storage demands of obesity. Diabetes 62: 3697-3708 
 
Caterson ID, Hubbard V, Bray GA, Grunstein R, Hansen BC, Hong Y, Labarthe D, 
Seidell JC, Smith SC, Jr. (2004) Prevention Conference VII: Obesity, a worldwide 
epidemic related to heart disease and stroke: Group III: worldwide comorbidities 
of obesity. Circulation 110: e476-483 
 
Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S (2003) Acute 
effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in 
the mouse. Biochem Biophys Res Commun 311: 915-919 
 
Chao PT, Yang L, Aja S, Moran TH, Bi S (2011) Knockdown of NPY expression in the 
dorsomedial hypothalamus promotes development of brown adipocytes and 
prevents diet-induced obesity. Cell Metab 13: 573-583 
68 
 
  
 
Chavez M, Kaiyala K, Madden LJ, Schwartz MW, Woods SC (1995) Intraventricular 
insulin and the level of maintained body weight in rats. Behav Neurosci 109: 528-
531 
 
Chelikani PK, Haver AC, Reeve JR, Jr., Keire DA, Reidelberger RD (2006) Daily, 
intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake 
and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 290: R298-305 
 
Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, 
Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, 
Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY et al (2000a) Inactivation 
of the mouse melanocortin-3 receptor results in increased fat mass and reduced 
lean body mass. Nat Genet 26: 97-102 
 
Chen AS, Metzger JM, Trumbauer ME, Guan XM, Yu H, Frazier EG, Marsh DJ, Forrest 
MJ, Gopal-Truter S, Fisher J, Camacho RE, Strack AM, Mellin TN, MacIntyre DE, 
Chen HY, Van der Ploeg LH (2000b) Role of the melanocortin-4 receptor in 
metabolic rate and food intake in mice. Transgenic Res 9: 145-154 
 
Chen HY, Trumbauer ME, Chen AS, Weingarth DT, Adams JR, Frazier EG, Shen Z, 
Marsh DJ, Feighner SD, Guan XM, Ye Z, Nargund RP, Smith RG, Van der Ploeg LH, 
Howard AD, MacNeil DJ, Qian S (2004) Orexigenic action of peripheral ghrelin is 
mediated by neuropeptide Y and agouti-related protein. Endocrinology 145: 2607-
2612 
 
Chen Q, Cao J, Jia Y, Yan Y, Pang G (2012) Modulation of mice fecal microbiota by 
administration of casein glycomacropeptide. Microbiology research 3: e3 
 
Cheung CC, Clifton DK, Steiner RA (1997) Proopiomelanocortin neurons are direct 
targets for leptin in the hypothalamus. Endocrinology 138: 4489-4492 
 
Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, 
Mosley AN, Chun J (2010) LPA receptors: subtypes and biological actions. Annu Rev 
Pharmacol Toxicol 50: 157-186 
 
Choi S, Lee M, Shiu AL, Yo SJ, Aponte GW (2007a) Identification of a protein 
hydrolysate responsive G protein-coupled receptor in enterocytes. Am J Physiol 
Gastrointest Liver Physiol 292: G98-G112 
 
Choi S, Lee M, Shiu AL, Yo SJ, Hallden G, Aponte GW (2007b) GPR93 activation by 
protein hydrolysate induces CCK transcription and secretion in STC-1 cells. Am J 
Physiol Gastrointest Liver Physiol 292: G1366-1375 
 
Choi YH, Li C, Page K, Westby A, Della-Fera MA, Lin J, Hartzell DL, Baile CA (2003) 
Melanocortin receptors mediate leptin effects on feeding and body weight but not 
adipose apoptosis. Physiol Behav 79: 795-801 
 
69 
 
  
Clark JT, Kalra PS, Crowley WR, Kalra SP (1984) Neuropeptide Y and human 
pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115: 427-
429 
 
Clarke IJ, Henry BA (2010) Targeting energy expenditure in muscle as a means of 
combating obesity. Clin Exp Pharmacol Physiol 37: 121-124 
 
Clarke JF, Young PW, Yonezawa K, Kasuga M, Holman GD (1994) Inhibition of the 
translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-
kinase inhibitor, wortmannin. Biochem J 300 ( Pt 3): 631-635 
 
Clegg DJ, Benoit SC, Reed JA, Woods SC, Dunn-Meynell A, Levin BE (2005) Reduced 
anorexic effects of insulin in obesity-prone rats fed a moderate-fat diet. Am J 
Physiol Regul Integr Comp Physiol 288: R981-986 
 
Clifford GM, Londos C, Kraemer FB, Vernon RG, Yeaman SJ (2000) Translocation of 
hormone-sensitive lipase and perilipin upon lipolytic stimulation of rat adipocytes. 
J Biol Chem 275: 5011-5015 
 
Coker RH, Miller S, Schutzler S, Deutz N, Wolfe RR (2012) Whey protein and 
essential amino acids promote the reduction of adipose tissue and increased 
muscle protein synthesis during caloric restriction-induced weight loss in elderly, 
obese individuals. Nutr J 11: 105 
 
Coomans CP, Geerling JJ, Guigas B, van den Hoek AM, Parlevliet ET, Ouwens DM, 
Pijl H, Voshol PJ, Rensen PC, Havekes LM, Romijn JA (2011) Circulating insulin 
stimulates fatty acid retention in white adipose tissue via KATP channel activation 
in the central nervous system only in insulin-sensitive mice. J Lipid Res 52: 1712-
1722 
 
Corcoran MP, Lamon-Fava S, Fielding RA (2007) Skeletal muscle lipid deposition 
and insulin resistance: effect of dietary fatty acids and exercise. Am J Clin Nutr 85: 
662-677 
 
Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, Low 
MJ (2001) Leptin activates anorexigenic POMC neurons through a neural network 
in the arcuate nucleus. Nature 411: 480-484 
 
Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, 
Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, 
Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD et al (2003) 
The distribution and mechanism of action of ghrelin in the CNS demonstrates a 
novel hypothalamic circuit regulating energy homeostasis. Neuron 37: 649-661 
 
Cummings DE, Overduin J (2007) Gastrointestinal regulation of food intake. J Clin 
Invest 117: 13-23 
 
70 
 
  
Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ 
(2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass 
surgery. N Engl J Med 346: 1623-1630 
 
Cusi K (2012) Role of obesity and lipotoxicity in the development of nonalcoholic 
steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142: 
711-725 e716 
 
Dam J, Jockers R (2013) Hunting for the functions of short leptin receptor isoforms. 
Mol Metab 2: 327-328 
 
Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, 
Nakazato M (2002) The role of the gastric afferent vagal nerve in ghrelin-induced 
feeding and growth hormone secretion in rats. Gastroenterology 123: 1120-1128 
 
Date Y, Toshinai K, Koda S, Miyazato M, Shimbara T, Tsuruta T, Niijima A, Kangawa 
K, Nakazato M (2005) Peripheral interaction of ghrelin with cholecystokinin on 
feeding regulation. Endocrinology 146: 3518-3525 
 
DeFronzo RA, Tripathy D (2009) Skeletal muscle insulin resistance is the primary 
defect in type 2 diabetes. Diabetes Care 32 Suppl 2: S157-163 
 
Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C (2005) Effect 
of peptide YY3-36 on food intake in humans. Gastroenterology 129: 1430-1436 
 
Della-Zuana O, Revereault L, Beck-Sickinger A, Monge A, Caignard DH, Fauchere JL, 
Henlin JM, Audinot V, Boutin JA, Chamorro S, Feletou M, Levens N (2004) A potent 
and selective NPY Y5 antagonist reduces food intake but not through blockade of 
the NPY Y5 receptor. Int J Obes Relat Metab Disord 28: 628-639 
 
Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodes-Cabau J, 
Bertrand OF, Poirier P (2008) Abdominal obesity and the metabolic syndrome: 
contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28: 
1039-1049 
 
Dideriksen KJ, Reitelseder S, Petersen SG, Hjort M, Helmark IC, Kjaer M, Holm L 
(2011) Stimulation of muscle protein synthesis by whey and caseinate ingestion 
after resistance exercise in elderly individuals. Scand J Med Sci Sports 21: e372-383 
 
Diraison F, Moulin P, Beylot M (2003) Contribution of hepatic de novo lipogenesis 
and reesterification of plasma non esterified fatty acids to plasma triglyceride 
synthesis during non-alcoholic fatty liver disease. Diabetes Metab 29: 478-485 
 
Dockray GJ (2013) Enteroendocrine cell signalling via the vagus nerve. Curr Opin 
Pharmacol 13: 954-958 
 
Donahey JC, van Dijk G, Woods SC, Seeley RJ (1998) Intraventricular GLP-1 reduces 
short- but not long-term food intake or body weight in lean and obese rats. Brain 
Res 779: 75-83 
71 
 
  
 
Donath MY, Dalmas E, Sauter NS, Boni-Schnetzler M (2013) Inflammation in 
obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab 17: 
860-872 
 
Donnelly D (2012) The structure and function of the glucagon-like peptide-1 
receptor and its ligands. Br J Pharmacol 166: 27-41 
 
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) 
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with 
nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351 
 
Doucet E, Laviolette M, Imbeault P, Strychar I, Rabasa-Lhoret R, Prud'homme D 
(2008) Total peptide YY is a correlate of postprandial energy expenditure but not 
of appetite or energy intake in healthy women. Metabolism 57: 1458-1464 
 
Drover VA, Ajmal M, Nassir F, Davidson NO, Nauli AM, Sahoo D, Tso P, Abumrad NA 
(2005) CD36 deficiency impairs intestinal lipid secretion and clearance of 
chylomicrons from the blood. J Clin Invest 115: 1290-1297 
 
Druce MR, Wren AM, Park AJ, Milton JE, Patterson M, Frost G, Ghatei MA, Small C, 
Bloom SR (2005) Ghrelin increases food intake in obese as well as lean subjects. Int 
J Obes (Lond) 29: 1130-1136 
 
Drucker DJ (2006) Enhancing the action of incretin hormones: a new whey 
forward? Endocrinology 147: 3171-3172 
 
Duca FA, Covasa M (2012) Current and emerging concepts on the role of peripheral 
signals in the control of food intake and development of obesity. Br J Nutr 108: 
778-793 
 
Eckardt K, Taube A, Eckel J (2011) Obesity-associated insulin resistance in skeletal 
muscle: role of lipid accumulation and physical inactivity. Rev Endocr Metab Disord 
12: 163-172 
 
Edwards GL, Ladenheim EE, Ritter RC (1986) Dorsomedial hindbrain participation 
in cholecystokinin-induced satiety. Am J Physiol 251: R971-977 
 
Elias CF, Aschkenasi C, Lee C, Kelly J, Ahima RS, Bjorbaek C, Flier JS, Saper CB, 
Elmquist JK (1999) Leptin differentially regulates NPY and POMC neurons 
projecting to the lateral hypothalamic area. Neuron 23: 775-786 
 
Elias CF, Lee C, Kelly J, Aschkenasi C, Ahima RS, Couceyro PR, Kuhar MJ, Saper CB, 
Elmquist JK (1998) Leptin activates hypothalamic CART neurons projecting to the 
spinal cord. Neuron 21: 1375-1385 
 
Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB (1998) Distributions of leptin 
receptor mRNA isoforms in the rat brain. J Comp Neurol 395: 535-547 
 
72 
 
  
Enriori PJ, Evans AE, Sinnayah P, Jobst EE, Tonelli-Lemos L, Billes SK, Glavas MM, 
Grayson BE, Perello M, Nillni EA, Grove KL, Cowley MA (2007) Diet-induced 
obesity causes severe but reversible leptin resistance in arcuate melanocortin 
neurons. Cell Metab 5: 181-194 
 
Fair AM, Montgomery K (2009) Energy balance, physical activity, and cancer risk. 
Methods Mol Biol 472: 57-88 
 
Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, Fruchart JC, Briggs M, 
Spiegelman BM, Auwerx J (1999) Regulation of peroxisome proliferator-activated 
receptor gamma expression by adipocyte differentiation and determination factor 
1/sterol regulatory element binding protein 1: implications for adipocyte 
differentiation and metabolism. Mol Cell Biol 19: 5495-5503 
 
Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD (1997) Role of 
melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 
385: 165-168 
 
Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, 
LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB (2002) Lysophosphatidic acid is a 
bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582: 257-264 
 
Faouzi M, Leshan R, Bjornholm M, Hennessey T, Jones J, Munzberg H (2007) 
Differential accessibility of circulating leptin to individual hypothalamic sites. 
Endocrinology 148: 5414-5423 
 
Farnfield MM, Breen L, Carey KA, Garnham A, Cameron-Smith D (2012) Activation 
of mTOR signalling in young and old human skeletal muscle in response to 
combined resistance exercise and whey protein ingestion. Appl Physiol Nutr Metab 
37: 21-30 
 
Faulconbridge LF, Grill HJ, Kaplan JM, Daniels D (2008) Caudal brainstem delivery 
of ghrelin induces fos expression in the nucleus of the solitary tract, but not in the 
arcuate or paraventricular nuclei of the hypothalamus. Brain Res 1218: 151-157 
 
Fekete C, Sarkar S, Rand WM, Harney JW, Emerson CH, Bianco AC, Beck-Sickinger 
A, Lechan RM (2002) Neuropeptide Y1 and Y5 receptors mediate the effects of 
neuropeptide Y on the hypothalamic-pituitary-thyroid axis. Endocrinology 143: 
4513-4519 
 
Fekete C, Singru PS, Sanchez E, Sarkar S, Christoffolete MA, Riberio RS, Rand WM, 
Emerson CH, Bianco AC, Lechan RM (2006) Differential effects of central leptin, 
insulin, or glucose administration during fasting on the hypothalamic-pituitary-
thyroid axis and feeding-related neurons in the arcuate nucleus. Endocrinology 
147: 520-529 
 
Ferry G, Tellier E, Try A, Gres S, Naime I, Simon MF, Rodriguez M, Boucher J, Tack I, 
Gesta S, Chomarat P, Dieu M, Raes M, Galizzi JP, Valet P, Boutin JA, Saulnier-Blache 
JS (2003) Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid 
73 
 
  
synthesis, and activates preadipocyte proliferation. Up-regulated expression with 
adipocyte differentiation and obesity. J Biol Chem 278: 18162-18169 
 
Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A (2000) The effect of glucagon-like 
peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes 
Relat Metab Disord 24: 288-298 
 
Frayn KN, Arner P, Yki-Jarvinen H (2006) Fatty acid metabolism in adipose tissue, 
muscle and liver in health and disease. Essays Biochem 42: 89-103 
 
Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW (2003) Integrative 
physiology of human adipose tissue. Int J Obes Relat Metab Disord 27: 875-888 
 
Freedman DJ, Tacket CO, Delehanty A, Maneval DR, Nataro J, Crabb JH (1998) Milk 
immunoglobulin with specific activity against purified colonization factor antigens 
can protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis 
177: 662-667 
 
Frestedt JL, Zenk JL, Kuskowski MA, Ward LS, Bastian ED (2008) A whey-protein 
supplement increases fat loss and spares lean muscle in obese subjects: a 
randomized human clinical study. Nutr Metab (Lond) 5: 8 
 
Freudenberg A, Petzke KJ, Klaus S (2012) Comparison of high-protein diets and 
leucine supplementation in the prevention of metabolic syndrome and related 
disorders in mice. J Nutr Biochem 23: 1524-1530 
 
Frid AH, Nilsson M, Holst JJ, Bjorck IM (2005) Effect of whey on blood glucose and 
insulin responses to composite breakfast and lunch meals in type 2 diabetic 
subjects. Am J Clin Nutr 82: 69-75 
 
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in 
mammals. Nature 395: 763-770 
 
Galic S, Oakhill JS, Steinberg GR (2010) Adipose tissue as an endocrine organ. Mol 
Cell Endocrinol 316: 129-139 
 
Gallardo N, Bonzon-Kulichenko E, Fernandez-Agullo T, Molto E, Gomez-Alonso S, 
Blanco P, Carrascosa JM, Ros M, Andres A (2007) Tissue-specific effects of central 
leptin on the expression of genes involved in lipid metabolism in liver and white 
adipose tissue. Endocrinology 148: 5604-5610 
 
Gao D, Ning N, Wang C, Wang Y, Li Q, Meng Z, Liu Y, Li Q (2013) Dairy products 
consumption and risk of type 2 diabetes: systematic review and dose-response 
meta-analysis. PLoS One 8: e73965 
 
Garber AJ (2011) Incretin effects on beta-cell function, replication, and mass: the 
human perspective. Diabetes Care 34 Suppl 2: S258-263 
 
74 
 
  
Gaudel C, Nongonierma AB, Maher S, Flynn S, Krause M, Murray BA, Kelly PM, 
Baird AW, FitzGerald RJ, Newsholme P (2013) A whey protein hydrolysate 
promotes insulinotropic activity in a clonal pancreatic beta-cell line and enhances 
glycemic function in ob/ob mice. J Nutr 143: 1109-1114 
 
Geerling JJ, Boon MR, Kooijman S, Parlevliet ET, Havekes LM, Romijn JA, Meurs IM, 
Rensen PC (2014) Sympathetic nervous system control of triglyceride metabolism: 
novel concepts derived from recent studies. J Lipid Res 55: 180-189 
 
Gibbs J, Young RC, Smith GP (1973) Cholecystokinin decreases food intake in rats. J 
Comp Physiol Psychol 84: 488-495 
 
Glatz JF, Luiken JJ, Bonen A (2010) Membrane fatty acid transporters as regulators 
of lipid metabolism: implications for metabolic disease. Physiol Rev 90: 367-417 
 
Goldberg IJ, Eckel RH, Abumrad NA (2009) Regulation of fatty acid uptake into 
tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res 50 Suppl: 
S86-90 
 
Grider JR (1994) Role of cholecystokinin in the regulation of gastrointestinal 
motility. J Nutr 124: 1334S-1339S 
 
Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo 
RA (1989) Glucose and free fatty acid metabolism in non-insulin-dependent 
diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84: 
205-213 
 
Gunnarsson PT, Winzell MS, Deacon CF, Larsen MO, Jelic K, Carr RD, Ahren B 
(2006) Glucose-induced incretin hormone release and inactivation are differently 
modulated by oral fat and protein in mice. Endocrinology 147: 3173-3180 
 
Guo Y, Ma L, Enriori PJ, Koska J, Franks PW, Brookshire T, Cowley MA, Salbe AD, 
Delparigi A, Tataranni PA (2006) Physiological evidence for the involvement of 
peptide YY in the regulation of energy homeostasis in humans. Obesity 14: 1562-
1570 
 
Gustafson B, Gogg S, Hedjazifar S, Jenndahl L, Hammarstedt A, Smith U (2009) 
Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am J 
Physiol Endocrinol Metab 297: E999-E1003 
 
Hackney KJ, Bruenger AJ, Lemmer JT (2010) Timing protein intake increases 
energy expenditure 24 h after resistance training. Med Sci Sports Exerc 42: 998-
1003 
 
Hagan MM, Rushing PA, Pritchard LM, Schwartz MW, Strack AM, Van Der Ploeg LH, 
Woods SC, Seeley RJ (2000) Long-term orexigenic effects of AgRP-(83---132) 
involve mechanisms other than melanocortin receptor blockade. Am J Physiol Regul 
Integr Comp Physiol 279: R47-52 
 
75 
 
  
Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM (1997) 
Physiological response to long-term peripheral and central leptin infusion in lean 
and obese mice. Proc Natl Acad Sci U S A 94: 8878-8883 
 
Hall WL, Millward DJ, Long SJ, Morgan LM (2003) Casein and whey exert different 
effects on plasma amino acid profiles, gastrointestinal hormone secretion and 
appetite. Br J Nutr 89: 239-248 
 
Hamad EM, Taha SH, Abou Dawood AG, Sitohy MZ, Abdel-Hamid M (2011) 
Protective effect of whey proteins against nonalcoholic fatty liver in rats. Lipids 
Health Dis 10: 57 
 
Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ (2007) 
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, 
and energy expenditure. J Clin Invest 117: 143-152 
 
Hasler CM (2002) Functional foods: benefits, concerns and challenges-a position 
paper from the american council on science and health. J Nutr 132: 3772-3781 
 
Havrankova J, Roth J, Brownstein M (1978) Insulin receptors are widely 
distributed in the central nervous system of the rat. Nature 272: 827-829 
 
Hayes MR, Skibicka KP, Leichner TM, Guarnieri DJ, DiLeone RJ, Bence KK, Grill HJ 
(2010) Endogenous leptin signaling in the caudal nucleus tractus solitarius and 
area postrema is required for energy balance regulation. Cell Metab 11: 77-83 
 
He T, Giuseppin ML (2014) Slow and fast dietary proteins differentially modulate 
postprandial metabolism. Int J Food Sci Nutr 65: 386-390 
 
Hill JO, Wyatt HR, Peters JC (2012) Energy balance and obesity. Circulation 126: 
126-132 
 
Holm C (2003) Molecular mechanisms regulating hormone-sensitive lipase and 
lipolysis. Biochem Soc Trans 31: 1120-1124 
 
Horowitz JF, Klein S (2000) Lipid metabolism during endurance exercise. Am J Clin 
Nutr 72: 558S-563S 
 
Huang XF, Liu YX, Rahardjo GL, McLennan PL, Tapsell LC, Buttemer WA (2008) 
Effects of diets high in whey, soy, red meat and milk protein on body weight 
maintenance in diet-induced obesity in mice. Nutr Diet 65: S53-S59 
 
Hursel R, van der Zee L, Westerterp-Plantenga MS (2010) Effects of a breakfast 
yoghurt, with additional total whey protein or caseinomacropeptide-depleted 
alpha-lactalbumin-enriched whey protein, on diet-induced thermogenesis and 
appetite suppression. Br J Nutr 103: 775-780 
 
76 
 
  
Hwa JJ, Witten MB, Williams P, Ghibaudi L, Gao J, Salisbury BG, Mullins D, Hamud F, 
Strader CD, Parker EM (1999) Activation of the NPY Y5 receptor regulates both 
feeding and energy expenditure. Am J Physiol 277: R1428-1434 
 
Iizuka K, Horikawa Y (2008) ChREBP: a glucose-activated transcription factor 
involved in the development of metabolic syndrome. Endocr J 55: 617-624 
 
Itani SI, Ruderman NB, Schmieder F, Boden G (2002) Lipid-induced insulin 
resistance in human muscle is associated with changes in diacylglycerol, protein 
kinase C, and IkappaB-alpha. Diabetes 51: 2005-2011 
 
Jakubowicz D, Froy O (2013) Biochemical and metabolic mechanisms by which 
dietary whey protein may combat obesity and Type 2 diabetes. J Nutr Biochem 24: 
1-5 
 
Jensen J, Lai YC (2009) Regulation of muscle glycogen synthase phosphorylation 
and kinetic properties by insulin, exercise, adrenaline and role in insulin 
resistance. Arch Physiol Biochem 115: 13-21 
 
Jewett DC, Cleary J, Schaal DW, Thompson T, Levine AS (1993) 
[Leu31,Pro34]neuropeptide Y (NPY), but not NPY 20-36, produces discriminative 
stimulus effects similar to NPY and induces food intake. Brain Res 631: 129-132 
 
Jump DB (2011) Fatty acid regulation of hepatic lipid metabolism. Curr Opin Clin 
Nutr 14: 115-120 
 
Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW (2000) Obesity induced 
by a high-fat diet is associated with reduced brain insulin transport in dogs. 
Diabetes 49: 1525-1533 
 
Kakigi R, Yoshihara T, Ozaki H, Ogura Y, Ichinoseki-Sekine N, Kobayashi H, Naito H 
(2014) Whey protein intake after resistance exercise activates mTOR signaling in a 
dose-dependent manner in human skeletal muscle. Eur J Appl Physiol 114: 735-742 
 
Kalra SP, Dube MG, Fournier A, Kalra PS (1991) Structure-function analysis of 
stimulation of food intake by neuropeptide Y: effects of receptor agonists. Physiol 
Behav 50: 5-9 
 
Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I (2001) Chronic 
central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-
related protein mRNA levels and body weight in rats. Diabetes 50: 2438-2443 
 
Kanoski SE, Zhao S, Guarnieri DJ, DiLeone RJ, Yan J, De Jonghe BC, Bence KK, Hayes 
MR, Grill HJ (2012) Endogenous leptin receptor signaling in the medial nucleus 
tractus solitarius affects meal size and potentiates intestinal satiation signals. Am J 
Physiol Endocrinol Metab 303: E496-503 
 
Karpe F, Dickmann JR, Frayn KN (2011) Fatty acids, obesity, and insulin resistance: 
time for a reevaluation. Diabetes 60: 2441-2449 
77 
 
  
 
Karra E, Batterham RL (2010) The role of gut hormones in the regulation of body 
weight and energy homeostasis. Mol Cell Endocrinol 316: 120-128 
 
Keogh JB, Clifton P (2008) The effect of meal replacements high in 
glycomacropeptide on weight loss and markers of cardiovascular disease risk. Am J 
Clin Nutr 87: 1602-1605 
 
Keogh JB, Woonton BW, Taylor CM, Janakievski F, Desilva K, Clifton PM (2010) 
Effect of glycomacropeptide fractions on cholecystokinin and food intake. Br J Nutr 
104: 286-290 
 
Kerner J, Hoppel C (2000) Fatty acid import into mitochondria. Biochim Biophys 
Acta 1486: 1-17 
 
Kersten S (2001) Mechanisms of nutritional and hormonal regulation of 
lipogenesis. EMBO Rep 2: 282-286 
 
Keung W, Palaniyappan A, Lopaschuk GD (2011) Chronic central leptin decreases 
food intake and improves glucose tolerance in diet-induced obese mice 
independent of hypothalamic malonyl CoA levels and skeletal muscle insulin 
sensitivity. Endocrinology 152: 4127-4137 
 
Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP (1981) C-terminal octapeptide of 
cholecystokinin decreases food intake in man. Am J Clin Nutr 34: 154-160 
 
Kleinridders A, Schenten D, Konner AC, Belgardt BF, Mauer J, Okamura T, 
Wunderlich FT, Medzhitov R, Bruning JC (2009) MyD88 signaling in the CNS is 
required for development of fatty acid-induced leptin resistance and diet-induced 
obesity. Cell Metab 10: 249-259 
 
Koch L, Wunderlich FT, Seibler J, Konner AC, Hampel B, Irlenbusch S, Brabant G, 
Kahn CR, Schwenk F, Bruning JC (2008) Central insulin action regulates peripheral 
glucose and fat metabolism in mice. J Clin Invest 118: 2132-2147 
 
Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K, Niijima A, Furuya 
M, Inomata N, Osuye K, Nakazato M (2005) The role of the vagal nerve in 
peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146: 2369-
2375 
 
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a 
growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660 
 
Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC, Caro JF (1996) Response 
of leptin to short-term and prolonged overfeeding in humans. J Clin Endocrinol 
Metab 81: 4162-4165 
 
Konner AC, Janoschek R, Plum L, Jordan SD, Rother E, Ma X, Xu C, Enriori P, Hampel 
B, Barsh GS, Kahn CR, Cowley MA, Ashcroft FM, Bruning JC (2007) Insulin action in 
78 
 
  
AgRP-expressing neurons is required for suppression of hepatic glucose 
production. Cell Metab 5: 438-449 
 
Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haider W, Schmitz F, Bonner-
Weir S, Kanarek R, Beinborn M (1999) The cholecystokinin-A receptor mediates 
inhibition of food intake yet is not essential for the maintenance of body weight. J 
Clin Invest 103: 383-391 
 
Krashes MJ, Shah BP, Koda S, Lowell BB (2013) Rapid versus delayed stimulation 
of feeding by the endogenously released AgRP neuron mediators GABA, NPY, and 
AgRP. Cell Metab 18: 588-595 
 
Krissansen GW (2007) Emerging health properties of whey proteins and their 
clinical implications. J Am Coll Nutr 26: 713S-723S 
 
Kruzel ML, Harari Y, Chen CY, Castro GA (2000) Lactoferrin protects gut mucosal 
integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation 
24: 33-44 
 
Lacroix IME, Li-Chan ECY (2012) Dipeptidyl peptidase-IV inhibitory activity of 
dairy protein hydrolysates. Int Dairy J 25: 97-102 
 
Lafontan M, Berlan M (1993) Fat cell adrenergic receptors and the control of white 
and brown fat cell function. J Lipid Res 34: 1057-1091 
 
Lam SM, Moughan PJ, Awati A, Morton HR (2009) The influence of whey protein 
and glycomacropeptide on satiety in adult humans. Physiol Behav 96: 162-168 
 
Langin D (2006) Control of fatty acid and glycerol release in adipose tissue 
lipolysis. Comptes rendus biologies 329: 598-607; discussion 653-595 
 
Large V, Peroni O, Letexier D, Ray H, Beylot M (2004) Metabolism of lipids in 
human white adipocyte. Diabetes Metab 30: 294-309 
 
Lass A, Zimmermann R, Haemmerle G, Riederer M, Schoiswohl G, Schweiger M, 
Kienesberger P, Strauss JG, Gorkiewicz G, Zechner R (2006) Adipose triglyceride 
lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective 
in Chanarin-Dorfman Syndrome. Cell Metab 3: 309-319 
 
Leckstrom A, Lew PS, Poritsanos NJ, Mizuno TM (2011) Central melanocortin 
receptor agonist reduces hepatic lipogenic gene expression in streptozotocin-
induced diabetic mice. Life Sci 88: 664-669 
 
Lee WJ, Farmer JL, Hilty M, Kim YB (1998) The protective effects of lactoferrin 
feeding against endotoxin lethal shock in germfree piglets. Infect Immun 66: 1421-
1426 
 
Lenard NR, Berthoud HR (2008) Central and peripheral regulation of food intake 
and physical activity: pathways and genes. Obesity 16 Suppl 3: S11-22 
79 
 
  
 
Leshan RL, Bjornholm M, Munzberg H, Myers MG, Jr. (2006) Leptin receptor 
signaling and action in the central nervous system. Obesity 14 Suppl 5: 208S-212S 
 
Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI (2005) 
Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102: 11070-11075 
 
Li G, Zhang Y, Rodrigues E, Zheng D, Matheny M, Cheng KY, Scarpace PJ (2007) 
Melanocortin activation of nucleus of the solitary tract avoids anorectic 
tachyphylaxis and induces prolonged weight loss. Am J Physiol Endocrinol Metab 
293: E252-258 
 
Lieverse RJ, Jansen JB, Masclee AA, Lamers CB (1995) Satiety effects of a 
physiological dose of cholecystokinin in humans. Gut 36: 176-179 
 
Lieverse RJ, Masclee AA, Jansen JB, Lamers CB (1994) Plasma cholecystokinin and 
pancreatic polypeptide secretion in response to bombesin, meal ingestion and 
modified sham feeding in lean and obese persons. Int J Obes Relat Metab Disord 18: 
123-127 
 
Lin J, Choi YH, Hartzell DL, Li C, Della-Fera MA, Baile CA (2003) CNS melanocortin 
and leptin effects on stearoyl-CoA desaturase-1 and resistin expression. Biochem 
Biophys Res Commun 311: 324-328 
 
Lin S, Boey D, Herzog H (2004) NPY and Y receptors: lessons from transgenic and 
knockout models. Neuropeptides 38: 189-200 
 
Lin S, Thomas TC, Storlien LH, Huang XF (2000) Development of high fat diet-
induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab 
Disord 24: 639-646 
 
Lobo S, Wiczer BM, Smith AJ, Hall AM, Bernlohr DA (2007) Fatty acid metabolism 
in adipocytes: functional analysis of fatty acid transport proteins 1 and 4. J Lipid 
Res 48: 609-620 
 
Longato L, Tong M, Wands JR, de la Monte SM (2012) High fat diet induced hepatic 
steatosis and insulin resistance: Role of dysregulated ceramide metabolism. 
Hepatology research : the official journal of the Japan Society of Hepatology 42: 412-
427 
 
Lowell BB, Bachman ES (2003) Beta-Adrenergic receptors, diet-induced 
thermogenesis, and obesity. J Biol Chem 278: 29385-29388 
 
Luhovyy BL, Akhavan T, Anderson GH (2007) Whey proteins in the regulation of 
food intake and satiety. J Am Coll Nutr 26: 704S-712S 
 
Lynch CJ, Halle B, Fujii H, Vary TC, Wallin R, Damuni Z, Hutson SM (2003) Potential 
role of leucine metabolism in the leucine-signaling pathway involving mTOR. Am J 
Physiol Endocrinol Metab 285: E854-863 
80 
 
  
 
Lynch CJ, Hutson SM, Patson BJ, Vaval A, Vary TC (2002) Tissue-specific effects of 
chronic dietary leucine and norleucine supplementation on protein synthesis in 
rats. Am J Physiol Endocrinol Metab 283: E824-835 
 
MacNeil DJ (2007) NPY Y1 and Y5 receptor selective antagonists as anti-obesity 
drugs. Curr Top Med Chem 7: 1721-1733 
 
Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, 
Ranganathan S, et al. (1995) Leptin levels in human and rodent: measurement of 
plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-
1161 
 
Mano-Otagiri A, Iwasaki-Sekino A, Nemoto T, Ohata H, Shuto Y, Nakabayashi H, 
Sugihara H, Oikawa S, Shibasaki T (2010) Genetic suppression of ghrelin receptors 
activates brown adipocyte function and decreases fat storage in rats. Regul Pept 
160: 81-90 
 
Mano-Otagiri A, Ohata H, Iwasaki-Sekino A, Nemoto T, Shibasaki T (2009) Ghrelin 
suppresses noradrenaline release in the brown adipose tissue of rats. J Endocrinol 
201: 341-349 
 
Mansbach CM, 2nd, Gorelick F (2007) Development and physiological regulation of 
intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and 
the intracellular packaging and secretion of chylomicrons. Am J Physiol Gastrointest 
Liver Physiol 293: G645-650 
 
Margareto J, Aguado M, Oses-Prieto JA, Rivero I, Monge A, Aldana I, Marti A, 
Martinez JA (2000) A new NPY-antagonist strongly stimulates apoptosis and 
lipolysis on white adipocytes in an obesity model. Life Sci 68: 99-107 
 
Marino JS, Xu Y, Hill JW (2011) Central insulin and leptin-mediated autonomic 
control of glucose homeostasis. Trends Endocrinol Metab 22: 275-285 
 
Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher SL, Burn P, Palmiter 
RD (1999) Response of melanocortin-4 receptor-deficient mice to anorectic and 
orexigenic peptides. Nat Genet 21: 119-122 
 
Martinez JA, Aguado M, Fruhbeck G (2000) Interactions between leptin and NPY 
affecting lipid mobilization in adipose tissue. J Physiol Biochem 56: 1-8 
 
Mashiko S, Ishihara A, Iwaasa H, Sano H, Oda Z, Ito J, Yumoto M, Okawa M, Suzuki J, 
Fukuroda T, Jitsuoka M, Morin NR, MacNeil DJ, Van der Ploeg LH, Ihara M, Fukami 
T, Kanatani A (2003) Characterization of neuropeptide Y (NPY) Y5 receptor-
mediated obesity in mice: chronic intracerebroventricular infusion of D-
Trp(34)NPY. Endocrinology 144: 1793-1801 
 
Maury E, Brichard SM (2010) Adipokine dysregulation, adipose tissue 
inflammation and metabolic syndrome. Mol Cell Endocrinol 314: 1-16 
81 
 
  
 
McGowan MK, Andrews KM, Grossman SP (1992) Chronic intrahypothalamic 
infusions of insulin or insulin antibodies alter body weight and food intake in the 
rat. Physiol Behav 51: 753-766 
 
McGowan MK, Andrews KM, Kelly J, Grossman SP (1990) Effects of chronic 
intrahypothalamic infusion of insulin on food intake and diurnal meal patterning in 
the rat. Behav Neurosci 104: 373-385 
 
McMinn JE, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW (2000) Effect of 
intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and 
neuropeptide expression. Am J Physiol Regul Integr Comp Physiol 279: R695-703 
 
McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, Humphreys SM, Ruge 
T, Gilbert M, Fielding BA, Frayn KN, Karpe F (2011) Downregulation of adipose 
tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes 
60: 47-55 
 
Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Morgan PJ, Trayhurn 
P (1996) Coexpression of leptin receptor and preproneuropeptide Y mRNA in 
arcuate nucleus of mouse hypothalamus. J Neuroendocrinol 8: 733-735 
 
Mercer JG, Moar KM, Rayner DV, Trayhurn P, Hoggard N (1997) Regulation of 
leptin receptor and NPY gene expression in hypothalamus of leptin-treated obese 
(ob/ob) and cold-exposed lean mice. FEBS Lett 402: 185-188 
 
Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR 
(2000) Loss of insulin signaling in hepatocytes leads to severe insulin resistance 
and progressive hepatic dysfunction. Mol Cell 6: 87-97 
 
Milanski M, Degasperi G, Coope A, Morari J, Denis R, Cintra DE, Tsukumo DM, Anhe 
G, Amaral ME, Takahashi HK, Curi R, Oliveira HC, Carvalheira JB, Bordin S, Saad MJ, 
Velloso LA (2009) Saturated fatty acids produce an inflammatory response 
predominantly through the activation of TLR4 signaling in hypothalamus: 
implications for the pathogenesis of obesity. J Neurosci 29: 359-370 
 
Miyoshi H, Perfield JW, 2nd, Souza SC, Shen WJ, Zhang HH, Stancheva ZS, Kraemer 
FB, Obin MS, Greenberg AS (2007) Control of adipose triglyceride lipase action by 
serine 517 of perilipin A globally regulates protein kinase A-stimulated lipolysis in 
adipocytes. J Biol Chem 282: 996-1002 
 
Miyoshi H, Souza SC, Zhang HH, Strissel KJ, Christoffolete MA, Kovsan J, Rudich A, 
Kraemer FB, Bianco AC, Obin MS, Greenberg AS (2006) Perilipin promotes 
hormone-sensitive lipase-mediated adipocyte lipolysis via phosphorylation-
dependent and -independent mechanisms. J Biol Chem 281: 15837-15844 
 
Moran TH, Katz LF, Plata-Salaman CR, Schwartz GJ (1998) Disordered food intake 
and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 274: R618-
625 
82 
 
  
 
Moran TH, Smedh U, Kinzig KP, Scott KA, Knipp S, Ladenheim EE (2005) Peptide 
YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in 
rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 288: R384-388 
 
Morato PN, Lollo PC, Moura CS, Batista TM, Camargo RL, Carneiro EM, Amaya-
Farfan J (2013) Whey protein hydrolysate increases translocation of GLUT-4 to the 
plasma membrane independent of insulin in wistar rats. PLoS One 8: e71134 
 
Moreno-Navarrete JM, Ortega FJ, Bassols J, Ricart W, Fernandez-Real JM (2009) 
Decreased circulating lactoferrin in insulin resistance and altered glucose 
tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. J Clin 
Endocrinol Metab 94: 4036-4044 
 
Morifuji M, Sakai K, Sanbongi C, Sugiura K (2005) Dietary whey protein 
downregulates fatty acid synthesis in the liver, but upregulates it in skeletal muscle 
of exercise-trained rats. Nutrition 21: 1052-1058 
 
Morris DL, Rui L (2009) Recent advances in understanding leptin signaling and 
leptin resistance. Am J Physiol Endocrinol Metab 297: E1247-1259 
 
Morrison CD, Morton GJ, Niswender KD, Gelling RW, Schwartz MW (2005) Leptin 
inhibits hypothalamic Npy and Agrp gene expression via a mechanism that 
requires phosphatidylinositol 3-OH-kinase signaling. Am J Physiol Endocrinol Metab 
289: E1051-1057 
 
Morton GJ, Blevins JE, Williams DL, Niswender KD, Gelling RW, Rhodes CJ, Baskin 
DG, Schwartz MW (2005) Leptin action in the forebrain regulates the hindbrain 
response to satiety signals. J Clin Invest 115: 703-710 
 
Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006) Central 
nervous system control of food intake and body weight. Nature 443: 289-295 
 
Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD (1994) Localization of the 
melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control 
circuits in the brain. Mol Endocrinol 8: 1298-1308 
 
Mu HL, Hoy CE (2004) The digestion of dietary triacylglycerols. Prog Lipid Res 43: 
105-133 
 
Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, Delzenne NM, Cani PD 
(2010) The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst 
Biol 6: 392 
 
Mullins D, Kirby D, Hwa J, Guzzi M, Rivier J, Parker E (2001) Identification of potent 
and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in 
vivo. Mol Pharmacol 60: 534-540 
 
83 
 
  
Murphy EF, Cotter PD, Healy S, Marques TM, O'Sullivan O, Fouhy F, Clarke SF, 
O'Toole PW, Quigley EM, Stanton C, Ross PR, O'Doherty RM, Shanahan F (2010) 
Composition and energy harvesting capacity of the gut microbiota: relationship to 
diet, obesity and time in mouse models. Gut 59: 1635-1642 
 
Nassir F, Wilson B, Han X, Gross RW, Abumrad NA (2007) CD36 is important for 
fatty acid and cholesterol uptake by the proximal but not distal intestine. J Biol 
Chem 282: 19493-19501 
 
Neary MT, Batterham RL (2009) Gut hormones: implications for the treatment of 
obesity. Pharmacol Ther 124: 44-56 
 
Nguyen P, Leray V, Diez M, Serisier S, Le Bloc'h J, Siliart B, Dumon H (2008) Liver 
lipid metabolism. J Anim Physiol Anim Nutr (Berl) 92: 272-283 
 
Nieuwenhuizen AG, Hochstenbach-Waelen A, Veldhorst MA, Westerterp KR, 
Engelen MP, Brummer RJ, Deutz NE, Westerterp-Plantenga MS (2009) Acute 
effects of breakfasts containing alpha-lactalbumin, or gelatin with or without 
added tryptophan, on hunger, 'satiety' hormones and amino acid profiles. Br J Nutr 
101: 1859-1866 
 
Nilaweera KN, Giblin L, Ross RP (2010) Nutrient regulation of enteroendocrine 
cellular activity linked to cholecystokinin gene expression and secretion. J Physiol 
Biochem 66: 85-92 
 
Nilsson M, Holst JJ, Bjorck IM (2007) Metabolic effects of amino acid mixtures and 
whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin 
Nutr 85: 996-1004 
 
Nilsson NO, Stralfors P, Fredrikson G, Belfrage P (1980) Regulation of adipose 
tissue lipolysis: effects of noradrenaline and insulin on phosphorylation of 
hormone-sensitive lipase and on lipolysis in intact rat adipocytes. FEBS Lett 111: 
125-130 
 
Nogueiras R, Lopez M, Dieguez C (2010) Regulation of lipid metabolism by energy 
availability: a role for the central nervous system. Obes Rev 11: 185-201 
 
Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, Haynes WG, 
Patterson JT, Disse E, Pfluger PT, Lopez M, Woods SC, DiMarchi R, Dieguez C, 
Rahmouni K, Rohner-Jeanrenaud F, Tschop MH (2009) Direct control of peripheral 
lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic 
nervous system and blunted in diet-induced obesity. J Neurosci 29: 5916-5925 
 
Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, 
Pfluger PT, Castaneda TR, Neschen S, Hofmann SM, Howles PN, Morgan DA, Benoit 
SC, Szanto I, Schrott B, Schurmann A, Joost HG, Hammond C, Hui DY, Woods SC et al 
(2007) The central melanocortin system directly controls peripheral lipid 
metabolism. J Clin Invest 117: 3475-3488 
 
84 
 
  
Norton LE, Wilson GJ, Layman DK, Moulton CJ, Garlick PJ (2012) Leucine content of 
dietary proteins is a determinant of postprandial skeletal muscle protein synthesis 
in adult rats. Nutr Metab (Lond) 9: 67 
 
Obici S, Zhang BB, Karkanias G, Rossetti L (2002) Hypothalamic insulin signaling is 
required for inhibition of glucose production. Nat Med 8: 1376-1382 
 
Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS (1997) 
Antagonism of central melanocortin receptors in vitro and in vivo by agouti-
related protein. Science 278: 135-138 
 
Ono H, Pocai A, Wang Y, Sakoda H, Asano T, Backer JM, Schwartz GJ, Rossetti L 
(2008) Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin 
resistance in rats. J Clin Invest 118: 2959-2968 
 
Ono T, Murakoshi M, Suzuki N, Iida N, Ohdera M, Iigo M, Yoshida T, Sugiyama K, 
Nishino H (2010) Potent anti-obesity effect of enteric-coated lactoferrin: decrease 
in visceral fat accumulation in Japanese men and women with abdominal obesity 
after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr 104: 
1688-1695 
 
Orskov C, Wettergren A, Holst JJ (1993) Biological effects and metabolic rates of 
glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy 
subjects are indistinguishable. Diabetes 42: 658-661 
 
Osaka T, Endo M, Yamakawa M, Inoue S (2005) Energy expenditure by intravenous 
administration of glucagon-like peptide-1 mediated by the lower brainstem and 
sympathoadrenal system. Peptides 26: 1623-1631 
 
Pages C, Daviaud D, An S, Krief S, Lafontan M, Valet P, Saulnier-Blache JS (2001) 
Endothelial differentiation gene-2 receptor is involved in lysophosphatidic acid-
dependent control of 3T3F442A preadipocyte proliferation and spreading. J Biol 
Chem 276: 11599-11605 
 
Pal S, Ellis V, Dhaliwal S (2010) Effects of whey protein isolate on body 
composition, lipids, insulin and glucose in overweight and obese individuals. Br J 
Nutr 104: 716-723 
 
Pan X, Hussain MM (2012) Gut triglyceride production. Biochim Biophys Acta 
1821: 727-735 
 
Panetti TS, Magnusson MK, Peyruchaud O, Zhang Q, Cooke ME, Sakai T, Mosher DF 
(2001) Modulation of cell interactions with extracellular matrix by 
lysophosphatidic acid and sphingosine 1-phosphate. Prostaglandins 64: 93-106 
 
Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, Streutker C, 
Holland D, Cao X, Baggio LL, Drucker DJ (2013) GLP-1 receptor activation 
indirectly reduces hepatic lipid accumulation but does not attenuate development 
of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 154: 127-139 
85 
 
  
 
Pedersen NL, Nagain-Domaine C, Mahe S, Chariot J, Roze C, Tome D (2000) 
Caseinomacropeptide specifically stimulates exocrine pancreatic secretion in the 
anesthetized rat. Peptides 21: 1527-1535 
 
Pennings B, Boirie Y, Senden JM, Gijsen AP, Kuipers H, van Loon LJ (2011) Whey 
protein stimulates postprandial muscle protein accretion more effectively than do 
casein and casein hydrolysate in older men. Am J Clin Nutr 93: 997-1005 
 
Perrin C, Knauf C, Burcelin R (2004) Intracerebroventricular infusion of glucose, 
insulin, and the adenosine monophosphate-activated kinase activator, 5-
aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, controls muscle 
glycogen synthesis. Endocrinology 145: 4025-4033 
 
Petervari E, Balasko M, Garami A, Soos S, Szekely M (2009) Suppression of food 
intake by intracerebroventricular injection of alpha-MSH varies with age in rats. 
Acta Physiol Hung 96: 483-487 
 
Petschow BW, Talbott RD (1990) Growth promotion of Bifidobacterium species by 
whey and casein fractions from human and bovine milk. J Clin Microbiol 28: 287-
292 
 
Petschow BW, Talbott RD, Batema RP (1999) Ability of lactoferrin to promote the 
growth of Bifidobacterium spp. in vitro is independent of receptor binding capacity 
and iron saturation level. J Med Microbiol 48: 541-549 
 
Pichon L, Potier M, Tome D, Mikogami T, Laplaize B, Martin-Rouas C, Fromentin G 
(2008) High-protein diets containing different milk protein fractions differently 
influence energy intake and adiposity in the rat. Br J Nutr 99: 739-748 
 
Pihlanto-Leppala A, Marnila P, Hubert L, Rokka T, Korhonen HJ, Karp M (1999) The 
effect of alpha-lactalbumin and beta-lactoglobulin hydrolysates on the metabolic 
activity of Escherichia coli JM103. J Appl Microbiol 87: 540-545 
 
Pilvi TK, Harala S, Korpela R, Mervaala EM (2009) Effects of high-calcium diets 
with different whey proteins on weight loss and weight regain in high-fat-fed 
C57BL/6J mice. Br J Nutr 102: 337-341 
 
Pilvi TK, Korpela R, Huttunen M, Vapaatalo H, Mervaala EM (2007) High-calcium 
diet with whey protein attenuates body-weight gain in high-fat-fed C57Bl/6J mice. 
Br J Nutr 98: 900-907 
 
Pilvi TK, Seppanen-Laakso T, Simolin H, Finckenberg P, Huotari A, Herzig KH, 
Korpela R, Oresic M, Mervaala EM (2008a) Metabolomic changes in fatty liver can 
be modified by dietary protein and calcium during energy restriction. World J 
Gastroenterol 14: 4462-4472 
 
86 
 
  
Pilvi TK, Storvik M, Louhelainen M, Merasto S, Korpela R, Mervaala EM (2008b) 
Effect of dietary calcium and dairy proteins on the adipose tissue gene expression 
profile in diet-induced obesity. J Nutrigenet Nutrigenomics 1: 240-251 
 
Posey KA, Clegg DJ, Printz RL, Byun J, Morton GJ, Vivekanandan-Giri A, Pennathur S, 
Baskin DG, Heinecke JW, Woods SC, Schwartz MW, Niswender KD (2009) 
Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin 
resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296: E1003-
1012 
 
Power O, Hallihan A, Jakeman P (2009) Human insulinotropic response to oral 
ingestion of native and hydrolysed whey protein. Amino Acids 37: 333-339 
 
Pritchard LE, Turnbull AV, White A (2002) Pro-opiomelanocortin processing in the 
hypothalamus: impact on melanocortin signalling and obesity. J Endocrinol 172: 
411-421 
 
Rahman MM, Kim WS, Ito T, Kumura H, Shimazaki K (2009) Growth promotion and 
cell binding ability of bovine lactoferrin to Bifidobacterium longum. Anaerobe 15: 
133-137 
 
Raposinho PD, White RB, Aubert ML (2003) The melanocortin agonist Melanotan-
II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does 
not affect the NPY-driven suppressive effects on the gonadotropic and 
somatotropic axes in the male rat. J Neuroendocrinol 15: 173-181 
 
Reddy JK, Goel SK, Nemali MR, Carrino JJ, Laffler TG, Reddy MK, Sperbeck SJ, Osumi 
T, Hashimoto T, Lalwani ND, et al. (1986) Transcription regulation of peroxisomal 
fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA 
dehydrogenase in rat liver by peroxisome proliferators. Proc Natl Acad Sci U S A 
83: 1747-1751 
 
Reddy JK, Hashimoto T (2001) Peroxisomal beta-oxidation and peroxisome 
proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 
21: 193-230 
 
Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver 
disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290: G852-
858 
 
Redinger RN (2009) Fat storage and the biology of energy expenditure. Transl Res 
154: 52-60 
 
Reidelberger RD, Castellanos DA, Hulce M (2003) Effects of peripheral CCK 
receptor blockade on food intake in rats. Am J Physiol Regul Integr Comp Physiol 
285: R429-437 
 
Reitelseder S, Agergaard J, Doessing S, Helmark IC, Lund P, Kristensen NB, Frystyk 
J, Flyvbjerg A, Schjerling P, van Hall G, Kjaer M, Holm L (2011) Whey and casein 
87 
 
  
labeled with L-[1-13C]leucine and muscle protein synthesis: effect of resistance 
exercise and protein ingestion. Am J Physiol Endocrinol Metab 300: E231-242 
 
Rieu I, Balage M, Sornet C, Debras E, Ripes S, Rochon-Bonhomme C, Pouyet C, 
Grizard J, Dardevet D (2007) Increased availability of leucine with leucine-rich 
whey proteins improves postprandial muscle protein synthesis in aging rats. 
Nutrition 23: 323-331 
 
Ritter RC, Covasa M, Matson CA (1999) Cholecystokinin: proofs and prospects for 
involvement in control of food intake and body weight. Neuropeptides 33: 387-399 
 
Robidoux J, Martin TL, Collins S (2004) Beta-adrenergic receptors and regulation 
of energy expenditure: a family affair. Annu Rev Pharmacol Toxicol 44: 297-323 
 
Rosen ED, MacDougald OA (2006) Adipocyte differentiation from the inside out. 
Nat Rev Mol Cell Biol 7: 885-896 
 
Rother E, Brandl R, Baker DL, Goyal P, Gebhard H, Tigyi G, Siess W (2003) Subtype-
selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation 
triggered by the lipid core of atherosclerotic plaques. Circulation 108: 741-747 
 
Royle PJ, McIntosh GH, Clifton PM (2008) Whey protein isolate and 
glycomacropeptide decrease weight gain and alter body composition in male 
Wistar rats. Br J Nutr 100: 88-93 
 
Ruan H, Lodish HF (2003) Insulin resistance in adipose tissue: direct and indirect 
effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14: 447-455 
 
Ryan KK, Woods SC, Seeley RJ (2012) Central nervous system mechanisms linking 
the consumption of palatable high-fat diets to the defense of greater adiposity. Cell 
Metab 15: 137-149 
 
Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid 
metabolism. Nature 414: 799-806 
 
Sam AH, Troke RC, Tan TM, Bewick GA (2012) The role of the gut/brain axis in 
modulating food intake. Neuropharmacology 63: 46-56 
 
Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI 
(2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. 
J Biol Chem 279: 32345-32353 
 
Sangiao-Alvarellos S, Vazquez MJ, Varela L, Nogueiras R, Saha AK, Cordido F, Lopez 
M, Dieguez C (2009) Central ghrelin regulates peripheral lipid metabolism in a 
growth hormone-independent fashion. Endocrinology 150: 4562-4574 
 
Sato I, Arima H, Ozaki N, Watanabe M, Goto M, Hayashi M, Banno R, Nagasaki H, 
Oiso Y (2005) Insulin inhibits neuropeptide Y gene expression in the arcuate 
nucleus through GABAergic systems. J Neurosci 25: 8657-8664 
88 
 
  
 
Schelbert KB (2009) Comorbidities of obesity. Prim Care 36: 271-285 
 
Scherer T, Buettner C (2011) Yin and Yang of hypothalamic insulin and leptin 
signaling in regulating white adipose tissue metabolism. Rev Endocr Metab Disord 
12: 235-243 
 
Scherer T, O'Hare J, Diggs-Andrews K, Schweiger M, Cheng B, Lindtner C, Zielinski 
E, Vempati P, Su K, Dighe S, Milsom T, Puchowicz M, Scheja L, Zechner R, Fisher SJ, 
Previs SF, Buettner C (2011) Brain insulin controls adipose tissue lipolysis and 
lipogenesis. Cell Metab 13: 183-194 
 
Schlesinger JB, van Harmelen V, Alberti-Huber CE, Hauner H (2006) Albumin 
inhibits adipogenesis and stimulates cytokine release from human adipocytes. Am J 
Physiol Cell Physiol 291: C27-33 
 
Schwartz MW, Marks JL, Sipols AJ, Baskin DG, Woods SC, Kahn SE, Porte D, Jr. 
(1991) Central insulin administration reduces neuropeptide Y mRNA expression in 
the arcuate nucleus of food-deprived lean (Fa/Fa) but not obese (fa/fa) Zucker 
rats. Endocrinology 128: 2645-2647 
 
Schwarz JM, Linfoot P, Dare D, Aghajanian K (2003) Hepatic de novo lipogenesis in 
normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-
carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 77: 
43-50 
 
Scott MM, Williams KW, Rossi J, Lee CE, Elmquist JK (2011) Leptin receptor 
expression in hindbrain Glp-1 neurons regulates food intake and energy balance in 
mice. J Clin Invest 121: 2413-2421 
 
Scott V, Kimura N, Stark JA, Luckman SM (2005) Intravenous peptide YY3-36 and 
Y2 receptor antagonism in the rat: effects on feeding behaviour. J Neuroendocrinol 
17: 452-457 
 
Semenkovich CF, Wims M, Noe L, Etienne J, Chan L (1989) Insulin regulation of 
lipoprotein lipase activity in 3T3-L1 adipocytes is mediated at posttranscriptional 
and posttranslational levels. J Biol Chem 264: 9030-9038 
 
Semjonous NM, Smith KL, Parkinson JR, Gunner DJ, Liu YL, Murphy KG, Ghatei MA, 
Bloom SR, Small CJ (2009) Coordinated changes in energy intake and expenditure 
following hypothalamic administration of neuropeptides involved in energy 
balance. Int J Obes (Lond) 33: 775-785 
 
Seo S, Ju S, Chung H, Lee D, Park S (2008) Acute effects of glucagon-like peptide-1 
on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. 
Endocr J 55: 867-874 
 
Shalev A, Holst JJ, Keller U (1997) Effects of glucagon-like peptide 1 (7-36 amide) 
on whole-body protein metabolism in healthy man. Eur J Clin Invest 27: 10-16 
89 
 
  
 
Shen J, Tanida M, Niijima A, Nagai K (2007) In vivo effects of leptin on autonomic 
nerve activity and lipolysis in rats. Neurosci Lett 416: 193-197 
 
Shertzer HG, Woods SE, Krishan M, Genter MB, Pearson KJ (2011) Dietary whey 
protein lowers the risk for metabolic disease in mice fed a high-fat diet. J Nutr 141: 
582-587 
 
Shi J, Ahlroos-Lehmus A, Pilvi TK, Kekkonen R, Korpela R, Mervaala EM (2011a) 
Comparison of the metabolic effects of milk-derived alpha-lactalbumin and amino 
acids mixture with equal composition in diet-induced obese mice. J Funct Foods 3: 
70-78 
 
Shi J, Ahlroos-Lehmus A, Pilvi TK, Korpela R, Tossavainen O, Mervaala EM (2012a) 
Metabolic effects of a novel microfiltered native whey protein in diet-induced 
obese mice. J Funct Foods 4: 440-449 
 
Shi J, Finckenberg P, Martonen E, Ahlroos-Lehmus A, Pilvi TK, Korpela R, Mervaala 
EM (2012b) Metabolic effects of lactoferrin during energy restriction and weight 
regain in diet-induced obese mice. J Funct Foods 4: 66-78 
 
Shi J, Tauriainen E, Martonen E, Finckenberg P, Ahlroos-Lehmus A, Tuomainen A, 
Pilvi TK, Korpela R, Mervaala EM (2011b) Whey protein isolate protects against 
diet-induced obesity and fatty liver formation. Int Dairy J 21: 513-522 
 
Shimizu H, Inoue K, Mori M (2007) The leptin-dependent and -independent 
melanocortin signaling system: regulation of feeding and energy expenditure. J 
Endocrinol 193: 1-9 
 
Shimomura I, Bashmakov Y, Horton JD (1999) Increased levels of nuclear SREBP-
1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol 
Chem 274: 30028-30032 
 
Shin K, Tomita M, Lonnerdal B (2000) Identification of lactoperoxidase in mature 
human milk. J Nutr Biochem 11: 94-102 
 
Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, 
Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K (2001) Ghrelin, an endogenous 
growth hormone secretagogue, is a novel orexigenic peptide that antagonizes 
leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor 
pathway. Diabetes 50: 227-232 
 
Shrestha YB, Vaughan CH, Smith BJ, Jr., Song CK, Baro DJ, Bartness TJ (2010) 
Central melanocortin stimulation increases phosphorylated perilipin A and 
hormone-sensitive lipase in adipose tissues. Am J Physiol Regul Integr Comp Physiol 
299: R140-149 
 
Shuto Y, Shibasaki T, Wada K, Parhar I, Kamegai J, Sugihara H, Oikawa S, 
Wakabayashi I (2001) Generation of polyclonal antiserum against the growth 
90 
 
  
hormone secretagogue receptor (GHS-R): evidence that the GHS-R exists in the 
hypothalamus, pituitary and stomach of rats. Life Sci 68: 991-996 
 
Simon MF, Daviaud D, Pradere JP, Gres S, Guigne C, Wabitsch M, Chun J, Valet P, 
Saulnier-Blache JS (2005) Lysophosphatidic acid inhibits adipocyte differentiation 
via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome 
proliferator-activated receptor gamma2. J Biol Chem 280: 14656-14662 
 
Sipols AJ, Baskin DG, Schwartz MW (1995) Effect of intracerebroventricular insulin 
infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. 
Diabetes 44: 147-151 
 
Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG (1997) Effects of leptin on 
insulin sensitivity in normal rats. Endocrinology 138: 3395-3401 
 
Skibicka KP, Grill HJ (2008) Energetic responses are triggered by caudal brainstem 
melanocortin receptor stimulation and mediated by local sympathetic effector 
circuits. Endocrinology 149: 3605-3616 
 
Skibicka KP, Grill HJ (2009) Hypothalamic and hindbrain melanocortin receptors 
contribute to the feeding, thermogenic, and cardiovascular action of melanocortins. 
Endocrinology 150: 5351-5361 
 
Slawik M, Vidal-Puig AJ (2007) Adipose tissue expandability and the metabolic 
syndrome. Genes & nutrition 2: 41-45 
 
Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A (2007) Effects of PYY1-36 and 
PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat 
metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292: E1062-
1068 
 
Small CJ, Kim MS, Stanley SA, Mitchell JR, Murphy K, Morgan DG, Ghatei MA, Bloom 
SR (2001) Effects of chronic central nervous system administration of agouti-
related protein in pair-fed animals. Diabetes 50: 248-254 
 
Small CJ, Liu YL, Stanley SA, Connoley IP, Kennedy A, Stock MJ, Bloom SR (2003) 
Chronic CNS administration of Agouti-related protein (Agrp) reduces energy 
expenditure. Int J Obes Relat Metab Disord 27: 530-533 
 
Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ (1981) Abdominal vagotomy 
blocks the satiety effect of cholecystokinin in the rat. Science 213: 1036-1037 
 
Sprong RC, Schonewille AJ, van der Meer R (2010) Dietary cheese whey protein 
protects rats against mild dextran sulfate sodium-induced colitis: role of mucin and 
microbiota. J Dairy Sci 93: 1364-1371 
 
Stafford JM, Yu F, Printz R, Hasty AH, Swift LL, Niswender KD (2008) Central 
nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. 
Diabetes 57: 1482-1490 
91 
 
  
 
Stahl A, Hirsch DJ, Gimeno RE, Punreddy S, Ge P, Watson N, Patel S, Kotler M, 
Raimondi A, Tartaglia LA, Lodish HF (1999) Identification of the major intestinal 
fatty acid transport protein. Mol Cell 4: 299-308 
 
Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF (1986) Neuropeptide Y 
chronically injected into the hypothalamus: a powerful neurochemical inducer of 
hyperphagia and obesity. Peptides 7: 1189-1192 
 
Stanley BG, Leibowitz SF (1985) Neuropeptide Y injected in the paraventricular 
hypothalamus: a powerful stimulant of feeding behavior. Proc Natl Acad Sci U S A 
82: 3940-3943 
 
Suominen AH, Glimm DR, Tedesco D, Okine EK, McBurney MI, Kennelly JJ (1998) 
Intestinal nutrient-gene interaction: the effect of feed deprivation and refeeding on 
cholecystokinin and proglucagon gene expression. J Anim Sci 76: 3104-3113 
 
Tajima D, Masaki T, Hidaka S, Kakuma T, Sakata T, Yoshimatsu H (2005) Acute 
central infusion of leptin modulates fatty acid mobilization by affecting lipolysis 
and mRNA expression for uncoupling proteins. Exp Biol Med (Maywood) 230: 200-
206 
 
Tamura S, Shimomura I (2005) Contribution of adipose tissue and de novo 
lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 115: 1139-1142 
 
Tang-Christensen M, Havel PJ, Jacobs RR, Larsen PJ, Cameron JL (1999) Central 
administration of leptin inhibits food intake and activates the sympathetic nervous 
system in rhesus macaques. J Clin Endocrinol Metab 84: 711-717 
 
Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh 
SP (1996) Central administration of GLP-1-(7-36) amide inhibits food and water 
intake in rats. Am J Physiol 271: R848-856 
 
Tang JE, Moore DR, Kujbida GW, Tarnopolsky MA, Phillips SM (2009) Ingestion of 
whey hydrolysate, casein, or soy protein isolate: effects on mixed muscle protein 
synthesis at rest and following resistance exercise in young men. J Appl Physiol 
(1985) 107: 987-992 
 
Tauriainen E, Storvik M, Finckenberg P, Merasto S, Martonen E, Pilvi TK, Korpela R, 
Mervaala EM (2011) Skeletal muscle gene expression profile is modified by dietary 
protein source and calcium during energy restriction. J Nutrigenet Nutrigenomics 
4: 49-62 
 
Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, 
Pfluger P, Castaneda TR, Muzzin P, Schurmann A, Szanto I, Tschop MH, Rohner-
Jeanrenaud F (2006) Ghrelin action in the brain controls adipocyte metabolism. J 
Clin Invest 116: 1983-1993 
 
92 
 
  
Thompson BR, Lobo S, Bernlohr DA (2010) Fatty acid flux in adipocytes: the in's 
and out's of fat cell lipid trafficking. Mol Cell Endocrinol 318: 24-33 
 
Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, Guan JL, 
Wang QP, Funahashi H, Sakurai T, Shioda S, Matsukura S, Kangawa K, Nakazato M 
(2003) Ghrelin-induced food intake is mediated via the orexin pathway. 
Endocrinology 144: 1506-1512 
 
Tranberg B, Hellgren LI, Lykkesfeldt J, Sejrsen K, Jeamet A, Rune I, Ellekilde M, 
Nielsen DS, Hansen AK (2013) Whey protein reduces early life weight gain in mice 
fed a high-fat diet. PLoS One 8: e71439 
 
Tremaroli V, Backhed F (2012) Functional interactions between the gut microbiota 
and host metabolism. Nature 489: 242-249 
 
Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. 
Nature 407: 908-913 
 
Turnbaugh PJ, Baeckhed F, Fulton L, Gordon JI (2008) Diet-induced obesity is 
linked to marked but reversible alterations in the mouse distal gut microbiome. 
Cell Host Microbe 3: 213-223 
 
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An 
obesity-associated gut microbiome with increased capacity for energy harvest. 
Nature 444: 1027-1031 
 
Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, 
Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR 
(1996) A role for glucagon-like peptide-1 in the central regulation of feeding. 
Nature 379: 69-72 
 
Valet P, Pages C, Jeanneton O, Daviaud D, Barbe P, Record M, Saulnier-Blache JS, 
Lafontan M (1998) Alpha2-adrenergic receptor-mediated release of 
lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth. J 
Clin Invest 101: 1431-1438 
 
van den Hoek AM, Heijboer AC, Voshol PJ, Havekes LM, Romijn JA, Corssmit EP, Pijl 
H (2007) Chronic PYY3-36 treatment promotes fat oxidation and ameliorates 
insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab 292: E238-245 
 
van den Hoek AM, Voshol PJ, Karnekamp BN, Buijs RM, Romijn JA, Havekes LM, Pijl 
H (2004) Intracerebroventricular neuropeptide Y infusion precludes inhibition of 
glucose and VLDL production by insulin. Diabetes 53: 2529-2534 
 
Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, van Vught AJ, 
Westerterp KR, Engelen MP, Brummer RJ, Deutz NE, Westerterp-Plantenga MS 
(2009a) Dose-dependent satiating effect of whey relative to casein or soy. Physiol 
Behav 96: 675-682 
 
93 
 
  
Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, Westerterp KR, 
Engelen MP, Brummer RJ, Deutz NE, Westerterp-Plantenga MS (2009b) A breakfast 
with alpha-lactalbumin, gelatin, or gelatin + TRP lowers energy intake at lunch 
compared with a breakfast with casein, soy, whey, or whey-GMP. Clin Nutr 28: 
147-155 
 
Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, Westerterp KR, 
Engelen MP, Brummer RJ, Deutz NE, Westerterp-Plantenga MS (2009c) Effects of 
complete whey-protein breakfasts versus whey without GMP-breakfasts on energy 
intake and satiety. Appetite 52: 388-395 
 
Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, 
Morgan LM, Holst JJ, Astrup A (2001) A meta-analysis of the effect of glucagon-like 
peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol 
Metab 86: 4382-4389 
 
Vergoni AV, Bertolini A, Mutulis F, Wikberg JE, Schioth HB (1998) Differential 
influence of a selective melanocortin MC4 receptor antagonist (HS014) on 
melanocortin-induced behavioral effects in rats. Eur J Pharmacol 362: 95-101 
 
Volek JS, Volk BM, Gomez AL, Kunces LJ, Kupchak BR, Freidenreich DJ, Aristizabal 
JC, Saenz C, Dunn-Lewis C, Ballard KD, Quann EE, Kawiecki DL, Flanagan SD, 
Comstock BA, Fragala MS, Earp JE, Fernandez ML, Bruno RS, Ptolemy AS, Kellogg 
MD et al (2013) Whey protein supplementation during resistance training 
augments lean body mass. J Am Coll Nutr 32: 122-135 
 
Voshol PJ, Rensen PC, van Dijk KW, Romijn JA, Havekes LM (2009) Effect of plasma 
triglyceride metabolism on lipid storage in adipose tissue: studies using genetically 
engineered mouse models. Biochim Biophys Acta 1791: 479-485 
 
Voss-Andreae A, Murphy JG, Ellacott KL, Stuart RC, Nillni EA, Cone RD, Fan W 
(2007) Role of the central melanocortin circuitry in adaptive thermogenesis of 
brown adipose tissue. Endocrinology 148: 1550-1560 
 
Vrang N, Kristensen P, Tang-Christensen M, Larsen PJ (2002) Effects of leptin on 
arcuate pro-opiomelanocortin and cocaine-amphetamine-regulated transcript 
expression are independent of circulating levels of corticosterone. J 
Neuroendocrinol 14: 880-886 
 
Walrand S, Zangarelli A, Guillet C, Salles J, Soulier K, Giraudet C, Patrac V, Boirie Y 
(2011) Effect of fast dietary proteins on muscle protein synthesis rate and muscle 
strength in ad libitum-fed and energy-restricted old rats. Br J Nutr 106: 1683-1690 
 
Wang L, Saint-Pierre DH, Tache Y (2002) Peripheral ghrelin selectively increases 
Fos expression in neuropeptide Y - synthesizing neurons in mouse hypothalamic 
arcuate nucleus. Neurosci Lett 325: 47-51 
 
94 
 
  
Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M (2011) Health and 
economic burden of the projected obesity trends in the USA and the UK. Lancet 
378: 815-825 
 
Warne JP, Alemi F, Reed AS, Varonin JM, Chan H, Piper ML, Mullin ME, Myers MG, 
Jr., Corvera CU, Xu AW (2011) Impairment of central leptin-mediated PI3K 
signaling manifested as hepatic steatosis independent of hyperphagia and obesity. 
Cell Metab 14: 791-803 
 
Watson RT, Kanzaki M, Pessin JE (2004) Regulated membrane trafficking of the 
insulin-responsive glucose transporter 4 in adipocytes. Endocr Rev 25: 177-204 
 
Weiner JA, Chun J (1999) Schwann cell survival mediated by the signaling 
phospholipid lysophosphatidic acid. Proc Natl Acad Sci U S A 96: 5233-5238 
 
Weinstock PH, Levak-Frank S, Hudgins LC, Radner H, Friedman JM, Zechner R, 
Breslow JL (1997) Lipoprotein lipase controls fatty acid entry into adipose tissue, 
but fat mass is preserved by endogenous synthesis in mice deficient in adipose 
tissue lipoprotein lipase. Proc Natl Acad Sci U S A 94: 10261-10266 
 
Weyer C, Gautier JF, Danforth E, Jr. (1999) Development of beta 3-adrenoceptor 
agonists for the treatment of obesity and diabetes--an update. Diabetes Metab 25: 
11-21 
 
Wiedmer P, Chaudhary N, Rath M, Yi CX, Ananthakrishnan G, Nogueiras R, Wirth 
EK, Kirchner H, Schweizer U, Jonas W, Veyrat-Durebex C, Rohner-Jeanrenaud F, 
Schurmann A, Joost HG, Tschop MH, Perez-Tilve D (2012) The HPA axis modulates 
the CNS melanocortin control of liver triacylglyceride metabolism. Physiol Behav 
105: 791-799 
 
Williams DL, Baskin DG, Schwartz MW (2006) Leptin regulation of the anorexic 
response to glucagon-like peptide-1 receptor stimulation. Diabetes 55: 3387-3393 
 
Williams DL, Baskin DG, Schwartz MW (2009a) Evidence that intestinal glucagon-
like peptide-1 plays a physiological role in satiety. Endocrinology 150: 1680-1687 
 
Williams DL, Baskin DG, Schwartz MW (2009b) Hindbrain leptin receptor 
stimulation enhances the anorexic response to cholecystokinin. Am J Physiol Regul 
Integr Comp Physiol 297: R1238-1246 
 
Williams DL, Schwartz MW, Bastian LS, Blevins JE, Baskin DG (2008) 
Immunocytochemistry and laser capture microdissection for real-time quantitative 
PCR identify hindbrain neurons activated by interaction between leptin and 
cholecystokinin. J Histochem Cytochem 56: 285-293 
 
Williams KW, Margatho LO, Lee CE, Choi M, Lee S, Scott MM, Elias CF, Elmquist JK 
(2010) Segregation of acute leptin and insulin effects in distinct populations of 
arcuate proopiomelanocortin neurons. J Neurosci 30: 2472-2479 
 
95 
 
  
Wilson BD, Ollmann MM, Barsh GS (1999) The role of agouti-related protein in 
regulating body weight. Mol Med Today 5: 250-256 
 
Woods SC, Benoit SC, Clegg DJ, Seeley RJ (2004) Clinical endocrinology and 
metabolism. Regulation of energy homeostasis by peripheral signals. Best Pract Res 
Clin Endocrinol Metab 18: 497-515 
 
Woods SC, D'Alessio DA (2008) Central control of body weight and appetite. J Clin 
Endocrinol Metab 93: S37-50 
 
Woods SC, Lotter EC, McKay LD, Porte D, Jr. (1979) Chronic 
intracerebroventricular infusion of insulin reduces food intake and body weight of 
baboons. Nature 282: 503-505 
 
Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei 
MA, Bloom SR (2001a) Ghrelin enhances appetite and increases food intake in 
humans. J Clin Endocrinol Metab 86: 5992 
 
Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri 
S, Stanley SA, Ghatei MA, Bloom SR (2001b) Ghrelin causes hyperphagia and 
obesity in rats. Diabetes 50: 2540-2547 
 
Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts 
GH, Morgan DG, Ghatei MA, Bloom SR (2000) The novel hypothalamic peptide 
ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141: 
4325-4328 
 
Xu SP, Mao XY, Cheng X, Chen B (2013a) Ameliorating effects of casein 
glycomacropeptide on obesity induced by high-fat diet in male Sprague-Dawley 
rats. Food Chem Toxicol 56: 1-7 
 
Xu X, So JS, Park JG, Lee AH (2013b) Transcriptional control of hepatic lipid 
metabolism by SREBP and ChREBP. Semin Liver Dis 33: 301-311 
 
Yamauchi K, Tomita M, Giehl TJ, Ellison RT, 3rd (1993) Antibacterial activity of 
lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 61: 
719-728 
 
Yasuda T, Masaki T, Kakuma T, Yoshimatsu H (2003) Centrally administered 
ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats. 
Neurosci Lett 349: 75-78 
 
Yasuda T, Masaki T, Kakuma T, Yoshimatsu H (2004) Hypothalamic melanocortin 
system regulates sympathetic nerve activity in brown adipose tissue. Exp Biol Med 
(Maywood) 229: 235-239 
 
Yaswen L, Diehl N, Brennan MB, Hochgeschwender U (1999) Obesity in the mouse 
model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. 
Nat Med 5: 1066-1070 
96 
 
  
 
Yu Y, South T, Huang XF (2009) Inter-meal interval is increased in mice fed a high 
whey, as opposed to soy and gluten, protein diets. Appetite 52: 372-379 
 
Yue JT, Lam TK (2012) Lipid sensing and insulin resistance in the brain. Cell Metab 
15: 646-655 
 
Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B (1993) Chronic 
intracerebroventricular neuropeptide-Y administration to normal rats mimics 
hormonal and metabolic changes of obesity. Endocrinology 133: 1753-1758 
 
Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B (1994) 
Intracerebroventricular administration of neuropeptide Y to normal rats has 
divergent effects on glucose utilization by adipose tissue and skeletal muscle. 
Diabetes 43: 764-769 
 
Zemel MB (2004) Role of calcium and dairy products in energy partitioning and 
weight management. Am J Clin Nutr 79: 907S-912S 
 
Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D (2008) Hypothalamic 
IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and 
obesity. Cell 135: 61-73 
 
Zhou J, Keenan MJ, Losso JN, Raggio AM, Shen L, McCutcheon KL, Tulley RT, 
Blackman MR, Martin RJ (2011) Dietary Whey Protein Decreases Food Intake and 
Body Fat in Rats. Obesity 19: 1568-1573 
 
Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, Jones JE, Deysher 
AE, Waxman AR, White RD, Williams TD, Lachey JL, Seeley RJ, Lowell BB, Elmquist 
JK (2005) Mice lacking ghrelin receptors resist the development of diet-induced 
obesity. J Clin Invest 115: 3564-3572 
 
 
 
 
 
 
 
 97 
 
 
 
Chapter 2  
Whey protein isolate counteracts the 
effects of a high fat diet on energy intake 
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genes  
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2.1 ABSTRACT 
Intake of whey protein isolate (WPI) is known to reduce high-fat diet (HFD)-
induced body weight gain and adiposity. However, the molecular mechanisms are 
not fully understood. To this end, we fed C57BL/6J mice for 8 weeks with 10% 
energy as fat (low fat diet, LFD) or 45% energy as fat (HFD) enriched with either 
20% energy as casein (LFD and HFD) or WPI (HF-WPI). Metabolic parameters and 
the hypothalamic and epididymal adipose tissue expression of energy balance-
related genes were investigated. The HFD increased fat mass and plasma leptin 
levels and decreased dark phase energy intake, meal number, respiratory 
exchange ratio, and metabolic (VO2 and heat) and locomotor activity compared 
with the LFD. The HFD increased hypothalamic mRNA expression of the leptin 
receptor, insulin receptor (INSR) and carnitine palmitoyltransferase 1b (CPT1b). 
The HFD also reduced adipose tissue mRNA expression of glucose transporter 4 
(GLUT4) and INSR. In contrast, WPI reduced fat mass, normalised dark phase 
energy intake and increased meal size in HFD fed mice. The dietary protein did not 
impact on plasma leptin, insulin, glucose or glucagon-like peptide 1 levels, but 
increased plasma triacylglycerol (TAG) levels in HFD fed mice. At a cellular level, 
WPI significantly reduced the HFD-associated increase in hypothalamic mRNA 
expression of the leptin receptor, INSR, and CPT1b. Also, WPI prevented the HFD-
induced reduction in adipose tissue mRNA expression of INSR and GLUT4. In 
comparison to casein, the effects of WPI on energy intake and hypothalamic and 
adipose tissue gene expression may thus represent a state of reduced 
susceptibility to weight gain on a HFD. 
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2.2 INTRODUCTION 
Obesity develops when energy consumed in excess of daily metabolic 
requirements is stored as triacylglycerol (TAG) in the adipose tissue. The 
prevalence of obesity and associated conditions has reached epidemic proportions 
worldwide (Bruce & Byrne, 2009; Caterson et al, 2004), and therefore there is a 
growing interest to identify nutritional factors that could influence energy balance 
and thus could reduce the susceptibility to develop obesity, such as that caused by 
a high-fat diet (HFD)(Chalkley et al, 2002; Hill & Peters, 2002; Lin et al, 2000b). 
Whey protein isolate (WPI) is a mixture of milk proteins obtained after 
precipitation of casein during cheese production, and it contains β-lactoglobulin, α-
lactalbumin, bovine serum albumin, glycomacropeptide, immunoglobulins, 
lactoferrin and other minor proteins. WPI has received a lot of attention recently 
because of its associated health benefits (Krissansen, 2007). Prolonged intake of 
whey proteins has been found to improve insulin sensitivity and glucose 
homeostasis (Acheson et al, 2011; Gunnarsson et al, 2006; Nilsson et al, 2007; 
Shertzer et al, 2011). Also, using healthy lean subjects or rodents, a number of 
studies have reported a short-term reduction in energy intake and an increase in 
thermogenesis following WPI intake in comparison to other dietary proteins, 
including casein (Acheson et al, 2011; Hall et al, 2003; Yu et al, 2009; Zhou et al, 
2011). Although there are a discrepancies (Benton & Swan, 2007; Pichon et al, 
2008; Royle et al, 2008; Veldhorst et al, 2009), it is largely recognised that WPI 
intake influences the balance between energy intake and energy expenditure in the 
lean state (Luhovyy et al, 2007; McAllan et al, 2012). In contrast, the effects of WPI 
on energy intake and energy expenditure in the HFD-induced state are less well 
known, although WPI has been consistently shown to reduce HFD-induced body 
 100 
weight gain and adiposity (Pilvi et al, 2009; Pilvi et al, 2007; Shertzer et al, 2011; 
Shi et al, 2012; Shi et al, 2011). However, three studies have reported no effects on 
energy intake in mice fed a HFD with WPI for 11 (Shertzer et al, 2011), 14 (Shi et 
al, 2012) or 21 weeks (Pilvi et al, 2007), in comparison to HFD fed controls. In the 
study by Shertzer et al, (2011), WPI was found to increase metabolic activity, while 
Pilvi et al, (2007) found no changes in metabolic activity in the mice fed a HFD with 
WPI compared with those fed a control diet. It is possible that these discrepancies 
arise partly due to the difference in the duration of HF feeding, with prolonged 
feeding-induced neuroendocrine changes having a greater impact on the ability of 
WPI to regulate energy balance.  Thus, one could argue that a shorter duration of 
HF feeding (in comparison with the above-mentioned studies) may reveal how 
WPI affects physiological and cellular parameters important for energy balance 
regulation.  
This present study sought to investigate the short-term (8 week) impact of 
WPI in conjunction with a HFD, specifically focusing on how the dietary protein 
influences HFD-induced (1) body weight gain and body composition, (2) energy 
intake (total intake, meal number and meal size) and parameters related to energy 
expenditure (oxygen consumption, heat production and locomotor activity), (3) 
plasma levels of hormones and metabolites and (4) the hypothalamic and 
epididymal adipose tissue expression of genes involved in leptin and insulin 
signalling, inflammation and lipid metabolism.  
 
2.3 MATERIALS AND METHODS  
2.3.1 Animals, diets and reagents 
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Experiments involving mice were licensed under the Cruelty to Animals Act 1876 
and received ethical approval from the University College Cork Animal 
Experimentation Ethics Committee (no. 2011/005). Male 3-4 week old C57BL/6J 
mice (Harlan, Middlesex, UK)  were maintained at 20-22oC and 45-65 % humidity, 
with a 12h light 12h dark cycle (06:00-18:00). Mice had ad libitum access to food 
and water throughout the trials and all diets were purchased from Research diets 
(New Brunswick, NJ, USA). The experimental diets were a low fat diet (LFD; 10% 
energy as fat and 20% energy as casein; #D12450), a HFD (45% energy as fat and 
20% energy as casein; #D12451) and a HFD with WPI (HF-WPI) (Alacentm 895; 
NZMP, New Zealand) in place of the casein protein (45% energy as fat and 20% 
energy as WPI). All reagents were purchased from Sigma unless otherwise stated. 
    
2.3.2 Experimental protocol  
The dietary challenges were performed on grouped housed mice (4 per home 
cage) following a four week acclimatisation period, during which the animals were 
fed a LFD. As we intended to measure the effect of the above-mentioned diets on 
energy intake and metabolic parameters using TSE Phenomaster cages (TSE 
systems, Bad Homburg, Germany), by housing the mice individually in these 
specialised cages, it was important to first determine the length of time the animals 
may need to be acclimatised to this new cage environment. This was investigated 
in Study 1. In Study 2, we assessed the effect of the LFD, the HFD and the HF-WPI 
diet on energy intake and metabolic parameters using the above-mentioned cages, 
following the pre-established acclimatisation period. 
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Study 1: Mice were fed a LFD for 7 weeks (n = 8). In weeks 5 and 6, the 
animals were individually housed in the TSE Phenomaster cages (TSE systems, Bad 
Homburg, Germany) for 3 days and energy intake and metabolic parameters were 
measured on day 2 and 3. At the end of the third day, the animals were placed back 
in their appropriate home cages. Food intake in the Phenomaster cages was 
measured using high-precision weighing sensors associated with feeding stations. 
Oxygen consumption (ml/h/kg; VO2) and CO2 production (ml/h/kg; VCO2) were 
measured by indirect open-circuit calorimetry. The sensors measured the levels of 
food consumed and VO2 and VCO2 in each cage every 9 minutes. A meal was 
defined as an intake greater than 0.01g. Energy intake was calculated from 16.10 
kJ/g for the LFD. The respiratory exchange ratio (RER) was calculated from 
VCO2/VO2. Locomotor activity was measured using a multi-dimensional infrared 
beam system, and was defined as the total number of infrared beam breaks in the 
X- and Y-axis.  
Study 2: The experimental protocol is outlined in Figure 2.1. For 8 weeks, 
three weight-matched groups of mice were fed the LFD, the HFD or the HF-WPI 
diet (n = 8). Body weights were measured weekly. In weeks 5 and 6, the energy 
intake and metabolic activity was measured in the individual mice using the TSE 
Phenomaster cages (Fig 2.1). As mentioned earlier, the animals were housed in the 
Phenomaster cages for 3 days. Following a 2 day acclimatisation period (see 
results section for study 1), data was collected on the third day, after which the 
mice were placed back in their home cages. The same parameters mentioned 
earlier were measured. Energy intake was calculated as described earlier for the 
LFD and using 19.80 kJ/g for the HFD and the HF-WPI diet. Heat production 
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(kcal/h/kg) was calculated using the Weir equation (Weir, 1949)(3.941 × VO2 + 
1.106 × VCO2) and converted to kJ/h/kg (1kcal = 4.184 kJ). The food quotient (FQ), 
defined as the ideal diet-specific VCO2:VO2 ratio, was calculated for each diet as 
described previously (Longo et al, 2010). In week 8, after a 6-8h fast, body 
composition was determined by nuclear magnetic resonance (NMR) using the 
Bruker minispec LF50H (Bruker optics, Ettlingen, Germany). Also, at this time 
point, plasma was collected from fasted anesthetised mice to measure glucagon-
like peptide 1 (GLP-1), insulin, glucose, leptin and TAG levels. The animals were 
then immediately culled by cervical dislocation, and tissues of interest were 
dissected and snap-frozen in liquid nitrogen (liver and adipose) or on dry ice 
(brain). 
 
2.3.3 Plasma hormones, glucose and TAG 
Blood collected into BD Vacutainer EDTA tubes (Franklin Lakes, NJ, USA) from 
fasted anesthetised (65mg/kg ketamine and 13mg/kg xylazine) mice was treated 
with 500,000 KIU/L aprotinin and 0.1mM diprotin A (Sigma, Arklow, Ireland) to 
prevent degradation of plasma peptides by dipeptidyl aminopeptidase IV (DPPIV), 
trypsin and other related proteolytic enzymes. Blood was centrifuged at 2000rpm 
and 4oC for 15 minutes, and plasma was isolated and stored at -80oC. Enzyme-
linked immunosorbent assays (ELISA) were used to measure plasma levels of GLP-
1 (Linco Research, St. Charles, MO, USA), leptin and insulin (Crystal Chem, Downers 
Grove, IL, USA). Plasma glucose and TAG levels were measured using colorimetric 
assay kits (Glucose: Calibochem, Darmstadt, Germany; TAG: Wako Chemicals, 
Richmond, VI, USA). Homeostatic model assessment of insulin resistance (HOMA-
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IR) values were determined using the formula: fasting plasma insulin (µU/ml) × 
fasting plasma glucose (mmol/L)/ 22.5 (Matthews et al, 1985). 
 
2.3.4 Liver TAG 
Lipids from frozen liver samples (50mg) were extracted according to the Folch 
method (Folch et al, 1957). Briefly, lipids in each sample were extracted using a 2:1 
(v/v) solution of chloroform-methanol and aliquots of the organic phase were 
collected, dried and re-suspended in duplicate in the infinity TAG lipid stable 
reagent (Thermo Scientific, Middletown, VA, USA) or the LabAssay TAG kit reagent 
(Wako Chemicals, Richmond, VI, USA). TAG levels in the samples were determined 
according the manufacturers’ instructions, and for samples resuspended in infinity 
TAG lipid stable reagent, lipid quantification was performed using a TAG chemistry 
calibrator (Pointe Scientific, Canton, MI, USA).  
 
2.3.5 RNA extraction and complementary DNA synthesis 
Total RNA was isolated from hypothalamic and epididymal adipose tissues into 
diethylpyrocarbonate-treated distilled water using the RNeasy lipid tissue mini kit 
(Qiagen, Hilden, Germany) according to the manufacturers’ instructions. To 
remove any potential genomic DNA contamination, on-column DNase treatment 
(Qiagen, Hilden, Germany) was performed during RNA isolation. Complementary 
DNA (cDNA) was synthesised from 1μg of total RNA using 2.5ng/μl random 
hexamer primers (Bioline, London, UK), 0.5mM deoxyribonucleotide triphosphate 
(dNTP) (Promega, Madison, WI, USA), 2U/μl RNase inhibitor (Promega, Madison, 
WI, USA) and the First Strand Synthesis System containing the Super Script II 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA), according to the 
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manufacturers’ instructions. A parallel reaction without the inclusion of the 
reverse transcriptase enzyme was also performed as a negative control.  
 
2.3.6 Real-time PCR analysis 
The amplification of the cDNA was performed in the Lightcycler 480 system 
(Roche, Penzberg, Germany) using 0.25μM primers (Eurofins MWG operon, 
Ebersberg, Germany), 1μl cDNA and the Lightcycler 480 SYBR Green I Master kit 
(Roche, Penzberg, Germany), according to manufacturers’ instructions. Real-time 
PCR conditions were: 95oC for 10 min followed by 50 cycles at 95oC for 10s, 60 or 
55oC for 5s, and 72oC for 15s. Primer sequences used are given in Table 2.1. 
Melting Curve analysis allowed validation of the authenticity of the real-time PCR 
products. Automated sequencing was performed to verify the sequences of these 
PCR products. Data obtained as Cp values were normalised to the expression of 18-
S and β-actin according to ΔΔCp = ΔCp target gene – ΔCp housekeeping gene. 18-S 
and β-actin have been shown to be appropriate housekeeping genes for both the 
adipose tissue (Guo et al, 2012; Hoggard et al, 2009; Mracek et al, 2010; Yasmeen 
et al, 2013) and the hypothalamus (Giraudo et al, 2010; Hao et al, 2010; Sellayah et 
al, 2008). The relative gene expression was calculated using 2-ΔΔCp and it is shown 
compared to that of the LFD group. 
 
2.3.7 Immunoblot analysis 
Adipose tissue samples (approximately 1ml lysis buffer per 200mg; n=3) were 
homogenized in lysis buffer (50mM HEPES, 150mM NaCl, 1mM EDTA, 1mM EGTA, 
1% Nonident P40 (NP40), 0.5mM dithiothreitol (DTT) and 0.1mM Na3VO4), 
containing protease inhibitors (0.1mM phenylmethylsulphonyl-fluoride (PMSF), 
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2μg/ml aprotinin, 2μg/ml leupeptin, 0.02mM NaF and 0.025mM NaPPi) and 
centrifuged at 12,000 g for 10 min to remove insoluble debris. Protein 
concentrations were analysed using the bicinchoninic acid (BCA) reagent (Pierce 
Biotechnology, Rockford, IL, USA). Protein lysate (20µg) was mixed with 4X sample 
buffer (333mM Tris-HCl, 3% SDS, 26.7% Glycerol, 130mM DTT and 0.2% 
Bromophenol Blue) and heated for 10 minutes at 95°C before loading onto a 
NuPAGE® 4-12% Bis-Tris gel (Invitrogen, Carlsbad, CA, USA). Protein bands were 
separated using SDS-PAGE electrophoresis in MOPS running buffer and transferred 
to PVDF membranes (BioRad, Hemel Hempstead, UK). Tris-buffered saline solution 
containing 0.1% Tween-20 was used as wash buffer, which was supplemented 
with 2% bovine serum albumin (BSA) (Sigma, Arklow, Ireland) and 3% non-fat dry 
milk (Marvel: Premier foods Ltd., Birmingham, UK) for the blocking solution and 
with 1% BSA and 1% non-fat dry milk for the antibody diluent. Blocked 
membranes were exposed to a 1:500 dilution of primary antibody against the 
insulin receptor β (INSR-β)(sc-711: Santa Cruz Biotechnology, Heidelberg, 
Germany). Horseradish peroxidise-conjugated (HRP) secondary antibody (1:8000 
dilution; Jackson Immuoresearch, Newmarket, Suffolk, UK) was used to visualise 
the bound primary antibody. Membranes were stained with a 1:15000 dilution of a 
β-actin-HRP antibody (A3854: Sigma, Arklow, Ireland) to correct for sample 
loading. Visualisation was performed with the enhanced chemiluminescence (ECL) 
Western blotting Substrate Kit (Pierce Biotechnology, Rockford, IL, USA). 
 
2.3.8 Statistical analysis 
All data are presented as means ± SEM. Differences between the experimental 
groups were analysed by one-way or two-way ANOVA with tukey post hoc 
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pairwise comparisons. Body weight differences over 8 weeks were analysed by 
two-way repeated-measures ANOVA with bonferroni post hoc pairwise 
comparisons. Statistical analysis of immunoblot data was performed using a 
multiple comparisons Kruskal-Wallis test followed by Mann-Whitney U tests for 
individual comparisons. Significance was accepted at P < 0.05, and the statistical 
analysis was performed using GraphPad Prism version 3.03 (San Diego, CA, USA), 
Minitab version 15 (State College, PA, USA) and Sigma Stat version 3.1 (Chicago, IL, 
USA). 
 
2.4 RESULTS 
2.4.1 Body weight and composition 
Body weight trajectories over the 8-week treatment period showed that mice on 
the HFD and the HF-WPI diet were significantly heavier than the LFD group from 
the second and seventh weeks respectively (Fig 2.2A). Importantly, the HF-WPI 
group gained significantly less body weight than the HFD group (P < 0.05; Fig 
2.2B). At week 8, the total body fat (%) in the HF-WPI fed mice was significantly 
lower than in the HFD fed mice (P < 0.05; Fig 2.2C), but the total  body fat (%) was 
still greater than in the LFD fed mice (P < 0.001). Furthermore, the total  lean mass 
(%) was higher in the HF-WPI group compared to the HFD fed group (P < 0.05; Fig 
2.2D), and as anticipated it was lower in the HFD and HF-WPI diet fed mice than in 
the LFD group (P < 0.001).  
 
2.4.2 Plasma hormones, glucose and TAG, and hepatic TAG levels  
At week 8, plasma leptin concentrations were higher in HFD and HF-WPI groups 
compared with LFD group (P < 0.05), while plasma TAG levels were greater in the 
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HF-WPI group compared with both the LFD and HFD groups (P < 0.05) (Table 2.2). 
There was no significant difference in plasma glucose, insulin, HOMA-IR and GLP-1 
levels amongst the three diet groups (Table 2.2). Hepatic TAG levels (mg/g liver) 
were determined using the infinity TAG lipid stable reagent or the LabAssay TAG 
kit following extraction of the lipids. The data generated using the former revealed 
that HFD-fed mice had a higher hepatic TAG level than the LFD group (P < 0.05; 
Table 2.2). Whilst hepatic TAG levels in the HF-WPI diet fed mice were lower than 
those in the HFD group, the values did not differ significantly from those of either 
the LFD or HFD group. In contrast, the data generated using the LabAssay TAG kit 
showed that the hepatic TAG values (mg/g liver) for the HF-WPI diet (58.68 ± 
3.92) fed mice were significantly lower than the HFD group (90.9 ± 8.65) (P < 
0.05), whilst the values for the HF-WPI group were not significantly different from 
those of the LFD group (46.65 ± 3.09). 
 
2.4.3 Energy intake, energy expenditure and respiratory exchange ratio 
Study 1: The LFD fed mice were individually housed in the Phenomaster 
cages during weeks 5 and 6 of the 7 week dietary challenge. In the three day 
housing period in the Phenomaster cages, the energy intake, VO2, RER and 
locomotor activity in the animals were similar on day 2 and 3 of the housing period 
(supplementary Fig 2.1). We interpreted this data to suggest that by day 2, the 
mice had been acclimatised to the new Phenomaster cage environment and that 
data gathered on day 3 represents an accurate measure of their energy intake and 
metabolic activity. Previous studies have also used a 48 hour period for 
acclimatisation, before measuring the metabolic and feeding behaviours in mice 
using similar specialised cages (Czyzyk et al, 2010; Dubois et al, 2000). 
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Study 2: Energy intake and metabolic activity were measured as described 
earlier in weeks 5 and 6 of the 8 week dietary challenge. Energy intake was lower 
during the dark phase for the HFD group compared to both HF-WPI and LFD fed 
mice (P < 0.05) (Fig 2.3A). The average meal size over the same period was not 
significantly different between LFD and HFD fed mice, while the HF-WPI diet fed 
mice had a greater average meal size than both LFD and HFD groups (P < 0.05) (Fig 
2.3B). The meal number during the dark phase was reduced for both the HFD and 
HF-WPI groups compared to the LFD fed mice (P < 0.001) (Fig 2.3C). No difference 
in energy intake-related parameters was found between all groups during the light 
phase (Fig 2.3A-C). The FQ calculated for LFD, HFD and HF-WPI diet are shown in 
Fig 2.4A. The respiratory exchange ratio (RER) of both the HFD and HF-WPI fed 
groups were lower than that of the LFD group in both light and dark phases (P < 
0.05; Fig 2.4A). The VO2, heat production and locomotor activity of the HFD fed 
mice during the dark phase were lower than the LFD group (P < 0.05; Fig 2.4B-D). 
In the HF-WPI diet fed mice, these parameters did not differ significantly from that 
of either the LFD or HFD groups during the dark phase. No differences in the 
above-mentioned parameters were observed between all groups during the light 
phase (Fig 2.4B-D).  
 
2.4.4 Adipose tissue gene and protein expression 
The mRNA expression of glucose transporter 4 (GLUT4) (Fig 2.5A), insulin 
receptor (INSR) (Fig 2.5B), beta-3 adrenergic receptor (β-3AR) (Fig 2.5C) and fatty 
acid synthase (FASN) (Fig 2.5D) was significantly lower in the HFD group than in 
the LFD fed mice (P < 0.05). The mRNA expression of INSR and GLUT4 was 
increased in HF-WPI diet fed mice compared with the HFD fed mice (P < 0.05), 
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such that the expression was not significantly different from that of the LFD group 
(Fig 2.5A-B). Similarly, the mRNA expression of β-3AR in the HF-WPI diet group 
was increased compared to HFD group, but did not reach statistical significance. 
The mRNA expression of FASN was not affected by the HF-WPI diet (Fig 2.5D). No 
significant difference in expression of the following genes was found between all 
three diet groups: PPARγ (1.00 ± 0.17 in LFD vs. 0.93 ± 0.24 in HFD vs. 1.09 ± 0.18 
in HF-WPI), lipoprotein lipase (LPL) (1.00 ± 0.16 in LFD vs. 1.37 ± 0.21 in HFD vs. 
1.54 ± 0.20 in HF-WPI), carnitine palmitoyltransferase 1b (CPT1b) (1.00 ± 0.15 in 
LFD vs. 1.24 ± 0.22 in HFD vs. 1.24 ± 0.14 in HF-WPI), fatty acid transporter 
protein 1 (FATP1) (1.00 ± 0.13 in LFD vs. 0.83 ± 0.13 in HFD vs. 0.93 ± 0.10 in HF-
WPI), tumour necrosis factor alpha (TNF-α) (1.00 ± 0.14 in LFD vs. 2.35 ± 0.82 in 
HFD vs. 1.43 ± 0.31 in HF-WPI) and cluster of differentiation 68 (CD68) (1.00 ± 
0.17 in LFD vs. 2.95 ± 1.05 in HFD vs. 1.37 ± 0.28 in HF-WPI).  
 The association between diet and INSR gene expression was further 
explored by investigating the protein expression of INSR-β in the epididymal 
adipose tissue (Fig 2.6).  Intake of the HFD decreased the protein expression of 
INSR-β compared with the LFD group, similar to mRNA expression, although the 
decreased protein expression did not reach statistical significance (Fig. 2.6). The 
protein expression of INSR-β did not differ between the HFD and HF-WPI groups 
(Fig. 2.6). 
 
2.4.5 Hypothalamic gene expression  
Given the key central effects on feeding and on adipocyte metabolism (Nogueiras 
et al, 2010; Nogueiras et al, 2007), we next focussed our attention on the 
hypothalamus and investigated whether the diets affected the expression of energy 
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balance-related genes in this brain region. The data showed that the HFD group 
had increased mRNA expression of pro-opiomelanocortin (POMC) (Fig 2.7A), 
leptin receptor (ObR) (Fig 2.7B), INSR (Fig 2.7C), CPT1b (Fig 2.7D), PPARγ (Fig 
2.7E) and CD68 (Fig 2.7F) compared to LFD fed mice (P < 0.001). Similarly, an 
increase in mRNA expression for TNF-α was observed with HFD feeding (P < 0.05; 
Fig 2.7G). The mRNA expression of ObR, INSR, CPT1b and TNF-α was significantly 
lower in the HF-WPI diet fed mice than in the HFD group (Fig 2.7B-D & G) (P < 
0.05), with no significant difference in expression being observed for POMC and 
CD68 between the two groups. The mRNA expression of PPARγ in the HF-WPI diet 
fed mice also showed a trend towards a decrease compared with the HFD values (P 
= 0.06). The observed mRNA expression of ObR, INSR, CPT1b, PPARγ and CD68 
was still elevated in the HF-WPI group compared with the LFD group (P < 0.05).  
 
2.5 DISCUSSION 
Mammals are able to defend perturbations in their body weight and adiposity by a 
complex interaction between central and peripheral tissues. The intake of a HFD is 
known to shift the defended body weight to a higher set point through changes in 
the mechanisms regulating energy balance (Ryan et al, 2012). To better 
understand how WPI may influence this shift in energy balance during an 8 week 
HFD feeding trial, we compared energy balance-related parameters in LFD, HFD 
and HFD with WPI (HF-WPI) fed mice at weeks 5 and 6, and at week 8. In 
agreement with recent findings (Pilvi et al, 2009; Pilvi et al, 2007; Shertzer et al, 
2011; Shi et al, 2011), WPI reduced HFD-induced weight gain and adiposity. 
Interestingly, HF-WPI diet fed mice had increased energy intake but unaltered 
energy expenditure-related parameters compared with HFD fed mice. WPI also 
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influenced hypothalamic and adipose tissue gene expression in the latter mice. To 
our knowledge, the present study is the first to show that WPI has an impact on 
energy intake by affecting the meal size and also causes changes to hypothalamic 
cellular activity in HFD fed mice. 
High-fat feeding in mice has been shown to differentially impact upon 
energy intake in a temporal fashion, with no difference observed in weeks 1-4, a 
significant reduction in energy intake during weeks 5-12, and a progressive 
increase in energy intake in week 13 onwards compared with the LFD fed controls 
(Lin et al, 2000b). Consistent with these findings, during weeks 5 and 6, we found a 
reduced energy intake in the HFD fed mice compared to the mice fed the LFD. We 
further observed that this reduction is due to the dark phase consummatory 
behaviour, possibly resulting from the reduction in meal number. The data 
suggests that mice fed the HFD are attempting to regulate their energy intake at 
weeks 5 and 6 during the diet-induced shift in the body weight (set point). Intake 
of WPI, in place of casein, increased HFD-induced dark phase energy intake to a 
level comparable with that observed in the LFD group, probably by increasing the 
meal size. The differential effects of WPI and casein on HFD-induced energy intake 
may arise due to differential kinetics of digestion and/or metabolism of the two 
proteins and the associated neuroendocrine changes, given that whey proteins are 
known to be digested fast, thus releasing associated bioactive components into the 
circulatory system much quicker than that observed with casein digestion (Hall et 
al, 2003; Luhovyy et al, 2007). Previous studies have shown that WPI reduces 
energy intake compared to other dietary proteins in the lean state (Yu et al, 2009; 
Zhou et al, 2011), with one study suggesting that whey proteins increase intermeal 
interval compared to soy proteins (Yu et al, 2009). In the obese state, the effects of 
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WPI on energy intake appear to be lost, yet the dietary proteins still attenuate 
HFD-induced obesity (Pilvi et al, 2009; Pilvi et al, 2007; Shertzer et al, 2011; Shi et 
al, 2012; Shi et al, 2011). The discrepancies between these data and those of the 
present study, in particular with regard to energy intake, may be related to the 
differences in the dietary macronutrient and micronutrient composition (45% 
energy as fat vs. 60% energy as fat; casein vs. soy as the control; and altered 
calcium content in the diet) and/or the study duration (8 weeks vs. up to 21 
weeks) that were used to assess the energy balance impact of whey proteins 
(McAllan et al, 2012). It is also possible that some of these discrepancies may have 
arisen due to the fact that we subjected the grouped housed mice to a single 
housing environment in the TSE Phenomaster cages to measure their energy 
intake. Indeed, individual housing can induce stress in C57BL/6J mice, resulting in 
a decreased food intake by 3h following exposure to the new environment 
(Saegusa et al, 2011). However, the effect of the novelty stress is lost after 6h in the 
new environment as the food intake in these mice becomes similar to that of the 
controls. To minimise any such effect of single housing on physiological 
parameters in the present study, we allowed mice a 2 day acclimatisation period in 
the new TSE Phenomaster cages before measuring their energy balance-related 
parameters. Indeed, our preliminary investigation (Study 1) revealed that on days 
2 and 3 of the housing period, the mice consumed a similar energy content and 
exhibited similar metabolic activity (Supplementary Fig 2.1). 
We, as others (Longo et al, 2010; Westerterp, 1993) have found an 
association between FQ, RER and energy balance. In a state of “perfect” energy and 
nutrient balance (energy homeostasis), the FQ equals the RER. In the present 
study, the RER was much lower than FQ for all dietary groups during the light 
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phase. This is expected given that during this phase, mice consume less calories 
and have reduced metabolic (VO2 and heat) and locomotor activities compared to 
the dark phase. The potential mismatch between energy intake and energy 
expenditure that causes the fat oxidation, as indicated by the RER being lower than 
FQ, is likely to represent a mechanism to obtain the required energy to sustain 
metabolic activity in the mice during the light phase (Westerterp, 1993). During 
the dark phase, the RER of the HFD group was close to the FQ, but the RER of the 
LFD group was much higher than the FQ. This indicates that for the HFD group, 
energy intake is closer to energy utilisation, while for the LFD group, a much 
greater energy intake is required to meet the energy demands of these animals. 
This suggestion is supported by the data showing that both energy intake and 
overall metabolic (VO2 and heat) and locomotor activity in the mice on the HFD 
was much lower than those observed in the LFD fed mice. The data support the 
suggestion that mice fed the HFD for 5 to 6 weeks are attempting to regulate their 
energy supply with their energy demands to maintain their bodyweight, in the 
similar way to what the LFD fed mice do, but at a set point much higher than the 
latter group (Ryan et al, 2012). Interestingly, during the dark phase, mice on the 
WPI diet had a RER almost equal to their theoretical FQ, yet the expected 
association between energy intake and parameters linked to energy expenditure 
did not exist, as these mice had a much higher energy intake than the HFD fed 
mice, but had metabolic and locomotor activities similar to those of the HFD fed 
mice. The present data suggest that WPI does not have a significant impact upon 
metabolic activity in HFD fed mice. This is not in agreement with the data from 
another study (Shertzer et al, 2011) in which it was shown that HFD fed mice 
drinking WPI-supplemented water had increased VO2 levels and mitochondrial 
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respiration rates compared with the HFD controls. However, unlike in the present 
study, the two dietary groups in the Shertzer et al, (2011) study were consuming 
disproportionate amounts of protein due to WPI been present in the drinking 
water in addition to the protein received in the diet. Therefore, the increased 
metabolic activity observed in the WPI group in the above-mentioned study may 
simply have resulted from the increased protein intake-induced metabolism rather 
than due to an effect of protein source. In the absence of an elevated metabolic 
activity, energy consumed by HF-WPI fed mice in the present study could be 
utilised for another biological activity, such as muscle metabolism, resulting in an 
increased total lean mass (%) in the HF-WPI group compared to the HFD group by 
week 8. 
 Feeding the HFD for 8 weeks increased overall fat mass compared to LFD 
feeding, which concurs with previous studies (Chalkley et al, 2002; Lin et al, 
2000b). Feeding WPI to the HFD fed mice decreased overall fat content in the body, 
with decreased TAG accumulation in the liver, although the statistical significance 
of this decrease varied depending upon the type of assay kit used to measure the 
lipid content in the liver or upon the efficiency of the Folch lipid extraction method 
(Hanson & Lester, 1980). The results are nonetheless consistent with previous 
findings reported in the literature (Shertzer et al, 2011; Shi et al, 2011) that WPI 
reduces liver TAG levels. The effects of the dietary challenges on tissue lipid 
metabolism were also reflected at the gene expression level. We showed that HFD 
feeding decreased the mRNA expression of INSR, GLUT4 and FASN in the 
epididymal adipose tissue compared with LFD feeding. Given the involvement of 
these genes in adipocyte lipogenesis (Herman et al, 2012; Kersten, 2001), the data 
suggest that a HFD decreases endogenous TAG production in the epididymal 
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adipose tissue. Interestingly, we as others (Collins et al, 1997; Moraes et al, 2003; 
Sawa & Harada, 2006), observed a reduction in the expression of β3-AR in the 
epididymal adipose tissue with HFD feeding. As β3-AR plays an important role in 
energy homeostasis due to its impact on lipolysis and thermogenesis (Collins et al, 
1997; Moraes et al, 2003; Sawa & Harada, 2006), it is likely that this reduction in 
gene expression coupled with the reduced activity of the protein product that is 
known to occur in HFD fed mice (Collins et al, 1997; Moraes et al, 2003; Sawa & 
Harada, 2006) contributes to the increased TAG accumulation and hence the 
adiposity in these mice. Similarly, the HFD-induced increase expression of lipid 
responsive PPARγ (Diano et al, 2011; Ryan et al, 2011) and CPT1b (Bonnefont et 
al, 2004; Gao et al, 2009) in the hypothalamus is consistent with the recent 
findings that the HFD increases fatty acid accumulation in the brain (Borg et al, 
2012; Posey et al, 2009). Thus, the present data suggests that HFD fed mice have 
greater lipid storage in multiple tissues compared with the LFD fed mice, 
potentially leading to the shift in their defended body weight to a higher level. The 
reduction in overall body and hepatic fat content described here with the HF-WPI 
diet feeding has been reported by other studies, which have shown the effects of 
WPI on adipocyte cross-sectional area and liver TAG levels in HFD fed mice (Shi et 
al, 2011). In fact, compared with a diet with casein as the protein source, a whey 
protein diet fed to rats reduced the expression and activity of key lipogenic 
enzymes in the liver (Morifuji et al, 2005). We further suggest that lipid 
accumulated in the hypothalamus may also be decreased with WPI intake because 
of the significantly lower hypothalamic CPT1b expression coupled with a trend 
towards a decreased expression of PPARγ (P = 0.06). These cellular changes 
occurred in a background of elevated plasma TAG levels, suggesting a reduced 
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plasma lipid uptake and/or storage in the tissues in HF-WPI diet fed mice 
compared with HFD controls. The present investigation revealed that WPI does not 
affect expression of LPL or FATP1 that are involved in fatty acid extraction 
(Fielding & Frayn, 1998) and transport (Gimeno, 2007) to the epididymal adipose 
tissue, respectively, although we cannot rule out the possibility that WPI may have 
affected the protein expression or activity of the above-mentioned genes, causing 
the HF-WPI fed mice to have elevated plasma TAG but reduced adiposity compared 
to HFD fed mice. To explore the possibility that WPI may have influenced lipid 
storage, we investigated genes involved in lipid metabolism within the adipose 
tissue. The lack of a WPI effect on adipose expression of FASN and CPT1b, may 
suggest that adipose tissue-specific lipogenesis and β-oxidation pathways 
(Bonnefont et al, 2004) are unaffected by WPI intake. Interestingly, we observed a 
trend toward an increase in β3-AR expression in epididymal adipose tissue of the 
HF-WPI fed mice. A longer duration of WPI intake (21 weeks) was found to 
significantly increase the adipose expression of β3-AR compared to the control 
HFD group (Pilvi et al, 2008). These data suggest the possibility that WPI increases 
lipolysis in adipocytes via activation of β3-AR, possibly arising as a consequence of 
effects of the dietary protein on the central nervous system (CNS), given that CNS 
outflow to the adipose tissue activates β3-AR (McAllan et al, 2013; Nogueiras et al, 
2010; Nogueiras et al, 2009; Nogueiras et al, 2007).  
 HFD-induced development of obesity is associated with increased 
inflammation (Gustafson et al, 2009; Harford et al, 2011; Isakson et al, 2009) and is 
accompanied by functional peripheral and central resistance to both leptin (Levin 
& Dunn-Meynell, 2002; Lin et al, 2000a; Lin et al, 2000b; Munzberg & Myers, 2005; 
Van Heek et al, 1997) and insulin (Chalkley et al, 2002; Felig, 1984; Kahn & Flier, 
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2000; Pedersen et al, 1991; Posey et al, 2009). Evidence from the present study 
also suggests that the components of the leptin and insulin signalling pathway 
acting in the hypothalamus and the adipose may be affected by the HFD. Feeding of 
the HFD for 8 weeks increased the expression of CD68 and TNF-α in the 
hypothalamus. In parallel, we observed an increased expression of INSR in the 
hypothalamus, and a reduced expression of INSR and GLUT4 in the adipose tissue 
with HFD feeding. These findings are consistent with the suggestion that insulin 
resistance is partly instigated by an inflammatory response to a HFD (De Souza et 
al, 2005; McGillicuddy et al, 2011; Pedersen et al, 1991). The increased expression 
of the leptin receptor and its downstream target POMC in the hypothalamus of 
HFD fed mice compared to the LFD fed controls, corroborates with previous data 
(Lin et al, 2000a; Nilaweera et al, 2007; Townsend et al, 2008). The changes in the 
expression of the leptin receptor may be a homeostatic mechanism attempting to 
defend against HFD-induced body weight gain, in a background of elevated plasma 
leptin, hypothalamic inflammation and increased PPARγ expression, which all 
contribute to central leptin resistance (Lu et al, 2011; Ryan et al, 2011). The 
increased hypothalamic expression of genes linked to the leptin and insulin 
signalling pathways in response to a HFD may thus represent an elevated 
threshold needed to initiate physiological responses of these hormones (Posey et 
al, 2009; Ryan et al, 2012; Van Heek et al, 1997). In the epididymal adipose tissue 
and in the hypothalamus, WPI reversed the HFD-associated effects on the mRNA 
expression of INSR (both tissues), GLUT4 (adipose) and leptin receptor 
(hypothalamus), although the expression of INSR-β isoform in the adipose tissue 
did not differ from that of the HFD group. Differences in INSR mRNA and INSR-β 
protein expression could have arisen due to effects of the diet on transcription, 
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translation and/or processing of the mature precursor protein or may also have 
arisen due to the differences in the sensitivity of the techniques (real-time PCR vs 
immunoblotting) used to measure expression. Despite these differences, WPI-
induced changes in the expression of genes linked to the leptin and insulin 
signalling pathways were observed to occur in concert with reduced tissue lipid 
accumulation and potentially lower inflammation, specifically in the 
hypothalamus, since the expression of TNF-α in the hypothalamus was 
significantly lower in the HF-WPI diet fed mice compared to the HFD fed mice. The 
gene expression profile in the WPI-fed mice may thus represent a lower threshold 
(or higher sensitivity) to leptin and insulin action, which may allow the CNS 
outflow to the adipose tissue to activate and normalise the expression of β3-AR as 
that observed in week 8 of the HF-WPI dietary challenge. The investigation of gene 
expression in specific nuclei within the hypothalamus may allow future 
investigators to further define the role of this brain region in mediating the effects 
of WPI intake on the adipose tissue.  
In summary, we showed that WPI causes an overall reduction in fat mass in 
HFD fed mice, normalises their energy intake, possibly by affecting meal size, and 
influences their hypothalamic and adipose tissue expression of genes linked to 
leptin and insulin signalling pathways and lipid metabolism. Further work is 
needed to determine how WPI appears to prevent plasma TAG storage in the 
tissues and whether this contributes to potentially increased leptin and insulin 
sensitivity in the hypothalamus and the adipose tissue. Overall, the present data 
collected at two different time points (at weeks 5/6 and week 8) are consistent 
with the suggestion that WPI partially or completely reverses the HFD-induced 
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physiological and cellular changes, which may therefore represent a state of 
reduced susceptibility to weight gain on a HFD. 
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Table 2.1  Sequences of primers used for Real-time PCR analysis 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
PPARγ 5’-tcaggtttgggcggatgc-3’ 5’-tcagcgggaaggactttatgtatg-3’ 
FASN 5’-tccacctttaagttgccctg-3’ 5’-tctgctctcgtcatgtcacc-3’ 
LPL 5’-tgtctaactgccacttcaaccac-3’ 5’-gggcacccaactctcatacattc-3’ 
GLUT4 5’-ggcctgcccgaaagagtc-3’ 5’-aggagctggagcaaaggac-3’ 
β-3 AR 5’-cgccttcaacccggtcatctactg-3’ 5’-ggtggactctgcctggcttcaac-3’ 
INSR 5’-gatttccccaacgtgtcctctac-3’ 5’-caatgcggtacccagtgaagtg-3’ 
CPT1b 5’-cgagaggggcggactgagactg-3’ 5’-ggctaggcggtacatgttttggtg-3’ 
POMC 5’-gggcaagcgctcctactccatg-3’ 5’-ctcgccttccagctccctcttg-3’ 
ObR 5’-gaccgccgaacacaaccgatgac-3’ 5’-acacctagctggcgaaaaactgaag-3’ 
TNF-α 5’-tggcctccctctcatcag-3’ 5’-acttggtggtttgctacgac-3’ 
CD68 5’-cacttcgggccatgtttctcttg-3’ 5’-aggggctggtaggttgattgtcgtc-3’ 
FATP1 5’-ccggtgtggtggctgctcttctc-3’ 5’-gctgccatctccccgccataaatg-3’ 
β-actin 5’-agagggaaatcgtgcgtgac-3’ 5’-caatagtgatgacctggcgt-3’ 
18-s 5’-aggaccgcggttctattttgttgg-3’ 5’-atgctttcgctct-ggtccgtcttg-3’ 
PPARγ, Peroxisome proliferator activated receptor gamma;  FASN, Fatty acid synthase;  LPL, 
Lipoprotein lipase;  GLUT4, Glucose transporter 4;  β-3 AR, Beta-3 adrenergic receptor;  INSR, 
Insulin receptor;  CPT1b, Carnitine palmitoyltransferase 1b;  POMC,  Pro-opiomelanocortin; ObR, 
Leptin receptor;  TNF-α, Tumour necrosis factor alpha;  CD68, Cluster of differentiation 68;  FATP1, 
Fatty acid transporter 1. 
 
 
 
 
 
 
 
 
 
Table 2.2  Plasma levels of hormones and TAG,  and hepatic TAG accumulation 
(Mean values with standard error of the means; n = 7-8) 
 
WPI, Whey protein isolate; GLP-1, Glucagon-like peptide 1; TAG, Triacylglycerol; HOMA-IR, 
homeostatic model assessment-insulin resistance.  
a,b Mean values in each row with different superscript letters were significantly different (P < 0.05). 
 
 
 
Group Low fat  High fat  High fat WPI 
 Mean SEM  Mean SEM  Mean SEM 
Leptin (ng/ml) 3.07a 0.34  33.78b 6.27  18.79b 5.05 
GLP-1 (pM) 6.63 0.28  6.00 0.13  6.15 0.32 
Insulin (ng/ml) 0.21 0.01  0.31 0.04  0.26 0.04 
Glucose (nmol/µl) 10.65 1.40  11.60 1.00  12.18 0.49 
HOMA-IR 2.67 0.39  4.17 0.62  3.46 0.32 
Plasma TAG  (mg/dl) 94.93a 7.54  112.70a 5.18  146.47b 7.73 
Liver TAG (mg/g liver) 48.61a 5.55  91.48b 20.06  59.35ab 5.29 
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Figure 2.1 Timeline of dietary treatments and experimental measurements. 
C57BL/6J mice were fed for 8 weeks with diets containing 10% energy as fat (low 
fat diet, LFD) or 45% energy as fat (high fat diet, HFD) with either 20% energy as 
casein (LFD and HFD) or whey protein isolate (WPI) (HF-WPI). To measure 
metabolic parameters at weeks 5 to 6, mice were individually housed in TSE 
phenomaster cages for 3 days with data being collected in the final 24h of the 
housing period. In week 8, the body composition was measured following a 6-8 h 
fast, and then plasma and tissue samples were isolated.   
 
 
 
 
 
 
 
 
 
 
 130 
 
Figure 2.2  Effect of feeding a low-fat diet (LFD, ), a high-fat diet (HFD, ) or 
a HFD with whey protein isolate (HF-WPI, ) for 8 weeks upon (A) body 
weight, (B) body weight gain, (C) total fat mass (%) and (D) total lean mass (%) in 
C57BL/6J mice. Values are means (n = 8 per group), with standard errors 
represented by vertical bars.  Mean value was significantly different from that of 
the group fed the LFD diet: *P < 0·05, **P < 0·01, ***P < 0·001. Mean value was 
significantly different from that of the group fed the HFD diet: #P < 0·05, ##P < 0·01.  
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Figure 2.3  Effect of feeding a low fat diet (LFD), high fat diet (HFD) or HFD with 
whey protein isolate (HF-WPI) for 5 to 6 weeks upon (A) energy intake (B) meal 
size and (C) meal number in C57BL/6J mice. Experimental data, collected from 
individual mice at 9 minute intervals over a 24 hour period using TSE 
phenomaster cages, are shown for light and dark phases. Values are means (n = 8 
per group), with standard errors represented by vertical bars:  * P < 0.05. 
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Figure 2.4  Effect of feeding a low fat diet (LFD), high fat diet (HFD) or HFD with 
whey protein isolate (HF-WPI) for 5 to 6 weeks upon (A) respiratory exchange 
ratio (RER), (B) oxygen consumption (VO2), (C) heat production and (D) locomotor 
activity in C57BL/6J mice. Experimental data, collected from individual mice at 9 
minute intervals over a 24 hour period using TSE phenomaster cages, are shown 
for the light and dark phases. The food quotient (FQ; -----) used in (A) is defined as 
the ideal diet-specific VCO2:VO2 ratio, and was calculated for each diet as described 
previously (Longo et al, 2010). Values are means (n = 8 per group), with standard 
errors represented by vertical bars: * P < 0.05, ** P < 0.01. 
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Figure 2.5  Effect of feeding a low fat diet (LFD), high fat diet (HFD) or HFD with 
whey protein isolate (HF-WPI) for 8 weeks upon epididymal adipose tissue mRNA 
expression of (A) glucose transporter 4 (GLUT4), (B) insulin receptor (INSR) (C) 
beta-3 adrenergic receptor (β-3AR) and (D) fatty acid synthase (FASN) in 
C57BL/6J mice. The mRNA expressions were normalised using 18-S and β-actin 
according to ΔΔCp = ΔCp target gene – ΔCp housekeeping gene. The gene 
expressions were calculated using 2-ΔΔCp and are shown in comparison to that of 
the LFD group. Values are means (n = 7-8 per group), with standard errors 
represented by vertical bars. Mean value was significantly different from that of 
the LFD diet group: *P < 0·05, **P < 0·01.  Mean value was significantly different 
from that of the HFD diet group: #P < 0·05.   
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Figure 2.6  Effect of feeding a low fat diet (LFD), high fat diet (HFD) or HFD with 
whey protein isolate (HF-WPI) for 8 weeks upon epididymal adipose tissue protein 
expression of insulin receptor-β (INSR-β) in C57BL/6J mice, as measured by 
immunoblot. The protein expression of INSR-β relative to the expression of β-actin 
is shown in (A) and the images of the corresponding immunoblot are shown in (B). 
Values are means (n = 3 per group), with their standard errors represented by 
vertical bars. 
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Figure 2.7  Effect of feeding a low fat diet (LFD), high fat diet (HFD) or HFD with 
whey protein isolate (HF-WPI) for 8 weeks upon hypothalamic mRNA expression 
of (A) pro-opiomelanocortin (POMC), (B) leptin receptor (ObR), (C) insulin 
receptor (INSR), (D) carnitine palmitoyltransferase 1b (CPT1b), (E) PPARγ , (F) 
cluster of differentiation 68 (CD68) and (G) TNF-α,  in C57BL/6J mice. The mRNA 
expressions were normalised using 18-S and β-actin according to ΔΔCp = ΔCp target 
gene – ΔCp housekeeping gene. The relative gene expressions were calculated using 
2-ΔΔCp and are shown compared to the LFD group. Values are means (n = 6-8 per 
group), with their standard errors represented by vertical bars. Mean value was 
significantly different compared to LFD group: *P < 0.05, **P < 0.01, ***P < 0.001; 
and significantly different compared to HFD group: #P < 0.05, ###P < 0.001. 
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Supplementary figure 2.1  The effect of feeding a low fat diet for 5-6 weeks on 
(A) energy intake, (B) oxygen consumption (VO2), (C) respiratory exchange ratio 
(RER) and (D) locomotor activity in C57BL/6J mice. Metabolic parameters were 
measured in mice (n = 8) housed individually for 3 days in the TSE phenomaster 
cages. Experimental data collected at 9 minute intervals are shown for light and 
dark phases of days 2 and 3. Data represent mean values ± SEM (n = 8). *** P < 
0.001. 
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3.1 ABSTRACT 
Macronutrient quality and composition are important determinants of energy 
balance and the gut microbiota. Here, we investigated how changes to protein 
quality (casein versus whey protein isolate; WPI) and the protein to carbohydrate 
(P/C) ratio within a high fat diet (HFD) impacts on these parameters. Mice were 
fed a low fat diet (LFD; 10% kJ) or a high fat diet (HFD; 45% kJ) for 21 weeks with 
either casein (20% kJ) or WPI at 20%, 30% or 40% kJ. In comparison to casein, 
WPI at a similar energy content normalised energy intake, increased lean mass and 
caused a trend towards a reduction in fat mass (P = 0.08), but the protein challenge 
did not alter oxygen consumption or locomotor activity. WPI reduced HFD-induced 
plasma leptin and liver triacylglycerol, and partially attenuated the reduction in 
adipose FASN mRNA in HFD-fed mice. High throughput sequence-based analysis of 
faecal microbial populations revealed microbiota in the HFD-20% WPI group 
clustering closely with HFD controls, although WPI specifically increased 
Lactobacillaceae/Lactobacillus and decreased Clostridiaceae/Clostridium in HFD-
fed mice. There was no effect of increasing the P/C ratio on energy intake, but the 
highest ratio reduced HFD-induced weight gain, fat mass and plasma 
triacylglycerol, non-esterified fatty acids, glucose and leptin levels, while it 
increased lean mass and oxygen consumption. Similar effects were observed on 
adipose mRNA expression, where the highest ratio reduced the HFD-associated 
expression of UCP-2, TNFα and CD68 and increased the diet-associated expression 
of β3-AR, LPL, IR, IRS-1 and GLUT4. The P/C ratio also impacted on gut microbiota, 
with populations in the 30/40% WPI groups clustering together and away from 
the 20% WPI group. Taken together, our data show that increasing the P/C ratio 
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has a dramatic effect on energy balance and the composition of gut microbiota, 
which is distinct from that caused by changes to protein quality. 
 
3.2 INTRODUCTION 
It is widely recognised that levels of obesity and related clinical conditions such as 
diabetes, stroke, hyperlipidemia and cardiovascular disease are increasing 
worldwide (Caterson et al, 2004). Importantly, the development of obesity 
increases the set point at which the body weight, and more specifically body fat, is 
defended, thus making its reversal difficult to achieve (Guo et al, 2009; Ryan et al, 
2012). As such, there is an increased research interest to develop effective 
treatments for this disease. 
Dairy proteins belonging to the whey fraction (a by-product of cheese 
manufacture) have been increasingly tested for their potential anti-obesity effect, 
and specifically for their ability to reduce high fat diet (HFD)-associated body 
weight and fat mass gain (Pilvi et al, 2007; Shertzer et al, 2011; Shi et al, 2011). Shi 
et al., (2012) showed that replacing 5%, 50% or 100% of the dietary casein 
protein-derived energy content with a lactoperoxidase and lactoferrin-enriched 
whey protein isolate (WPI) caused a proportional suppression of body weight gain 
in HFD fed mice. We have previously demonstrated that a WPI-related reduction in 
body weight and fat mass gain in HFD fed mice was accompanied by a 
normalisation of energy intake and the complete or partial reversal of energy 
balance-related gene expression in the adipose tissue and the hypothalamus 
(McAllan et al, 2013b). While these data suggest that whey proteins have specific-
effects on energy balance, such effects appear be modified by the macronutrient 
composition in the diet (Pichon et al, 2008). In the latter study, it was shown that 
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increasing the lipid to carbohydrate ratio within a whey protein-rich diet 
significantly reduced energy intake and bodyweight gain in rats. Collectively, these 
data suggest that protein quality and macronutrient composition are important 
determinants of energy balance. 
Interestingly, diet is also an important factor in determining the 
composition of the gut microbiota (Turnbaugh et al, 2009; Wu et al, 2011) and 
specific gut microbiota signatures are associated with obesity phenotypes in 
animals and humans (Backhed et al, 2004; Murphy et al, 2010; Turnbaugh et al, 
2006). Notably, studies have shown specific whey proteins to possess anti-
microbial activity (Freedman et al, 1998; Shin et al, 2000; Yamauchi et al, 1993), 
and that the digestive process itself facilitates the formation of potent 
antimicrobial whey-derived peptides, such as pepsin catalysed lactoferrin to 
lactoferricin (Hoek et al, 1997). A study by Sprong et al., (2010) demonstrated that 
in comparison to casein, whey protein intake increased levels of Lactobacilli and 
Bifidobacteria in a rat model of colitis. However, in a more recent study whey 
protein intake was found to have no influence on gut microbiota composition in 
mice fed a HFD for 7 or 13 weeks (Tranberg et al, 2013). Key unanswered 
questions are; could whey proteins specifically influence the gut microbiota 
composition associated with prolonged high fat feeding, and would any changes 
relate to energy balance? Could changes to the protein to carbohydrate ratio 
within a HFD vary the gut microbiota profile and energy balance in a different way 
to changes to protein quality? 
To assess WPI specific effects on above parameters, we subjected male 
C57BL/6J mice to 21 weeks of either a low fat diet (LFD) with 20% kJ casein or a 
HFD with 20% kJ casein or WPI. In addition, using two additional HFD dietary 
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groups containing 30 or 40% kJ WPI, we evaluated the impact of increasing the 
protein to carbohydrate (P/C) ratio within the HFD on parameters of interest. The 
present data showed that WPI had a specific effect on energy balance and gut 
microbiota, while increasing the P/C ratio within the HFD led to dramatic 
alterations in energy balance, body composition, metabolic health and the 
composition of the gut microbiota.  
 
3.3 MATERIALS AND METHODS 
3.3.1 Ethics Statement 
All research involving mice was licensed under the Cruelty to Animal Act 1876 and 
received ethical approval from the University College Cork Animal Ethics Review 
Committee (#2011/005). 
 
3.3.2 Animals 
Male 3-4 week old C57BL/6J mice (Harlan, Oxon, UK) were group housed either 5 
per cage (Study 1) or 4 per cage (Study 2) in individually ventilated cages and 
acclimatised for four weeks in a light (06:00-18:00), temperature (21 ± 1oC) and 
humidity (45-65%) controlled environment with free access to water and a low fat 
diet (LFD; 10% kJ fat and 20% kJ casein; #D12450, Research diets; New 
Brunswick, NJ, USA).  
 
3.3.3 Experimental protocol 
Two studies were performed to assess how the WPI-derived energy content within 
a HFD (Study 1) or LFD (Study 2) impacts on energy balance-related parameters in 
mice over a 21 week (Study 1) or 7 week period (Study 2). 
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Study 1: Following the acclimatisation period, weight-matched dietary 
groups were maintained on the LFD or switched to either a HFD (45% kJ fat and 
20% kJ casein; #D12451) or a HFD with WPI (Alacentm 895 NZMP, New Zealand) at 
an energy content of  20% kJ (HFD-20% WPI), 30% kJ (HFD-30% WPI) or 40% kJ 
(HFD-40% WPI) (Supplementary table 1) (n = 10) for a total of 21 weeks. Body 
weights were measured weekly. Energy intake in group housed mice was 
measured by weighing the food hopper each week until week 16. During weeks 17-
20, energy intake and metabolic activity in individual mice was measured using 
TSE Phenomaster cages (TSE systems, Bad Homburg, Germany). Following this 
analysis and prior to re-housing the mice in their home cages, faecal pellets were 
collected from individual mice for examination of the microbial composition via 
pyrosequencing and subsequent bioinformatic analysis. At the end of the 
experimental period, mice were fasted for 6 hours and the body composition was 
measured by NMR using the Bruker minispec LF50H (Bruker optics, Ettlingen, 
Germany). The mice were then anesthetised using ketamine (65mg/kg 
bodyweight) and xylazine (13mg/kg bodyweight). Blood was collected from these 
anesthetised mice into vacutinater EDTA tubes (BD, USA) and treated with 
Aprotinin (500,000 KIU/L final concentration; Sigma, Ireland) and Diprotin A 
(0.1mM final concentration; Sigma, Ireland) to protect plasma peptides from 
proteolytic degradation. Plasma was isolated from blood by centrifugation at 
2000rpm and 4oC for 15 minutes. The mice were then sacrificed by cervical 
dislocation, and tissues of interest were dissected and snap frozen in liquid 
nitrogen (liver, adipose and stomach) or on dry ice (brain). Plasma and tissue 
samples were stored at -80oC until analysis.  
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Study 2: Weight matched mice were provided with either the LFD or a LFD 
with WPI replacing the casein protein (LFD-WPI; 10% kJ fat and 20% kJ WPI) (n = 
8) for 7 weeks. Body weights were measured weekly. Energy intake and metabolic 
activity in individual mice was measured during weeks 5 and 6 using the TSE 
Phenomaster system. After the analysis, mice were re-housed, as before, in the 
home cages and the experiment was terminated at the end of week 7. 
 
3.3.4 Analysis of metabolic parameters 
The TSE Phenomaster cages comprised an open-circuit indirect calorimetry 
system with gas sensing units to measure oxygen consumption (ml/h/kg) (VO2) 
and CO2 production (ml/h/kg) (VCO2). The cages also contained high-precision 
sensor-associated feeding baskets to accurately measure food intake (g), with a 
meal defined as intake over 0.01g. A multi-dimensional infrared beam system 
allowed the measurement of locomotor activity, which was defined as the total 
number of infrared beam breaks in the X- and Y-axis. The mice were singly housed 
in TSE Phenomaster cages for a total of 3 days, with data collected during the final 
24 hours, following a 2 day acclimatisation to the new cage environment. The 
acclimatisation period was established based on the data from our previous study 
(McAllan et al, 2013b). Heat production (kcal/h/kg) in individual mice was 
calculated using the Weir equation (3.941 × VO2 + 1.106 × VCO2)(Weir, 1949), and 
this was converted to kJ/h/kg using 1kcal = 4.184 kJ. The respiratory exchange 
ratio (RER) was calculated by VCO2/VO2. Energy intake was calculated from food 
intake measurements using the energy content of the diets supplied by the 
manufacturer. 
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3.3.5 Microbial DNA extraction, amplification and high throughput DNA 
sequencing 
Total metagenomic DNA was extracted from individual faecal samples using QIamp 
DNA Stool Mini Kit (Qiagen, Hilden, Germany), after an additional bead-beating 
step. Bacterial composition was determined by sequencing of 16S rRNA amplicons 
(V4-V5 region; 408nt long) generated by a separate PCR reaction for each sample 
(in triplicate) using universal 16S primers, where, the forward primer (5’-
AYTGGGYDTAAAGNG) with attached molecular identifier tags between 454 
adapter sequence and target-specific primer sequence, and the reverse primer V5 
(5’-CCGTCAATTYYTTTRAGTTT) (Claesson et al, 2010), were used along with 
Biomix Red (Bioline, London UK). The template DNA was amplified under the 
following PCR conditions for a total of 35 cycles: 94˚C for 2 minutes and 1 minute 
respectively (initialization and denaturation), 56˚C for 60 seconds (annealing) and 
72˚C for 60 seconds (elongation), proceeded by a final elongation stage of 2 
minutes. Negative control reactions with PCR grade water in place of template 
DNA were used to confirm a lack of contamination. Amplicons were pooled and 
cleaned using the AMPure XP purification system (Beckman and Coulter, Takeley, 
UK) and DNA concentration was determined using the NANODROP 3300 
Fluorospectrometer (Thermo Scientific, USA) coupled with the Quant-it™ 
Picogreen® dsDNA Assay Kit (Invitrogen, Paisley, UK). Equal volumes of each 
sample were then pooled together and underwent a final cleaning and 
quantification stage. Amplicons were sequenced in-house on a Roche GS FLX 
Titanium platform. 
 
3.3.6.Bioinformatics 
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Raw sequencing reads were ‘de-noised’ using traditional techniques implemented 
in the Ribosomal Database Project Pyrosequencing (RDP) Pipeline with ambiguous 
bases, non exact primer matches and reads shorter than 150bp being excluded. 
Trimmed FASTA files were then BLASTed against a previously published 16S-
specific database using default parameters. The resulting files were then parsed 
using the MEGAN software package, which assigns reads to the National Centre for 
Biotechnology Information (NCBI) taxonomies via the lowest common ancestor 
algorithm. Results were filtered prior to tree construction and summarisation by 
the use of bit scores from within MEGAN where a cut-off bit score of 86 was 
employed (Rea et al, 2011; Urich et al, 2008). The QIIME software suite was 
employed to achieve clustering of sequence reads into operational taxonomic units 
(OTUs) (Caporaso et al, 2010). Chimeric OTUs were removed using the 
ChimeraSlayer program (Haas et al, 2011) and phylogenetic trees were 
constructed using the FastTreeMP tool (Price et al, 2010). Beta diversity values 
were calculated based on Bray Curtis, weighted and unweighted UniFrac distances, 
and the KING viewer was used to visualise resulting PCoA plots (Chen et al, 2009; 
Huson et al, 2007). Sequence reads were deposited in the European Nucleotide 
Archive (EHA) under the accession number PRJEB4636. 
 
3.3.7 Plasma analysis 
Colorimetric assays were used to measure plasma levels of glucose (Calibochem, 
Darmstadt, Germany), triacylglycerol (TAG; Wako Chemicals, Richmond, VI, USA) 
and non-esterified fatty acids (NEFA; Abcam, Cambridge, UK). Commercially 
available ELISA kits were used to analyse plasma levels of insulin, leptin (Crystal 
Chem, Downers Grove, IL, USA), glucagon-like peptide 1 (GLP-1; Millipore, St. 
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Charles, MO, USA) and corticosterone (Enzo Life sciences, Farmingdale, NY, USA). 
The homeostasis model assessment of insulin resistance (HOMA-IR) was 
determined using the formula: fasting plasma insulin (µU/ml) × fasting plasma 
glucose (mmol/L)/ 22.5 (Matthews et al, 1985).  To measure plasma amino acid 
levels, samples were first deproteinised by mixing with equal volumes of 24% 
(w/v) tri-chloroacetic acid. The samples were then allowed to stand for 10 minutes 
before been centrifuged at 14400 x g (Microcentaur, MSE, UK) for 10 minutes. 
Supernatants were mixed with 0.2 M sodium citrate buffer, pH 2.2, and the plasma 
concentration of amino acids were quantified using a Jeol JLC-500/V amino acid 
analyser (Jeol Ltd., Garden city, UK) fitted with a Jeol Na+ high performance cation 
exchange column. 
 
3.3.8 Liver TAG analysis 
Total lipids from liver samples (approx. 50mg) were extracted as described 
previously (McAllan et al, 2013b) using the Folch extraction method (Folch et al, 
1957). Briefly, total lipids were extracted using a 2:1 (v/v) chloroform-methanol 
solution, into which a 0.88% NaCl solution was added before centrifugation at 
2000rpm and 4oC for 30mins. Aliquots of the organic phase were collected, dried 
and re-suspended in the LabAssay TAG reagent (Wako Chemicals, Richmond, VI, 
USA) to measure TAG levels using the LabAssay TAG kit according the 
manufacturer’s protocol.  
 
3.3.9 Real-Time PCR analysis 
Total RNA was isolated from tissues using RNeasy mini (liver and stomach) or 
RNeasy lipid mini (adipose and hypothalamus) kits (Qiagen, Hilden, Germany) 
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according to manufacturers’ instructions. RNA was treated with DNase (Qiagen, 
Hilden, Germany) during RNA isolation to eliminate any potential genomic DNA 
contamination. The reverse transcription of 1μg of RNA into complementary DNA 
(cDNA) was performed using 2.5ng/µl random hexamer primers (Bioline, London, 
UK), 0.5mM dNTP (Promega, Madison, VI, USA), 2U/μl RNase inhibitor (Promega, 
Madison, VI, USA), and the Superscript II first stand system (Invitrogen, Carlsbad, 
CA, USA) according to the manufactures’ instructions. Gene expression was 
measured by the Roche Lightcycler 480 system (Rotkreuz, Switzerland) via 
amplification of 1μl cDNA using the Lightcycler SYBR Green I Mastermix kit 
(Roche, Penzberg, Germany) and 2.5μM gene-specific primers (Eurofins MWG 
operon, Ebersberg, Germany) in a 10μl total reaction volume. Primer sequences 
used are listed in supplementary table 2. PCR conditions were; 10mins at 95oC, 
followed by 50 cycles of 95oC for 10s, 58-65oC for 5s and 72oC for 15s.  Authenticity 
of PCR products was determined by melting curve analysis and by automated 
sequencing. Crossing point (Cp) of fluorescence signals were used to calculate 
target gene expression by 2-ΔΔCp, following normalisation against housekeeping 
genes according to ΔΔCp = ΔCp target gene – ΔCp housekeeping gene. 
Housekeeping genes used were β-actin (liver, stomach and hypothalamus), 
YWHAZ (liver and hypothalamus), 18-S (adipose) and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (adipose and stomach).  Relative gene expression is 
shown in comparison to the LFD group. 
 
3.3.10 Statistical analysis 
Data are expressed as means ± standard error of the mean (SEM). Differences 
between experimental dietary groups were analysed by one-way or two-way 
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ANOVA followed by pairwise comparisons using tukey or bonferroni post hoc tests, 
respectively. Body weight trajectories were analysed by two-way repeated 
measures ANOVA with bonferroni post hoc tests. Non-parametric data was 
compared by Kruskal-Wallis ANOVA followed by Dunn’s pairwise comparisons. 
Significance levels were set at P ≤ 0.05, and statistical analysis was performed 
using Graphpad prism (ver. 5.04; San Diego, CA, USA) and Minitab (ver.15; State 
College, PA, USA). 
 
3.4 RESULTS 
3.4.1 WPI inclusion or increasing the P/C ratio within a HFD alters body 
composition and plasma amino acids 
Fig. 3.1A-B demonstrates that body weight gain of HFD-20% WPI fed mice was 
similar to HFD controls. However, intake of WPI was seen to have a specific effect 
on body composition, with HFD-20% WPI fed mice having an increased lean mass 
(%) (P < 0.05), and a trend towards a reduction in fat mass (%) (P = 0.08) 
compared to the HFD control group (Fig. 3.1C). Increasing the WPI derived energy 
content in the HFD to 40% and proportionally reducing the carbohydrate energy 
content led to a significant reduction in body weight gain compared to all other 
HFD-WPI groups (P < 0.001), with observed values similar to that seen for the LFD 
group. This was accompanied by significantly reduced body fat mass and increased 
lean mass levels in the HFD-40% WPI fed mice compared to HFD control and other 
WPI diets groups (P < 0.001), while the body composition of the HFD-30% WPI 
group did not differ from that of the HFD-20% WPI group (Fig. 3.1C).  
Comparison of the plasma amino acid profiles, including those that could 
influence lean and fat mass, revealed an impact of WPI and the P/C ratio (Table 
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3.1). WPI specific effects were observed on glutamic acid, aspartic acid and glycine, 
which either decreased (glutamic acid and aspartic acid) or increased (glycine) 
compared to HFD fed mice (P < 0.05) (Table 3.1). Changes in macronutrient ratio in 
HFD-40% WPI decreased plasma histidine, phenylalanine, serine and threonine 
levels compared to the lowest P/C ratio (20% WPI) (P < 0.01) (Table 3.1).  
 
3.4.2 The WPI-enriched HFD normalised energy intake, while increasing the 
P/C ratio accentuated metabolism 
The cumulative energy intake (MJ) for the dietary groups (2 cages/group, all with 
n = 5 mice), measured over the first 16 weeks did not significantly differ between 
LFD, HFD and HFD-20% WPI groups (24.73 ± 2.70 vs. 27.69 ± 1.54 vs. 29.40 ± 0.31, 
respectively). In contrast, data gathered by individually housing the mice in TSE 
Phenomaster cages in weeks 17-20 demonstrated that the energy intake of the 
HFD-WPI groups was greater than that of the HFD control group during both the 
light and dark phases (P < 0.05), while being similar to that of the LFD group (Fig. 
3.2A). Increasing the P/C ratio had no significant effect on cumulative energy 
intake (MJ) in HFD fed mice (20% WPI, 29.40 ±0.31 vs. 30% WPI, 30.01 ± 0.62 vs. 
40% WPI, 26.71 ± 0.15). Energy intake measurements from TSE Phenomaster 
cages corroborated this data (Fig. 3.2A). There was also no significant effect on 
meal number or meal size of altering the P/C ratio (i.e. between WPI groups; Fig. 
3.2B-C). 
The HFD-20% WPI diet had no impact on VO2, heat production, locomotor 
activity or respiratory exchange ratio (RER) when compared to HFD fed mice (Fig. 
3.3A-D). Increasing the P/C ratio was found to impact on energy expenditure with 
HFD-40% WPI fed mice having significantly increased levels of dark phase VO2 
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compared to HFD-20% and 30% WPI fed mice (P < 0.001) (Fig. 3.3A). A similar 
change in heat production was observed between the groups, albeit data was only 
significant between HFD-40% and HFD-30% WPI groups (P < 0.05) (Fig. 3.3B). 
There was no effect of WPI or P/C ratio on locomotor activity (Fig. 3.3C). RER 
values of all HFD groups were lower than the LFD group in both the light and dark 
phases, consistent with increased fat metabolism (P < 0.001) (Fig. 3.3D).  
Investigation of the above parameters in mice fed a LFD with WPI or casein 
for 7 weeks (Study 2) revealed that WPI does not influence body weight, energy 
intake, VO2, locomotor activity or RER in a low fat background (Supplementary Fig. 
3.1A-D). 
  
3.4.3 Increasing the protein to carbohydrate ratio attenuated the adverse 
metabolic impact of HFD 
Specific effects of WPI and the P/C ratio were observed on lipid metabolism-
related gene expression and on tissue lipid deposition. Firstly, the decrease in 
epididymal adipose tissue fatty acid synthase (FASN) mRNA expression with HFD 
feeding, was somewhat attenuated by WPI challenge (P < 0.05), with no added 
benefit of increasing the P/C ratio on the expression of this gene (Fig. 3.4A). 
Notably, the epididymal mRNA expression of a number of other genes were altered 
by the P/C ratio, specifically, fatty acid transporter 1 (FATP1), beta-3 adrenergic 
receptor (β3-AR), peroxisome proliferator-activated receptor gamma (PPARγ), 
uncoupling protein 2 (UCP-2) and lipoprotein lipase (LPL) (P ≤ 0.05) (Fig. 3.4A-B). 
In the liver, WPI specifically reduced TAG levels (Table 3.2) and the mRNA 
expression of fatty acid binding protein 1 (FABP1) compared to HFD fed mice 
(Table 3.3). The highest P/C ratio (40% WPI) significantly decreased mRNA levels 
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of cluster of differentiation 36 (CD36) and PPARγ (P < 0.05) (Table 3.3), 
dramatically reduced liver TAG levels compared to 20/30% WPI fed mice (Table 
3.2), and normalised the elevated plasma levels of TAG and NEFA observed with 
HFD feeding (P ≤ 0.05) (Table 3.2). Finally, the mRNA levels of lipid metabolism-
related carnitine palmitoyltransferase 1a-c (CPT1a-c), fatty acid transport protein 
5 (FATP5) and PPARα, in tissues of interest, were not influenced by the dietary 
challenges (Fig.3.4A & Tables 3.3-3.4). 
Increasing the P/C ratio reduced plasma glucose levels, particularly in the 
40% WPI group (P < 0.05) (Table 3.2). In parallel HOMA-IR values were also 
reduced (P < 0.05), but the change in plasma insulin concentration did not reach 
statistical significance (Table 3.2). At a cellular level, the highest P/C ratio 
normalised the HFD-induced reduction in epididymal adipose tissue mRNA 
expression of insulin receptor (IR) and insulin receptor substrate 1 (IRS-1), and 
partially prevented the HFD-induced reduction in glucose transporter 4 (GLUT4) 
(Fig. 3.4B) (P < 0.001). In the hypothalamus, WPI specifically increased IR mRNA 
expression (P < 0.05), as did P/C ratio, with the highest P/C ratio having the 
greatest impact (Table 3.4). Epididymal adipose tissue mRNA expression of 
inflammatory markers, namely tumour necrosis factor (TNF)-α and cluster of 
differentiation (CD) 68 only responded to the highest P/C ratio, which significantly 
reduced the expression of both in a HFD background (Fig. 3.4B) (P < 0.001). In the 
hypothalamus, whilst TNF-α mRNA expression was elevated by HFD feeding, 
neither WPI nor the P/C ratio influenced its levels, although there was a trend 
towards a decrease for the highest P/C ratio (40% WPI) (Table 3.4). None of the 
dietary challenges influenced hepatic glucose transporter 2 (GLUT2), IRS-1 and 
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TNF-α mRNA expression (Table 3.3) or hypothalamic IRS-1 mRNA expression 
(Table 3.4). 
The increased plasma leptin concentration in response to the HFD was 
significantly blunted by WPI intake with dramatic reductions seen at the highest 
P/C ratio (P < 0.001) (Table 3.2). Yet, the hypothalamic expression of genes known 
to be responsive to plasma leptin levels were unaffected, specifically mRNA levels 
of leptin receptor (ObR), pro-opiomelanocortin (POMC), neuropeptide Y (NPY) and 
growth hormone secretagogue receptor (GHS-R) (Table 3.4). In addition, gastric 
mRNA expression for the orexigenic hormone ghrelin was not found to 
significantly differ between all dietary treatment groups (1.00±0.37, LFD vs. 1.11 
±0.40, HFD vs. 0.73±0.35, 20% WPI vs. 0.29±0.28, 30% WPI vs. 1.07 ± 0.45, 40% 
WPI). Plasma corticosterone levels were also elevated with HFD feeding, but were 
not influenced by protein source (WPI or casein) or P/C ratio (Table 3.2). Similarly, 
there was no effect of WPI on the HFD-associated suppression of adipose 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) (Fig. 3.4B), or the HFD-induced 
increase in glucocorticoid receptor (GCCR) in the hypothalamus (Table 3.4). 
 
3.4.4 WPI inclusion or increasing the P/C ratio within a HFD altered the 
composition of gut microbiota  
A total of 251,395 V4-V5 16S rRNA sequence reads were generated which 
corresponded to an average of 50,279 reads per diet group or 5,130 reads per 
animal. α-diversity values were calculated for biodiversity (Shannon index), 
species richness (Chao1) and the number of species relative to the abundance in 
the sample (Simpson diversity index). When α-diversity values were compared by 
diet group, the only difference observed was a significantly higher microbial 
 154 
richness (Chao1) within the HFD microbiota compared to the HFD-30% WPI (P = 
0.028). Principal coordinate analysis (based on unweighted UniFrac distances) 
(Fig. 3.5) of the sequence data highlighted a clustering of the LFD, HFD and HFD-
20% WPI group microbial populations, while HFD-30% and 40% WPI groups 
clustered in a close proximity to each other and distinctly from the LFD, HFD and 
HFD-20% WPI group clusters. Indeed, the LFD diet with casein as a protein source 
clustered most closely with the HFD containing the casein protein. 
Phylogenetic analysis revealed several significant microbial population 
shifts between the HFD control and WPI groups (Table 3.5). At the family level, all 
WPI diet groups had significantly increased proportions of Lactobacillaceae and 
significantly decreased proportions of Clostridiaceae compared to the HFD control 
group. Bifidobacteriaceae populations were increased in both the HFD-20% WPI 
and HFD-30% WPI diet groups compared to the HFD control, while in contrast 
they were significantly lower in the HFD-40% WPI group compared to the HFD 
control. The aforementioned patterns were also observed with respect to the 
corresponding genera (Lactobacillus, Clostridium and Bifidobacterium respectively) 
(Table 3.5). Also at the genus level, proportions of Rikenella were significantly 
higher in the HFD-40% WPI group compared to the HFD-20/30% WPI groups, 
while proportions of Peptostreptococcus were significantly higher in the HFD-40% 
WPI group than in any other diet group (Table 3.5). Specific comparison of the 
microbiota of the HFD-20% WPI and HFD control was deemed particularly 
important given that the changes occurring here reflected changes resulting 
specifically from the presence of whey protein, rather than casein, in the diet, and 
not simply a change in the P/C ratio in the diet. In addition to the changes in the 
Lactobacillus, Clostridium and Bifidobacterium populations (and associated 
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families) referred to above, it was also noted that the proportions of Desulfovibrio 
and Mucisprillum (genus) were increased in the HFD-20% WPI, relative to the HFD 
control animals. 
 
3.5 DISCUSSION 
The key findings of this study are that WPI has a specific effect on HFD-induced 
energy intake, metabolic health and gut microbiota composition. Additionally, with 
the exception of energy intake, increasing the P/C ratio, by increasing WPI dietary 
content, was seen to dramatically alter the above-mentioned parameters. 
 
3.5.1 Energy intake 
Cumulative energy intake measured up to week 16 did not significantly differ 
between LFD and HFD fed mice. Whilst this is consistent with data reported 
elsewhere (Tranberg et al, 2013), HFD feeding has also been shown to increase or 
decrease energy intake in rodents (Lin et al, 2000; Sclafani et al, 1993). Differences 
between these reported data may relate to variances in diet composition, including 
fat source/composition, or it may be due to differences in the palatability of the 
LFD used as the control (Sclafani et al, 1993; West & York, 1998). 
 In this study, there was a discrepancy in energy intake in HFD fed mice 
depending on the housing environment (single or group housed). In contrast to the 
group housed environment up to week 16, HFD fed mice when individually housed 
in metabolic cages during weeks 17-20 showed a hypophagic response compared 
to LFD fed mice. It is possible that these differences may be related to the accuracy 
of the method used to measure food intake in group versus single housed mice, 
although if this was an error due to methodology, then it would likely to have 
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influenced all dietary groups equally and not just the HFD group. Alternatively, the 
different behavioural responses could be result of social isolation, which has been 
shown to decrease energy intake and elevate plasma corticosterone levels 
(Saegusa et al, 2011; Yamada et al, 2013). However, socially isolated mice adapt to 
their new environment and consume similar amounts of food as pre-adapted 
singularly housed mice 6 hr post-novelty stress, yet interestingly 24hr later their 
food intake reduces significantly once again in the new environment, suggesting 
that stress of social isolation could extend up to 24h (Yamada et al, 2013). We 
showed that group housed mice on a LFD when placed in isolation adapt to the 
new environment and continue to consume similar amounts of food by day 2 and 3 
in the new location (McAllan et al, 2013b), and consequently we used the day 3 
time point to measure energy intake in this study. Rodents on a HFD have been 
shown to display increased anxiety (Buchenauer et al, 2009), and have an over-
active hypothalamic-pituitary-adrenal axis (Dallman, 2010; Sharma & Fulton, 
2013) resulting in elevated plasma corticosterone levels, as demonstrated here. 
This could explain why HFD fed mice are more susceptible to stress stimuli with 
more pronounced reductions in energy intake compared to LFD fed counterparts 
subjected to the same stress levels (Finger et al, 2011; Harris et al, 1998; Zhou et 
al, 1999). Consequently, in a HFD background, it’s possible that social isolation-
induced stress responses could have had a greater impact on energy intake with 
effects lasting up to the 3 day housing period as used in this study. Given the 
finding that whey proteins such as lactoferrin and ɑ-lactalbumin and native whey 
protein itself reduce stress (Kamemori et al, 2004; Markus et al, 2002; Markus et 
al, 2000; Takeuchi et al, 2003; Vekovischeva et al, 2013), it is possible that 
replacing the casein protein with an equivalent WPI content caused normalisation 
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of energy intake in HFD-fed mice by affecting a specific feeding behaviour related 
mechanism(s), with increasing the WPI protein-derived bioactives having no 
further effect. This WPI effect on energy intake appeared be specific to the HFD-
induced neuroendocrine state because mice on the LFD with WPI showed similar 
energy intake to casein diet-fed controls. Since neither WPI nor increasing the P/C 
ratio influenced plasma corticosterone levels, adipose tissue expression of 11β-
HSD1 or hypothalamic expression of GCCR in HFD fed mice, it is possible that WPI 
may have affected other central mechanisms mediating stress responses not 
investigated in this study (Ghosal et al, 2013; Herman & Cullinan, 1997; Viau et al, 
1999), either independently or in combination with key mechanisms regulating 
energy balance. Given that leptin decreases meal size and number (Bady et al, 
2006; Brown et al, 2006; Hulsey et al, 1998), and WPI reduced the HFD-induced 
increase in plasma leptin levels, it’s possible that WPI-derived bioactives could 
have specifically influenced the circadian rhythm of leptin production and/or 
action within the neuroendocrine state of HFD-fed mice in a socially isolated 
environment. Additionally, the reduction in plasma amino acids associated with 
WPI intake (see below), could also have acted as a possible central trigger to 
increase energy intake in WPI groups compared to the HFD control in the single 
house environment.  
HFD feeding has been shown to cause a gain of weight in rats up to the 
duration of a test period lasting 76 weeks, with animal’s body weight gain 
responding to changes to the dietary fat content introduced at various time points 
(Peckham et al, 1962). Lin et al, (2000) also demonstrated that mice on a HFD for 
19 weeks are still responsive to intracerebroventricular administration of leptin. 
These data suggest that energy balance-related mechanisms are able to respond to 
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energetic challenges even after prolonged high fat intake. High protein intake 
within a HFD suppresses energy intake (Freudenberg et al, 2012; Pichon et al, 
2006) albeit not consistently (Schwarz et al, 2012; Shertzer et al, 2011), and in our 
study, the P/C ratio did not alter energy intake in either housing environment. This 
could be a result of the quantity or composition of the macronutrient used in the 
test diets. Indeed, data from human trials showed that increasing the protein 
dietary content (10/15% to 30%) only decreased energy intake when the 
carbohydrate content was kept constant (Blatt et al, 2011; Weigle et al, 2005). This 
further highlights the importance of designing appropriate experimental diets with 
the correct macronutrient composition for uncovering the energy balance-related 
impact of the dietary component under investigation. 
 
3.5.2 Metabolic health 
Replacement of the casein protein with an equivalent energy content of WPI (i.e. 
20%) did not specifically alter metabolic activity, heat production or locomotor 
activity in HFD or LFD fed mice. In contrast, Acheson et al, (2011) showed that 
whey has a greater thermic effect than casein or soy in humans. These differences 
in data may be related to the fact that the latter study only investigated an acute 
post-prandial response to a defined test meal, or it may relate to how different 
species (humans versus mice) digest and metabolise dietary proteins. Shetzer et al, 
(2011) found that mice consuming a HFD and WPI supplemented drinking water 
have enhanced oxygen consumption compared to mice drinking unsupplemented 
water. In this instance, the increased metabolic activity may have arisen simply 
due to the increased protein intake (proteins from diet and from WPI 
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supplemented water). In fact, this corroborates with the data presented here, 
which show that increasing the P/C ratio resulted in increased energy expenditure 
(VO2 and heat production) and darkphase locomotor activity, resulting presumably 
from the increased catabolism of ingested dietary protein, coupled with thermic 
effects of WPI compared to casein (Acheson et al, 2011) and/or due to increased 
deposition of lean mass with WPI content (Kanda et al, 2013; Pennings et al, 2011; 
Tipton et al, 2007). Interestingly, Zhang et al, (2007) showed that HFD fed mice on 
leucine supplemented drinking water have reduced fasting plasma levels of 
aspartic acid, glutamic acid, and phenylalanine, as well as increased VO2 and 
reduced adiposity compared to HFD controls. Given the influence of leucine on 
WPI-induced muscle hypertrophy (Norton et al, 2012; Rieu et al, 2007) and its 
unique ability to regulate the translation of protein synthesis (Norton & Layman, 
2006), it is possible that the elevated leucine content found normally in the WPI 
diets may have enhanced muscle protein synthesis by directing other amino acids 
towards protein synthesis and/or catabolism (Bender, 2012; Garlick et al, 1999), 
with the required energy been derived possibly from fat catabolism (McAllan et al, 
2013a). Consistent with the latter suggestion, we found an increased lean mass and 
a trend towards a reduction in fat mass with decreased plasma levels of several 
amino acids, but not leucine, when the casein protein in a HFD was replaced with 
WPI or when the P/C ratio in the HFD was increased. 
WPI intake appeared to cause a trend towards a reduction in fat mass, and 
in the liver this manifested as a WPI specific reduction in TAG levels, which was 
accompanied by the suppression of FABP1 mRNA expression, similar to previous 
findings (Hamad et al, 2011; Pilvi et al, 2008; Shertzer et al, 2011; Shi et al, 2011). 
In the epididymal adipose tissue, WPI prevented the HFD-induced reduction in 
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FASN gene expression, albeit a recent study reported that WPI may not 
meaningfully affect the epididymal tissue in HFD fed mice, but instead impact on 
the subcutaneous fat pad to a greater extent (Tranberg et al, 2013). These data 
suggest that WPI affects cellular activity in the liver and in specific adipose tissue 
depots. While it has been suggested that whey protein may facilitate enhanced 
post-prandial chylomicron clearance via an alteration in LPL expression/activity 
(Mortensen et al, 2009; Pal et al, 2010), here we did not find a WPI specific effect 
on LPL expression or plasma TAG levels, but we did observe that intake of the 
highest P/C ratio (40%-WPI) led to an increase adipose tissue LPL mRNA 
expression which was accompanied by significant reduction in plasma TAG levels, 
and a complete reversal of HFD effects on genes involved in lipid accumulation 
(PPARγ), fatty acid transport (FATP1), and lipolysis (β3-AR). Given that HF 
feeding/obesity down-regulates β3-AR mRNA expression (Collins et al, 1999), our 
data suggests an increased adipocyte lipolysis, and a reduction in adipose TAG 
storage in HFD-40% WPI fed mice. Yet the endogenous CPT1b-associated β-
oxidation pathway and the UCP-2-associated pathway in epididymal adipose tissue 
seemed to be unaffected (CTP1b) or suppressed (UCP-2) by raising the P/C ratio. 
This data raises the possibility that the free fatty acids generated from the 
potentially increased availability of β3-AR in the adipose may have been re-
directed for utilisation by other physiological processes active in the HFD-40% 
group, possibly leading to the increased metabolic activity (VO2) observed in the 
animals. It is also noteworthy that WPI has been shown to increase faecal fat 
excretion compared to casein (Pilvi et al, 2007), which may have also contributed 
to the decreased plasma TAG and NEFA seen here with intake of the highest P/C 
ratio diet (HFD-40% WPI). 
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Given the link between HFD-induced obesity, low-grade inflammation and 
insulin resistance (Gustafson et al, 2009; McGillicuddy et al, 2011), one could argue 
that the dramatic reduction in fat mass observed with the highest P/C ratio may 
underlie the effects on inflammatory markers in the adipose tissue (TNF-α and 
CD68) and the hypothalamus (TNF-α), along with the simultaneous changes in 
expression of genes involved in insulin signalling (IR, IRS-1 and GLUT4 in the 
adipose, IRS-1 in liver and IR in the hypothalamus), and the reduction in plasma 
glucose in these mice. Improvements to insulin sensitivity with WPI have been 
reported previously (Belobrajdic et al, 2004; Pichon et al, 2008), but our data 
suggested that only an increased P/C ratio in the HFD facilitated improvements to 
insulin signalling pathway associated gene expression, particularly in the adipose, 
in parallel with  reduced HOMA-IR values.  
 
3.5.3 Composition of gut microbiota 
While many of the effects described above may be due to direct WPI or P/C ratio-
host interactions, the effect of WPI and P/C ratio on the composition of the gut 
microbiota may also play an important role in adiposity and weight gain in these 
animals. Here, high-throughput sequencing based analyses of faecal microbial 
populations revealed the clustering of the microbiota from animals in receipt of 
the 30% and 40% WPI diets away from those in receipt of 20% WPI or HFD-casein 
diets. Tranberg et al, (2013) recently suggested that the efficient absorption of 
dairy whey proteins in the small intestine may explain the absence of changes in 
the faecal microbiota. This may explain the clustering of the microbiota from 
animals fed 20% WPI or HFD-casein diets in our study. However, it is apparent 
that the high concentrations of WPI present in the 30% and 40% WPI diets 
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employed in our study had a more profound effect, possibly due to additional whey 
proteins finding their way to the large intestine and/or the overall change in the 
P/C ratio in the diet. Consumption of the 30% and 40% WPI diets did not result in 
a shift in the microbiota toward that of the LFD animals and thus the effects on 
weight gain are not simply due to an overall conversion to a LFD-like microbiota.  
Specific taxonomic changes were also noted in response to the different 
diets. In all cases dietary WPI resulted in significant increases in Lactobacillaceae/ 
Lactobacillus and decreases in Clostridiaceae/Clostridium. Increased proportions of 
Lactobacillus have previously also been observed in a study of individuals 
following a regime of calorie restriction and exercise (Santacruz et al, 2009).  
However, in contrast, increased proportions of Lactobacillus have also been noted 
in HFD fed rats (Parnell & Reimer, 2012) and diet-induced obese mice (Clarke et al, 
2013). Whilst specific species of Lactobacillus have been associated with both lean 
and obese gut microbiota profiles and also to play a role in obesity and immune 
response regulation (Armougom et al, 2009; Erickson & Hubbard, 2000; 
Ouwehand et al, 1999), due to the length of the 16S sequences generated and the 
high degree of sequence homology, we cannot assess changes in proportions of 
Lactobacillus at the species level. An increase in the proportions of 
Bifidobacteriaceae/Bifidobacterium was also observed in both the HFD-20% WPI 
and HFD-30% WPI compared to the HFD group. This result, combined with the 
aforementioned increases in Lactobacillaceae/Lactobacillus, mirror those reported 
by Sprong et al,  (2010) who suggest that whey proteins act as grow factors for 
certain species of bacteria by an amino acid composition mediated mechanism. 
This pattern did not extend to the HFD-40% WPI group suggesting that, at these 
high protein levels, other factors are at play. Our observations are also consistent 
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with previous findings that high proportions of the class Clostridiales are 
associated with the gut microbiota of animals fed a HFD (Hildebrandt et al, 2009), 
while fasting reduces the levels of Clostridium (Sonoyama et al, 2009). Notably, 
Clostridiaceae can produce short chain fatty acids as a product of their metabolism 
(Sousa et al, 2007), which can play an important role in the regulation of immune 
cells and has been associated with inflammation and obesity (Schwiertz et al, 
2010). These differences, as well as others in the Proteobacteria, Actinobacteria, 
Deferribacteres (phylum), Desulfovibrionaceae, Deferribacteraceae, Veillonellaceae 
(family), Desulfovibrio and Mucispirillum (genus) taxa in the HFD-20% whey 
protein, relative to HFD controls (20% casein) are particularly notable as these 
reflect changes resulting from the specific presence of whey proteins in the diet, in 
place of casein, rather than changes in the P/C ratio. Changes in relative 
proportions may be attributed to (a) the ability of bacteria to utilise whey proteins 
as a growth medium, (b) the anti-microbial activity of whey protein/peptide 
components, (c) decreased competition as a result of the whey proteins/peptides 
antimicrobial activity or (d) whey protein mediated changes in the host. 
Ultimately, the question of cause versus effect remains unanswered, and so while 
the changes to the microbiota observed may contribute to the mechanisms 
involved in controlling weight gain, further studies, with for example germ free 
animals, will be required to determine this definitively. 
 
3.5.4 WPI effects on energy balance from a whole animal context 
Focusing on the experimental data gathered between weeks 17-21, during which 
we measured metabolic parameters, faecal microbial population, body 
composition and tissue and plasma levels of energy balance-related parameters, it 
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is clear that WPI intake increased energy intake associated with the HFD without 
altering energy expenditure, as measured by VO2 and locomotor activity. However, 
the body composition and body weight in the HFD-WPI group does not appear to 
reflect a positive energy balance, as animals showed a trend towards a reduction in 
fat mass and increased lean mass. It is noteworthy in this regard that WPI has been 
shown to increase faecal fat excretion (Pilvi et al, 2007) and we also observed 
some subtle changes in the gut microbiota at a phylogenic level that are associated 
with non-obese states, raising the possibility of a reduced intestinal TAG 
absorption in the HFD-WPI groups with increased energy intake, leading to similar 
body weight trajectories as HFD controls. Increasing the P/C ratio by changing WPI 
from 30% to 40% did not alter energy intake but significantly accentuated energy 
expenditure with a concurrent dramatic change in physiology.  
 In summary, our results show that WPI specifically normalises energy 
intake, increases lean mass and causes a trend towards a reduction in fat mass 
associated with prolonged high fat feeding.  Raising the P/C ratio had no effect on 
energy intake but augmented metabolic activity and beneficially altered gene 
expression profiles for lipid metabolism, inflammation and insulin signalling, 
particularly in the adipose tissue. High-throughput analyses of gut microbiota 
revealed distinct changes in microbial populations, with an increased P/C ratio 
causing clustering of 30/40% WPI groups together and distinct from those of HFD 
and 20% WPI groups, but with specific phylogenetic differences existing between 
the latter groups. These data indicate that changes to P/C ratio have a dramatic 
effect on energy balance and the composition of the gut microbiota distinct from 
that seen with changes to protein source.  Future studies should focus on 
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determining whether the effects demonstrated for the highest P/C ratio are 
specific to the WPI content, a consequence of macronutrient change, or both.  
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Table 3.1  Plasma amino acid levels (µmol/L) in mice fed a 45% kJ high fat diet (HFD) or HFD with 20%, 30% or 40% kJ whey protein 
isolate (WPI) for 21 weeks1 
1 Data are means ± SEM (n = 7-10). In each row, values without a common letter significantly differ, P < 0.05; NS, non-significant. 
 HFD 20% WPI 30% WPI 40% WPI P value 
Alanine 170.91 ± 8.82a 163.83 ± 11.59ab 137.44 ± 9.72ab 127.15 ± 8.46b <.05 
Arginine 41.74 ± 4.82 38.41 ± 7.16 56.39 ± 7.60 39.08 ± 4.34 NS 
Aspartic acid 7.47 ± 1.25a 3.63 ± 0.51b 3.49 ± 0.51b 4.85 ± 1.02ab <.05 
Cysteine 11.95 ± 1.34 8.87 ± 1.37 8.93 ± 1.33 7.86 ± 1.72 NS 
Glutamic acid   90.76 ± 3.42a 74.74 ± 1.89b 75.25 ± 1.86b 71.25 ± 2.69b <.001 
Glycine 106.22 ± 4.28a 131.43 ± 3.57b 116.45 ± 4.52ab 131.92 ± 2.69b <.001 
Histidine 75.43 ± 2.12a 74.93 ± 2.98a 68.21 ± 3.35ab 64.21 ± 2.51b <.05 
Isoleucine 213.81 ± 8.87 207.87 ± 9.09 195.27 ± 5.74 186.78 ± 10.17 NS 
Leucine 91.86 ± 9.66 81.36 ± 6.65 66.93 ± 6.69 69.71 ± 10.21 NS 
Lysine 113.81 ± 5.88 108.18 ± 8.30 102.57 ± 8.39 88.29 ± 4.07 NS 
Methionine 23.94 ± 1.77 23.65 ± 0.75 21.05 ± 0.97 20.40 ± 1.08 NS 
Phenylalanine 46.92 ± 1.70a 41.13 ± 1.13ab 38.23 ± 1.52bc 33.30 ± 2.35c <.001 
Proline 118.26 ± 10.14 127.63 ± 9.63 106.04 ± 11.02 104.39 ± 11.93 NS 
Serine 68.18 ± 5.69ab 74.98 ± 2.29a 62.42 ± 2.57ab 55.73 ± 2.12b <.01 
Threonine 92.71 ± 2.93a 87.63 ± 2.49a 78.29 ± 2.95ab 69.28 ± 3.96b <.01 
Tyrosine 40.29 ± 2.47a 36.37 ± 1.12ab 33.76 ± 1.54ab 29.63 ± 2.77b <.01 
Valine 154.51 ± 8.65a 130.59 ± 5.99ab 118.40 ± 6.69b 113.16 ± 9.49b <.01 
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Table 3.2  Hepatic TAG accumulation and plasma levels of hormones and metabolites in mice fed a 10% kJ low fat diet (LFD), 45% kJ 
high fat diet (HFD) or HFD with 20%, 30% or 40% kJ whey protein isolate (WPI) for 21 weeks1 
1 Data are means ± SEM (n = 5-10). In each row, values without a common letter significantly differ, P ≤ 0.05; NS, non-significant. 
TAG, triacylglycerol; NEFA, non-esterified fatty acids; GLP-1, glucagon-like peptide 1; HOMA-IR, homeostasis model assessment of 
insulin resistance. 
 
 LFD HFD 20% WPI 30% WPI 40% WPI P value 
Liver TAG (mg/g tissue) 71.47 ± 9.17a 139.03 ± 6.92b 104.94 ± 5.88c 107.21 ± 8.83c 70.82 ± 7.64a <.001 
Leptin (ng/ml) 4.41 ± 0.75a 84.69 ± 3.17b 53.78 ± 5.67c 51.12 ± 4.69c 15.01 ± 4.07a <.001 
Plasma TAG (mg/dl) 39.85 ± 2.91a 56.90 ± 6.31b 45.15 ± 4.32ab 52.36 ± 3.91ab 40.19 ± 3.96a <.05 
Plasma NEFA (mmol/L) 0.37 ± 0.09a 0.67 ± 0.07b 0.64 ± 0.05b 0.63 ± 0.06b 0.36 ± 0.05a <.01 
Corticosterone (ng/ml) 150.0 ± 21.7a 319.0 ± 48.6b 286.8 ± 31.9ab 334.1 ± 36.7b 277.1 ± 35.5ab <.01 
GLP-1 (pM) 25.03 ± 2.47 33.15 ± 2.83 28.07 ± 2.3 27.88 ± 1.98 24.03 ± 2.25 NS 
Glucose (mmol/L) 9.14 ± 1.24a 15.68 ± 0.83b 13.92 ± 0.95b 14.08 ± 1.05b 9.25 ± 0.77a <.001 
Insulin (ng/ml) 0.29 ± 0.05 0.55 ± 0.08 0.40 ± 0.10 0.37 ± 0.04 0.31 ± 0.06 NS 
HOMA-IR 2.48 ± 0.67a 9.79 ± 1.07b 6.81 ± 2.58ab 6.20 ± 0.95ab 3.04 ± 0.64a <.01 
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Table 3.3  Relative hepatic gene expression in mice fed a 10% kJ low fat diet (LFD), 45% kJ high fat diet (HFD) or HFD with 20%, 30% or 
40% kJ whey protein isolate (WPI) for 21 weeks1 
1Data are means ± SEM (n = 7-10). In each row, values without a common letter significantly differ, P < 0.05; NS, non-significant.  
Gene expression shown relative to the LFD control group set at 1.00. 
CD36, Cluster of differentiation 36; PPARγ, Peroxisome proliferator-activated receptor gamma; FABP1, Fatty acid binding protein 1; 
IRS-1, Insulin receptor substrate 1; CPT1a, Carnitine palmitoyltransferase 1a; GLUT2, Glucose transporter 2; FATP5, Fatty acid 
transporter 5; FASN, Fatty acid synthase; PPARɑ, Peroxisome proliferator-activated receptor alpha; TNF-α, Tumour necrosis factor 
alpha. 
 
 LFD HFD 20% WPI 30% WPI 40% WPI P value 
CD36 1.00 ± 0.20a 2.85 ± 0.34b 2.98 ± 0.45b 2.17 ± 0.25ab 1.50 ± 0.25a <.05 
PPARγ 1.00 ± 0.12a 3.00 ± 0.57b 2.30 ± 0.49b 1.88 ± 0.46b 0.85 ± 0.13a <.001 
FABP1 1.00 ± 0.09ab 1.27 ± 0.10b 0.86 ± 0.06ac 1.27 ± 0.17bc 0.71 ± 0.09a <.001 
IRS-1 1.00 ± 0.15a 0.58 ± 0.04b 0.69 ± 0.05ab 0.68 ± 0.06ab 0.79 ± 0.06ab <.01 
CPT1a 1.00 ± 0.08 0.85 ± 0.08 0.97 ± 0.06 0.90 ± 0.13 0.86 ± 0.10 NS 
GLUT2 1.00 ± 0.09 0.76 ± 0.04 1.02 ± 0.08 0.97 ± 0.09 0.89 ± 0.05 NS 
FATP5 1.00 ± 0.21 0.89 ± 0.07 0.88 ± 0.07 1.16 ± 0.07 1.24 ± 0.12 NS 
FASN 1.00 ± 0.36 0.46 ± 0.14 0.54 ± 0.19 0.40 ± 0.06 0.32 ± 0.04 NS 
PPARα 1.00 ± 0.04 1.13 ± 0.05 1.21 ± 0.05 1.17 ± 0.10 1.28 ± 0.11 NS 
TNF-α 1.00 ± 0.26 0.84 ± 0.15 1.12 ± 0.18 0.80 ± 0.09 0.71 ± 0.10 NS 
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Table 3.4  Relative hypothalamic gene expression in mice fed a 10% kJ low fat diet (LFD), 45% kJ high fat diet (HFD) or HFD with 20%, 
30% or 40% kJ whey protein isolate (WPI) for 21 weeks1 
1Data are means ± SEM (n = 5-10). In each row, values without a common letter significantly differ, P < 0.05; NS, non-significant.  
Gene expression shown relative to the LFD control group set at 1.00.  
IR, Insulin receptor; GCCR, Glucocorticoid receptor; TNF-α, Tumour necrosis factor alpha; POMC, Pro-opiomelancortin; NPY, 
Neuropeptide Y; ObR, Leptin receptor; GHS-R, Growth hormone secretatgogue receptor; PPARγ, Peroxisome proliferator activated 
receptor gamma; CPT1c, Carnitine palmitoyltransferase 1c; IRS-1, Insulin receptor substrate 1
 LFD HFD 20% WPI 30% WPI 40% WPI P value 
IR 1.00 ± 0.03ab 0.97 ± 0.07a 1.22 ± 0.04bc 1.37 ± 0.04cd 1.55 ± 0.08d <.05 
GCCR 1.00 ± 0.09a 1.40 ± 0.10b 1.34 ± 0.07ab 1.30 ± 0.08ab 1.42 ± 0.09b <.05 
TNF-α 1.00 ± 0.05a 1.76 ± 0.09b 1.57 ± 0.13b 1.47 ± 0.14ab 1.40 ± 0.25ab <.01 
POMC 1.00 ± 0.08 0.99 ± 0.06 1.01 ± 0.06 0.98 ± 0.06 1.00 ± 0.08 NS 
NPY 1.00 ± 0.04 1.02 ± 0.09 0.90 ± 0.06 0.88 ± 0.05 0.92 ± 0.08 NS 
ObR 1.00 ± 0.11 0.92 ± 0.05 0.99 ± 0.05 1.07 ± 0.07 0.95 ± 0.05 NS 
GHS-R 1.00 ± 0.07 0.98 ± 0.06 0.98 ± 0.08 1.02 ± 0.11 1.04 ± 0.09 NS 
PPARγ 1.00 ± 0.36 1.07 ± 0.04 0.95 ± 0.05 0.99 ± 0.05 0.98 ± 0.07 NS 
CPT1c 1.00 ± 0.09 0.92 ± 0.04 0.91 ± 0.01 0.97 ± 0.06 0.86 ± 0.04 NS 
IRS-1 1.00 ± 0.04 0.99 ± 0.04 0.97 ± 0.02 1.06 ± 0.08 1.00 ± 0.06 NS 
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Table 3.5  Gut microbiota composition as % of reads in mice fed a 45% kJ high fat 
diet (HFD) or HFD with 20%, 30% or 40% kJ whey protein isolate (WPI) for 21 
weeks1 
 HFD 20% WPI 30% WPI 40% WPI 
Phylum     
Proteobacteria 0.36a 0.63b 0.34ab 0.32a 
Actinobacteria 0.63a 1.82b 3.79b 0.36c 
Deferribacteres 0.57a 1.61b 1.56ab 2.03b 
     
Family     
Desulfovibrionaceae 0.12a 0.31b 0.21ab 0.23ab 
Rikenellaceae 6.71ab 7.54b 3.9a 6.4ab 
Bacteroidaceae 0.44a 0.42a 0.16b 0.21b 
Lactobacillaceae 0.21a 3.03b 4.6b 2.14b 
Bifidobacteriaceae 0.43a 1.71b 3.66b 0.22c 
Deferribacteraceae 0.57a 1.59b 1.32ab 2.03ab 
Peptostreptococcaceae  0.62a 1.79a 1.54a 8.01b 
Succinivibrionaceae 0.13a 0.15a 0b 0b 
Clostridiaceae 1.31a 0b 0b 0b 
Veillonellaceae 0.02a 0.12b 0a 0a 
     
Genus     
Anaerobiospirillum 0.13a 0.15a 0b 0b 
Desulfovibrio 0.07a 0.22b 0.17ab 0.15ab 
Alistipes 4.33ab 4.41a 2.24b 3.76ab 
Rikenella 1.04ab 0.49b 0.68b 1.08b 
Bacteroides 0.44a 0.4a 0.16b 0.21ab 
Oscillibacter 0.24a 0.67ab 0.42ab 0.52b 
Lactobacillus 0.2a 3.03b 4.6b 2.39b 
Bifidobacterium 0.43a 1.71b 3.66b 0.22c 
Mucispirillum 0.57a 1.61b 1.56ab 1.92ab 
Coprococcus 0.11ab 0.23b 0.06a 0.06ab 
Turicibacter 0.56a 0.35a 0.15ab 0b 
Clostridium  1.3a 0b 0b 0b 
Peptostreptococus  0.1a 0.14a 0.12a 0.78b 
1Data are means ± SEM (n = 10). Statistically significant differences generated 
using the Kruskal-Wallis algorithm. In each row values without a common letter 
significantly differ, P ≤ 0.05.  
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Figure. 3.1  Impact of whey protein isolate and protein to carbohydrate ratio on body 
weight and composition. (A) Shows the body weight trajectories of mice during 21 weeks 
of dietary treatment with a 10% kJ low fat diet (LFD), 45% kJ high fat diet (HFD) or a HFD 
with 20, 30 or 40% kJ whey protein isolate (WPI). Body weight gain (B) and body 
composition (C) of mice after 21 weeks on experimental diets are also shown. Data 
represent mean values ± SEM (n = 10 per group). Groups that do not share a common 
letter are significantly different at P < 0.05. 
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Figure. 3.2  Impact of whey protein isolate and protein to carbohydrate ratio on energy 
intake. Energy intake (A) and feeding behaviour (meal size & meal number) (B-C) was 
measured using TSE Phenomaster cages at weeks 17-20 for mice on either a 10% kJ low 
fat diet (LFD), 45% kJ high fat diet (HFD) or a HFD with 20, 30 or 40% kJ whey protein 
isolate (WPI). Experimental data collected from individual mice at 9 minute intervals over 
a 24 hour period are shown as mean values ± SEM (n = 8-10 per group) for light and dark 
phases. In the light and dark phase, groups that do not share a common letter are 
significantly different at P < 0.05. 
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Figure 3.3  Impact of whey protein isolate and protein to carbohydrate ratio on metabolic 
activity. Metabolic activity was measured using TSE Phenomaster cages at 17-20 weeks for 
mice on either a 10% kJ low fat diet (LFD), 45% kJ high fat diet (HFD) or a HFD with 20, 30 
or 40% kJ whey protein isolate (WPI). Experimental data for (A) oxygen consumption 
(VO2), (B) heat production, (C) locomotor activity and (D) respiratory exchange ratio 
(RER), collected from individual mice at 9 minute intervals over a 24 hour period, are 
shown as mean values ± SEM (n = 8-10 per group) for light and dark phases. In the light 
and dark phase, groups that do not share a common letter are significantly different at P < 
0.05. 
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Figure 3.4  Impact of whey protein isolate and protein to carbohydrate ratio on adipose 
cellular activity. Epididymal adipose tissue gene expression was investigated in mice after 
21 weeks on a 10% kJ low fat diet (LFD), 45% kJ high fat diet (HFD), or HFD with 20, 30 or 
40% kJ whey protein isolate (WPI). Relative mRNA expression is shown for (A) fatty acid 
synthase (FASN), fatty acid transporter 1 (FATP1), cluster of differentiation 36 (CD36), β-3 
adrenergenic receptor (β3-AR), uncoupling protein 2 (UCP-2), lipoprotein lipase (LPL) and 
carnitine palmitolytransferase 1b (CPT1b), and (B) for peroxisome proliferator activated 
receptor γ (PPARγ), insulin receptor (IR), insulin receptor substrate 1 (IRS-1), glucose 
transporter 4 (GLUT4), 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), tumour 
necrosis factor ɑ (TNF-α) and CD68. Data represent mean values ± SEM (n = 9-10 per 
group). Gene expression is shown relative to the LFD control group set at 1.00. Groups that 
do not share a common letter are significantly different at P < 0.05.  
 184 
 
 
 
Figure 3.5  Impact of whey protein isolate and protein to carbohydrate ratio on the gut 
microbiota composition. Principal Coordinate analysis (PCoA) of unweighted Unifrac 
distances of the 16S rRNA sequences, demonstrating where sequences cluster according to 
diet group. Data was generated from analysis of faecal samples collected from mice on a 
10% kJ low fat diet (LFD, Δ), a 45% kJ high fat diet (HFD, ♦) or a HFD with 20% kJ whey 
protein isolate (HFD-20% WPI, ○), 30% kJ WPI (HFD-30% WPI, ◊) or 40% kJ WPI (HFD-
40% WPI, ●)(n=10). 
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Supplementary table 3.1  Composition of experimental diets1 
Contents (g) Diets     
 LFD HFD HFD 20% 
WPI 
HFD 30% 
WPI 
HFD 40% 
WPI 
Casein 200 200 0 0 0 
Whey protein isolate 0 0 200 300 400 
L-Cystine 3 3 3 4.5 6 
Corn Starch 315 72.8 72.8 47 0 
Maltodextrin 10 35 100 100 100 100 
Sucrose 350 172.8 172.8 97.1 42.6 
Cellulose, BW200 50 50 50 50 50 
Soybean oil 25 25 25 25 25 
Lard 20 177.5 177.5 177.5 177.5 
Mineral mix S10026A 10 10 10 10 10 
CaHPO4 13 13 13 13 13 
CaCO3 5.5 5.5 5.5 5.5 5.5 
C5H6K3O7.1H2O 16.5 16.5 16.5 16.5 16.5 
Vitamin mix V10001 10 10 10 10 10 
Choline Bitartrate 2 2 2 2 2 
Energy (kcal/g) 3.8 4.7 4.7 4.7 4.7 
Protein (% kcal) 20 20 20 30 40 
Carbohydrate (% kcal) 70 35 35 25 15 
Fat (% kcal) 10 45 45 45 45 
1 Diets formulated and produced by Research Diets Inc. (New Brunswick, NJ, USA) 
LFD, low fat diet; HF, high fat diet; WPI, whey protein isolate. 
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Supplemenary table 3.2  Sequences mouse specific primers used in real-time PCR 
analysis 
 
POMC, Pro-opiomelancortin; NPY, Neuropeptide Y; IR, Insulin receptor; IRS-1, 
Insulin receptor substrate 1; GLUT4, Glucose transporter 4; ObR, Leptin receptor; 
GCCR, Glucocorticoid receptor; TNF-α, Tumour necrosis factor alpha; CD36, 
Cluster of differentiation 36; β-3 AR, Beta 3 adrenergic receptor; CPT1a, 
Carnitine palmitoyltransferase 1a PPARγ, Peroxisome proliferator-activated 
receptor γ;; FATP1, Fatty acid transporter 1; FASN, Fatty acid synthase; FABP1, 
Fatty acid binding protein 1; LPL, Lipoprotein lipase; 11β-HSD1, 11β-
hydroxysteroid dehydrogenase type 1; UCP-2, Uncoupling protein 2; GHS-R, 
Growth hormone secretagogue receptor.  
 Forward primer (5’-3’) Reverse primer (5’-3’) 
POMC 5’-gggcaagcgctcctactccatg-3’ 5’-ctcgccttccagctccctcttg-3’ 
NPY 5’-ccctcgctctatctctgctcgtgtg-3’ 5’-gtagtatctggccatgtcctctgc-3’ 
IR 5’-gatttccccaacgtgtcctctac-3’ 5’-caatgcggtacccagtgaagtg-3’ 
IRS-1 5’-gcgcaggcaccatctcaacaacc-3’ 5’-gcacgcacccggaaggaacc-3’ 
GLUT4 5’-ggcctgcccgaaagagtc-3’ 5’-aggagctggagcaaaggac-3’ 
GLUT2 5’-tcctacttggcctatctgctgtgc-3’ 5’-tgccctgacttcctcttccaac-3’ 
ObR 5’-gaccgccgaacacaaccgatgac-3’ 5’-acacctagctggcgaaaaactgaag-3’ 
GCCR 5’-acctgacttccttgggggctatgaac-3’ 5’-caggcagagtttgggaggtggtc-3’ 
TNFα 5’-tggcctccctctcatcag-3’ 5’-acttggtggtttgctacgac-3’ 
CD36 5’-tgatactatgcccgcctctcc-3’ 5’-tttcccacactcctttctcctcta-3’ 
β3-AR 5’-cgccttcaacccggtcatctactg-3’ 5’-ggtggactctgcctggcttcaac-3’ 
PPARγ 5’-tcaggtttgggcggatgc-3’ 5’-tcagcgggaaggactttatgtatg-3’ 
PPARα 5’-atgggggtgatcggaggctaatag-3’ 5’-gggtggcaggaagggaacagac-3’ 
CPT1a 5’-agacttccaacgcatgacagcactg-3’ 5’-ctcggccccgcaggtagatg-3’ 
CPT1b 5’-cgagaggggcggactgagactg-3’ 5’-ggctaggcggtacatgttttggtg-3’ 
CPT1c 5’-caggtgcgggagtcggtgaag-3’ 5’-cagcagagcgtgggcataagc-3’ 
FATP1 5’-ccggtgtggtggctgctcttctc-3’ 5’-gctgccatctccccgccataaatg-3’ 
FATP5 5’- ccggcagcatggcgtaacag-3’ 5’-acacatttgcccgaagtccattg-3’ 
FASN 5’-tccacctttaagttgccctg-3’ 5’-tctgctctcgtcatgtcacc-3’ 
FABP1 5’-gaagcctcgttgccaccat-3’ 5’-cgatttctgacacccccttgat-3’ 
LPL 5’-tgctcccaacaatataagactcc-3’ 5’-aaggccaggtgtttcaatc-3’ 
11β-HSD1 5’-ccttggctgggaaaatgacc-3’ 5’-ctatgaggccaaggacacagagag-3’ 
UCP-2 5’-ccatttcctgcaccccgatttacttcc-3’ 5’-gctgggctggggatgaagatgaag-3’ 
GHS-R 5’-ccccgggacaccaacgagtg-3’ 5’-aagaccggcaggaagaagaagacg-3’ 
Ghrelin 5’-cagaaagcccagcagagaaaggaatc-3’ 5’-cggccatgctgctgatactgag-3’ 
CD68 5’-cacttcgggccatgtttctcttg-3’ 5’-aggggctggtaggttgattgtcgtc-3’ 
β-actin 5’-agagggaaatcgtgcgtgac-3’ 5’-caatagtgatgacctggcgt-3’ 
GAPDH 5’- ccattctcggccttgact-3’ 5- tgaaggtcggtgtgaacg-3’ 
18-S 5’-aggaccgcggttctattttgttgg-3’ 5’-atgctttcgctct-ggtccgtcttg-3’ 
YWHAZ 5’-cggagctgcgtgacatctgc-3’ 5’-cctcggccaagtaacggtagtag-3’ 
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Supplementary figure 3.1  Effect of a 10% kJ low fat diet with 20% kJ casein 
(LFD) or 20% kJ whey protein isolate (LFD-WPI) on (A) body weight, (B) energy 
intake (C) oxygen consumption (VO2) and (D) locomotor activity, measured in 
individual mice at 9 minute intervals over a 24 hour period using TSE 
Phenomaster cages. Data are shown as mean values ± SEM (n = 8-10 per group) for 
light and dark phases. 
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4.1 ABSTRACT 
Whey proteins have been shown to be acutely insulinotropic and to improve 
insulin sensitivity with prolonged intake. This study aimed to explore the 
underlying mechanisms. C57BL/6J mice were fed a 10% kJ fat and 20% kJ casein 
protein or whey protein isolate (WPI) diet for 7 (Study 1) or 15 weeks (Study 2), 
and energy balance and insulin signalling-related parameters were quantified. The 
7 weeks of WPI intake had no effect on weight gain and cumulative energy intake, 
and only caused a trend towards an increase in plasma fasting insulin levels (P = 
0.07), yet body fat was increased (P < 0.05) and insulin signalling-related gene 
expression decreased in the adipose tissue, skeletal muscle and liver. Moreover, 
lipolysis and lipid oxidation related gene expression was also decreased in the 
adipose tissue of these WPI fed mice. In contrast, 15 weeks of WPI intake reduced 
weight gain and cumulative energy intake (P < 0.05), with no change in insulin 
signalling-related gene expression. In both studies, WPI intake reduced the 
intestinal weight and length, while stomach weight was also reduced in the 15 
week study (P < 0.05). The decreased insulin signalling and lipid metabolism-
related gene expression coupled with the increased body fat in a background of 
plasma insulin levels that showed a trend towards an increase, suggested 
enhanced insulin signalling with WPI intake. This effect was largely reduced with 
prolonged WPI intake, presumably driven by the suppression of energy intake. 
Changes in gastrointestinal morphology, potentially similar to that caused by 
bariatric surgery, may underlie some of the WPI effects on insulin signalling-
related gene expression and energy intake. 
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4.2 INTRODUCTION 
Insulin is an important regulator of energy balance and glucose metabolism (Saltiel 
& Kahn, 2001). In regards to glucose homeostasis, insulin facilitates the uptake of 
glucose into both adipose tissue and skeletal muscle cells, for its storage as  
triacylglycerol (TAG) or utilisation in energy production via β-oxidation, 
respectively (Saltiel & Kahn, 2001). Insulin regulates this uptake of glucose in both 
tissues by promoting the expression and translocation of glucose transporter 4 
(GLUT4) to the cell surface (Watson et al, 2004). In energy balance regulation, 
central insulin action induces a catabolic response, reducing both energy intake 
and body weight (Brief & Davis, 1984; Ikeda et al, 1986). Conversely, in the 
periphery, insulin has an anabolic response, promoting the storage of lipids by the 
stimulation of fatty acid uptake and synthesis, and via the inhibition of TAG 
breakdown and release as fatty acids and glycerol (Saltiel & Kahn, 2001).  
Whey proteins are a by-product of cheese manufacture. These dietary 
proteins have gained considerable interest in recent years in relation to their 
health benefits (Luhovyy et al, 2007). Increasing evidence suggests that whey 
proteins exert a robust insulinotropic effect (Frid et al, 2005; Gaudel et al, 2013; 
Power et al, 2009), by both directly affecting its production and release, while also 
enhancing the translocation of GLUT4 to the plasma membrane (Morato et al, 
2013a; Morato et al, 2013b). Additionally, whey proteins stimulate incretin 
hormone release, both glucagon-like peptide 1 (GLP-1) and  glucose-dependent 
insulinotropic peptide (GIP), and increase their activity by suppressing dipeptidyl 
peptidase-4 (DPPIV) function, which together promotes glucose-dependent insulin 
section from pancreatic β-cells (Garber, 2011; Jakubowicz & Froy, 2013; Tulipano 
et al, 2011). We recently found that feeding whey protein isolate (WPI) to mice for 
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8 weeks normalises the high fat diet (HFD)-induced reduction in insulin receptor 
(IR) and GLUT4 gene expression in the epididymal adipose tissue (McAllan et al, 
2013). These changes occurred in the absence of an altered plasma insulin, GLP-1 
or glucose level, suggesting that WPI has a specific effect on insulin-related gene 
expression in this tissue. However, as body fat was also reduced by feeding the 
WPI in a high fat background, it is possible that the observed changes in gene 
expression may have been influenced by the altered fat mass in the animals.  
Therefore, in this study we sought to obtain further evidence supporting the 
suggestion that WPI has a specific effect on insulin signalling by using mice fed a 
low fat diet (LFD) with either casein or WPI. This strategy allowed us to delineate 
WPI effects on insulin action without the confounding impact of the associated 
dietary protein-induced reductions in fat mass seen in HFD fed mice. 
 
4.3 MATERIALS & METHODS  
4.3.1 Animals & diets 
Three week old C57BL/6J male mice (Harlan; Middlesex, UK) were housed as 
previously described (McAllan et al, 2013) and had ad libitum access to food and 
water throughout the trial. Mice were fed a diet containing 10% kJ fat, 70% kJ 
carbohydrate and 20% kJ casein protein (LF-CAS; #D12450; Research Diets, USA) 
or WPI (Alacentm 890 NZMP, Auckland, New Zealand) (LF-WPI). Mice were 
acclimatised to their environment for three weeks before experimental dietary 
treatment began. All procedures involving animals were approved by the 
University College Cork Animal Experimentation Ethics Committee and were 
licensed under the Cruelty to Animals Act 1876. 
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4.3.2 Experimental protocol  
Two separate studies were conducted lasting for 7 weeks (Study 1) and 15 weeks 
(Study 2). In both studies, following acclimatisation, mice were separated into two 
weight matched dietary groups and provided either the LF-CAS or LF-WPI diet (n = 
8). Body weight and energy intake were measured weekly. In addition, at week 6 
(Study 1) and week 14 (Study 2), energy intake and metabolic activity were 
measured using the TSE Phenomaster system (Bad Homburg, Germany). Body 
composition was determined by NMR using the Bruker minispec LF50H (Bruker 
optics, Ettlingen, Germany) at the end of each study, after a 6h fast. Subsequently 
mice were anesthetised and their blood was collected. The mice were then 
sacrificed by cervical dislocation, and tissues of interest were excised, weighed and 
immediately snap frozen in liquid nitrogen (liver, subcutaneous adipose, 
epididymal adipose, gastrocnemius muscle, small intestine and colon). Plasma and 
tissue samples were stored at -80oC. 
 
4.3.3 Biochemical analysis 
Blood collected into vacutinater EDTA tubes (BD; Franklin Lakes, NJ, USA) from 
anesthetised mice (ketamine; 65mg/kg, xylazine; 13mg/kg), was treated with 
Diprotin A and Aprotinin as described before (McAllan et al, 2014) to protect 
plasma peptides against proteolytic degradation. Plasma was isolated by 
centrifugation at 2000rpm and 4oC for 15mins, and was analysed using 
colorimetric assay kits to determine plasma concentrations of glucose 
(Calibochem, Darmstadt, Germany) and TAG (LabAssay TAG, Wako Chemicals, 
Richmond, VI, USA). ELISA kits were used to determine plasma concentrations of 
GLP-1 (Millipore, St. Charles, MO, USA), leptin and insulin (Crystal Chem, Downers 
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Grove, IL, USA). Homeostasis model assessment of insulin resistance (HOMA-IR) 
and hepatic triglyceride levels were measured as previously detailed (McAllan et 
al, 2014), while total faecal lipid content was determined by a modified version of 
that previously described (Chon et al, 2012; Newberry et al, 2006). Briefly, 
following an overnight incubation at room temperature in 1ml distilled water 
/100mg dry faecal weight, faecal samples were then vortexed thoroughly before 
the addition of 4 volumes of chloroform: methanol solution (2:1 v/v), after which 
0.2 volumes of NaCl solution (0.58% in distilled water) were added and samples 
were centrifuged at 2000rpm and 4oC for 20mins to separate the layers. The lower 
phase was collected into pre-weighed tubes, evaporated to dryness and re-
weighed to measure lipid content gravimetrically. 
 
4.3.4 Tissue gene expression 
Total RNA was isolated from tissues of interest (epididymal adipose tissue, liver, 
skeletal muscle, duodenum and ileum) and purified using RNeasy mini kits 
(Qiagen, Hilden, Germany), with accompanied DNase treatment used to prevent 
genomic DNA contamination. Complementary DNA (cDNA) was synthesised from 
isolated RNA and subjected to Real-time qPCR analysis as described previously 
(McAllan et al, 2013). Primer sequences of target and reference genes are listed in 
supplementary table 1. Target gene mRNA expressions were calculated using 2-
ΔΔCp, after normalising against housekeeping gene expression according to ΔΔCp= 
ΔCp target gene – ΔCp housekeeping gene. Housekeeping genes used were β-actin 
(adipose, liver, muscle, duodenum, and ileum), YWHAZ (liver and duodenum, 
ileum) and 18-S (adipose). The gene expression is shown relative to the LF-CAS 
group. 
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4.3.5 Statistical analysis 
The data are presented as the mean ± SEM. Dietary treatment effects were 
analysed using unpaired T-tests. A two-way Repeated measures ANOVA with 
Bonferroni multiple comparisons was used to analyse bodyweight trajectories over 
both treatment periods. Mann-Whitney U tests were used to analyse non-
parametric data. Statistical significant was established at P ≤ 0.05, and data 
analyses were performed using Graphpad Prism (ver. 6) and Minitab (ver. 15). 
 
4.4 RESULTS 
4.4.1 Weight gain and body composition 
Study 1: The figures 4.1(A & C) show that over the 7 week dietary period there was 
no difference in bodyweight or weight gain between the LF-WPI and LF-CAS 
groups. However, LF-WPI fed mice had significantly greater body fat mass (%) (P < 
0.05) and a lower lean mass (%) (P < 0.05) than their LF-CAS counterparts (Fig. 
4.1E). The weight and length of the small intestine was significantly lower in LF-
WPI fed mice compared to the LF-CAS controls (P < 0.001) (Fig. 4.2A and B), and 
there was a trend towards an increased in epididymal fat weight with WPI intake 
(Fig. 4.2A; P = 0.055). This change in fat mass was also reflected in plasma leptin 
levels (Table 4.2). In a previous study, using grouped housed mice, we investigated 
the energy balance-related effects of WPI in a low fat background and obtained 
similar results as reported here (McAllan et al, 2014). The group housed mice fed 
WPI for 7 weeks gained similar weight as casein fed mice (2.71 ± 1.05g WPI vs. 
2.73 ± 1.00g casein) and had a trend towards an increase in body fat mass (%) 
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(17.75 ± 1.44 WPI vs. 13.68 ± 0.45 casein; P = 0.08) and a significant decrease in 
lean mass (%) (65.97 ± 1.16 WPI vs. 69.38 ± 0.266 casein; P < 0.05). 
Study 2: After 15 weeks of dietary treatment total body weight gain was 
significantly reduced in the LF-WPI group compared to the LF-CAS group (Fig. 
4.1D; P < 0.05), although no significant difference in either body weight or body 
composition (fat or lean mass) was observed between the groups (Fig. 4.1B & F). 
This was reflected in plasma leptin levels, which showed no difference between the 
groups at the end of the study (Table 4.2). Again, the weight and length of the small 
intestine was reduced, but in addition the weight of the stomach was similarly 
reduced in the LF-WPI group (Fig 4.2C and D; P < 0.05). 
  
4.4.2 Energy intake and metabolism related parameters 
Study 1: Cumulative energy intake over the first 6 weeks did not significantly differ 
between LF-WPI and LF-CAS dietary groups (Fig. 4.1G), which was reflected in the 
24h energy intake and meal pattern (meal number or meal size) as determined 
using TSE Phenomaster cages at week 6. (Table 4.1) The latter analysis did 
nonetheless reveal a significant increase in dark phase water intake in LF-WPI fed 
mice (P < 0.05) (Table 4.1). However, there was no change in oxygen consumption 
(VO2), a marker of energy expenditure, or respiratory exchange ratio (RER), which 
predicts substrate utilisation, with WPI intake (Table 4.1). Moreover, WPI intake 
did not change faecal fat content (excretion), TAG levels in the plasma and/or liver 
that could correlate with the augmented fat deposition (Table 4.2). 
Study 2: In contrast to study 1, cumulative energy intake was significantly reduced 
in WPI fed mice over the first 13 weeks (Fig. 4.1H; P < 0.05). The 24h energy 
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intake, meal number and meal size as determined by TSE phenomaster cages in 
week 14 (Table 4.1), showed a reduction in the WPI group, although this was not 
significant. As before, VO2, RER and water intake did not differ between the diet 
groups (Table 4.1). Reductions in energy intake were not due to changes in satiety 
related hormone cholecystokinin (CCK) or proglucagon gene expression in the 
intestine (Table 4.5), which was corroborated with plasma GLP-1 levels (Table 
4.2). Furthermore, WPI intake contrastingly reduced peptide YY (PYY) expression 
in the ileum (Table 4.5).  
 
4.4.3 Insulin signalling and lipid metabolism related gene expression 
Study 1: At week 7, plasma glucose and TAG levels were similar between the 
dietary groups, while fasting plasma insulin did show a trend towards an increase 
(P = 0.07) in WPI fed mice (Table 4.2). The expression of genes fundamental to 
insulin signalling and glucose transport in the adipose tissue, namely IR, insulin 
receptor substrate 1 (IRS-1) and GLUT4, were all significantly reduced in LF-WPI 
fed mice compared to LF-CAS fed controls at 7 weeks (Fig 4.3A). Similarly, genes 
involved in lipolysis and β-oxidation, namely β-3 adrenergic receptor (β-3 AR), 
hormone sensitive lipase (HSL) and carnitine palmitoyltransferase 1b (CPT1b), 
were also down-regulated in WPI fed mice at 7 weeks (Fig. 4.3A). Similar gene 
expression changes were observed in the skeletal muscle and liver. In both tissues, 
there was a reduction in the mRNA expression of IRS-1, while there was also a 
trend towards a decrease in IR expression in skeletal muscle (Table 4.3 & 4.4).  In 
addition, hepatic levels of insulin-like growth factor 1 (IGF-1) were found to be 
significantly increased in LF-WPI fed mice (Table 4.4). Moreover, WPI also 
significantly reduced hepatic fatty acid synthase (FASN) and lipoprotein lipase 
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(LPL), and caused a trend towards a reduction in both fatty acid binding protein 1 
(FABP1) and peroxisome proliferator-activated receptor gamma (PPARγ) (Table 
4.4). In contrast, skeletal muscle expression of acetyl-CoA carboxylase (ACC) was 
significantly up-regulated in LF-WPI fed mice, while PPARγ mRNA expression also 
showed a trend towards an increase (Table 4.3; P = 0.07). 
Study 2: While plasma insulin, glucose and TAG levels remained unchanged by WPI 
challenge, in contrast to study 1 there was no significant dietary effect on insulin 
signalling, lipolysis or β-oxidation gene expression in the epididymal adipose 
tissue, liver or skeletal muscle; although there was a trend towards a decrease in 
skeletal muscle IRS-1 expression in the WPI fed animals (P = 0.06) (Table 4.3). In 
contrast, the expressions of FASN, ACC and cluster of differentiation 36 (CD36) 
were significantly up-regulated in the epididymal adipose tissue of WPI fed mice at 
15 weeks (P < 0.05), while LPL also showed a trend towards an increase (P = 0.08) 
(Fig. 4.3B). In the duodenum, there was a significant reduction in mRNA 
expression of IR and a trend towards a decrease in the expression of sodium-
glucose co-transporter 1 (SGLT-1) in the WPI group (Table 4.5), while there was 
also an increase in GLUT2 expression in the ileum of these mice (Table 4.5). The 
LF-WPI diet also reduced fatty acid transporter 4 (FATP4) mRNA levels in the 
ileum (Table 4.5).  
 
4.5 DISCUSSION 
Our results show that 7 weeks of WPI intake does not affect weight gain or energy 
intake but does increase percentage body fat, while also reducing insulin signalling 
associated gene expression in multiple tissues, and lipolysis and β-oxidation-
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associated gene expression in the epididymal adipose tissue. These changes 
occurred in a background of unaltered plasma glucose and GLP-1, with only a 
trend towards increased plasma insulin. In contrast, the 15 weeks of WPI intake, 
decreased weight gain and cumulative energy intake, and had no effect on insulin 
associated gene expression or on plasma hormones and metabolites, but did 
increase the expression of genes involved in lipid synthesis in the epididymal 
adipose tissue. As insulin facilitates cellular lipid storage and synthesis (Saltiel & 
Kahn, 2001), and suppresses energy intake (Brief & Davis, 1984; Ikeda et al, 1986), 
our data suggests that WPI has an effect on energy balance through its actions on 
insulin signalling. Importantly, in both studies WPI impacted on intestinal 
morphology, with significant reductions in both the weight and length of the small 
intestine, leading to the possibility that this could underlie how WPI affects insulin 
signalling and impacts on physiology. 
 Seven weeks of WPI intake facilitated whole body fat deposition, which was 
reflected by a trend towards an increased epididymal fat mass. Interestingly, this 
occurred without changing weight gain, presumably because their % lean mass 
was also decreased. The increased body fat cannot be explained by alterations to 
energy intake, metabolic activity, or faecal fat excretion as these did not differ 
between the two diet groups. As insulin promotes glucose and fatty acid uptake, 
augmenting lipid synthesis and storage, and suppresses intracellular lipolysis 
(Saltiel & Kahn, 2001), the observed changes may be related to a specific effect of 
WPI on insulin signalling. Indeed, both lipolytic and β-oxidation associated genes 
in the epididymal adipose tissue were suppressed in WPI fed mice. The concurrent 
reduction in mRNA expression of insulin and glucose related genes in the liver, 
adipose tissue and skeletal muscle demonstrated here, might reflect a negative 
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feedback response that is attempting to minimise further fat deposition. This is 
further supported by the finding that WPI intake increased hepatic IGF-1 mRNA 
expression, which has been shown to suppress further insulin production (Van 
Schravendijk et al, 1990; Zhang et al, 2007; Zhao et al, 1997) and is itself 
stimulated by insulin (Bereket et al, 1995; Phillips et al, 1998). Interestingly, given 
evidence that whey protein intake both promotes GLUT4 translocation to the cell 
surface (Morato et al, 2013a; Morato et al, 2013b) and normalises insulin 
signalling associated gene expression in the epididymal adipose tissue of mice fed 
a HFD (McAllan et al, 2013; Pilvi et al, 2009), the trend towards an increase in 
plasma insulin in WPI fed mice, coupled with the observed down-regulation of 
insulin-related gene expression in LF-WPI fed mice most likely represents a 
homeostatic response to increased WPI-induced insulin signalling, rather than a 
direct suppressive effect of WPI on insulin related gene expression. The difference 
in the results between these previous studies and the present work on how WPI 
influences the expression of genes related to insulin and glucose homeostasis may 
be related to the dietary composition in which WPI was presented to the animals 
(LFD vs. HFD). 
 Extending the WPI intake to 15 weeks reduced body weight gain, 
presumably because of the gradual decrease in cumulative energy intake, since 
neither metabolic rate, substrate utilisation nor faecal fat excretion differed 
between WPI and casein groups. Despite the change in energy intake and the fact 
that whey proteins are known to stimulate incretin hormone production 
(Gunnarsson et al, 2006), the levels of anorexigenic hormones GLP-1 and leptin in 
the plasma did not change in WPI fed mice, as neither did the intestinal gene 
expression of incretin hormones gastric inhibitory peptide (GIP) or proglucagon, 
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or the satiation factor CCK. Moreover, mRNA levels of the satiety hormone PYY 
were significantly decreased in the ileum of LF-WPI fed mice, albeit a similar effect 
of WPI has been reported on colonic expression of PYY mRNA previously (Xiao et 
al, 2005). Notably, whilst plasma insulin levels did not change, the insulin 
regulated FASN and ACC gene expression increased significantly in the epididymal 
adipose tissue, raising the possibility that insulin signalling may be enhanced in the 
WPI fed mice even after 15 weeks of dietary challenge, and that the reduction in 
cumulative energy intake may be, at least in part, a consequence of its central 
effects. Additionally, the reduction in stomach weight may also have contributed to 
the latter physiological change in a manner similar to bariatric surgery, which as 
part of the intervention reduces stomach size to achieve a significant decrease in 
food intake.  
Our data raises the key question that if WPI intake potentially influences 
insulin signalling in the 7 and 15 week studies, as suggested by the data, then how 
do WPI fed mice maintain their fasting glucose concentrations at a comparable 
level to casein fed animals? The observed down-regulation of the insulin and 
glucose-related gene expression across multiple tissues in the 7 week study may 
offer an explanation to this question, since this potential negative feedback 
mechanism could avoid excess insulin-dependent glucose transport and uptake 
into cells. Extending the feeding trial to 15 weeks caused a reduction in cumulative 
energy intake, with normalisation of plasma insulin and glucose related gene 
expression in tissues, presumably to maintain glucose homeostasis. The latter 
suggestion is further supported by the augmented ileum GLUT2 mRNA expression 
of WPI fed mice. In future studies glucose and/or insulin tolerance tests should 
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also be included to establish direct evidence of whether any alterations to insulin 
sensitivity or glucose clearance occur with WPI intake.  
At present we don’t know how WPI could potentially increase insulin 
signalling and glucose transport without substantially changing plasma insulin or 
GLP-1 as demonstrated here, and as shown by others in young male subjects 
(Akhavan et al, 2014) and in Wistar rats (Morato et al, 2013a) independently of 
effects on plasma insulin. Interestingly, one common denominator of our two 
studies here was the change in intestinal morphology, where both the weight and 
length of the tissue was reduced. It is noteworthy in this regard that surgical 
reduction of the intestinal length, as that achieved by attaching the distal small 
intestine to the stomach so that nutrients bypass the proximal part of the small 
intestine, causes enhanced insulin sensitivity that is independent of changes to 
energy intake or plasma levels of insulin or GLP-1 (Rubino et al, 2006; Salinari et 
al, 2013b). It has been proposed that the underlying cause may be due to a 
reduction in the production of yet unknown negative regulatory factors that 
impede insulin action, arising from the reduced exposure of the proximal intestinal 
cells to nutrient passage following by-pass surgery. In fact, duodenal-jejunal 
secreted proteins isolated from diabetic db/db mice, when injected intravenously, 
were found to impair insulin signalling in wild type mice (Salinari et al, 2013a). In 
the same way, WPI-induced shortening of the intestine, may have caused a 
surgery-like effect on the proximal small intestine with a presumed reduction in 
cell number in this region reducing production of the proposed factor. Whether or 
not the whey protein effect on the GI tract truly mimics gastric by-pass surgery and 
its potential health related outcomes remains to be determined. 
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In conclusion, the results here show that WPI intake in a low-fat diet 
background reduces body weight gain after prolonged (15 week) intake by 
suppressing energy intake. In the short-term (7 week) WPI appears to facilitate 
greater fat deposition, possibly via its effects on insulin signalling. In fact, we 
propose the associated reductions in insulin signalling-related gene expression 
across multiple tissues to be a negative feedback response to minimise additional 
insulin-induced fat deposition. In spite of a reduction in body weight gain at 15 
weeks prolonged WPI intake still appeared to enable a retention of body fat, which 
corresponded with enhanced lipogenic potential in the adipose tissue, arising 
possibly because of the above mentioned WPI-induced effects on insulin action, 
which could also be correlated to the reduction in energy intake. Our data also 
shows that WPI has a specific effect on intestinal morphology, whereby WPI 
decreased intestinal length irrespective of the duration of WPI feeding, and this 
may be linked to how WPI increases insulin signalling in multiple tissues and 
brings about changes in energy balance and body composition in mice. However 
further investigation is required to uncover the clinical significance of this 
alteration of the intestinal environment. 
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Table 4.1 
TSE phenomaster metabolic and energy intake measurements of mice fed a low fat 
diet with casein protein (LF-CAS) or whey protein isolate (LF-WPI) diet for 6 or 14 
weeks. 
Data are means ± SEM (n = 8). For each trial length, values in a row without a 
common letter differ significantly, P ≤ 0.05; NS, non-significant. 
 
VO2, oxygen consumption; VCO2, Carbon dioxide consumption; RER, Respiratory 
exchange ratio. 
 
 
  6 weeks 14 weeks 
 Phase LF-CAS LF-WPI LF-CAS LF-WPI 
Energy intake 
(kJ/mouse) 
Light 12.54 ± 1.54 10.41 ± 1.67 12.17 ± 1.46 10.40 ± 2.42 
Dark 40.61 ± 2.47 42.26 ± 2.43 43.06 ± 2.10 32.86 ±3.91 
Meal number 
Light 12.63 ± 1.22 9.5 ± 1.55 13.0 ± 1.1 20.3 ± 5.0 
Dark 32.5 ± 1.75 30.25 ± 1.98 31.9 ± 2.9 25.4 ± 3.0 
Meal size  
(kJ) 
Light 1.00 ± 0.09 1.14 ± 0.10 0.99 ± 0.16 0.80 ± 0.12 
Dark 1.28 ± 0.11 1.43 ± 0.10 1.46 ± 0.20 1.15 ± 0.19 
Water intake 
(ml/mouse) 
Light 0.49 ± 0.06 0.50 ± 0.07 0.61 ± 0.10 0.82 ± 0.22 
Dark 2.28 ± 0.22a 3.03 ± 0.15b 2.83 ± 0.32 3.65 ± 0.69 
VO2  
(ml/hr/kg) 
Light 3370.7 ± 78.7 3224.2 ± 45.4 3837.7 ± 132.9 3772.3 ± 69.9 
Dark 4181.6 ± 58.8 4125.3 ± 99.1 4351.0 ± 125.1 4417.4 ± 50.9 
RER  
(VCO2 / VO2) 
Light 0.85 ± 0.01 0.85 ± 0.01 0.83 ± 0.01 0.82 ± 0.03 
Dark 0.96 ± 0.01 0.97 ± 0.01 0.98 ± 0.01 0.92 ± 0.02 
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Table 4.2 
Plasma parameters, liver TAG levels and faecal lipid content in mice fed a low fat 
diet with casein protein (LF-CAS) or whey protein isolate (LF-WPI) for 7 or 15 
weeks. 
Data are means ± SEM (n = 8). For each trial length, values in a row without a 
common letter differ significantly, P ≤ 0.05. 
 
TAG, triacylglycerol; GLP-1, Glucagon-like peptide 1; HOMA-IR, homeostasis 
model assessment of insulin resistance. 
 7 weeks 15 weeks 
 LF-CAS LF-WPI LF-CAS LF-WPI 
Plasma TAG (mg/dL) 28.71 ± 4.07 39.95 ± 5.08 36.18 ± 1.42 33.68 ± 2.59 
Plasma leptin (ng/ml) 2.05 ± 0.26a 3.30 ± 0.49b 6.65 ± 1.53 5.80 ± 1.38 
Plasma GLP-1 (pM) 16.14 ± 1.25 20.64 ± 2.34 24.70 ± 3.50 23.59 ± 1.50 
Plasma glucose (mmol/L) 13.13 ± 0.95 11.67 ± 0.94 12.18 ± 1.57 13.11± 0.84 
Plasma insulin (ng/ml) 0.12 ± 0.01 0.16 ± 0.02 0.21 ± 0.01 0.22 ± 0.01 
HOMA-IR 1.76 ± 0.21 2.04 ± 0.17 3.07 ± 0.39 3.12 ± 0.16 
Liver TAG (mg/g Tissue) 32.88 ± 1.07 29.97 ± 1.63 54.62 ± 2.08 53.50 ± 2.32 
Faecal lipid content (%) 14.80 ± 1.69 13.88 ± 2.37 7.80 ± 0.58 9.13 ± 1.41 
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Table 4.3 
Relative skeletal muscle gene expression in mice fed a low fat diet with casein protein (LF-CAS) or whey protein isolate (LF-WPI) for 7 or 
15 weeks. 
 
Data are means ± SEM (n = 7-8). For each dietary trial length, values in a row without a common letter differ significantly, P < 0.05; NS, 
non-significant. Gene expressions are shown relative to the LF-CAS group which is set at 1.00. 
IR, Insulin receptor; GLUT4, Glucose transporter 4; IRS-1, Insulin receptor substrate 1; CPT1b, Carnitine palmitoyltransferase 1b; UCP-3, 
Uncoupling protein 3; PPARα, Peroxisome proliferator-activated receptor ɑ; PPARγ, Peroxisome proliferator-activated receptor γ; LPL, 
Lipoprotein lipase; M-GS, Muscle glycogen synthase; ACC, Acetyl-CoA carboxylase; CD36, Cluster of differentiation 36.  
 7 Weeks  15 Weeks 
 LF-CAS LF-WPI P value  LF-CAS LF-WPI P value 
IR 1.00 ± 0.14 0.71 ± 0.06 0.09  1.00 ± 0.19 1.01 ± 0.08 NS 
GLUT4 1.00 ± 0.10 1.04 ± 0.06 NS  1.00 ± 0.10 0.82 ± 0.05 NS 
IRS-1 1.00 ± 0.08 0.78 ± 0.04 <.05  1.00 ± 0.08 0.81 ± 0.04 0.06 
CPT1b 1.00 ± 0.08 0.87 ± 0.07 NS  1.00 ± 0.13 0.85 ± 0.06 NS 
UCP-3 1.00 ± 0.09 1.14 ± 0.09 NS  1.00 ± 0.17 0.94 ± 0.09  NS 
PPARα 1.00 ± 0.17 1.05 ± 0.18 NS  1.00 ± 0.17 0.93 ± 0.19 NS 
PPARγ 1.00 ± 0.12 1.72 ± 0.32 0.07  1.00 ± 0.26 0.89 ± 0.21 NS 
LPL 1.00 ± 0.16 1.48 ± 0.29 NS  1.00 ± 0.14 0.87 ± 0.16 NS 
M-GS 1.00 ± 0.10 1.05 ± 0.07 NS  1.00 ± 0.10 0.83 ± 0.05 NS 
ACC 1.00 ± 0.10 2.95 ± 0.82 <.05  1.00 ± 0.43 0.62 ± 0.21 NS 
CD36 1.00 ± 0.28 0.62 ± 0.10 NS  1.00 ± 0.14 1.05 ± 0.15 NS 
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Table 4.4 
Relative liver gene expression in mice fed a low fat diet with casein protein (LF-CAS) or whey protein isolate (LF-WPI) for 7 or 15 weeks. 
 
Data are means ± SEM (n = 7-8). For each dietary trial length, values in a row without a common letter differ significantly, P < 0.05; NS, 
non-significant. Gene expressions are shown relative to the LF-CAS group which is set at 1.00. 
GLUT2, Glucose transporter 2; IRS-1, Insulin receptor substrate 1; IGF-1, Insulin-like growth factor 1; CPT1a, Carnitine 
palmitoyltransferase 1a; UCP-2, Uncoupling protein 2; PPARα, Peroxisome proliferator-activated receptor ɑ; PPARγ, Peroxisome 
proliferator-activated receptor γ; L-GS, Liver glycogen synthase; FASN, Fatty acid synthase; ACC, Acetyl-CoA carboxylase; LPL, Lipoprotein 
lipase; FABP1, Fatty acid binding protein 1; CD36, Cluster of differentiation 36. 
 7 Weeks  15 Weeks 
 LF-CAS LF-WPI P value  LF-CAS LF-WPI P value 
GLUT2 1.00 ± 0.04 1.14 ± 0.08 NS  1.00 ± 0.12 1.03 ± 0.09 NS 
IRS-1 1.00 ± 0.04 0.81 ± 0.07 <.05  1.00 ± 0.12 0.93 ± 0.06 NS 
IGF-1 1.00 ± 0.05 1.21 ± 0.07 <.05  1.00 ± 0.09 0.95 ± 0.07 NS 
CPT1a 1.00 ± 0.12 1.12 ± 0.07 NS  1.00 ± 0.18 1.08 ± 0.12 NS 
UCP-2 1.00 ± 0.09 0.83 ± 0.04 NS  1.00 ± 0.07 1.07 ± 0.08 NS 
PPARα 1.00 ± 0.10 1.06 ± 0.05 NS  1.00 ± 0.14 1.06 ± 0.10 NS 
PPARγ 1.00 ± 0.23 0.48 ± 0.15 0.09  1.00 ± 0.17 0.76 ± 0.15 NS 
L-GS 1.00 ± 0.11 1.03 ± 0.10 NS  1.00 ± 0.16 0.93 ± 0.13 NS 
FASN 1.00 ± 0.10 0.54 ±0.12 <.05  1.00 ± 0.29 0.96 ± 0.12 NS 
ACC 1.00 ± 0.08 0.84 ± 0.07 NS  1.00 ± 0.14 1.10 ± 0.14 NS 
LPL 1.00 ± 0.10 0.36 ± 0.07 <.001  1.00 ± 0.09 0.96 ± 0.07 NS 
FABP1 1.00 ± 0.05 0.68 ± 0.16 0.08  1.00 ± 0.13 0.82 ± 0.07 NS 
CD36 1.00 ± 0.21 0.71 ± 0.29 NS  1.00 ± 0.20 0.92 ± 0.07 NS 
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Table 4.5 
Relative intestinal (duodenal & ileual) expression in mice fed a low fat diet 
with casein protein (LF-CAS) or whey protein isolate (LF-WPI) for 15 weeks. 
Data are means ± SEM (n = 6-8). P < 0.05 differ significantly; NS, non-significant. 
Gene expressions are shown relative to the LF-CAS group which is set at 1.00.   
IR, Insulin receptor, GLUT2, Glucose transporter 2; IRS-1, Insulin receptor 
substrate 1; SGLT-1, Sodium-glucose co-transporter 1; CCK, Cholecystokinin; 
GIP, Glucose-dependent insulinotrophic peptide; PYY, Peptide YY; PPARα, 
Peroxisome proliferator-activated receptor ɑ; FATP4, Fatty acid transport 
protein 4; FABP1, Fatty acid binding protein 1, CD36, Cluster of differentiation 
36; DGAT, Diglyceride acyltransferase. 
 
 LF-CAS LF-WPI P value 
Duodenum    
IR 1.00 ± 0.12 0.68 ± 0.09 0.05 
GLUT2 1.00 ± 0.09 0.94 ± 0.06 NS 
IRS-1 1.00 ± 0.09 0.84 ± 0.07 NS 
SGLT-1 1.00 ± 0.07 0.83 ± 0.05 0.07 
CCK 1.00 ± 0.05 0.76 ± 0.15 NS 
GIP 1.00 ± 0.10 0.65 ± 0.15 NS 
PPARα 1.00 ± 0.11 0.81 ± 0.10 NS 
FATP4 1.00 ± 0.06 1.13 ± 0.13 NS 
FABP1 1.00 ± 0.12 0.81 ± 0.09 NS 
CD36 1.00 ± 0.30 0.56 ± 0.12 NS 
DGAT 1.00 ± 0.12 0.81 ± 0.09 NS 
Occludin 1.00 ± 0.11 0.80 ± 0.07 NS 
Ileum    
IR 1.00 ± 0.04 1.00 ± 0.07 NS 
GLUT2 1.00 ± 0.21 1.89 ± 0.31 <.05 
IRS-1 1.00 ± 0.06 1.13 ± 0.17 NS 
SGLT-1 1.00 ± 0.09 0.99 ± 0.10 NS 
Proglucagon 1.00 ± 0.07 1.13 ± 0.17 NS 
PYY 1.00 ± 0.11 0.60 ± 0.06 <.01 
PPARα 1.00 ± 0.11 0.99 ± 0.12 NS 
FATP4 1.00 ± 0.08 0.77 ± 0.04 <.05 
FABP1 1.00 ± 0.45 1.87 ± 0.56 NS 
CD36 1.00 ± 0.19 1.56 ± 0.60 NS 
DGAT 1.00 ± 0.06 1.08 ± 0.10 NS 
Occludin 1.00 ± 0.05 0.85 ± 0.09 NS 
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Figure 4.1  Body weight, body composition and energy intake of C57BL/6J mice 
fed a low fat diet with casein protein (LF-CAS) or whey protein isolate (LF-WPI) for 
7 weeks (Study 1; A, C, E, G) or 15 weeks (Study 2; B, D, F & H). The body weight 
trajectories over the 7 week (A) and 15 week (B) dietary treatment periods. Total 
weight gain after 7 weeks (C) and 15 weeks (D) of dietary treatment. Body 
composition (lean and fat mass %) after 7 weeks (E) and 15 weeks (F) of dietary 
treatment. Cumulative energy intake over the first 6 weeks (G) and 13 weeks (H) 
of dietary treatment. Data represent means ± SEM (n = 8). * P < 0.05, ** P < 0.01. 
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Figure 4.2  Tissue weights and intestinal length in C57BL/6J mice fed a low fat diet 
with casein protein (LF-CAS) or whey protein isolate (LF-WPI) for 7 weeks (Study 
1; A-B) and 15 weeks (Study 2; C-D). Relative tissue weights after 7 weeks (A) and 
15 weeks (C) of dietary treatment. Intestinal lengths after 7 weeks (B) and 15 
weeks (D) of dietary treatment. Tissue weights are shown relative to casein fed 
animals, which were set as 1.00 for both studies. Data represent means ± SEM (n = 
8). * P < 0.05, ** P < 0.01, ***P < 0.001. SWAT, subcutaneous white adipose tissue; 
EWAT, epididymal white adipose tissue. 
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Figure 4.3  The effects of feeding C57BL/6J mice a low fat diet with casein protein 
(LF-CAS) or whey protein isolate (LF-WPI) for (A) 7 weeks (Study 1) or (B) 15 
weeks (Study 2) upon their epididymal adipose tissue mRNA expression of insulin 
receptor (IR), glucose transporter 4, (GLUT4), insulin substrate 1 (IRS-1), βeta-3 
adrenergic receptor (β3-AR), hormone sensitive lipase (HSL) carnitine 
palmitoyltransferase 1b (CPT1b), uncoupling protein 2 (UCP-2), peroxisome 
proliferator-activated receptor γ (PPARγ), lipoprotein lipase (LPL), fatty acid 
transporter 1 (FATP1), cluster of differentiation 36 (CD36), fatty acid synthase 
(FASN), acetyl-CoA carboxylase (ACC) and leptin. Gene expressions are shown 
relative to the LF-CAS group which is set at 1.00.  Data represent means ± SEM (n = 
8). * P < 0.05, ** P < 0.01. 
217 
 
 
 
 
Chapter 4 
SUPPLEMENTARY 
INFORMATION 
 
 
 
 
 
 
 
 
 
 
 
218 
 
Supplementary table 4.1 
Sequences of mouse specific primers used in real-time PCR analysis 
Acetyl-CoA carboxylase; β3-AR, Beta-3 adrenergic receptor; CD36, Cluster of 
differentiation 36; CPT1a, Carnitine palmitoyltransferase 1a; CCK, 
Cholecystokinin; DGAT, Diglyceride acyltransferase; FABP1, Fatty acid binding 
protein 1; FASN, Fatty acid synthase; FATP1, Fatty acid transport protein 1; GIP, 
 Forward primer (5’-3’) Reverse primer (5’-3’) 
ACC 5-tgttgagacgctggtttgtagaa-3’ 5’-ggtccttattattgtcccagacgta-3’ 
β3-AR 5’-cgccttcaacccggtcatctactg-3’ 5’-ggtggactctgcctggcttcaac-3’ 
CD36 5’-tgatactatgcccgcctctcc-3’ 5’-tttcccacactcctttctcctcta-3’ 
CPT1a 5’-agacttccaacgcatgacagcactg-3’ 5’-ctcggccccgcaggtagatg-3’ 
CPT1b 5’-cgagaggggcggactgagactg-3’ 5’-ggctaggcggtacatgttttggtg-3’ 
CCK 5’-gtgccgaggactacgaatacc-3’ 5’-tctgggagtcactgaaggaaacac-3’ 
DGAT 5’-cacaggtgccgtcttgggttatc-3’ 5’-cagacttggggtgtggctcagga-3’ 
FABP1 5’-gaagcctcgttgccaccat-3’ 5’-cgatttctgacacccccttgat-3’ 
FASN 5’-tccacctttaagttgccctg-3’ 5’-tctgctctcgtcatgtcacc-3’ 
FATP1 5’-ccggtgtggtggctgctcttctc-3’ 5’-gctgccatctccccgccataaatg-3’ 
FATP4 5’-tggcgtttcatccgggtcttcatc-3’ 5’-gcaaacagcaggggcaccgtcttc-3’ 
GIP 5’-tctctgttgctggtgctcctgttc-3’ 5’-gctctcctgtgcctctttgtcctc-3’ 
GLUT2 5’-tcctacttggcctatctgctgtgc-3’ 5’-tgccctgacttcctcttccaac-3’ 
GLUT4 5’-ggcctgcccgaaagagtc-3’ 5’-aggagctggagcaaaggac-3’ 
HSL 5’-ctattcagggacagaggcag-3’ 5’-cgatgtggtcttttggggc-3’ 
IGF-1 5’-gtgtggaccgaggggcttttac-3’ 5’-ggggcacagtacatctccagtctc-3’ 
IR 5’-gatttccccaacgtgtcctctac-3’ 5’-caatgcggtacccagtgaagtg-3’ 
IRS-1 5’-gcgcaggcaccatctcaacaacc-3’ 5’-gcacgcacccggaaggaacc-3’ 
Leptin  5’-ccccgcaccgctggaagtac-3’ 5’-atgtgccctgaaatgcggtatg-3’ 
LPL 5’-tgctcccaacaatataagactcc-3’ 5’-aaggccaggtgtttcaatc-3’ 
L-GS 5’-gagttgctggctcaccctgtag-3’ 5’-agcggcctctgagcattcttc-3’ 
M-GS 5’-tacgaccgcgcggccaatgacg-3’ 5’-cacagaccaacgccagccaacc-3’ 
Occludin 5’-atgtccggccgatgctctc-3’ 5’-tttggctgctcttgggtctgtat-3’ 
PPARα 5’-atgggggtgatcggaggctaatag-3’ 5’-gggtggcaggaagggaacagac-3’ 
PPARγ 5’-tcaggtttgggcggatgc-3’ 5’-tcagcgggaaggactttatgtatg-3’ 
Peptide YY 5’-ggacgcctaccctgccaaacca-3’ 5’-agtgccctcttcttaaaccaaaca-3’ 
Pro-glucagon 5’-agggacctttaccagtgatgtga-3’ 5’-acgagatgttgtgaagatggttgt-3’ 
SGLT-1 5’-gagccccgcggttactgc-3’ 5’-cctgcggctgctcctgtg-3’ 
UCP-2 5’-ccatttcctgcaccccgatttacttcc-3’ 5’-gctgggctggggatgaagatgaag-3’ 
UCP-3 5’-acaggcccacacggtccagaacc-3’ 5’-cccatcaggtcagtgcaaaacagagg-3’ 
β-actin 5’-agagggaaatcgtgcgtgac-3’ 5’-caatagtgatgacctggcgt-3’ 
18-S 5’-aggaccgcggttctattttgttgg-3’ 5’-atgctttcgctct-ggtccgtcttg-3’ 
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Glucose-dependent insulinotropic peptide; GLUT4, Glucose transporter 4; HSL, 
Hormone sensitive lipase; IGF-1, Insulin-like growth factor; IR, Insulin receptor; 
IRS-1; Insulin receptor substrate 1;  LPL, Lipoprotein lipase;  L-GS, Liver glycogen 
synthase;  M-GS, Muscle glycogen synthase; PPARγ, Peroxisome proliferator-
activated receptor γ; SGLT-1, Sodium-glucose co-transporter 1; UCP-2, 
Uncoupling protein 2. 
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Chapter 5 
Lysophosphatidic acid receptor 5 is a novel 
candidate in the regulation of 3T3-L1 pre-
adipocyte growth and differentiation 
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5.1 ABSTRACT 
Lysophosphatidic acid receptor 5 (LPA5) may have roles in the regulation of 
energy balance, although the supporting evidence is inconclusive. In the present 
study we sought to determine whether LPA5 could regulate adipocyte activity 
linked to lipid metabolism. To that end, LPA5 mRNA expression in mouse 
epididymal adipose tissue in response to energetic challenges was investigated, as 
well as the receptor’s influence on 3T3-L1 pre-adipocyte proliferation and 
differentiation. LPA5 mRNA expression was found to be increased in the 
epididymal adipose tissue of high fat diet fed mice and obese ob/ob mice compared 
to appropriate controls. Differentiation of wild type 3T3-L1 cells also increased 
LPA5 receptor mRNA expression. To understand the cellular role of the receptor, 
LPA5 mRNA was over-expressed in 3T3-L1 pre-adipocytes. This manipulation 
provided a growth advantage to the 3T3-L1 pre-adipocytes, and it also increased 
the mRNA expression of genes previously shown to be involved in cellular growth, 
namely β-actin and LPA1. Upon stimulation with an adipogenic cocktail, cellular 
differentiation was partially suppressed in 3T3-L1 pre-adipocytes over-expressing 
the receptor, as indicated by decreased mRNA expression of peroxisome 
proliferator activated receptor-γ, fatty acid synthase, glucose transporter 4 and β3-
adrenergic receptor, and by increased LPA1 mRNA expression. Correspondingly, 
lipid accumulation as measured by Oil red O lipid staining was significantly 
reduced in these differentiating cells over-expressing the receptor. These data 
suggest an important role for LPA5 in pre-adipocyte growth and differentiation.  
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5.2 INTRODUCTION 
Lysophosphatidic acid (LPA) is a bioactive glycerophospholipid that regulates a 
wide variety of cellular responses including platelet aggregation, cell proliferation 
and neurite retraction (Choi et al, 2010; Moolenaar, 1999). LPA has been detected 
in several biological fluids including the extracellular fluid in the adipose tissue 
(Choi et al, 2010; Valet et al, 1998) and is primarily produced by the hydrolysis of 
phospholipids resulting from the actions of a secreted lysophospholipase D 
enzyme, called autotaxin (Nakanaga et al, 2010). LPA mediates its effects through 
several G-protein coupled receptors (GPRs) (Choi et al, 2010). To date, six 
characterised LPA receptors (LPA1-6) have been identified, and these can be 
divided into two subfamilies; LPA1-3 belong to the endothelial cell differentiation 
(Edg) subfamily, while the structurally distinct LPA4-6 make up the non-Edg 
subfamily (Yanagida & Ishii, 2011). The receptors show a wide tissue distribution, 
although the level of expression of each of the LPA receptors varies between 
tissues (Choi et al, 2010). This, along with gene deletion studies (Choi et al, 2008), 
suggests that distinct receptors could mediate specific actions of LPA including the 
recently identified roles in the regulation of energy balance.  
It has been shown that LPA increases proliferation of 3T3-F442A pre-
adipocytes by activation of LPA1 (Pages et al, 2001; Valet et al, 1998), and 
suppresses their differentiation into lipid laden mature adipocytes by decreasing 
the expression of peroxisome proliferator activated receptor (PPAR)-γ2 (Simon et 
al, 2005). Moreover, mice generated with the targeted deletion of LPA1 show 
increased adiposity compared to wild-type mice (Simon et al, 2005). These data 
suggest important role(s) for LPA in the regulation of adipogenesis, the process by 
which pre-adipocytes attain a mature cell fate (Fajas, 2003). Recently, a potential 
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role for LPA5 (GPR93/92) in the regulation of food intake has been suggested 
based on the evidence that LPA5 activation in intestinal STC-1 enteroendocrine 
cells augments the production and the release of the satiation hormone 
cholecystokinin (CCK) (Choi et al, 2007a; Choi et al, 2007b). Moreover, the 
stimulation of CCK gene expression and protein secretion upon cell stimulation 
with protein hydrolysate was observed to be enhanced in these cells over-
expressing the LPA5 receptor, indicating a potential mechanism by which dietary 
protein could regulate food intake (Choi et al, 2007b).  
While the above data supports a role for LPA5 in the regulation of energy 
balance, here, we aimed to obtain further evidence of whether the receptor does 
indeed have a role in energy balance regulation. To this end, we focussed on the 
adipose tissue and assessed whether LPA5 could regulate the activity of these cells. 
We provide in vivo and in vitro evidence supporting a role for the receptor in the 
regulation of pre-adipocyte proliferation and differentiation.  
 
5.3 MATERIALS & METHODS 
5.3.1 Materials 
The pCI-neo plasmid containing the coding sequence of the rat LPA5 gene (Choi et 
al, 2007a), was kindly provided by Professor G. W. Aponte (University of California, 
Berkeley). All reagents were purchased from Sigma-Aldrich unless otherwise 
indicated. 
 
5.3.2 Animals 
Experiments involving mice were licensed under the Cruelty to Animals Act 1876 
and received ethical approval from the University College Cork Animal Ethics 
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Review Committee. Male 3-4 week old C57BL/6J mice (Harlan, UK) were group 
housed in cages (n = 5 per cage) maintained at 21 ± 1oC and humidity 55 ± 10%, 
with a 12 h light/dark cycle (06:00-18:00). Mice had ad libitum access to food and 
water, unless otherwise stated. Two experiments were conducted after the initial 
four week acclimatisation period. In the first, mice were either fasted or had ad 
libitum access to a low fat diet (LFD) (10% kJ as fat) (Research Diets, NJ, USA) for a 
24 hour period (n = 5). In the second experiment, mice were provided with either 
the LFD or a high fat diet (HFD) (45% kJ as fat) (Research Diets, NJ, USA) for 14 
weeks (n = 5). All mice were sacrificed by cervical dislocation. The epididymal 
adipose fat pads were harvested, and snap frozen in liquid nitrogen and stored at -
80oC. In addition, epididymal adipose tissue samples corresponding to lean (+/?) 
and obese (ob/ob) mice (n = 8) from a previous study (Murphy et al, 2010) were 
also used to investigate the expression of genes of interest. 
 
5.3.3 Cell culture 
3T3-L1 pre-adipocyte cells were purchased from European Cell Culture Collection. 
The 3T3-L1 pre-adipocytes were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% (v/v) foetal bovine serum and 1% (v/v) 
penicillin/streptomycin maintained at 37oC in a 5% (v/v) CO2 incubator. The 
media was changed every 2 days, and the cells were grown to approx. 80 % 
confluency, at which point they were harvested with trypsin, and either stored at -
80oC for subsequent analysis of gene expression (undifferentiated) or re-seeded 
into new plate(s). 
To generate the 3T3-L1 clones over-expressing LPA5 (3T3-LPA5), 3T3-L1 
cells in supplemented DMEM were seeded at 1x105 cells/ml into 35-mm cell 
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culture dishes. After 24 hours, the media was replaced with unsupplemented 
DMEM and the cells were transfected with 2µg of the pCI-neo plasmid containing 
the LPA5 DNA using the FuGENE HD transfection reagent (Clone 1), or the X-treme 
GENE HP transfection reagent (Roche, Germany) (Clone 2) according to the 
manufactures’ instructions. After 3 hours, supplemented DMEM was added to the 
dish to allow cell growth. Parallel experiments were also performed to transfect 
3T3-L1 cells with the pCI-neo plasmid (Promega, USA) without an insert DNA 
(3T3-NEO). The cells stably transfected with the plasmids of interest were selected 
using Geneticin (G418) (Promega, USA) at 500 µg/ml. All subsequent experiments 
involving stably transfected 3T3-LPA5 and 3T3-NEO cells contained G418 in the 
media. In experiments where cellular activity was compared between 3T3-LPA5 
and 3T3-NEO cells, the same passage number in both cell lines was used.  
To differentiate 3T3-L1 cell lines, the corresponding pre-adipocytes were 
seeded into either 35mm cell culture dishes at 2.5x105 cells/ml or 96 well plates at 
1.5x105 cells/ml. Two days post-confluency, the cells were stimulated with 5µg/ml 
of bovine insulin, 0.4µg/ml dexamethasone and 0.5mM 3-iso-butyl-1-
methylxanthine in supplemented DMEM. After 3 days, the adipogenic media was 
replaced with DMEM containing 5µg/ml bovine insulin. This step was performed 
every 2nd day thereafter until 10 days had passed since differentiation was 
initiated, at which point the cells were harvested for analysis of gene expression 
(35mm dishes) or stained with Oil red O for lipid quantification (96 well plates). 
 
5.3.4 Cell growth assay  
The xCELLigence system (Roche and ACEA biosciences) was used to measure cell 
growth in clone 1 of 3T3-NEO and 3T3-LPA5 pre-adipocytes. This system detects 
  
226 
electronic impedance resulting from changes in number/morphology of cells 
grown in E-plates (Roche). The relative changes are represented as cell index (CI), 
where CI = (Zi– Z0)/15 (Zi: individual time point impedance, Z0: Background 
impedance). Experiments to assess the impact of LPA5 over-expression on cell 
growth were conducted using cells seeded at 25 cells/μl in supplemented DMEM at 
200 µl per E-plate well. The CI for 3T3-NEO and 3T3-LPA5 pre-adipocytes was 
normalised to a single time point to account for any discrepancies in the starting 
cell number and was compared every hour over a 64 hour period. 
 
5.3.5 Oil red O staining and lipid quantification 
To stain differentiated 3T3-LPA5 and 3T3-NEO adipocytes, cells were washed 
twice with PBS before being fixed in 3.7% (w/v) paraformaldehyde for 1 hour. 
Cells were then washed again twice with PBS before being stained with 0.2% 
(w/v) Oil red O working solution for 20 minutes, after which time the cells were 
washed with distilled water until all excess Oil red O dye solution was removed. 
The working solution was a 3:2 ratio of Oil red O stock solution (0.35g Oil red O 
dye dissolved in 100ml isopropanol) to distilled water, which was filtered through 
a 0.2µm membrane before use. The Oil red O dye was extracted from stained 
adipocytes by treating them with equal volumes of 100% isopropanol, and the 
lipid content was quantified by measuring the absorbance of the solution at 
520nm. 
 
5.3.6 RNA extraction and Real-time PCR analysis 
Total RNA was isolated from frozen cell pellets (3T3-L1, 3T3-LPA5 and 3T3-NEO) 
and from mouse epididymal adipose tissue into diethylpyrocarbonate (DEPC) 
  
227 
treated distilled water using the RNeasy mini kit (Qiagen, Germany) according to 
the manufacturers’ instructions. To degrade any potential genomic DNA 
contamination, on-column DNase treatment (Qiagen, Germany) was performed 
during RNA isolation. Complementary DNA (cDNA) was synthesised from equal 
quantities (either 500ng or 1μg) of total RNA using 2.5ng/μl random hexamer 
primers (Bioline, UK), 0.5mM dNTP (Promega, USA), 2U/μl RNase inhibitor 
(Promega, USA) and the first strand synthesis system containing the Super Script II 
reverse transcriptase enzyme (Invitrogen, UK), according to the manufacturers’ 
instructions. A parallel reaction without the inclusion of the reverse transcriptase 
enzyme was also performed as a negative control. The amplification of the cDNA 
was performed in the Lightcycler 480 system (Roche) using 0.25μM primers 
(Eurofins MWG operon), 1μl cDNA and the Lightcycler 480 SYBR Green I Master kit 
(Roche), according to manufacturers’ instructions. Real-time PCR conditions were: 
95oC for 10 min followed by 50 cycles at 95oC for 10s, 60oC for 5s, and 72oC for 15s. 
Primers used are listed in table 1. Automated sequencing was performed to verify 
PCR product sequences. Melting curve analysis also allowed validation of the 
authenticity of the real-time PCR products. Data obtained as Cp values were 
normalised to the expression of either GAPDH (adipose tissue) or 18S (3T3-
adipocytes) according to ΔΔCp = ΔCp target gene – ΔCp housekeeping gene. The gene 
expression was expressed as 2-ΔΔCp and was shown relative to the expression of the 
control group. 
  
5.3.7 Statistical analysis 
Data are presented as means ± SEM, with results for the 3T3 cell line work being 
the mean of 3-4 independent experiments. Differences between experimental 
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groups were analysed by Students T-test or One way ANOVA with Tukey post-hoc 
multiple comparison analysis. Repeated measures two-way ANOVA with 
Bonferroni post-hoc multiple comparisons was used to analyse the cell growth 
measured using the xCELLigence system. Non-parametric data was analysed by 
Mann-Whitney tests. Significance was accepted at P < 0.05, and the statistical 
analysis was performed using GraphPad Prism version 6 (San Diego, CA, USA). 
 
5.4 RESULTS 
5.4.1 LPA5 expression was increased in the epididymal adipose tissue of obese 
mice and in differentiated pre-adipocytes  
Feeding a HFD for 14 weeks increased the body weight of mice (35.82 g ± 0.79 in 
HFD group vs. 26.06 g ± 1.70 in LFD group; P < 0.05) (n = 5). HFD feeding and ob 
gene mutation induced weight gain was associated with increased LPA5 mRNA 
expression in the epididymal adipose tissue (Fig. 5.1A and C). Fasting for 24 hours, 
decreased the body weight of mice (23.59 g ± 0.63 in fasted vs. 27.80 g ± 0.39 in ad 
libitum fed; P < 0.05) (n = 5), but did not affect the mRNA expressions of LPA5 (Fig. 
5.1E). The mRNA expression of LPA1 did not respond to any of the energetic 
challenges (Fig. 5.1B, D and F). The expression of adipogenesis associated genes 
PPARγ and fatty acid synthase (FASN) were also investigated. The energetic 
challenges did not significantly alter PPARγ mRNA expression (1.00 ± 0.18 in LFD 
vs. 0.89 ± 0.13 in HFD; 1.00 ± 0.12 in +/? vs. 1.20 ± 0.15 in ob/ob; 1.00 ± 0.37 in ad 
libitum vs. 1.81 ± 0.61 in fasted). FASN mRNA expression was decreased in HFD fed 
mice (1.00 ± 0.24 in LFD vs. 0.25 ± 0.04 in HFD; P < 0.05) and in obese ob/ob mice 
(1.00 ± 0.09 in +/? vs. 0.28 ± 0.03 in ob/ob; P < 0.001) with no significant change 
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observed in fasted mice compared to their respective controls (1.00 ± 0.57 in ad 
libitum vs. 0.45 ± 0.15 in fasted). 
 To obtain further insight into how the observed LPA5 gene expression 
changes in response to energetic challenges may relate to adipocyte function and 
lipid metabolism in the adipose tissue, we compared the expression between 
differentiated (Diff) and undifferentiated (Undiff) 3T3-L1 cells grown in vitro. 
Cellular differentiation increased mRNA expression of LPA5 (Fig. 5.2A). 
Differentiation also decreased LPA1 mRNA expression (Fig. 5.2B) and increased the 
mRNA expression of PPARγ (Fig. 5.2C; P < 0.001) and FASN (Fig. 5.2D; P < 0.001), 
as previously shown for 3T3-F442 cells (Schmid et al, 2005; Simon et al, 2005). 
 
5.4.2 LPA5 influenced 3T3-L1 pre-adipocyte cellular activity  
To further define the role of the receptor in adipogenesis, we first focused on the 
pre-adipocyte stage and assessed whether increasing the endogenous mRNA 
(which is low compared to differentiated stage) may alter cellular activity. To this 
end, two stable 3T3-L1 clones over-expressing the receptor mRNA (3T3-LPA5) 
were created (Fig. 5.3A-B). The mRNA expressions for both LPA1 (Fig. 5.3C-D) and 
β-actin (Fig. 5.3E-F) in both clones of 3T3-LPA5 cells were found to be increased 
compared to 3T3-NEO controls (P < 0.05). Investigation of cellular growth using 
xCELLigence technology revealed growth in clone 1 of the 3T3-LPA5 cells was 
increased compared to its respective clone of 3T3-NEO control cells (Fig. 5.4A), 
which became statistically significant at 52 hours (P < 0.05) and continued to 
increase in significance until termination of the experiment (P < 0.001).  
 
5.4.3 LPA5 influenced the cellular activity of differentiating pre-adipocytes 
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Differentiation of 3T3-LPA5 (clone 1) cells decreased LPA5 mRNA expression (Fig. 
5.5A), but increased LPA1 mRNA (Fig. 5.5B). In addition, the mRNA expressions of 
several other adipogenesis-associated genes, namely PPARγ, fatty acid synthase 
(FASN), β3-adrenergic receptor (β3-AR) and glucose transporter 4 (GLUT4) (Fig. 
5.5C-F), were also decreased in these cells over-expressing LPA5. However, the 
mRNA expressions of β-actin (3T3-NEO, 1.00 ± 0.14 vs. 3T3-LPA5, 0.79 ± 0.09) and 
Wnt10b (3T3-NEO, 1.00 ± 0.08 vs. 3T3-LPA5, 1.08 ± 0.12) (a ligand of the Wnt 
signalling pathway important for pre-adipocyte differentiation) were not 
significantly different between these differentiated 3T3-LPA5 and 3T3-NEO cells. 
To determine if the decreased adipogenesis-associated gene expression was also 
associated with an expected reduction in lipid accumulation, Oil red O staining and 
quantification was performed on cells at day 10 of differentiation. Data showed a 
significant reduction in relative lipid content in differentiating 3T3-LPA5 (clone 1) 
cells compared to 3T3-NEO (clone 1) controls (P < 0.001; Fig. 5.6A).  
 
5.5 DISCUSSION 
In the present study we show evidence that LPA5 could regulate cellular activity 
linked to pre-adipocyte growth and differentiation, which suggests an important 
role for the receptor in the regulation of adipogenesis. 
Development of adiposity in HFD fed and obese ob/ob mice is accompanied 
by cellular hyperplasia and hypertrophy (Faust et al, 1978; Hausman et al, 2001; 
Johnson et al, 1978; Lemonnier, 1972; Marques et al, 1998), suggesting a role for 
adipogenesis in the development of the phenotype. In contrast, food-deprivation, 
which decreases adiposity, does not change cell number (Miller et al, 1983). As 
LPA5 expression was increased in the epididymal adipose tissue of HFD fed and 
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obese ob/ob mice, but was not altered in 24h fasted mice, one could argue that the 
expression level of LPA5 in the obese mice could be linked to some change 
associated with the development of adiposity, including pre-adipocyte 
proliferation and/or differentiation. In further support of this suggestion, we 
observed an increased LPA5 mRNA expression in differentiating 3T3-L1 cells.  
To understand the cellular role of the receptor in the pre-adipocyte stage, 
we increased the endogenous levels of LPA5 mRNA, which is low compared to the 
differentiated state, by creating a stable pre-adipocyte 3T3-L1 cell line over-
expressing the LPA5 mRNA (3T3-LPA5). Previous studies have shown that (1) LPA5 
is expressed in RH7777 rat hepatoma cells and that its expression correlated with 
the (un)methylated status of the promoter (Okabe et al, 2011), (2) LPA5 activation 
of Rho/Rho-kinase signalling pathway causes changes in neurite retraction (Lee et 
al, 2006) and (3) this Rho-kinase signalling pathway initiates actin fibre formation 
(Arnsdorf et al, 2009), the disruption of which impedes cell growth and migration 
(Bunnell et al, 2011). Consistent with this notion of LPA5 signalling through the 
above pathway, we observed an increased β-actin expression in 3T3-L1 cells over-
expressing the receptor. Moreover, the investigation of cellular growth using 
xCELLigence technology revealed the growth of 3T3-LPA5 cells to be increased 
compared to its 3T3-NEO control cells. Thus the data are consistent with the 
suggestion that LPA5 activation in 3T3-L1 cells provides a growth advantage to the 
cells. 
LPA is known to promote pre-adipocyte proliferation via LPA1, as  knock-
down of LPA1 expression in 3T3-F442A pre-adipocytes suppresses the ability of 
LPA to induce cell proliferation (Pages et al, 2001). Our investigation found 
increased levels of LPA1 mRNA in pre-adipocytes over-expressing LPA5, suggesting 
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a functional relationship between LPA5 and LPA1 that may be important for 
cellular growth. Thus, given the important role of LPA1 in pre-adipocyte cell 
proliferation and its augmented expression in 3T3-LPA5 cells that display 
enhanced cellular growth compared to 3T3-NEO control cells, it could be argued 
that LPA5 and LPA1 may mediate distinct roles of LPA in pre-adipocyte growth or 
that the two receptors may transduce signals of different ligands that are 
important for regulating pre-adipocyte growth. The contrasting LPA5 and LPA1 
responses to HF feeding and ob gene mutation, and differentiation of 3T3-L1 cells, 
further suggest that the two receptors may have distinct activation and signalling 
mechanisms. 
It has been established (and also shown in the present study for at least 
some of the genes) that PPARγ, GLUT4, FASN and β3-AR mRNA expressions are 
increased during cellular differentiation with PPARγ increasing early, while the 
others show a late stage increase (Gregoire et al, 1998). We found that 3T3-L1 pre-
adipocytes over-expressing LPA5, when stimulated with an adipogenic cocktail, 
show a marked decrease in the expression of PPARγ, GLUT4, FASN and β3-AR  
mRNA compared to 3T3-NEO controls. Given the temporal variation in mRNA 
expression of these genes during differentiation as described above, it is likely that 
the observed effects in 3T3-LPA5 cells were due to LPA5 action during early stages 
of differentiation. Correspondingly, lipid accumulation as measured by Oil red O 
lipid staining was significantly reduced in these differentiating cells over-
expressing the receptor. The data therefore suggests that the receptor impedes 
cellular differentiation. Indeed, pre-adipocyte differentiation into mature fat cells 
is characterised by the appearance of lipid droplets and is associated with a down-
regulation of LPA1 mRNA expression (Pages et al, 2001; Simon et al, 2005), thus 
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the elevated LPA1 mRNA expression and reduced lipid accumulation in these 
differentiating cells over-expressing LPA5 (3T3-LPA5) further strengthens the 
suggestion that activation of this receptor impedes cellular differentiation.  
The differentiation process reduced LPA5 mRNA in 3T3-LPA5 cells, which 
was surprising given that at their pre-adipocyte stage the cells were over-
expressing the receptor via a stably transfected plasmid construct containing the 
coding sequence for LPA5. Since the construct was integrated into the genome, one 
could envisage that receptor signalling may have impeded expression of specific 
genes (PPARγ, FASN, GLUT4, β3-AR) important for cellular differentiation, but in 
doing so may also have created a cellular environment that could have prevented 
the subsequent expression of its own mRNA, which is naturally found to increase 
during differentiation. An alternative possibility is that LPA5 mRNA expression 
may be coupled to receptor activation, such that over-activation of the receptor, as 
that may be occurring in differentiating 3T3-LPA5 cells, could possibly have caused 
receptor internalisation (Lee et al, 2006) and down-regulation of its mRNA 
expression. This negative feedback mechanism may be more apparent in the 
differentiating 3T3-LPA5 cells because the cells were attempting to over-express 
the receptor in a background of elevating endogenous LPA5 mRNA during 
differentiation. 
Adipogenesis is known to be regulated by a diverse array of receptors, of 
which β3-AR is one example. While this receptor negatively regulates adipogenesis 
(Li et al, 2010), its mRNA increases during adipogenesis (Monjo et al, 2005), 
presumably to regulate this process. In a similar manner, the increased expression 
of LPA5 in adipogenesis may represent a mechanism that could regulate the extent 
to which pre-adipocytes may undergo growth and differentiation. Disruption of the 
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receptor activation or signalling, as that may be occurring during HFD feeding and 
by leptin deficiency (due to ob gene mutation), may lead to the development of the 
obese phenotype.  
In summary, we have shown that LPA5 expression is increased in the 
epididymal adipose tissue in response to HFD feeding and ob gene mutation, as 
well as in differentiated 3T3-L1 cells. Over-expression of the LPA5 receptor in 3T3-
L1 pre-adipocytes provided a growth advantage to the cells, with concurrent 
increases in the LPA1 and β-actin expression. In contrast, the manipulation 
impeded the cellular differentiation process, which was reflected by the down-
regulation of adipogenesis-related gene expression (PPARγ, FASN, GLUT4, β3-AR) 
and by reduced lipid accumulation in these cells. Whilst further work is required to 
establish whether LPA5 has a role in adipogenesis in vivo, our data does suggest it 
to be a new regulatory component in adipogenesis and provides the foundation for 
future work investigating the effect of LPA5 in adipocyte/adipose tissue, including 
whether it may be involved in mediating the direct effect of dietary proteins on 
adipose tissue function.  
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Table 5.1  Sequences of primers used for Real-time PCR 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
LPA5 5’-tgccaattcttcagccaacac-3’ 5’-tagtaggagaggcgcaggggaagtg-3’ 
LPA1 5’-cagcgcaacgagaaccctaatgg-3’ 5’-ccggctggcttccttctaaacc-3’ 
PPARγ 5’-tcaggtttgggcggatgc-3’ 5’-tcagcgggaaggactttatgtatg-3’ 
FASN 5’-tccacctttaagttgccctg-3’ 5’-tctgctctcgtcatgtcacc-3’ 
GLUT4 5’-ggcctgcccgaaagagtc-3’ 5’-aggagctggagcaaaggac-3’ 
β-3 AR 5’-cgccttcaacccggtcatctactg-3’ 5’-ggtggactctgcctggcttcaac-3’ 
β-actin 5’-agagggaaatcgtgcgtgac-3’ 5’-caatagtgatgacctggcgt-3’ 
WNT10b 5’-acgtgggaatggggtggctgtaac-3’ 5’-tgttgttgtggatccgcattctcg-3’ 
GAPDH 5’-tgaaggtcggtgtgaacg-3’ 5’-ccattctcggccttgact-3’ 
18-S 5’-aggaccgcggttctattttgttgg-3’ 5’-atgctttcgctctggtccgtcttg-3’ 
LPA5, Lysophosphatidic acid receptor 5; LPA1, Lysophosphatidic acid receptor 1; 
PPARγ, Peroxisome proliferator-activated receptor γ; FASN, Fatty acid synthase; 
GLUT4, Glucose transporter 4; β-3 AR, Beta-3 adrenergic receptor; WNT10b, 
Wingless-type MMTV integration site family, member 10B; GAPDH, 
Glyceraldehyde 3-phosphate dehydrogenase. 
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Figure 5.1  The effect of energetic challenges on epididymal adipose tissue gene 
expression. The mRNA expression of lysophosphatidic acid receptor 5 (LPA5) (A, C 
and E) and lysophosphatidic acid receptor 1 (LPA1) (B, D and F) in mice fed a low 
fat diet (LFD) vs. high fat diet (HFD) (A and B) for fourteen weeks (n = 5), in lean 
(+/?) vs. obese ob/ob mice (C and D) (n = 8), and in ad libitum fed vs. 24 hour 
fasted mice (E and F) (n = 4-5). The mRNA expressions were normalised to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and are shown relative to 
the respective controls. Data represent means ± SEM.  ** P < 0.01, ***P < 0.001. 
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Figure 5.2  The effect of differentiation on 3T3-L1 pre-adipocyte mRNA 
expressions of (A) lysophosphatidic acid receptor 5 (LPA5), (B) LPA1, (C) 
peroxisome proliferator-activated receptor (PPAR)-γ and (D) fatty acid synthase 
(FASN) were investigated by comparing their expression in undifferentiated 
(Undiff 3T3-L1) vs. differentiated (Diff 3T3-L1) wild-type 3T3-L1 cells. The mRNA 
expression was normalised to 18S expression and are shown relative to the 
undifferentiated group. Data represent means ± SEM of 3 independent 
experiments (n = 4). *P < 0.05, ***P < 0.001. 
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Figure 5.3  The effect of lysophosphatidic acid receptor 5 (LPA5) over-expression 
on 3T3-L1 pre-adipocyte mRNA expression. The mRNA expressions of LPA5 (A-B), 
LPA1 (C-D) and β-actin (E-F) in two independent clones of undifferentiated 3T3-L1 
pre-adipocytes stably transfected with either the pCI-neo plasmid containing LPA5 
DNA (Undiff 3T3-LPA5) or the pCI-neo vector without an insert DNA (Undiff 3T3-
NEO). The gene expressions for clone 1 shown in (A, C, E),  and for clone 2 in (B, D, 
F). The mRNA expressions were normalised to 18S expression. Data represent 
means ± SEM of 3-4 independent experiments, (n = 4). * P < 0.05, ** P < 0.01, ***P < 
0.001.  
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Figure 5.4  The effect of lysophosphatidic acid receptor 5 (LPA5) over-expression 
on 3T3-L1 pre-adipocyte growth. Cell growth is shown for undifferentiated 3T3-L1 
pre-adipocytes stably transfected with either the pCI-neo plasmid containing 
lysophosphatidic acid receptor 5 (LPA5) DNA (3T3-LPA5) or the pCI-neo vector 
without an insert DNA (3T3-NEO) over a 64 hr time frame. The relative changes in 
cell growth/morphology are represented as cell index (CI), where CI = (Zi– Z0)/15 
(Zi: individual time point impedance, Z0: Background impedance). Data represent 
means ± SEM of 3 independent experiments (n = 8). *P < 0.05, **P < 0.01, *** P < 
0.001. 
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Figure 5.5 The effect of differentiation on gene expression in 3T3-L1 pre-
adipocytes over-expressing lysophosphatidic acid receptor 5 (LPA5). The mRNA 
expression  for (A) LPA5, (B) LPA1, (C) peroxisome proliferator-activated receptor 
(PPAR)-γ, (D) fatty acid synthase (FASN), (E) β3 adrenergic receptor (β3-AR) and 
(F) glucose transporter 4 (GLUT4) at day 10 of differentiation treatment in 3T3-L1 
pre-adipocytes stably transfected with either the pCI-neo plasmid containing LPA5 
DNA (Diff 3T3-LPA5) or the pCI-neo vector without an insert DNA (Diff 3T3-NEO). 
The mRNA expression was normalised to 18S expression. Data represent means ± 
SEM of 3 independent experiments (n = 4). * P < 0.05, ** P < 0.01, ***P < 0.001.  
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Figure 5.6 The effect of differentiation on lipid accumulation in 3T3-L1 pre-
adipocytes over-expressing lysophosphatidic acid receptor 5 (LPA5). (A) Relative 
lipid content as measured by Oil Red O staining and quantification in 
undifferentiated and differentiating pre-adipocytes stably transfected with either 
the pCI-neo plasmid containing LPA5 DNA (3T3-LPA5) or the pCI-neo vector 
without an insert DNA (3T3-NEO). (B) Photo micrographs show the lipid vacuoles 
at day 10 in differentiated 3T3-NEO and 3T3-LPA5 pre-adipocytes. Data represent 
means ± SEM of 3 independent experiments (n = 6-10). ***P < 0.001.  
B 
A 
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6.1 INTRODUCTION 
WPI has been increasingly demonstrated to provide a beneficial effect on weight 
management (Pal & Radavelli-Bagatini, 2013), including  a specific ability to reduce 
weight gain and adiposity in HFD-fed rodents (Pichon et al, 2008; Pilvi et al, 2007; 
Shertzer et al, 2011; Shi et al, 2011; Tranberg et al, 2013). Interestingly, a recurring 
theme of these studies has been the observation that the reduction in adiposity 
associated with WPI intake occurs independently of any significant changes to 
energy intake. Indeed, this outcome has been consistently demonstrated in HFD 
rodent studies of varying lengths, including those lasting for 11, 14 and 21 weeks 
(Pilvi et al, 2007; Shertzer et al, 2011; Shi et al, 2012). This project was therefore 
conducted to investigate the hypothesis that WPI directly impacts on adiposity by 
influencing tissue lipid metabolism. In support of this hypothesis, we show that 
WPI reduces body fat and causes alterations to lipid metabolism and insulin 
signalling-related gene expression in the adipose tissue (Table 6.1). These effects 
of WPI may be due to the direct action of WPI, or its derivatives, on adipose tissue 
lipid metabolism, which may potentially be mediated through the dietary protein 
responsive receptor LPA5, given that it’s over expression in 3T3-L1 adipocytes 
resulted in a significant reduction in lipid accumulation during cellular 
differentiation. In addition to the direct effects, evidence also implicates indirect 
routes by which WPI could influence adiposity, specifically by deposition of lean 
mass, central regulatory pathways, changes in the gut microbiota and alterations 
to gastrointestinal morphology (Figure 6.1). 
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Table 6.1-Overview of key outcomes of WPI dietary inclusion* 
*The noted changes are relative to casein fed mice 
TAG; Triacylglycerol; EAT, Epididymal white adipose tissue; Metabolic, metabolic 
cage; Home, home cage; N/A, not available. ↑ = increased compared to casein; ↓ = 
decreased compared to casein; ↔ = no difference to casein 
 
IR, Insulin receptor; ObR, leptin receptor; CPT1b, carnitine palmitoyltransferase 
1b; TNF-ɑ, Tumour necrosis factor ɑ; GLUT4, glucose transporter 4; IRS-1, Insulin 
receptor substrate 1; FASN, fatty acid synthase; HSL, hormone sensitive lipase; 
CD36, cluster of differentiation; β3-AR,  β3-adrenergic receptor; ACC, acetyl CoA 
carboxylase 
 High fat diet Low fat diet 
Physiological 
response 
Short-term Long-term Short-term Long-term 
Energy intake 
↑ (Metabolic)  
↔ (Home) 
↑ (Metabolic) 
↔ (Home) 
↔(Metabolic)  
↔ (Home) 
↔(Metabolic) 
↓ (Home) 
Energy 
expenditure 
↔ ↔ ↔ ↔ 
Fat mass ↓ trend ↓ ↑ ↔ 
Lean mass ↑ ↑ ↓ ↔ 
Liver TAG ↓ ↓ ↔ ↔ 
Plasma glucose ↔ ↔ ↔ ↔ 
Plasma Insulin ↔ ↔ ↑ ↔ 
Plasma TAG ↑ ↓ ↔ ↔ 
Gut microbiota 
changes N/A 
↑ Bifidobacteria 
↑ Lactobacillus 
↓ Clostridium 
N/A N/A 
Hypothalamic 
gene expression 
↓ IR, ObR, 
CPT1b,   
TNF-ɑ. 
↑ IR N/A N/A 
EAT insulin 
signalling gene  
↑ GLUT 4, IR ↔ 
↓ GLUT 4, IR, 
IRS-1 
↔ 
EAT lipid 
metabolism genes 
↑ trend  β3-AR 
↑ trend  FASN 
↑ FASN ↓ β3-AR, HSL, 
CPT1b 
↑ ACC, FASN, 
CD36 
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6.2 DISCUSSION 
The hypothesis that WPI directly impacts on adiposity by influencing tissue lipid 
metabolism was investigated using HFD and LFD fed C57BL/6J mice. The results of 
the current study show that WPI impedes the progression of obesity, although 
differential effects on weight management are seen dependent on macronutrient 
composition of the WPI enriched diet and on the duration of feeding (Fig 6.1). 
These data will be of significant importance to the Irish food industry to develop 
Functional Foods that improve the health status of individuals. The data also 
shows how the use of WPI in the lean state may have detrimental implications in 
terms of body fat accumulation, at least in the short term, in the absence of an 
exercise regime. Furthermore, the contrasting results related to WPI in the 
literature, for example in terms of energy intake between this study and those of 
others (Bendtsen et al, 2013; Hall et al, 2003; Luhovyy et al, 2007; Pal & Ellis, 
2010; Pichon et al, 2008), raises the need to obtain an in depth understanding of 
the functions of constitute proteins in WPI to assess if their variability within 
distinct WPI’s, obtained by different extraction methods and conditions, may 
underlie the above mentioned variability and importantly, may also allow for the 
development of WPI’s with enhanced bioactivity by manipulation of such methods 
and conditions. 
 Whilst strict dietary interventions can cause up to 10% weight loss in obese 
individuals, maintaining the lost weight has been a challenge after cessation of the 
dietary intervention (Anderson et al, 2001; Crujeiras et al, 2010; Haufe et al, 2013; 
Ryttig & Rossner, 1995; Sarwer et al, 2009; Wang et al, 2008). This is because the 
weight rebound effect often seen following weight loss makes obesity reversal 
difficult to achieve (Ryan et al, 2012), and thus prevention, rather than treatment, 
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appears to be a much more attractive solution for combating the obesity epidemic. 
In this regard, this study clearly demonstrates the potential of WPI to prevent the 
progression of obesity, with data here demonstrating its ability to suppress HFD-
induced body fat accumulation even in response to prolonged high fat dietary 
exposure, and in the absence of a negative energy balance (Table 6.1). Moreover, 
by showing WPI effects on mice from early stages of development, the data here 
may offer an insight into how WPI could be utilised in the prevention of childhood 
obesity in humans and thereby open up a potential avenue to tackle the obesity 
epidemic. 
Our results show a specific WPI effect in terms of promoting the 
development of lean mass at the expense of fat accumulation in HFD fed mice, 
which is seen at both 8 and 21 week dietary challenge. These data are indicative of 
enhanced muscle protein synthesis, which is supported by previous findings 
showing a specific ability of WPI to enhance muscle protein synthesis compared to 
other protein sources (Norton et al, 2012; Pennings et al, 2011; Tang et al, 2009). 
These data could be exploited to create WPI enriched Functional Foods targeting 
elderly people suffering from sarcopenic obesity (Pennings et al, 2011; Pennings et 
al, 2012), which arises due to age-related muscle loss, and accompanying 
increased fat mass. Moreover, it suggests WPI supplements or enriched Functional 
Foods could also be utilised, as demonstrated in Frestedt et al, (2008), to maintain 
lean body mass content during weight loss in energy restriction dietary 
interventions. 
Another group of malnourished individuals that could benefit from WPI 
intake are patients that undergo bariatric surgery. This surgery is the only long-
term solution for obesity, but this treatment causes both fat and muscle loss. Thus, 
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as described above for people undergoing dietary restriction, these proteins could 
potentially be given to patients that had undergone bariatric surgery as a means to 
help prevent muscle loss and preserve their lean mass content. Notably, WPI 
effects on the gastrointestinal tract shown here, where the dietary proteins 
reduced stomach size and intestinal length in LFD fed mice, are similar to that seen 
in bariatric surgery. Whilst we did not investigate if these changes could underlie 
the reduced weight gain in HFD fed mice with WPI intake, the data nonetheless 
poses the possibility to create Functional Foods with WPI that could bring about a 
surgery like effect (“nutritional surgery”). However, direct evidence of whether 
whey protein effects on GIT morphology truly mimic those associated with gastric 
bypass surgery is required. This nonetheless is an exciting new area for future 
investigation, as it may also help to establish health claims for WPI incorporated 
Functional Foods, and may even eventually replace bariatric surgery, which is 
known to carry substantial health risks including death. Therefore, the data here 
has opened up key unanswered questions that require investigation; (1) Does WPI 
similarly influence intestinal morphology in the HFD background, and if so, is this 
altered by the HFD duration? (2) Do alterations to the gastrointestinal 
environment underlie some of the beneficial effects of WPI in HFD fed mice, 
including insulin signalling? and (3) What connection is there between intestinal 
morphology and gut microbiota changes observed with WPI intake?  
Surgical reduction in the length of the intestine so that nutrients by-pass the 
proximal small intestine has been shown to enhance insulin sensitivity 
independently of changes to plasma levels of insulin, GLP-1, energy intake or body 
weight (Rubino et al, 2006; Salinari et al, 2013b). It has been suggested that 
absence of nutrient passage in the proximal intestine, as that arises from gastric 
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bypass surgery, reduces negative regulatory factors that impede insulin action, and 
that this underlies the improved insulin action following surgery (Salinari et al, 
2013a). Notably, we observed that mice fed a low fat and high carbohydrate 
enriched WPI diet exhibit a reduced intestinal length and show increased fat 
accumulation, presumably due to a whey induced insulin driven anabolic effect 
which when combined with a high carbohydrate content leads to enhanced glucose 
disposal as lipid in tissues. Whether the latter effect on fat accumulation is due to a 
WPI induced surgery-like effect on the production of intestinal-derived negative 
regulatory factors of insulin action, remains to be determined. Thus, overall the 
data suggests that in a lean context, intake of Functional Foods enriched with WPI 
should be consumed in combination with low carbohydrate diets or with a proper 
exercise regime to maximise the beneficial effects of protein intake and to reduce 
the potential anabolic effects on lipid storage. These findings are of particular 
importance to the sport industry and to athletes, and also highlight that when 
developing Functional Foods it is important to evaluate how different dietary 
backgrounds influence their action and whether any have health implications arise 
from their consumption in these different dietary backgrounds. 
  Health claims are a key aspect of Functional Food development, and for this 
it is important to establish mechanisms of action. With regard to WPI, our data 
shows that WPI prevention of HFD-induced weight gain and fat mass was 
accompanied by increased deposition of lean mass, an energy consuming 
physiological process, and by altered gut microbiota composition, and 
hypothalamic gene expression changes linked to adipose catabolic output. 
However, because these changes were correlative, we weren’t able to definitely 
address the issue of how HFD-WPI fed mice consuming equivalent or more energy 
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than HFD controls were not storing this energy as body fat, particularly in the 
absence of a change in energy expenditure. Therefore, the work here has opened 
up the challenge to understand how this energy deficit arises? Interestingly, a 
recent study, which followed on from our short-term HFD study, showed an 
increased urinary metabolite loss with WPI intake that may help explain how some 
of this energy is being lost (Lillefosse et al, 2014). Thus, an overall impact of this 
work may be to promote a greater research focus on alternate modes of energy 
dissipation with WPI intake, which may uncover novel targets and associated 
pathways for therapeutic intervention. 
 Although others have demonstrated the potential of WPI to impact on tissue 
lipid metabolism (Pilvi et al, 2007; Pilvi et al, 2008; Shi et al, 2011; Tauriainen et al, 
2011), this project made an significant contribution to the field by further 
exploring these WPI effects on lipid metabolism in an effort to better understand 
the associated mechanisms. Firstly, the data showing a specific ability of WPI to 
suppress hepatic lipid accumulation, as demonstrated similarly elsewhere (Hamad 
et al, 2011; Shertzer et al, 2011; Shi et al, 2011), supports the suggestion of WPI 
being a potentially attractive option in the prevention and/or treatment of NAFLD, 
however the mechanism(s) involved will need to be uncovered to support these 
health claims. As WPI prevented HFD-induced reductions in epididymal β3-AR 
gene expression, the data also suggests an adipose tissue lipolysis potential of 
these dietary proteins, which may contribute to its ability to suppress fat mass 
gains. Interestingly, recent data has shown WPI to impact on the subcutaneous 
adipose tissue mass to greater extent than the epididymal adipose tissue 
(Tranberg et al, 2013). Thus, a possible limitation of the current work was the 
decision to only characterise WPI induced changes in the epididymal adipose 
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deposit, and therefore future investigations should investigate the impact of WPI 
on both adipose tissue deposits. 
The study here was also the first to explore whether WPI may indirectly 
influence adiposity through central signalling pathways, by measuring 
hypothalamic gene expression in HFD fed mice consuming WPI. In the short-term 
the inclusion of WPI suppressed HFD-induced increases in the expression of 
insulin receptor, leptin receptor, CPT1b, TNF-α and PPARγ, potentially 
representing a lower threshold of leptin and insulin action in the hypothalamus 
(Ryan et al, 2012), in association with reductions in both hypothalamic lipid 
accumulation and inflammation (Gao et al, 2009; Posey et al, 2009; Ryan et al, 
2011). Indeed, an increased catabolic outflow from the CNS, via the SNS, to the 
adipose tissue, induces lipolysis and causes a reduction in TAG storage by 
catecholamine mediated activation of β3-AR receptors. This pathway may help 
explain why adipose tissue β3-AR expression was maintained in the WPI fed mice, 
and in turn why their adiposity was reduced. The involvement of β3-AR in WPI 
mediated reductions in adiposity could be further explored by investigating the 
impact of WPI in adipose tissue β-adrenergic receptor knock-out mice.  
The ability of WPI to influence the gastrointestinal environment shown here 
through specific alterations to the gut microbiota composition in long-term HFD 
fed mice provides an exciting new avenue of WPI research. Specific changes in gut 
microbiota at the phylogenic level were that, in comparison to HFD fed casein 
controls, WPI consumption specifically increased Lactobacillus and 
Bifidobacterium levels, and reduced Clostridium levels to such an extent that they 
were undetectable. This profile is similar to that reported by Sprong et al, (2010) 
and thus may potentially represent a compositional shift beneficial to the 
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reduction of HFD-induced obesity. However, the true impact that WPI effects on 
the gut microbiota composition have in terms of the physiological outcomes 
observed with WPI intake, requires further investigation, possibly with the use of 
germ free mice.  Furthermore, whether or not the impact of WPI on gut microbiota 
relates to dietary protein-induced alterations in GIT morphology and 
improvements in gut barrier integrity (i.e. reduced permeability)(Benjamin et al, 
2012), are potential new avenues of research that if investigated may provide a 
major breakthrough in the field of obesity prevention. 
Understanding and then enhancing the bioavailability of food-derived 
bioactive components (e.g. bioactive peptides) to influence target tissues within 
the body will be increasingly more important in Functional Food research and 
design (Udenigwe & Aluko, 2012). WPI is no exception in this, and future work will 
set to uncover ways to maximise WPI bioactive uptake across the intestinal wall in 
sufficient quantities to cause its intended effect in target tissues within the body. 
Techniques that can influence digestion and absorption of WPI bioactive 
components, such as pre-hydrolysation, encapsulation and using treatments such 
as pressure and temperature to alter isolate physiochemical properties, could be 
utilised to enhance the bioactivity of WPI. Indeed, in a recent clinical trial involving 
prehypertensive patients, WPI encapsulated in lycopene micelles, which is a 
carotenoid resistant to human digestive enzymes, improved its effects on 
cardiovascular related parameters compared to WPI intake alone (Petyaev et al, 
2012). In relation to investigating bioavailability, identifying targets in the body for 
WPI bioactive components to act upon is also an important area of future research 
for Functional Food development and could also lead to therapeutic targets for 
obesity treatment in general. In this regard the work here identified, LPA5, as a 
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potential target; however future work is needed to further evaluate its role in 
adipocyte metabolism and to access if indeed it could mediate the effects of WPI 
derived bioactives on adipose tissue. 
Although the benefits of WPI intake are clearly evident, and the total dietary 
protein content used in our studies was around the recommended dietary level for 
humans, a drawback of the current research in terms of translating this work for 
human consumption is the nature of the dietary challenges used, since WPI was 
the only source of proteins in the diet, which is unlikely to represent the human 
situation. Therefore, future studies should investigate whether lower quantities of 
WPI may still prove effective in preventing weight gain and obesity, and thus be 
more directly applicable to the human context, and also investigate whether diets 
containing other protein sources as well as WPI still allow maintenance of the 
whey proteins effects. Notably, a recent mouse trial demonstrated that replacing 
5% of the dietary protein content in a HFD with a novel WPI leads to a significant 
reduction in HFD-induced obesity (Shi et al, 2011), suggesting that small quantities 
of WPI may still be effective.  Also, whilst the current study utilised one source of 
WPI, there are a wide variety of isolates derived from different extraction methods 
and conditions which are likely to provide WPI’s with different bioactivities. This 
would relate to the differences in amounts of individual whey proteins present in 
the isolates. This wide variation in available WPI’s used in the literature does 
create problems when attempting to compare findings across studies and 
uncovering the true potential for use in weight management. Thus, a greater 
understanding of the protein quality within distinct WPI’s and how each individual 
whey protein influences energy balance is required, so that a protein mix that 
provides the greatest beneficial effect for humans can be created. 
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6.3 CONCLUSION 
The data presented here revealed that the ability of WPI to influence lipid 
metabolism differed according to macronutrient content in which it is provided 
and also with the duration of the experimental treatment period. In fact, WPI 
inclusion into a HFD suppressed the diet-associated increases in fat mass and liver 
lipid accumulation in the short-term, while these WPI associated effects were 
diminished somewhat with prolonged HFD intake. In contrast, in a LFD 
background, the inclusion of WPI augmented body fat content in the short-term, 
while in the long-term it had no effect. Additionally, the data presented here 
provides support for direct and indirect actions of WPI on adiposity by influencing 
lipid metabolism in the tissue. Notably, our investigation into the functionality of 
Figure 6.1  The contribution of this study to the field of body weight regulation 
control by whey protein isolate (WPI). Overall, differential impacts of WPI were 
evident depending on the macronutrient background in which they were provided 
and the duration of feeding. The effects of WPI in a high fat diet (HFD) and a low fat 
diet (LFD) background are demonstrated in (A) and (B) respectively. Effects in 
green show outcomes observed only in the short-term (8 weeks in HFD; 7 weeks in 
LFD), blue in the long-term only (21 weeks in HFD; 15 weeks in LFD) and red 
shows outcomes observed in both the short-and long-term. 
 
β3-AR, Beta-3 adrenergic receptor; GI tract, gastrointestinal tract; GLUT4, glucose 
transporter 4; IR, Insulin receptor; SNS, sympathetic nervous system; TAG, 
triacylglycerol. 
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the LPA5 receptor, which is responsive to protein hydrolysate, identified it as a 
novel candidate in regulation of pre-adipocyte growth and differentiation, which 
suggests this receptor may mediate the potential direct dietary protein (or its 
derivative) effects on adipose tissue metabolism. In addition to the direct effects of 
WPI, evidence presented here also implicates indirect routes of WPI action, namely 
by lean mass deposition, modifications of hypothalamic regulatory pathways, gut 
microbiota changes and alterations to gastrointestinal morphology, which need to 
be investigated further to uncover the extent of their contribution to the WPI-
induced effects observed here. Moreover, the novel effects of WPI on the GIT 
environment (morphology and gut microbiota) found here, as well as the effects on 
central energy balance regulation (hypothalamic gene expression), potentially 
offer exciting new avenues of whey protein research. The work here also highlights 
the great potential of WPI to be utilised as a Functional Food in obesity prevention, 
particularly in relation to childhood obesity, while also demonstrating its potential 
to be applied in preventing lean mass loss in vulnerable groups such as the elderly 
and post-operative bariatric surgery patients. Overall, the work presented here 
may help to focus future studies exploring the weight management effects of WPI 
and its derived bioactives. 
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Replacement of dietary saturated fat with monounsaturated fat 
protects against obesity-induced adipose tissue inflammation and 
hyperinsulinemia 
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Introduction: Recent evidence indicates NLRP3-mediated processing of pro- to active 
IL-1β accentuates adipose tissue inflammation promoting insulin resistance (IR). 
Furthermore saturated fatty acids (SFA) but not monounsaturated fatty acids (MUFA) 
can prime pro-IL-1β production. In this study we hypothesized that replacement of SFA 
for MUFA in high-fat diets (HFD) would attenuate adipose inflammation through 
reduced priming of NLRP3 inflammasome and improve metabolic health despite 
development of obesity. 
 
Methods: C57BL/6 mice were placed on a chow or HFD (45% palm oil/45% olive oil) 
for 24 weeks. Glucose (GTT) and insulin (ITT) tolerance tests were performed. Energy 
expenditure was monitored using TSE Phenomaster. Insulin secretion response to 
glucose challenge was quantified by ELISA. Macrophage recruitment into adipose 
tissue was measured by flow cytometry. IL-1β secretion from cultured adipocytes and 
stromal vascular fraction (SVF) stimulated ±ATP (100μm) was quantified by ELISA. 
Insulin-induced phosphorylated AKT in adipose tissue was determined by immunoblot 
analysis. 
 
Results: A slight reduction in body-weight was observed in MUFA-fed mice compared 
to SFA-fed mice concomitant with increased VO2 and heat production. MUFA-fed 
mice were protected against obesity induced hyperinsulinemia despite exhibiting 
comparable glucose homeostasis to SFA-fed mice by GTT and ITT. M1 adipose tissue 
macrophage number was lower in MUFA-fed mice compared to SFA-fed mice. IL-1β 
cytokine secretion was lower from SVF of MUFA-fed mice with a corresponding 
improvement in adipose tissue insulin sensitivity. 
 
Conclusion: Dietary intake of MUFA protects against obesity-induced 
hyperinsulinemia coincident with reduced adipose tissue NLRP3 activation and IL-1β 
release. 
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